



US011981953B2

(12) **United States Patent**
Hull et al.

(10) **Patent No.:** **US 11,981,953 B2**
(45) **Date of Patent:** **May 14, 2024**

(54) **METHOD TO SCREEN COMPOUNDS FOR ANTIFUNGAL ACTIVITY AND PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT FUNGAL DISEASES BY INHIBITING SPORE GERMINATION**

FOREIGN PATENT DOCUMENTS

EP 0174477 A1 * 3/1986 C12Q 1/18
WO WO-0029610 A1 * 5/2000 G01N 33/533

OTHER PUBLICATIONS

(71) Applicant: **WISCONSIN ALUMNI RESEARCH FOUNDATION**, Madison, WI (US)

Huang ("Protein Composition of Infectious Spores Reveals Novel Sexual Development and Germination Factors in *Cryptococcus*" *PLoS Genet* 11(8), 2015, 1-28) (Year: 2015).*

(72) Inventors: **Christina Marie Hull**, Middleton, WI (US); **Mingwei Huang**, Madison, WI (US); **Sebastien Claude Ortiz**, Madison, WI (US)

Abhyankar ("Spore proteomics: the past, present and the future" *FEMS Microbiol Lett*, 2014, 358, 137-144. (Year: 2014).*

(73) Assignee: **Wisconsin Alumni Research Foundation**, Madison, WI (US)

Zhao, (Cytological and proteomic analyses of horsetail (*Equisetum arvense* L.) spore germination), *Frontiers in Plant Science*, 2015, 17:44, 1-20) (Year: 2015).*

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1447 days.

Alspaugh JA, Perfect JR, Heitman J. (1998) "Signal transduction pathways regulating differentiation and pathogenicity of *Cryptococcus neoformans*," *Fungal Genet Biol.* 25:1-14 (pmid:9806801).

(21) Appl. No.: **16/369,939**

Barkal LJ, Walsh NM, Botts MR, Beebe DJ, Hull CM. 2016. Leveraging a high resolution microfluidic assay reveals insights into pathogenic fungal spore germination. *Integr Biol* 8:603-615. <https://doi.org/10.1039/c6ib00012f>.

(22) Filed: **Mar. 29, 2019**

Botts et al., Isolation and characterization of *Cryptococcus neoformans* spores reveal a critical role for capsule biosynthesis genes in spore biogenesis. *Eukaryotic Cell*. Apr. 2009; 8(4):595-605. doi: 10.1128/EC.00352-08.

(65) **Prior Publication Data**
US 2019/0300926 A1 Oct. 3, 2019

Davidson RC, Blankenship JR, Kraus PR, De J Berrios M, Hull CM, D'Souza C, et al., A PCR-based strategy to generate integrative targeting alleles with large regions of homology. *Microbiology*. 2002; 148: 2607-2615. PMID: 12177355.

Related U.S. Application Data

Giles SS, Dagenais TRT, Botts MR, Keller NP, Hull CM (2009) "Elucidating the pathogenesis of spores from the human fungal pathogen *Cryptococcus neoformans*," *Infect Immun* 77(8):3491-3500 (pmid:19451235).

(60) Provisional application No. 62/649,802, filed on Mar. 29, 2018.

(Continued)

(51) **Int. Cl.**
C12Q 1/18 (2006.01)
A01N 33/10 (2006.01)
A01N 37/44 (2006.01)
A01N 41/12 (2006.01)
A01N 47/40 (2006.01)
A61K 31/137 (2006.01)
A61K 31/145 (2006.01)
A61K 31/155 (2006.01)
A61K 31/24 (2006.01)
A61P 31/10 (2006.01)
C12Q 1/66 (2006.01)

Primary Examiner — Robert J Yamasaki
Assistant Examiner — Charles Z Constantine
(74) *Attorney, Agent, or Firm* — Joseph T. Leone; DeWitt LLP

(52) **U.S. CL.**
CPC **C12Q 1/18** (2013.01); **A01N 33/10** (2013.01); **A01N 37/44** (2013.01); **A01N 41/12** (2013.01); **A01N 47/40** (2013.01); **A61K 31/137** (2013.01); **A61K 31/145** (2013.01); **A61K 31/155** (2013.01); **A61K 31/24** (2013.01); **A61P 31/10** (2018.01); **C12Q 1/66** (2013.01); **G01N 2333/375** (2013.01)

(57) **ABSTRACT**

A method of testing compounds for activity to inhibit germination of spores. The method includes the steps of providing bacterial, fungal, or plant spores transformed to contain and express a detectable marker, wherein the marker when expressed, is operationally linked to a spore-specific or yeast-specific protein, in a medium and under environmental conditions in which the spores will germinate, and measuring a first signal output generated by the marker prior to the spores initiating germination; contacting the spores of step (a) with a compound whose activity to inhibit germination of spores is to be measured; incubating the spores of step (b) under environmental conditions and for a time wherein spores not treated with the compound will germinate; and determining extent of germination of the spores by measuring a second signal output generated by the marker, wherein a difference between the first signal output and the second signal output is proportional to the extent of germination of the spores. Also described are compositions of matter for inhibiting spore germination in vitro and in vivo.

(58) **Field of Classification Search**
CPC C12Q 1/18
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2005/0119306 A1* 6/2005 Trail C12N 15/80
435/32

16 Claims, 13 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited

OTHER PUBLICATIONS

Handbook of Pharmaceutical Salts, Properties, Selection, and Use, P.H. Stahl and C.G. Wermuch, Eds., © 2008, Wiley-VCH (Zurich, Switzerland), ISBN: 978-3-90639-058-1 (Book—Copy Not Provided).

Huang M, Hebert AS, Coon JJ, Hull CM, (2015) Protein Composition of Infectious Spores Reveals Novel Sexual Development and Germination Factors in *Cryptococcus*, PLoS Genet 11(8): e1005490 (<https://doi.org/10.1371/journal.pgen.1005490>).

Kwon-Chung KJ, Edman JC, Wickes BL, (1992) "Genetic association of mating types and virulence in *Cryptococcus neoformans*," *Infect Immun.* 60:602-605 (pmid:1730495).

Moore TD, Edman JC, (1993) "The alpha-mating type locus of *Cryptococcus neoformans* contains a peptide pheromone gene," *Mol Cell Biol.* 13:1962-1970 (pmid:8441425).

Rajasingjam R, Smith RM, Park BJ, Jarvis JM, Govender N, Chiller TM, Denning DW, Loyse A, Boulware DR, (2017) "Global burden

of disease of HIV-associated cryptococcal meningitis: and updated analysis" *Lancet Infectious Disease* 17: 873-881 (pmid:2848341).

Sherman F, Fink GR, Hicks JB. Laboratory course manual for methods in yeast genetics. Cold Spring Harbor Laboratory; 1987 (Book—Copy Not Provided).

Sherman F. (2002) "Getting started with yeast," *Methods Enzymol.* 350:3-41 (pmid:12073320).

Toffaletti DL, Rude TH, Johnston SA, Durack DT, Perfect JR. Gene transfer in *Cryptococcus neoformans* by use of biolistic delivery of DNA. *J Bacteriol.* 1993; 175: 1405-1411. PMID: 8444802.

Velagapudi R, Hsueh Y-P, Geunes-Boyer S, Wright JR, Heitman J, (2009) "Spores as infectious propagules of *Cryptococcus neoformans*," *Infect Immun.* 77:4345-4355 (pmid:19620339).

Walsh NM, Wuthrich M, Wang H, Klein B, and Hull CM. 2017. Characterization of C-type lectins reveals an unexpectedly limited interaction between *Cryptococcus neoformans* spores and Dectin-1. *PLoS One* 12(3):e0173866.

* cited by examiner





FIG. 1

FIG. 2A



FIG. 2B






FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 4




FIG. 5B

FIG. 5A




FIG. 6




FIG. 7A




FIG. 7B




FIG. 8B




FIG. 8A




FIG. 9

1

**METHOD TO SCREEN COMPOUNDS FOR
ANTIFUNGAL ACTIVITY AND
PHARMACEUTICAL COMPOSITIONS AND
METHODS TO TREAT FUNGAL DISEASES
BY INHIBITING SPORE GERMINATION**

CROSS-REFERENCE TO RELATED
APPLICATIONS

Priority is hereby claimed to provisional application Ser. No. 62/649,802, filed Mar. 29, 2018, which is incorporated herein by reference.

FEDERAL FUNDING STATEMENT

This invention was made with government support under AI089370 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND

Spores are an essential cell type required for long-term survival across diverse organisms and are a hallmark of fungal reproduction, persistence, and dispersal. Among human fungal pathogens, spores are presumed infectious particles, but relatively little is known about this robust cell type. Sporulation enables a relative quiescence—a type of hibernation—that contributes to the survival of fungi. However, sporulation also requires a transition back into a vegetative form so that the fungi can replicate—i.e., germination. Germination, despite its central importance in fungal reproduction and pathology in plants and animals, is not well understood.

Spores are a particularly successful cell type used by many microorganisms, including bacteria, fungi, and protozoa to survive unsuitable growth conditions and/or to disperse to new environments. Among eukaryotes, some of the most environmentally resistant spores are those of fungi, and much of our current understanding of spores comes from studies in model fungi such as *Saccharomyces cerevisiae* and *Aspergillus nidulans*. There are two general categories of fungal spores—sexual and asexual, and both forms occur across diverse fungal species via myriad developmental strategies. For example, in the budding yeast *S. cerevisiae* sexual spores are formed when yeast diploids are subject to nitrogen starvation and a non-fermentable carbon source, resulting in four haploid ascospores; *S. cerevisiae* does not produce asexual spores. In contrast, the filamentous fungus *Aspergillus nidulans* produces both asexual and sexual spores via the development of multicellular fruiting structures with thousands of spores per structure. In all instances, however, spores are adapted for general survivability.

As a consequence, fungal spores share three basic characteristics: First, mature spores are relatively metabolically quiescent, allowing them to remain dormant for long periods of time under sub-optimal growth conditions (e.g. in the absence of nutrients). Second, spores are resistant to environmental stresses, such as high temperatures, desiccation, and UV radiation, thus facilitating long-term survival and/or dispersal across great distances. Third, upon encountering growth-promoting environments, spores rapidly escape quiescence and germinate to resume vegetative growth. As a result, fungi are ubiquitous across all ecosystems on earth.

Spore-producing fungi commonly generate spores with thick, protective coats and robust stress resistance. Spores respond to different environmental signals to initiate germination, depending on their adapted niches. For example,

2

spores of *S. cerevisiae* germinate readily in response to the presence of a fermentable carbon source. In contrast, spores of *Talaromyces marosporus* require nutrients and a rigorous external trigger of very high temperature or pressure. These triggers generally result in responses such as water uptake, cell wall remodeling, and activation of nutrient metabolism and protein synthesis, leading to active fungal growth.

The transition from dormant particle to actively growing cell is particularly important because fungal survival cannot occur in the absence of the ability to germinate when (and only when) appropriate for vegetative growth. Environmental fungi are well adapted to their niches, and interestingly, these adaptations have led to a handful of fungi with the ability to cause life-threatening diseases in humans. *Histoplasma capsulatum*, *Blastomyces dermatitidis*, *Aspergillus fumigatus*, *Coccidioides immitis*, *Sporothrix schenckii*, *Penicillium marneffeii*, and *Cryptococcus neoformans* are the most common environmental fungi that can cause disease in humans. The general route of infection is by inhaling cells from environmental sources. Spores (sexual or asexual, depending on the fungus) are the most likely infectious particles for all of these pathogens; however, very little is known about their basic spore biology, making the development of disease prevention and treatment strategies challenging.

Among human fungal pathogens, the most common cause of fatal fungal disease (and a well-developed model for study) is *Cryptococcus neoformans*, a primarily opportunistic pathogenic yeast that causes meningoencephalitis. People with AIDS are particularly susceptible, and there are an over 200,000 cases and nearly as many deaths annually worldwide from cryptococcosis. Rajasingham R, Smith R M, Park B J, Jarvis J M, Govender N, Chiller T M, Denning D W, Loyse A, Boulware D R (2017) “Global burden of disease of HIV-associated cryptococcal meningitis: and updated analysis” *Lancet Infectious Disease* 17: 873-881 (pmid:2848341). *C. neoformans* is ubiquitous in the environment, and inhalation of aerosolized spores and/or yeast is the most common route of infection of humans. Under laboratory conditions, spores are produced through sexual development between haploid yeast of opposite mating types (α and α) or by α fruiting. In response to specific environmental conditions, cells form filaments and fruiting bodies (basidia) from which haploid, recombinant spores bud in chains.

Spores of *C. neoformans* exhibit the fundamental properties of most fungal spores, such as stability in the absence of nutrients and resistance to a variety of environmental stresses, including high temperature, desiccation, and oxidative stress. These spores have also been shown to germinate efficiently and synchronously in response to nutrients, and they germinate and cause disease in a mouse inhalation model of infection. See Velagapudi R, Hsueh Y-P, Geunes-Boyer S, Wright J R, Heitman J (2009) “Spores as infectious propagules of *Cryptococcus neoformans*,” *Infect Immun* 77:4345-4355 (pmid:19620339) and Giles S S, Dagenais T R T, Botts M R, Keller N P, Hull C M (2009) “Elucidating the pathogenesis of spores from the human fungal pathogen *Cryptococcus neoformans*,” *Infect Immun* 77:3491-3500 (pmid:19451235). These findings indicate that *C. neoformans* spores harbor intrinsic properties that facilitate survival in the environment, maintain spore viability and stability, and initiate germination in response to external signals, including those of a mammalian host.

Current antifungal therapeutics are relatively limited because of high toxicity or insufficient efficacy. These issues arise because, unlike bacteria, fungi are eukaryotes. Thus, fungi are far more similar (metabolically and biochemically)

to plants and animals than are bacteria. In short, compounds that interfere with fungal biology or are toxic to fungi, tend also to interfere with or be toxic to humans and animals.

A comparatively small number of antifungal compounds are approved for human, veterinary, and agricultural use in the United States. Focusing on antifungal drugs approved for use in humans, the gold standard by which all other antifungal pharmaceuticals are measured in terms of systemic antifungal activity is the polyene amphotericin B, first marketed in 1955. It is widely used to treat life-threatening fungal infections such as invasive mucormycosis, cryptococcal meningitis, aspergillosis, and candidiasis. While highly effective against fungi, amphotericin B itself has a slew of well-known and potentially life-threatening side effects. When administered intravenously, amphotericin B typically induces a debilitating set of symptoms, including high fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, dyspnea and tachypnea, drowsiness, and generalized weakness. Kidney damage is a commonly reported side effect. As a result, amphotericin B is administered with very close monitoring of the patient by health-care professionals.

Other antifungal compounds approved for use in humans include imidazoles (e.g., miconazole), triazoles (e.g., fluconazole), and thiazole antifungals (e.g., abafungin). Most of these types of antifungal compounds, however, are used topically, rather than systemically. They are much less toxic than amphotericin B, but not as efficacious.

Echinocandins are a much newer class of systemic antifungal compounds approved for use in humans. The echinocandins are macrocyclic lipopeptides. Their structure is characterized by (typically) a 6-mer macrocyclic peptoid moiety bonded to a long (e.g., >C10) hydrocarbon tail. Echinocandins inhibit the synthesis of glucan in the cell wall of fungi via noncompetitive inhibition of the enzyme 1,3- β glucan synthase. In this sense, they exert a pharmacological activity against fungi that is analogous to the pharmacological activity of beta-lactam antibiotics against bacteria. Echinocandins are also far less toxic than amphotericin B, but again, not as effective.

Thus, there remains a long-felt and unmet need for a method to test new and existing compounds for their ability to inhibit fungal growth.

SUMMARY

While vegetative fungi are similar metabolically and biochemically to other eukaryotic cells, fungi also sporulate and germinate. Thus, chemical inhibitors of fungal germination are potentially highly useful compounds in antifungal compositions (i.e., human and veterinary pharmaceuticals, topical and systemic pharmaceuticals, and agricultural and industrial fungicides). Thus, disclosed herein is a fluorescence-based quantitative germination assay suitable for high throughput screening. Using the subject germination assay, a screening of a 75,000-compound library yielded 108 germination-inhibiting compounds. Some of these compounds exhibited specific activity to inhibit germination of *Cryptococcus* spores (as contrasted to inhibiting vegetative cell growth). This indicates that germination itself is an effective target in developing antifungal drugs for prophylactic use in at-risk patients.


Thus, disclosed herein is a method of testing compounds for activity to inhibit germination of spores. The method comprises providing bacterial, fungal, or plant spores transformed to contain and express a detectable marker, wherein the marker is operationally linked to a spore-specific or


yeast-specific protein, in a medium and under environmental conditions in which the spores will germinate, and measuring a first signal output generated by the marker prior to the spores initiating germination. The spores are then contacted with a compound whose activity to inhibit germination of spores is to be measured. The spores are then incubated under environmental conditions and for a time wherein spores not treated with the compound will germinate. The extent of germination of the spores is determined by measuring a second signal output generated by the marker, wherein a difference between the first signal output and the second signal output is proportional to the extent of germination of the spores.

In certain versions of the method, the marker is operationally linked to a spore-specific protein selected from the group consisting of XP_567740.1 (SEQ. ID. NO: 2), XP_566791.1 (SEQ. ID. NO: 4), XP_570303.1 (SEQ. ID. NO: 6), XP_571089.1 (SEQ. ID. NO: 8), XP_571997.1 (SEQ. ID. NO: 10), XP_569295.1 (SEQ. ID. NO: 12), XP_569173.1 (SEQ. ID. NO: 14), XP_569068.1 (SEQ. ID. NO: 16), XP_569336.1 (SEQ. ID. NO: 18), XP_567136.1 (SEQ. ID. NO: 20), XP_568990.1 (SEQ. ID. NO: 22), XP_570610.1 (SEQ. ID. NO: 24), XP_571921.1 (SEQ. ID. NO: 26), XP_572925.1 (SEQ. ID. NO: 28), XP_570796.1 (SEQ. ID. NO: 30), XP_571548.1 (SEQ. ID. NO: 32), XP_570447.1 (SEQ. ID. NO: 34), and XP_571343.1 (SEQ. ID. NO: 36).

Another version of the method comprises the steps described previously, and further comprising plotting the area and aspect ratio of the spores and any germinated cells after the incubation of step (c). Because spores tend to be smaller and have a more oblong aspect ratio than do germinated, vegetative cells, the extent of germination can be determined by measuring the distribution of the cells' area versus aspect ratio. Again, in this version of the method, the marker, if present, is operationally linked to a spore-specific protein selected from the group consisting of XP_567740.1 (SEQ. ID. NO: 2), XP_566791.1 (SEQ. ID. NO: 4), XP_570303.1 (SEQ. ID. NO: 6), XP_571089.1 (SEQ. ID. NO: 8), XP_571997.1 (SEQ. ID. NO: 10), XP_569295.1 (SEQ. ID. NO: 12), XP_569173.1 (SEQ. ID. NO: 14), XP_569068.1 (SEQ. ID. NO: 16), XP_569336.1 (SEQ. ID. NO: 18), XP_567136.1 (SEQ. ID. NO: 20), XP_568990.1 (SEQ. ID. NO: 22), XP_570610.1 (SEQ. ID. NO: 24), XP_571921.1 (SEQ. ID. NO: 26), XP_572925.1 (SEQ. ID. NO: 28), XP_570796.1 (SEQ. ID. NO: 30), XP_571548.1 (SEQ. ID. NO: 32), XP_570447.1 (SEQ. ID. NO: 34), and XP_571343.1 (SEQ. ID. NO: 36).


Also disclosed herein are antifungal compositions and method of using them as topical and systemic fungicides for industrial, agricultural, and pharmaceutical uses. Disclosed herein is a composition of matter for inhibiting germination of fungal spores, the composition comprising a spore germination-inhibiting concentration of a compound selected from the group consisting of





and salts thereof, in combination with a vehicle.

Also disclosed herein is a pharmaceutical composition for inhibiting fungal infection in mammals (as well as the corresponding method of inhibiting topical or systemic fungal infections in mammals, including humans), the composition comprising a spore germination-inhibiting amount of a compound selected from the group consisting of:



wherein R is linear or branched C₁₋₁₂ alkyl and "x" is an integer of from 1 to 12, and salts thereof, in combination with a pharmaceutically suitable vehicle.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph showing that *C. neoformans* var. *grubii* spores are pathogenic in a murine model of cryptococcosis. Groups of eight AJ/Cr mice were infected with *C. neoformans* var. *grubii* spores (10⁵) or yeast (10⁷) via intranasal inhalation. See Giles et al. *Infect. Immun.* 2009, 77(8):3491. Time post-infection (in days) is shown in the X-axis; percent of surviving mice is shown on the Y-axis.

FIG. 2A is a series of scanning electron micrographs showing morphological transitions during germination. The

6

germinating spore is false-colored green; the emerging yeast wall is false-colored yellow, and the resulting daughter cell is false-colored orange. Bar=1 μm for 0, 4, and 8 Hr; bar=2 μm for 12 Hr.

FIG. 2B is a series of micrographs analogous to those in FIG. 2A using transmission electron microscopy rather than scanning electron microscopy. Bars=500 nm.

FIG. 3A is a schematic diagram of a screening assay for an uninhibited germination reporter strain as it undergoes germination (left-hand panel) and graphs depicting germination as reported by NanoLuciferase (NL) activity (top right, NanoLuc®-brand luciferase, Promega Corporation, Madison, Wis.), and as measured by optical density (OD) (bottom right). The schematic pictures below show the morphology and number of cells over time. This example depicts a yeast-specific protein.

FIG. 3B is a schematic diagram showing the workflow for the screening assay.

FIG. 3C shows representative plates from the screening assay described in FIGS. 3A and 3B, showing wells that contain germination-inhibiting compounds in red.

FIG. 3D is a schematic diagram of the transformation construct containing a marker, in this case a gene encoding luciferase ("Nano-Luc").

FIG. 4 is a flow chart showing the workflow of a high-throughput screening assay according to the present disclosure.

FIG. 5A shows schematic views of a microliter-scale well device and how it operates. The microfluidic device includes an input port connected to a culture well connected to an output port. Each microfluidic chamber is built upon a transparent support, such as a glass microscope slide. The microfluidic device is dimensioned and configured to culture and image non-adherent cells, such as spores and germinated fungi, yeast, and the like. The top panel of FIG. 5A shows a perspective view of a single microfluidic culturing device. The middle panel of FIG. 5A shows six (6) such devices disposed on a glass slide. Each of the six devices shown is filled with 10 μL of blue dye. The bottom panel of FIG. 5A shows a front elevation cutaway of the device shown in the top panel.

FIG. 5B depicts representative raw images of the fungal cells (spores and germinated cells) in the device shown in FIG. 5A. Image processing steps are then applied to the raw images to discriminate between spores and germinated cells. These process steps may include, without limitation, applying a density threshold to the raw images and then automatically detecting and measuring the cells 2-D area and aspect ratio.

FIG. 6 depicts how photos of germinating spores in the micro-device depicted in FIG. 5A were analyzed for the size and shape of the cells and the aspect ratio calculated. This was done using modified algorithms of ImageJ, a public domain, open-source, Java-based image processing program, which was developed originally by Wayne Rasband at the Research Services Branch of the National Institutes of Health. ImageJ can be downloaded free of charge at <https://imagej.nih.gov/ij/download.html>. The images of the cells are then plotted based on their 2-D area (X-axis) versus their aspect ratio (Y-axis) as shown in the right-hand panels of FIG. 6. Spores, because they are more oblong and smaller in area, plot to the bottom left-hand side of the histogram; germinated cells, because they are more spherical and larger in area, plot to the upper right quadrant of the plots.

FIG. 7A depicts a series of photographic analyses showing that germination in microscale devices as described herein can be determined by cell area versus aspect ratio.

Thus, each panel in FIG. 7A depicts the germination dynamics of spores visualized by 2D histograms of cell area vs. aspect ratio. Data are also shown as a stacked bar plot of the population composition over time (at lower right). Colors are normalized on each plot such that yellow represents the area and aspect ratio combination with the most cells observed and dark blue represents area and aspect ratio combinations that were not observed. Cells in the lower left quadrant are defined as spores; cells in the upper right quadrant as yeast; all remaining cells are classified as intermediates.

FIG. 7B shows 2D histograms as in FIG. 7A, but for a 16-hour germination of *Cryptococcus* spores using PBS as a control (no germination), synthetic dextrose growth medium (SD) alone (full germination in the absence of compounds), and fluconazole (16 mg/mL) in the presence of growth medium.

FIGS. 8A and 8B show that pentamidine treatment lowers fungal burden in mouse lung. FIG. 8A is a graph showing lung colony-forming units quantified for each mouse infected with JEC20×JEC21 yeast. The test group of mice were treated with 4 mg/kg/day pentamidine; the control group of mice were treated with 1×PBS; *p<0.05 for two-tailed paired t-test.

FIG. 8B is a graph depicting lung colony-forming units quantified for each mouse infected with JEC20×JEC21. Again, the test mice were treated with 4 mg/kg/day pentamidine; the control mice were given 1×PBS; **p<0.01 for two-tailed paired t-test.

FIG. 9 is a graph showing that pentamidine prophylactically inhibits fungal spore germination in vivo. FIG. 9 depicts lung colony-forming units quantified for each mouse infected with JEC20×JEC21 spores. The test group of mice were treated with 4 mg/kg/day pentamidine; the control group of mice were treated with 1×PBS. **p<0.01 for two-tailed paired t-test. See Examples for complete details.

DETAILED DESCRIPTION

Abbreviations and Definitions:

The term “pharmaceutically-suitable salt” refers to any acid or base addition salt whose counter-ions are non-toxic

to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base or free acid are not vitiated by side effects ascribable to the counterions. A host of pharmaceutically-suitable salts are well known in the art. For basic active ingredients, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically-suitable salt by ion exchange procedures. Pharmaceutically-suitable salts include, without limitation, those derived from mineral acids and organic acids, explicitly including hydrohalides, e.g., hydrochlorides and hydrobromides, sulphates, phosphates, nitrates, sulphamates, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, gentisates, isethionates, di-p-toluoyltartrates, methane sulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates, quinate, and the like. Base addition salts include those derived from alkali or alkaline earth metal bases or conventional organic bases, such as triethylamine, pyridine, piperidine, morpholine, N-methylmorpholine, and the like. See, for example, “Handbook of Pharmaceutical Salts, Properties, Selection, and Use,” P. H. Stahl and C. G. Wermuch, Eds., © 2008, Wiley-VCH (Zurich, Switzerland), ISBN: 978-3-90639-058-1.

“Spore-specific molecule” refers to any molecule, moiety, or protein that is highly overrepresented in abundance in spores relative to yeast. Conversely, “Yeast-specific molecule” refers to any molecule, moiety, or protein that is highly overrepresented in abundance in yeast relative to spores. Specifically included in the terms are the proteins identified in Huang M, Hebert A S, Coon J J, Hull C M (2015) “Protein Composition of Infectious Spores Reveals Novel Sexual Development and Germination Factors in *Cryptococcus*,” PLoS Genet 11(8): e1005490 (<https://doi.org/10.1371/journal.pgen.1005490>). These spore-specific proteins were repeatedly identified by mass spectrometry in spore samples and never in yeast samples and are encoded by the following genes:

TABLE 1

Genes encoding spore-specific proteins.			
Gene	JEC21 ID	Predicted functions/domains	Deletion phenotype(s)
Group 1: Replication and Chromosome Biology			
TOP1	CNI03280	topoisomerase1	sporulation defects
IRR1	CNA07890	nuclear cohesion complex component	inviable
Group 2: Transcription and Splicing			
RSC9	CNB00580	chromatin remodeling complex component	cell fusion defect
DST1	CNF01160	general transcription elongation factor TFIIS	sporulation defect
PRP31	CNB05520	U4/U6-U5 snRNP complex component	inviable
PRP11	CND02290	SF3a splicing factor complex component	inviable
Group 3: Cellular Transport			
BCH1	CNG02530	specialized cargo export from Golgi	filamentation defect
SFH5	CNE04320	non-classical phosphatidylinositol transfer protein	no phenotype
DDI1	CNC00460	vSNARE binding protein	sporulation defect
EMC3	CNF02470	protein folding in the ER	decreased spore yield
Group 4: Carbohydrate Metabolism			
GRE202	CNG01830	D-lactaldehyde dehydrogenase	decreased spore yield
ISP1 ^c	CNB02490	conserved in fungi/short chain dehydrogenase	filamentation defect

TABLE 1-continued

Genes encoding spore-specific proteins.			
Gene	JEC21 ID	Predicted functions/domains	Deletion phenotype(s)
ISP3	CND04560	conserved in fungi/mannose-6-phosphate isomerase	no phenotype
ISP4	CNK01510	conserved in fungi/glycosyl hydrolase Group 5: Proteins of Unknown Function	no phenotype
ISP2	CNE01730	<i>Cryptococcus</i> -specific/no conserved domains	increased sporulation; slow germination
ISP5	CNB04980	conserved in fungi/ferritin-like superfamily domain	no phenotype
ISP6	CNA04360	<i>Cryptococcus</i> -specific/transmembrane domain	no phenotype
ISP7	CND00650	<i>Cryptococcus</i> -specific/no conserved domains	no phenotype

*Genes encoding proteins with no obvious homologs were named ISP for identified Spore Protein.

dDoi: 10.1371/journal.pgen.1005490.t003

The spore-specific genes and proteins identified in the above table have the nucleotide and amino acid sequences and protein ID's shown in the Sequence Listing at SEQ. ID. NOS 1-36.

Yeast-specific proteins include, but are not limited to, CND06170, XP_570090.1 (SEQ. ID. NOS. 37 and 38); CND01050, XP_570422.1 (SEQ. ID. NOS. 39 and 40); CNH01340, XP_572322.1 (SEQ. ID. NOS. 41 and 42); CNN02360, XP_568723.1 (SEQ. ID. NOS. 43 and 44); CNB01440, XP_568816.1 (SEQ. ID. NOS. 45 and 46); CNG00410, XP_571739.1 (SEQ. ID. NOS. 47 and 48); CNH02740, XP_572447.1 (SEQ. ID. NOS. 49 and 50); CNJ01750, XP_567350.1 (SEQ. ID. NOS. 51 and 52); CNI02030, XP_572658.1 (SEQ. ID. NOS. 53 and 54); CNB05750, XP_569316.1 (SEQ. ID. NOS. 55 and 56); CNI03560, XP_572607.1 (SEQ. ID. NOS. 57 and 58); CNK01820, XP_567661.1 (SEQ. ID. NOS. 59 and 60); CNI00900, XP_572819.1 (SEQ. ID. NOS. 61 and 62); CNK02880, XP_567883.1 (SEQ. ID. NOS. 63 and 64); CNF00610, XP_571239.1 (SEQ. ID. NOS. 65 and 66); and CNI00870, XP_572850.1 (SEQ. ID. NOS. 66 and 67). These yeast-specific proteins, which are shown in the Sequence Listing, can be utilized as markers of germination.

The gene and encoded protein encoded by CNK01510 (SEQ. ID. NOS. 1 and 2, respectively) is the preferred spore-specific molecule to be labeled in accordance with the assay disclosed herein.

The terms "label," "marker," "probe," "reporter," and "tag" are used interchangeably and mean a molecular moiety or probe of any structure or configuration, that can be detected by any means, now known or developed in the future, by which a vegetative cell, spore, or molecule bearing such a "label," "marker," "probe," "reporter," or "tag" can be distinguished from cells, spores, or molecules not bearing such a "label," "marker," "probe," "reporter," or "tag." The terms include, without limitation, radioactive labels, fluorescent labels, chromophoric labels, affinity-based labels (such as antibody-type markers), chemiluminescent labels, and the like. Conventional radioactive isotopes used for detection include, without limitation, ³²P, ²H and many others. A huge number of fluorescent and chromophoric probes are known in the art and commercially available from numerous worldwide suppliers, including Life Technologies (Carlsbad, Calif., USA), Enzo Life Sciences (Farmingdale, N.Y., USA), and Sigma-Aldrich (St. Louis, Mo., USA). Luciferase is the preferred marker. Complete kits for accomplishing luciferase labeling to a desired substrate are commercially available from several suppliers,

including Promega Corporation, Madison, Wis. (e.g., Promega's NanoLuc®-brand vectors and NanoGlo®-brand luciferase assay systems).

The term "operationally linked" or "operationally connected" when referring to joined polynucleotide sequences denotes that the sequences are in the same reading frame and upstream regulatory sequences will perform as such in relation to downstream structural sequences. Polynucleotide sequences which are operationally linked are not necessarily physically linked directly to one another but may be separated by intervening nucleotides which do not interfere with the operational relationship of the linked sequences. Similarly, when referring to joined polypeptide sequences, operationally linked means that the functionality of the individual joined segments are substantially identical as compared to their functionality prior to being operationally linked. For example, a fluorescent protein or chemiluminescent protein can be fused to a polypeptide of interest and in the fused state retain its fluorescence or chemiluminescence, while the fused polypeptide of interest also retains its original biological activity.

All strains used in the working examples were of the serotype D background (*Cryptococcus neoformans* var. *neoformans* strains JEC20 (ATCC 96909) and JEC21 (ATCC 96910 and ATCC MYA-565). See Kwon-Chung K J, Edman J C, Wickes B L (1992) "Genetic association of mating types and virulence in *Cryptococcus neoformans*," *Infect Immun.* 60:602-605 (pmid:1730495) and Moore T D, Edman J C (1993) "The alpha-mating type locus of *Cryptococcus neoformans* contains a peptide pheromone gene," *Mol Cell Biol.* 13:1962-1970 (pmid:8441425). All were handled using standard techniques and media as described in Sherman F. (2002) "Getting started with yeast," *Methods Enzymol.* 350:3-41 (pmid:12073320) and Alspaugh J A, Perfect J R, Heitman J. (1998) "Signal transduction pathways regulating differentiation and pathogenicity of *Cryptococcus neoformans*," *Fungal Genet Biol.* 25:1-14 (pmid:9806801).

Numerical ranges as used herein are intended to include every number and subset of numbers contained within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.

All references to singular characteristics or limitations of the present invention shall include the corresponding plural characteristic or limitation, and vice-versa, unless otherwise specified or clearly implied to the contrary by the context in

which the reference is made. The indefinite articles “a” and “an” mean “one or more” unless explicitly stated otherwise.

All combinations of method or process steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.

The methods disclosed herein can comprise, consist of, or consist essentially of the essential elements and limitations of the method described, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in microbiology, biochemistry, and/or mycology.

The Method:

At the core of the present invention is the realization that targeting a cellular process that is specific to organisms that sporulate—namely, spore germination—is likely to yield highly effective antifungal compositions that exhibit fewer side-effects than conventional antifungal drugs when used in humans. (Organisms that produce spores include fungi, bacteria, protists, plant seeds, ferns, and the like.) What then is needed then is a high-throughput assay that can evaluate compounds for their ability to inhibit fungal spore germination. As shown in FIG. 1, it is known that spores are infectious agents. FIG. 1 is a graph showing survivability in a widely accepted mouse model of cryptococcosis. See Giles et al. *Infect. Immun.* 2009, 77(8):3491. Here, mice were infected with spores or yeast of *C. neoformans* var. *grubii*. Spores (10^5) or yeast (10^5) were administered to the test animals via intranasal inhalation. Mice infected with spores are shown in black circles; mice infected with yeast are shown in white circles. As can be seen in FIG. 1, the mice died at virtually identical rates. In other words, *Cryptococcus* spores are just as virulent as the yeast form.

The method functions on two principles. The first principle is that the vegetative form of organisms, especially fungi, are very different, morphologically than their corresponding spores. This is shown quite convincingly in FIGS. 2A and 2B. FIG. 2A is a series of scanning electron micrographs showing the morphological transitions that take place during germination of *C. neoformans* spores. A *C. neoformans* spore is shown in the far left photo. The germinating spore is false-colored green. The emerging yeast wall is false-colored yellow. This can be seen initially in the photo second from the left and then in a much more pronounced fashion in the third photo of the series. The daughter cell is false-colored orange and is seen clearly in the far right photo. A simple visual comparison between the far left and far right photos in FIG. 2A illustrates the significant morphological differences between a spore of *C. neoformans* (on the left) and a yeast (vegetative form, on the right). As can be seen from FIG. 2A, the spore is roughly cylindrical and clearly has a major axis that is much longer than its minor axis. The vegetative yeast form, in contrast is more nearly spherical or globular. Its major and minor axes are much closer in physical length. FIG. 2B shows the same phenomenon using using transmission electron microscopy rather than scanning electron microscopy. Spores are quantitatively smaller and more oblong than yeast.

The second principle is that the inventors have identified 18 proteins that are expressed at far greater levels in the spore form as contrasted to the yeast form. Thus, by affixing a marker to one or more of these spore-specific proteins, the extent of germination can be tracked by following changes in the signal generated by the marker as the spore-specific protein is degraded during the germination process.

The first step of the method is to provide bacterial, fungal, or plant spores transformed to contain and express a detect-

able marker, wherein the marker is operationally linked to a spore-specific or a yeast-specific protein. The marker is preferably a protein fluorophore or protein chemiluminescent marker, such as luciferase, fluorescent protein A, green fluorescent protein, etc. The marker protein is incorporated into spores or yeast by fusing the gene encoding the marker protein to a spore-specific or yeast-specific target gene. The spore then produces the spore-specific protein with the marker attached. (Or the yeast then produces the yeast-specific protein with the marker attached.) The marker will thus generate a first signal associated with the spores. That first signal remains unchanged for as long as the spores remain intact. However, when the spore germinates, the spore-specific protein and its attached marker are degraded, which then alters the signal generated by the attached marker (or the yeast-specific marker is increased). A second signal measurement taken after germination is thus proportional to the extent of germination.

This process is shown schematically in FIG. 3A. As shown in the left-hand side of the figure, the yeast form of the organism (in this case *C. neoformans*) was transformed to contain a fusion construct comprising a spore-specific protein fused to a luciferase gene. The transformed yeast were cultured to yield a population of propagating yeast that include the fusion construct. The yeast were then induced to sporulate. A first measure of the signal generated by the luciferase marker generated by the fusion construct is taken. This is shown at Time=0 in the two right-hand graphs depicted in FIG. 3A. The upper graph show the signal generated by the reporter as the spore germinate. The lower graph shows the optical density of the culture solution at 600 nm (OD_{600}) over the same time period. As can be seen from the two graphs, as the spore germinate and multiply, the optical density increases (as the number of cells increases). In a corresponding fashion, the signal generated by the marker displays a proportional rise. The schematic pictures below show the morphology and number of cells over time.

The assay can be implemented in a massively redundant, massively high-throughput format that is easily automated using conventional multiwell plates and robotic equipment. (Laboratory robotics for handling multiwell culture plates are available from a host of international commercial suppliers, including Agilent Technologies (Santa Clara, Calif.), Beckman Coulter (Grants Pass, Oreg.), Hudson Robotics (Springfield, N.J.), and many others.) For a non-limiting example, see FIG. 3B, which is a schematic diagram showing the workflow for a high-throughput screening assay according to the present disclosure. As shown in FIG. 3B, the method can be implemented using conventional 384-well incubation plates. Spores to be studied are modified to contain a suitable marker, as described earlier. The spores are then incubated in a multiwell plate in a suitable germination medium. For many fungi, yeast extract-peptone-dextrose growth medium (YPD or YEPD) is suitable. (YPD is a well known medium for fungal germination and contains roughly 2% w/v bacto-peptone, 1% w/v yeast extract, and 2% w/v dextrose. A 1 L batch is made by combining 20 g bacto-peptone, 10 g yeast extract, and 20 g dextrose, adding water to 1 L and then autoclaving before use.)

A first signal from each well of the multiwell plate is then taken at the start of the incubation period. The contents of each well can be arranged in any suitably logical fashion, with positive and negative control wells, and wells containing compounds to be tested for their ability to inhibit germination of the spores, perhaps in appropriate serial dilutions of the compounds. The entire multiwell plate is then cultured for a time, temperature, humidity, etc. that is

conductive to germination of the spores. After a set time, and OD600 measurement may optionally be taken to confirm that in the control wells the spores responded appropriately. The cells are then lysed, luciferase substrate is added, and a second measurement of the signal generated by the marker is taken. The extent of germination can then be determined by comparing the first signal to the second.

FIG. 3C shows a representative multiwell plate from the resulting from the method just described. Positive and negative control wells are in columns 23 and 24, respectively. Wells that contain germination-inhibiting compounds in various shades of pink/red, with the darker red hues indicating great inhibitory activity. The signals can be gathered, digitized, recorded, and compared using a photomultiplier tube, in conventional fashion. Thus, wells H11, K11, C15, M16, and C21 all appear to contain very effective germination-inhibiting compounds.

FIG. 3D shows a schematic diagram of a vector used to transform a spore so that it includes a marker responsive to germination

An exemplary protocol, using luciferase as the marker, can be accomplished using commercial kits and largely following the manufacturer's instructions on how to use the kit. A preferred kit for is Promega's Nano-Luc®-brand vectors and Nano-Glo®-brand luciferase assay system.

Briefly, homologous recombination is utilized to tag spore proteins with luciferase under their endogenous promoters. See FIG. 3D. In this fashion, their expression levels in the spores will remain undisturbed by tagging. As illustrated in FIG. 3D, the transformation construct contains three parts (A, B, and, C). Part A includes the sequence that encodes ISP4 but without a stop codon. Part B includes NanoLuc sequence (GeneBank sequence number KM359770) and *C. neoformans* URAS gene (GenBank sequence number AE017347.1), the latter of which serves as a selection marker for cell transformation. Part C includes the 3' UTR of ISP4, so that together with Part A, the transformation construct will be more favorably integrated into the genome through homologous recombination. Individual parts were generated by regular PCR and the full-length transformation construct was created using fusion PCR. See Davidson R C, Blankenship J R, Kraus P R, de J Berrios M, Hull C M, D'Souza C, et al. A PCR-based strategy to generate integrative targeting alleles with large regions of homology. *Microbiology*. 2002; 148: 2607-2615. PMID: 12177355. The construct was transformed into cells by biolistic transformation before selection. See Toffaletti D L, Rude T H, Johnston S A, Durack D T, Perfect J R. Gene transfer in *Cryptococcus neoformans* by use of biolistic delivery of DNA. *J Bacteriol*. 1993; 175: 1405-1411. PMID: 8444802.

The present inventors have identified a significant number of proteins in *C. neoformans* that were detected in spores only. Thus, these proteins are all candidates for labelling in the present invention. In *C. neoformans* and in other fungi where the corresponding genes are conserved, one or more of the following proteins can be labelled with the marker: XP_567740.1 (SEQ. ID. NO: 2), XP_566791.1 (SEQ. ID. NO: 4), XP_570303.1 (SEQ. ID. NO: 6), XP_571089.1 (SEQ. ID. NO: 8), XP_571997.1 (SEQ. ID. NO: 10), XP_569295.1 (SEQ. ID. NO: 12), XP_569173.1 (SEQ. ID. NO: 14), XP_569068.1 (SEQ. ID. NO: 16), XP_569336.1 (SEQ. ID. NO: 18), XP_567136.1 (SEQ. ID. NO: 20), XP_568990.1 (SEQ. ID. NO: 22), XP_570610.1 (SEQ. ID. NO: 24), XP_571921.1 (SEQ. ID. NO: 26), XP_572925.1 (SEQ. ID. NO: 28), XP_570796.1 (SEQ. ID. NO: 30), XP_571548.1 (SEQ. ID. NO: 32), XP_570447.1 (SEQ. ID. NO: 34), XP_571343.1 (SEQ. ID. NO: 36).

FIG. 4 is a flow chart showing the workflow of a high-throughput screening assay according to the present disclosure. Here, the figure shows how a large library of 75,000 compounds was screened using the present method set up in high-throughput format. As shown on the left-hand side of the figure, the full library was first subjected to a primary screening comprising a 10-hour germination, followed by evaluating which compounds showed initial interest as germination inhibitors. This yielded 2,100 putative "hits," i.e., compounds that at least initially showed promise as germination inhibitors. These 2,100 hits were then re-screened and the upper 900 best performing inhibitors were tested further. These 900 compounds were then re-screened using longer germination and yeast growth incubation times. This resulted in 270 compounds being advanced for further study. This group of 270 compounds was then studied using the method described herein to determine if any of the compounds inhibited spore germination and/or fungal growth in a dose-dependent fashion. This final screen yielded 108 compounds from the original 75,000 compounds that inhibited fungal spore germination and/or yeast growth in a dose-dependent fashion.

As shown in the middle panel of FIG. 4, the 108 compounds that were "hits" were then clustered by structural similarity and further tested to see if their anti-fungal properties were germination specific (i.e., primarily germination inhibitory), non-specific, or primarily growth specific. As shown in the right-hand graphs of FIG. 4, 37 of the compounds specifically inhibited germination in a dose-dependent manner; 52 of the compounds were non-specific, dose-dependent inhibitors; and 19 of the compounds specifically inhibited vegetative fungal growth in a dose-dependent manner.

As shown in FIGS. 5A and 5B, the method described herein can also be formatted for continuous studies using a microfluidic test bed. The test bed, depicted schematically in FIG. 5A, comprises a microliter-scale culture well having an input port and an output port. That is, the device includes an input port operationally linked in fluid connection to a culture well which is operationally linked in fluid connection to an output port. Each microfluidic chamber is built upon a transparent support, such as a glass microscope slide. The microfluidic device is dimensioned and configured to culture and image non-adherent cells, such as spores and germinated fungi, yeast, and the like. The top panel of FIG. 5A shows a perspective view of a single microfluidic culturing device. The middle panel of FIG. 5A shows six (6) such devices disposed on a glass slide. These six devices held 10 μ L blue dye. The bottom panel of FIG. 5A shows a front elevation cutaway of the device shown in the top panel. In this bottom panel, fluid flow is depicted as moving from left-to-right. Non-adherent cells are retained within the culture well, while the medium gently flows above them. Compounds to be tested are introduced through the input port, where they then flow to the culture well to interact with the cells therein. When built on an optically transparent substrate, the cells can be visualized and photographed in real time, as shown in the photos in FIG. 5B.

FIG. 5B depicts representative raw images of the fungal cells (spores, germinating cells, and yeast) in the device shown in FIG. 5A. Various imaging processing steps, described in detail below, are then applied to the raw images to discriminate among spores, germinating cells, and yeast. These process steps may include, without limitation, applying a density threshold to the raw images and then automatically detecting and measuring the cells' 2-D area and aspect ratio.

FIG. 6 shows how computer processing can be brought to bear to automatically discriminate between ungerminated spores and vegetative yeast after a culture period has been completed. The left-hand side of FIG. 6 shows the three raw photographs from FIG. 5B. These are raw photographs of the germinating spores in the microfluidic device shown in FIG. 5A. The photos are digitized from the outset. The digitized images were analyzed for the size and shape of each cell in each image. The area of each cell, as well as its aspect ratio can be determined using a public domain, open-source, Java-based image processing program called ImageJ. Several other commercial image processing software packages can also accomplish this task. For example, Stream-brand image analysis software from Olympus Corporation (Waltham, Mass.) and PAX-it brand image analysis software from MIS, Inc. (Villa Park, Ill.). The images of the cells are then plotted based on their 2-D area (X-axis) versus their aspect ratio (Y-axis) as shown in the right-hand panels of FIG. 6. As can be seen from the plots in FIG. 6, the spores (upper plot) cluster in a distinctly different location and with a distinctly different distribution as compared to the vegetative yeast (lower plot). This is because spores, being more oblong and smaller in area, plot to the left-hand side of the histogram—indicating smaller average area and ovoid nature in the photographs. Spores tend toward a wider distribution of their aspect ratios and areas. This may be due to the fact that the spores settle in the device at many angles. When photographed, spore aspect ratios and sizes are more variable than in reality. Yeast, because they are more spherical and larger in area regardless of the position from which they are photographed, plot in a tight cluster in the upper right quadrant of the histograms.

Further examples of how spores, germinating cells, and yeast can be compared is shown in FIGS. 7A and 7B. FIG. 7A depicts a series of photographic analyses further demonstrating that germination in microscale devices as described herein can be determined by cell area versus aspect ratio. Each panel in FIG. 7A depicts the germination dynamics of spores visualized by 2D histograms of cell area vs aspect ratio, as well as a stacked bar plot of the population composition over time (at lower right). Colors are normalized on each plot such that yellow represents the area and aspect ratio combination with the most cells observed and dark blue represents area and aspect ratio combinations that were not observed. Cells in the lower left quadrant are defined as spores; cells in the upper right quadrant as yeast; all remaining cells are classified as intermediates undergoing germination. FIG. 7B shows 2D histograms as in FIG. 7A, but for a 16-hour germination of *Cryptococcus* spores using PBS as a control (no germination), synthetic dextrose growth medium (SD) alone (full germination in the absence of compounds), and the antifungal compound fluconazole (16 mg/mL) in the presence of growth medium. In this study, we demonstrate that spore germination is a viable target for antifungal development by identifying and characterizing FDA approved drugs able to inhibit both spore germination and yeast replication. These inhibitors have the potential of becoming tools to probe the essential fungal process of spore germination, or repurposed into antifungal therapies. Importantly, we determined that one of the drugs, Pentamidine, was effective at lowering fungal burden in vivo and could be repurposed as a prophylactic treatment against *Cryptococcus* pathogens.

Germination Provides a Suitable Target for the Development of Novel Antifungals:

Limited therapies exist to combat fungal disease. Humans and fungi share many biological processes due to their

eukaryotic nature. Because fungi-specific drug targets are difficult to find, potent antifungal agents often have toxic side-effects in humans. In the quest to find novel fungal-specific targets, the field has mainly focused on the cell membrane processes (ergosterol biosynthesis), and the fungal cell wall ($\beta(1,3)$ -glucan synthesis). While these targets have been effective in the discovery of antifungals in the past; the lack of novel antifungal therapies is an indication that these targets currently have limited success. It is critical that novel fungi-specific targets are identified for the development of new antifungals. This requires identifying new cell processes to probe that are unique to fungi. Fungal spore germination provides one of these novel targets.

Fungal spore germination has been previously suggested to be a modified cell cycle. Recently discovered evidence suggests otherwise. In previous studies we identified and characterized spore-enriched proteins. One of these proteins (Isp2) was found to stall germination for two hours prior to initiating vegetative growth. Isp2 showed no apparent phenotype in vegetatively growing yeast. Isp2, along with other spore germination-specific results, indicate that it is unlikely that germination is simply a modified cell cycle. Spore germination is not only a unique fungal process but is also unlike any process defined in humans. The uniqueness of fungal spore germination makes it a prime process to probe in the effort to develop novel antifungals. The examples below show that using germination inhibition as a signal can identify drugs that could be repurposed in the treatment of invasive fungal diseases.

Targeting Germination Provides a Mechanism for Prevention:

In addition to providing a fungal-specific drug targets, targeting germination provides a unique opportunity for preventing fungal disease. Spores are stress-resistant cell types that are known infectious particles of many fungal pathogens, and have distinct phenotypes compared to yeast when interacting with hosts. Developing antifungals that target all potential infectious particles could be used to protect against fungal pathogens through prophylaxis treatment. If a low toxicity antifungal is found, prophylactic treatment could be administered to immunocompromised individuals, the population most at risk of developing invasive fungal infections.

Screening Characterized Drugs Allows for the Potential Development of Tools:

The screening of already approved FDA drugs provides a unique opportunity to screen drugs that often have known targets. By screening compounds with known inhibition targets, pathways can be identified that could be potentially important to fungal spore germination. These compounds can be used to probe fungal spore germination to help understand this critical fungal differentiation process. One of the clearest examples of a potential tool in this study was alexidine hydrochloride, which had strong antifungal activity and was a potent inhibitor of fungal spore germination. See the Examples section. This drug has previously been reported to inhibit phospholipases of *Cryptococcus* (Ganendren et al., 2004). This may suggest that phospholipases are important for viability of fungal spores. The ability of alexidine to inhibit other fungal processes, however, is unclear. In the future, we will use alexidine as a tool to probe the molecular events of phospholipid biosynthesis in fungal spore germination.

Pentamidine, a Potential Antifungal Prophylactic Against *Cryptococcus* Infection:

Screening FDA-approved drugs has the benefit of potential repurposing as these drugs could reach patients in need


sooner than novel compounds. The Examples section shows that pentamidine has huge promise in repurposing for a variety of reasons. Pentamidine, an antiparasitic, is only approved for use against one fungal pathogen, *Pneumocystis*. Pentamidine is approved for use in immunocompromised individuals, which is the primary group of individuals infected by *Cryptococcus* pathogens. Pentamidine already exists in an aerosolized formulation which allows for the drug to build up in the lung, which is the main site where *Cryptococcus* pathogens establish infections. Finally, this drug is already approved for use prophylactically against *Pneumocystis*, which would suggest that pentamidine could be used to protect immunocompromised individuals from cryptococcosis.

The Examples section shows that pentamidine was able to inhibit *Cryptococcus* infectious particles in vitro, was effective at lowering fungal burden in a mouse model of infection and, when used prophylactically, was able to inhibit spore germination in vivo, suggesting that pentamidine can build up in the lung sufficiently to inhibit this stress resistant cell type. The ability to inhibit both cell types, and the nature of this drug, suggest that it could make an ideal prophylactic against *Cryptococcus* pathogens which cause hundreds of thousands of deaths per year in immunocompromised individuals. While pentamidine is often not the first choice for prophylaxis against *Pneumocystis*, the data presented herein shows that pentamidine can be used to protect patients against other fungal pathogens generally and *Cryptococcus* spp. specifically.

Pharmaceutical Compositions:

Using the method disclosed herein, the inventors identified four (4) FDA-approved compounds with germination-inhibiting properties that are effective antifungal therapeutics. These four compounds are disulfiram, pentamidine, otilonium bromide, and benzethonium chloride.

Thus, also disclosed herein are pharmaceutical compositions for inhibiting topical and systemic fungal infection in mammals. The compositions comprise a spore germination-inhibiting amount of a compound selected from the group consisting of:



wherein R is linear or branched C₁₋₁₂ alkyl and "x" is an integer of from 1 to 12, and pharmaceutically suitable salts thereof, in combination with a pharmaceutically suitable vehicle.

The active ingredients may be used in combination with a standard, well-known, non-toxic pharmaceutically suitable carrier, adjuvant or vehicle such as, for example, phosphate buffered saline, water, ethanol, polyols, vegetable oils, a wetting agent or an emulsion such as a water/oil emulsion. The composition may be in either a liquid, solid or semi-solid form. For example, the composition may be in the form of a tablet, capsule, ingestible liquid or powder, injectible, suppository, or topical ointment or cream. Proper fluidity can be maintained, for example, by maintaining appropriate particle size in the case of dispersions and by the use of surfactants. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Besides such inert diluents, the composition may also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents, perfuming agents, and the like.

Suspensions, in addition to the active compounds, may comprise suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth or mixtures of these substances.

Solid dosage forms such as tablets and capsules can be prepared using techniques well known in the art of pharmacy. For example, compounds as described herein can be tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders such as acacia, cornstarch or gelatin, disintegrating agents such as potato starch or alginic acid, and a lubricant such as stearic acid or magnesium stearate. Capsules can be prepared by incorporating these excipients into a gelatin capsule along with antioxidants and the relevant active agent.

For intravenous administration, the compounds may be incorporated into commercial formulations such as Intralipid®-brand fat emulsions for intravenous injection. ("Intralipid" is a registered trademark of Fresenius Kabi AB, Uppsalla, Sweden.) Where desired, the individual components of the formulations may be provided individually, in kit form, for single or multiple use. A typical intravenous dosage of a representative compound as described herein is from about 0.1 mg to 100 mg daily and is preferably from 0.5 mg to 3.0 mg daily. Dosages above and below these stated ranges are specifically within the scope of the claims.

Possible routes of administration of the pharmaceutical compositions include, for example, enteral (e.g., oral and rectal) and parenteral. For example, a liquid preparation may be administered, for example, orally or rectally. Additionally, a homogenous mixture can be completely dispersed in water, admixed under sterile conditions with physiologically acceptable diluents, preservatives, buffers or propellants in order to form a spray or inhalant. The route of administration will, of course, depend upon the desired effect and the medical state of the subject being treated. The dosage of the composition to be administered to the patient may be determined by one of ordinary skill in the art and depends upon various factors such as weight of the patient, age of the patient, immune status of the patient, etc., and is ultimately at the discretion of the medical professional administering the treatment.

With respect to form, the composition may be, for example, a solution, a dispersion, a suspension, an emulsion

or a sterile powder which is then reconstituted. The composition may be administered in a single daily dose or multiple doses.

The present disclosure also includes treating fungal infections (topical and systemic) in mammals, including humans, by administering a spore germination-inhibiting amount of one or more compounds described herein. In particular, the compositions of the present invention may be used to treat fungal infections of any and all description.

The above-described pharmaceutical compositions may be utilized in connection with non-human animals, both domestic and non-domestic, as well as humans.

EXAMPLES

The following examples are included to provide a more complete description of the methods and compositions disclosed and claimed herein. The examples are not intended to limit the scope of the claims in any fashion.

Strain Manipulation, Media and Spore Isolation:

The following strains were used and handled using standard techniques and media as previously described. (Sherman et al., 1987). *Cryptococcus neoformans* serotype D: JEC20, JEC21, JEC20-GFP, JEC21-GFP (Walsh et al. 2018), serotype A: H99, *Candida albicans*: SC5314 and *Aspergillus fumigatus*: AF293. Spores were isolated from cultures as previously described. (Botts et al., 2009). Briefly, yeast of both mating types (JEC20 and JEC21) were grown on YPD for 2 days at 30° C. combined in phosphate buffered saline (PBS) mixed to a 1:1 ratio and spotted onto V8 pH 7 agar plates. Plates were incubated for 5 days at 25° C. and spots were resuspended in 70% Percoll in 1×PBS. Spores were counted using a hemocytometer.

MIC/MFC Experiments:

All minimum inhibitory concentration (MIC) experiments were based on EUCAST methodology. (European Committee on Antimicrobial Susceptibility Testing, a standards-setting committee of the European Society of Clinical Microbiology and Infectious Diseases; EUCAST Development Laboratory for fungi, Statens Serum Institut, Building 211, Artillerivej 5, DK-2300 Copenhagen, Denmark; www.eucast.org.) Yeast cells were grown overnight in liquid YPD and used to inoculate fresh YPD. After 6-hour incubation, yeast cells were washed in 1×PBS and quantified using a hemocytometer. For each drug, 1.25×10^5 yeast cells were incubated in RPMI, and 0.33M MOPS, pH 7 at varying concentrations of inhibitors, with a final volume of 200 μ L. *Cryptococcus neoformans* cells were incubated for 2 days at 30° C. while *Candida albicans* strains were incubated for 2 days at 35° C. OD₆₀₀ readings were used to assess the MIC values for each drug. To determine minimum fungicidal concentrations (MFC) values, 3 μ L per well were plated on YPD and allowed to grow for 2 days. Spinning down of 96-well plates and washing did not alter the read outs of the MFC experiment.

For *Aspergillus fumigatus* MIC, conidia were collected using 0.01% Tween 80 in PBS after 3 days of growth on glucose medium media plates. Conidia at a final concentration of 2×10^4 cells were incubated in RPMI, 0.33 M MOPS, and 2% glucose at pH 7 at varying concentrations of inhibitors, with a final volume of 200 μ L. MIC values were assessed based on the lowest concentration of drug that had complete absence of germ tubes or hyphae.

Quantitative Germination Assay:

All germination assays are based on Barkal et al., 2016. Briefly, microfluidic devices were loaded with 1×10^5 spores, and at 0 hours, SD media with drug of interest, were added

to the sample. Spores were allowed to germinate at 30° C. in a humidified chamber and cells were monitored every two (2) hours for 16 hours. Each assay was performed in two (2) individual wells with three (3) field of views acquired from each well. All images were analyzed as previously described based on cell shape and size. Population ratio of spores, intermediate, and yeast cells were determined. Error bars in plots are based on variation between all fields of view acquired. All experiments were able to be reproduced independently. After the 16-hour experiment, samples were plated on YPD and allowed to grow at 30° C. to determine if drugs were completely germicidal or not based on lack of growth. If assays were unable to be performed in microfluidic devices, the 2×10^5 spores were incubated in identical conditions outside of PDMS devices and only loaded into devices for image acquisition.

Fungal Burden Animal Studies:

All yeast cells were cultured overnight in YPD, washed and diluted to 5×10^6 cells. For JEC20 and JEC21, 2.5×10^6 cells of each were combined. Spores were cultured as previously described and diluted to 2×10^6 cells. All experiments were performed on 8- to 10-week old C57BL/6J (Jackson Laboratory, Bar Harbor, Me., USA) female mice (5 mice per group). All mice were infected intranasally with a total of 50 μ L. All dosing was performed with 4 mg/kg/day or 1×PBS for three (3) days either prior to infection or 1-day post-infection. Mice were sacked day-4 post-infection and lungs were collected, processed, and fungal burden was assessed.

In Vivo Germination:

Female mice, 8- to 10-week-old C57BL/6J (Jackson Laboratory) female mice (3 mice per group) were used. Mice were dosed with either 4mg/kg/day or 1×PBS (50 μ L) for three (3) consecutive days. Mice were intranasally infected with 2×10^6 JEC20-GFPxJEC21-GFP spores, strains described in Walsh et al., 2018. After 8 hours post-infection, mice were sacked and lavaged with 0.05% TirtanX in 1×PBS. Lavage suspension underwent a series of treatments and washes, in order: red blood cell lysis (ACK lysing buffer, 2 mL, 5 minutes), formaldehyde fixation (4%, 500 μ L, 30 minutes) and calcofluor white staining (25 μ g/mL, 20 μ L for 1 minute). Cells (50-100 per mouse) were imaged, and identified as *Cryptococcus neoformans* cells based on green fluorescent signal or cyan staining from calcofluor staining. Cells surface area and aspect ratio were measured in ImageJ and cells were classified as spores, intermediates, or yeast based on size and shapes parameters used in the quantitative germination assay.

Identifying Inhibitors of Germination and Growth

To identify inhibitors of *Cryptococcus neoformans* spore germination, a high throughput screen was developed that utilizes a nanoluciferase construct to monitor whether spores germinate in the presence of inhibitor. Briefly a protein luciferase construct was created resulting in a low luciferase signal for non-germinated spores and a high signal from germinated and replicating cells. The screen was coupled with OD₆₀₀ readings to monitor the ability of compounds to inhibit yeast replication. The examples focused on FDA-approved drugs, as these drugs have the potential of being repurposed into antifungal therapeutics. To determine whether any FDA-approved drugs were able to inhibit *Cryptococcus neoformans* spore germination and yeast replication, the aforementioned high throughput screen was performed on the L1300 Selleck FDA-Approved Drug Library containing an array of 1108 compounds. This library of compounds is available commercially from Selleck Chemicals, 14408 W Sylvanfield Drive, Houston, Tex. 77014, USA.

21

The screening was successful at identifying known anti-fungal drugs as inhibitors of yeast replication as indicated by an OD₆₀₀ signal of less than 75% of the negative control (Table 2). For the purpose of these examples, antifungal drugs were defined as any FDA-approved drug used in the treatment of fungal infections. Of these 23 known antifungal drugs, only six (6) were identified as inhibitors of spore germination, indicated by a luciferase signal of less than 30% of the negative control. These germination inhibitors demonstrated normal nanoluciferase signal dose response curves (data not shown).

TABLE 2

Antifungal drugs used to treat fungal infections and their ability to inhibit <i>Cryptococcus neoformans</i> spore germination (based on luciferase signal) and yeast replication (based on OD ₆₀₀).			
	Drugs	Germination Percent Luciferase Signal	Replication Percent OD ₆₀₀
Inhibitors of Germination (6) Less than 30% Luciferase Signal	Pentamidine HCl	6.5	38.3
	Bifonazole	13.6	33.4
	Econazole nitrate	16.1	33.1
	Isoconazole nitrate	16.8	37.0
	Tioconazole	25.0	36.8
	Miconazole nitrate	25.5	38.2
Non-inhibitors of Germination (17)	Butoconazole nitrate	41.5	33.4
	Fenticonazole nitrate	49.1	36.4
	Naftifine HCl	55.5	34.5
	Sulconazole nitrate	57.8	40.9
	Butenafine HCl	57.5	32.9
	Tolnaftate	60.2	47.3
	Liranaftate	64.8	37.6
	Clotrimazole	65.9	34.1

22

TABLE 2-continued

Antifungal drugs used to treat fungal infections and their ability to inhibit <i>Cryptococcus neoformans</i> spore germination (based on luciferase signal) and yeast replication (based on OD ₆₀₀).		
Drugs	Germination Percent Luciferase Signal	Replication Percent OD ₆₀₀
Fluconazole	84.0	72.2
Amphotericin B	84.6	45.7
Amorolfine HCl	88.6	41.4
Casposfungin acetate	89.7	48.5
Climbazole	151.5	38.9
Ketoconazole	154.8	35.4
Itraconazole	159.6	58.9
Posaconazole	167.2	46.7
Voriconazole	173.9	35.8

In addition to the antifungal drugs from the screen, 60 other inhibitors of yeast replication were identified, 16 of which were also inhibitors of spore germination (Table 3). These inhibitors have a wide range of clinical functions, including quaternary ammonium compounds (“QACs”) and mammalian target of rapamycin (“mTOR” inhibitors (i.e.,) which are known to have broad effects on eukaryotic processes. Some drugs used in treating neurological diseases were also identified. Finally, antimicrobial and antihelminth drugs were also identified to inhibit germination. All compounds, with the exception of doxercalciferol, demonstrated appropriate nanoluciferase dose response curves (data not shown). Only a handful of compounds were pursued further in the examples due to limited availability of certain drugs. Representatives from each group, however, were selected for further characterization. Finally, five inhibitors of only germination were identified (see below).

TABLE 3

FDA-approved drugs able to inhibit spore germination and yeast replication. List of drugs, their ability to inhibit <i>Cryptococcus neoformans</i> spore germination (based on luciferase signal) and yeast replication (based on OD ₆₀₀), as well as their function as listed by L1300 Selleck FDA Approved Drug Library.				
		Germination Percent Luciferase Signal	Replication Percent OD ₆₀₀	Function
Germination and Growth Inhibitors	Cetylpyridinium chloride	4.2	31.9	Infection
	Domiphen bromide	4.4	63.9	Infection
	Cetrimonium bromide	4.4	63.2	Infection
	Alexidine HCl	4.6	29.6	
	Otilonium bromide	6.9	29.0	Cardiovascular Disease
	Benzethonium chloride	6.9	30.3	Neurological Disease
	Niclosamide	7.8	43.4	
	PCI-32765	10.6	70.3	Neurological Disease
	Everolimus	15.7	67.7	Cancer
	Doxercalciferol	17.1	55.2	Endocrinology
	Rapamycin	18.5	61.8	Immunology
	Temsirolimus	21.3	59.2	Cancer
	Ezetimibe	22.0	51.3	Cardiovascular Disease
	Dequalinium chloride	22.3	47.9	
	Disulfiram	22.7	65.6	Neurological Disease
	Biperiden HCl	23.4	56.6	Neurological Disease

Together these results give a set of compounds that are germination inhibitors and replication inhibitors that can be further investigated as potential targets for repurposing or to elucidate germination processes. Inhibitors of both germination and yeast replication were prioritized for further study.

Antifungal Drugs are Inhibitors of Fungal Pathogen Vegetative Growth:

To confirm the ability of the known antifungals to inhibit yeast replication, minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) testing was performed on the top three germination inhibition hits. All three antifungal compounds inhibited replication of *Cryptococcus neoformans* yeast of both serotype A and D, while being less potent against *Candida albicans* (Table 4). All of the antifungal drugs were fungicidal with the exception of bifonazole against H99.

TABLE 4

Ability to inhibit fungal pathogens of antifungal drug germination-inhibitor hits. MIC/MFC values of top three germination inhibitors against prominent human fungal pathogens.				
	<i>Cryptococcus neoformans</i> (JEC21)		<i>Cryptococcus neoformans</i> (H99)	
	MIC (µg/mL)	MFC (µg/mL)	MIC (µg/mL)	MFC (µg/mL)
Pentamidine isethionate	1.56	3.13	6.25	6.25
Bifonazole	6.25	6.25	6.25	>100
Econazole nitrate	<0.78	6.25	<0.78	6.25

	<i>Candida albicans</i> (SC5314)		<i>Aspergillus Fumigatus</i> (AF293)
	MIC (µg/mL)	MFC (µg/mL)	MIC (µg/mL)
Pentamidine isethionate	50	50	>100
Bifonazole	>100	>100	>100
Econazole nitrate	6.25	12.5	3.13

Pentamidine and bifonazole were unable to inhibit *Aspergillus fumigatus* while econazole nitrate was able to inhibit its growth. It is important to note the *Aspergillus fumigatus* inhibition testing is performed on conidia, their asexual spore (Table 4). Together these results confirm the ability of these antifungals to inhibit fungal growth in a fungicidal manner.

Antifungal Drugs are Inhibitors of Fungal Spore Germination:

Once yeast replication inhibition was confirmed, the ability of the drugs to inhibit spore germination was characterized using a quantified microfluidics-based germination assay where the changes in size and morphology are monitored as small ovoid spores germinate into large circular yeast.

Pentamidine isethionate was able to successfully inhibit spore germination as seen by a decrease in morphology transition (data not shown). While germination is not completely halted, the spores were only able to circularize partially and unable to transition into the yeast state. It is important to note that all of the spores were inhibited, indicating that none of the ~10,000 spores showed inherent resistance and escape from inhibition. Due to the hydrophobic nature of bifonazole and econazole nitrate, the PDMS devices resulted in sequestration of the compounds and the assays could not be performed in the microfluidic devices.

To determine if these compounds had an effect on spore germination, the assay was performed outside of the microfluidic device and imaged at 0 and 16 hours. Both econazole nitrate and bifonazole were able to inhibit spore germination effectively with spore escape apparent in bifonazole-treated spores as determined by a yeast population increase. None of these drugs were fully germicidal at these concentrations. These assays confirm that the high throughput screen identified antifungal drugs that are potent inhibitors of spore germination.

FDA Drug Hits are Inhibitors of Fungal Pathogen Vegetative Growth:

To determine the ability of the 16 non-antifungal drugs to inhibit yeast growth, MIC and MFC testing was performed on nine of the 16 drugs. The nine drugs were selected based on dose response curves, drug availability and ensuring that all classes of inhibitors were tested. Seven inhibitors were able to inhibit yeast replication to varying degrees (Table 5) while biperiden HCl and ezetimibe, were unable to inhibit yeast growth (data not shown). All drugs were tested against *Aspergillus fumigatus* with varying degrees of success. Notably alexidine was extremely potent against *A. fumigatus*. Additionally, cetylpyridinium bromide, otilonium bromide, benzethonium chloride and disulfiram were all able to inhibit *A. fumigatus*. (Table 5)

TABLE 5

Ability to inhibit fungal pathogens of FDA drugs germination-inhibitor hits. MIC/MFC values of germination inhibitors against prominent human fungal pathogens.				
	<i>Cryptococcus neoformans</i> (JEC21)		<i>Cryptococcus neoformans</i> (H99)	
	MIC (µg/mL)	MFC (µg/mL)	MIC (µg/mL)	MFC (µg/mL)
Cetylpyridinium chloride	<0.78	<0.78	<0.78	<0.78
Alexidine HCl	<0.78	<0.78	<0.78	<0.78
Otilonium bromide	3.13	3.13	3.13	3.13
Benzethonium chloride	3.13	3.13	3.13	3.13
Niclosamide	<0.78	1.56	1.56	>100
Temsirolimus	6.25	6.25	6.25	6.25
Disulfiram	3.13	3.13	6.25	6.25

	<i>Candida albicans</i> (SC5314)		<i>Aspergillus Fumigatus</i> (AF293)
	MIC (µg/mL)	MFC (µg/mL)	MIC (µg/mL)
Cetylpyridinium chloride	1.56	3.13	1.56
Alexidine HCl	<0.78	<0.78	<0.78
Otilonium bromide	3.13	3.13	6.25
Benzethonium chloride	6.25	12.5	12.5
Niclosamide	>100	>100	>100
Temsirolimus	1.56	1.56	>100
Disulfiram	6.25	12.5	25

These results indicate that these FDA-approved drugs have the ability to inhibit fungal pathogen vegetative growth and kill fungal cells. While some of these drugs have previously been shown to have antifungal activities, some have not.

FDA Drug Hits are Inhibitors of Fungal Spore Germination:

To determine the ability of these seven drugs, which inhibit fungal vegetative growth, to inhibit spore germination; germination assays were performed on the drugs at a

concentration of 25 $\mu\text{g}/\text{mL}$. All seven of these drugs were able to inhibit germination to different extents (data not shown).

Five of the seven drugs were tested in microfluidic devices. Alexidine hydrochloride, an antimicrobial, and otilonium bromide, an antimuscarinic used to treat irritable bowel syndrome, were both able to completely inhibit spore germination, as seen by the lack of change in morphology. Both of these drugs were fully germicidal. Niclosamide, an antihelminth that inhibits oxidative phosphorylation, was also able to completely inhibit germination, but was not fully germicidal. Temozolimolimus, an mTOR inhibitor used in some cancer treatments, was able to partially inhibit germination and appeared to stall germination strongly between 6 and 8 hours. When spores were exposed to temsirolimus they were able to circularize but appeared to have difficulty growing in size. Finally, disulfiram, an alcohol dehydrogenase inhibitor used in the treatment of alcoholism, was a weak inhibitor of germination leading to about a 2-hour stall in germination overall at this concentration. At higher concentrations, a similar stall to that observed with temsirolimus was observed (data not shown). Neither temsirolimus nor disulfiram were germicidal.

Cetylpyridinium chloride and benzethonium chloride, both quaternary ammonium salts, were unable to be tested in the microfluidic devices due to their viscosity and were therefore tested in outside the devices and imaged at 0 and 16 hours. Both drugs were able to inhibit spore germination completely and were fully germicidal at this concentration. These assays confirm that the method disclosed herein has utility to identify a variety of non-antifungal, FDA-approved drugs that are able to inhibit fungal spore germination to varying degrees. These results also start to elucidate potential molecular processes crucial for fungal spore germination.

Pentamidine Ubiquitously Slows Germination:

Pentamidine was selected for further study due to many factors that make it a good candidate for repurposing. A range of concentrations of pentamidine isethionate was tested in a germination assay. As concentrations of pentamidine increased, spore germination became slower. However, no individual spores were able to escape inhibition, as seen by the lack of spores in the yeast state at higher concentrations. While pentamidine was not germicidal at lower concentration, at 50 $\mu\text{g}/\text{mL}$ pentamidine showed germicidal activity. These results suggest that pentamidine slows the germination of spores ubiquitously and at high enough concentrations is sporicidal.

Pentamidine Treatment Lowers Fungal Burden in Mouse Lung:

Pentamidine is a successful inhibitor of *Cryptococcus neoformans* yeast replication in vitro. For repurposing potential, it is important to determine drug efficacy in vivo. For this purpose, the ability of pentamidine to lower the fungal burden in mouse lungs infected by both spores and yeast was determined. One-day post-infection intranasal dosing was begun at 4 mg/kg/day and the mice were treated for three consecutive days. On the fourth day post-infection, lungs were collected and fungal burden was determined. Pentamidine-treated mice had significantly lower fungal burdens in the lung than PBS-treated mice, in both yeast- and spore-infected mice. See FIG. 8A and FIG. 8B, respectively. These results indicate that pentamidine is able to inhibit yeast replication in vivo.

Prophylactic Pentamidine Inhibits Spore Germination In Vivo:

Pentamidine is a successful inhibitor of spore germination in vitro. It is important, though, to determine drug efficacy in vivo. Therefore, the ability of pentamidine to inhibit germination of spores in mouse lungs was determined. To determine if prophylactic pentamidine had an effect on fungal lung burden, mice were treated with 4 mg/kg/day of pentamidine or 1 \times PBS for three consecutive days. After three days of infection, mice were infected with JEC20 \times JEC21 spores and 4-days post infection, mouse lungs were collected and lung fungal burden was determined. The results are shown in FIG. 9. As evidenced by data in FIG. 9, pentamidine prophylaxis was successful in decreasing spore-mediated lung burden. These results indicate that spore germination was inhibited in vivo.

In vivo spore germination has never been characterized mainly due to technical hurdles. Using a novel assay, *Cryptococcus neoformans* cells were recovered from prophylactically treated, spore-infected mouse lungs 8 hours post infection. This was an early enough time point where no budding yeast were recovered from mouse lungs, ensuring that all cells were spore derived and not budding derived. Based on size and shape of the cells, the level of in vivo spore germination was quantified. Prophylactic pentamidine was able to inhibit spore germination as indicated by a higher spore percent and a lower yeast percent in pentamidine-treated mice. Together these results demonstrate that prophylactic pentamidine has in vivo activity against *Cryptococcus neoformans* spores, indicating it is useful to prophylactically treat (i.e., prevent) fungal infection.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 68

<210> SEQ ID NO 1

<211> LENGTH: 804

<212> TYPE: DNA

<213> ORGANISM: *Cryptococcus neoformans*

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(804)

<400> SEQUENCE: 1

atg tct gac gac gga caa gta caa agg gga aag gcc ggc att agc tgg 48
Met Ser Asp Asp Gly Gln Val Gln Arg Gly Lys Ala Gly Ile Ser Trp
1 5 10 15

ccg gct caa gaa cta acc tcg gat ccc att gcc aaa ttc ttc cag tac 96
Pro Ala Gln Glu Leu Thr Ser Asp Pro Ile Ala Lys Phe Phe Gln Tyr

-continued

20				25				30								
ggc	tct	aaa	ctc	tca	tgg	cac	tgg	aac	tgg	acc	aag	cat	tgg	aag	ggc	144
Gly	Ser	Lys	Leu	Ser	Trp	His	Trp	Asn	Trp	Thr	Lys	His	Trp	Lys	Gly	
		35					40					45				
cct	ctg	gtg	ccg	gag	acc	tct	gac	gac	ctt	gag	att	gac	gca	gaa	ttt	192
Pro	Leu	Val	Pro	Glu	Thr	Ser	Asp	Asp	Leu	Glu	Ile	Asp	Ala	Glu	Phe	
	50					55				60						
gtg	ccc	atg	atc	tgg	tca	ccc	caa	tct	tta	gat	gat	ggg	tgc	gac	ttg	240
Val	Pro	Met	Ile	Trp	Ser	Pro	Gln	Ser	Leu	Asp	Asp	Gly	Cys	Asp	Leu	
65				70					75					80		
caa	gaa	gga	tgg	aat	ctt	ctc	ttg	ggt	ttc	aac	gag	cct	gac	ctc	gac	288
Gln	Glu	Gly	Trp	Asn	Leu	Leu	Leu	Gly	Phe	Asn	Glu	Pro	Asp	Leu	Asp	
			85						90					95		
aac	gaa	gct	ggt	gca	agc	cat	cgc	tct	ccg	cag	gaa	gct	gca	gac	gcg	336
Asn	Glu	Ala	Val	Ala	Ser	His	Arg	Ser	Pro	Gln	Glu	Ala	Ala	Asp	Ala	
		100					105					110				
tgg	atc	cag	ctg	gca	caa	ctc	cgt	acc	gat	cca	gac	aac	cag	cac	ctc	384
Trp	Ile	Gln	Leu	Ala	Gln	Leu	Arg	Thr	Asp	Pro	Asp	Asn	Gln	His	Leu	
	115					120						125				
gtt	tcc	ccc	gct	gta	gca	tcc	aac	gtg	gaa	tgg	ctt	aaa	gag	ttc	ctc	432
Val	Ser	Pro	Ala	Val	Ala	Ser	Asn	Val	Glu	Trp	Leu	Lys	Glu	Phe	Leu	
130						135					140					
tcc	ctg	att	cca	gaa	gac	act	tat	ccc	gcc	tac	ttg	gct	gtg	cac	ctc	480
Ser	Leu	Ile	Pro	Glu	Asp	Thr	Tyr	Pro	Ala	Tyr	Leu	Ala	Val	His	Leu	
145			150						155					160		
tac	aca	acc	act	ttt	gat	gat	ttt	gtc	ggc	aag	atg	gag	atg	tac	cac	528
Tyr	Thr	Thr	Thr	Phe	Asp	Asp	Phe	Val	Gly	Lys	Met	Glu	Met	Tyr	His	
			165						170					175		
aac	gag	ttt	gga	ttg	cct	att	atc	ttg	act	gaa	ttc	tgc	atg	cag	agt	576
Asn	Glu	Phe	Gly	Leu	Pro	Ile	Ile	Leu	Thr	Glu	Phe	Cys	Met	Gln	Ser	
		180					185					190				
tgg	gac	gaa	ggt	ggt	cca	ggc	cca	gag	gac	cag	cag	caa	gtc	cat	gat	624
Trp	Asp	Glu	Gly	Val	Pro	Gly	Pro	Glu	Asp	Gln	Gln	Gln	Val	His	Asp	
		195				200						205				
tac	atg	ggc	caa	aca	aca	aaa	tgg	ctt	gat	gaa	act	gac	tat	ggt	att	672
Tyr	Met	Gly	Gln	Thr	Thr	Lys	Trp	Leu	Asp	Glu	Thr	Asp	Tyr	Val	Ile	
	210					215					220					
aag	tac	tgt	tgg	ttt	ggc	gct	ggt	cgt	gat	acg	gcg	aac	ttg	cac	gac	720
Lys	Tyr	Cys	Trp	Phe	Gly	Ala	Val	Arg	Asp	Thr	Ala	Asn	Leu	His	Asp	
225				230					235					240		
gtc	cac	ccc	ttc	aac	cga	ctc	atg	gat	gaa	aac	ggc	gag	att	acc	cca	768
Val	His	Pro	Phe	Asn	Arg	Leu	Met	Asp	Glu	Asn	Gly	Glu	Ile	Thr	Pro	
			245						250					255		
ttg	ggt	ttc	caa	tac	atg	tat	ggt	ggg	cat	gag	taa					804
Leu	Gly	Phe	Gln	Tyr	Met	Tyr	Gly	Gly	His	Glu						
			260				265									

<210> SEQ ID NO 2

<211> LENGTH: 267

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 2

Met	Ser	Asp	Asp	Gly	Gln	Val	Gln	Arg	Gly	Lys	Ala	Gly	Ile	Ser	Trp
1				5					10					15	
Pro	Ala	Gln	Glu	Leu	Thr	Ser	Asp	Pro	Ile	Ala	Lys	Phe	Phe	Gln	Tyr
		20						25					30		
Gly	Ser	Lys	Leu	Ser	Trp	His	Trp	Asn	Trp	Thr	Lys	His	Trp	Lys	Gly
		35					40					45			

-continued

Pro Leu Val Pro Glu Thr Ser Asp Asp Leu Glu Ile Asp Ala Glu Phe
 50 55 60

Val Pro Met Ile Trp Ser Pro Gln Ser Leu Asp Asp Gly Cys Asp Leu
 65 70 75 80

Gln Glu Gly Trp Asn Leu Leu Leu Gly Phe Asn Glu Pro Asp Leu Asp
 85 90 95

Asn Glu Ala Val Ala Ser His Arg Ser Pro Gln Glu Ala Ala Asp Ala
 100 105 110

Trp Ile Gln Leu Ala Gln Leu Arg Thr Asp Pro Asp Asn Gln His Leu
 115 120 125

Val Ser Pro Ala Val Ala Ser Asn Val Glu Trp Leu Lys Glu Phe Leu
 130 135 140

Ser Leu Ile Pro Glu Asp Thr Tyr Pro Ala Tyr Leu Ala Val His Leu
 145 150 155 160

Tyr Thr Thr Thr Phe Asp Asp Phe Val Gly Lys Met Glu Met Tyr His
 165 170 175

Asn Glu Phe Gly Leu Pro Ile Ile Leu Thr Glu Phe Cys Met Gln Ser
 180 185 190

Trp Asp Glu Gly Val Pro Gly Pro Glu Asp Gln Gln Gln Val His Asp
 195 200 205

Tyr Met Gly Gln Thr Thr Lys Trp Leu Asp Glu Thr Asp Tyr Val Ile
 210 215 220

Lys Tyr Cys Trp Phe Gly Ala Val Arg Asp Thr Ala Asn Leu His Asp
 225 230 235 240

Val His Pro Phe Asn Arg Leu Met Asp Glu Asn Gly Glu Ile Thr Pro
 245 250 255

Leu Gly Phe Gln Tyr Met Tyr Gly Gly His Glu
 260 265

<210> SEQ ID NO 3
 <211> LENGTH: 1821
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1821)

<400> SEQUENCE: 3

atg tcg acc ctt ccc att tat cac ccc gtt cca acg gac gag aaa cac	48
Met Ser Thr Leu Pro Ile Tyr His Pro Val Pro Thr Asp Glu Lys His	
1 5 10 15	
cca ata tct gcc act ttg gta gac ggc gag ttt gac cct cgc tac att	96
Pro Ile Ser Ala Thr Leu Val Asp Gly Glu Phe Asp Pro Arg Tyr Ile	
20 25 30	
cat ccc gcc gca atc ggc tct caa tac ctt tat att ggc ggt ccc cgc	144
His Pro Ala Ala Ile Gly Ser Gln Tyr Leu Tyr Ile Gly Gly Pro Arg	
35 40 45	
agc gcc tat cag gcc gcg aag gac aag tac gct ggc ttg tcc aaa gtc	192
Ser Ala Tyr Gln Ala Ala Lys Asp Lys Tyr Ala Gly Leu Ser Lys Val	
50 55 60	
aag aaa ggt ctc ctc gct ctt gcc gtt gtt tgg ttc ggt ctt gtc gtt	240
Lys Lys Gly Leu Leu Ala Leu Ala Val Val Trp Phe Gly Leu Val Val	
65 70 75 80	
ggc cat cag gct gcg cgt ctt gct ggc ggc aaa tgc cac cag gac gct	288
Gly His Gln Ala Ala Arg Leu Ala Gly Gly Lys Cys His Gln Asp Ala	
85 90 95	
cat cat gct ccc gcc gaa ttt ggc gtg aag cag tgg aga gac cac tca	336
His His Ala Pro Ala Glu Phe Gly Val Lys Gln Trp Arg Asp His Ser	

-continued

100				105				110								
tct	cat	cga	ttt	ggt	ggc	cct	atc	ttc	ctc	gag	gat	ggt	cca	ctt	gac	384
Ser	His	Arg	Phe	Gly	Gly	Pro	Ile	Phe	Leu	Glu	Asp	Gly	Pro	Leu	Asp	
		115					120					125				
tgt	cat	ggt	ggc	cgt	aaa	gac	cgt	gct	cct	gag	gag	ctt	tct	tcc	gtt	432
Cys	His	Gly	Gly	Arg	Lys	Asp	Arg	Ala	Pro	Glu	Glu	Leu	Ser	Ser	Val	
		130				135					140					
gcc	act	gtc	tac	gag	tcc	atc	aac	ggt	gtc	ggg	agc	aac	gat	gct	acc	480
Ala	Thr	Val	Tyr	Glu	Ser	Ile	Asn	Val	Val	Gly	Ser	Asn	Asp	Ala	Thr	
		145			150					155				160		
gac	att	ctc	tcc	gcc	aac	gcc	tct	ttc	cct	ctc	aaa	ctt	ggc	cgt	ggc	528
Asp	Ile	Leu	Ser	Ala	Asn	Ala	Ser	Phe	Pro	Leu	Lys	Leu	Gly	Arg	Gly	
			165						170					175		
aag	cac	ttt	gat	ctc	acc	ttc	caa	ggt	gag	ggt	aac	gtc	atc	atc	tcg	576
Lys	His	Phe	Asp	Leu	Thr	Phe	Gln	Gly	Glu	Gly	Asn	Val	Ile	Ile	Ser	
		180					185					190				
agg	gct	gag	gag	gag	tct	gaa	gac	tct	act	gtc	aac	ggt	ttt	ggt	gag	624
Arg	Ala	Glu	Glu	Glu	Ser	Glu	Asp	Ser	Thr	Val	Asn	Val	Phe	Val	Glu	
		195				200					205					
tct	act	tgg	tcc	ggt	gag	gag	gct	gaa	ggg	gtc	aag	atg	ttg	tct	gga	672
Ser	Thr	Trp	Ser	Gly	Glu	Glu	Ala	Glu	Gly	Val	Lys	Met	Leu	Ser	Gly	
		210				215					220					
aaa	cac	tct	cac	gct	ctc	tct	ggt	gct	tct	tct	caa	tcc	tcg	tct	cat	720
Lys	His	Ser	His	Ala	Leu	Ser	Val	Ala	Ser	Ser	Gln	Ser	Ser	Ser	His	
		225			230					235					240	
att	gtc	cac	ctt	ggt	ctt	cct	gcc	aac	aag	aag	cgt	ctt	cct	tcc	atc	768
Ile	Val	His	Leu	Val	Leu	Pro	Ala	Asn	Lys	Lys	Arg	Leu	Pro	Ser	Ile	
			245						250					255		
tct	atc	ttt	tct	acc	aag	gac	ctt	act	ctt	gat	atc	cat	cca	tct	ggt	816
Ser	Ile	Phe	Ser	Thr	Lys	Asp	Leu	Thr	Leu	Asp	Ile	His	Pro	Ser	Val	
			260				265						270			
cag	gac	atc	cac	gtg	gga	aag	ctc	tcc	ctc	aag	tct	gag	agc	ggt	gat	864
Gln	Asp	Ile	His	Val	Gly	Lys	Leu	Ser	Leu	Lys	Ser	Glu	Ser	Gly	Asp	
		275				280						285				
atc	aag	ctt	cct	acc	ctc	gct	gtc	aac	aag	ctc	gtg	gct	gag	acc	gta	912
Ile	Lys	Leu	Pro	Thr	Leu	Ala	Val	Asn	Lys	Leu	Val	Ala	Glu	Thr	Val	
		290				295					300					
acc	ggt	gac	gtc	ggc	ggt	aac	ttc	aac	gtc	agc	aac	tct	ttc	ggt	gtc	960
Thr	Gly	Asp	Val	Gly	Asn	Phe	Asn	Val	Ser	Asn	Ser	Phe	Val	Val		
		305			310				315					320		
aag	aca	gtc	aca	ggt	aac	att	aac	gcc	att	ggt	aac	ggt	ggt	cct	cac	1008
Lys	Thr	Val	Thr	Gly	Asn	Ile	Asn	Ala	Ile	Val	Asn	Val	Val	Pro	His	
			325						330					335		
tcc	cca	cct	aag	gac	aag	ctt	aac	ctt	cat	aac	ggt	gat	gcc	aag	cac	1056
Ser	Pro	Pro	Lys	Asp	Lys	Leu	Asn	Leu	His	Asn	Val	Asp	Ala	Lys	His	
			340				345					350				
gag	cac	aag	aag	ttt	gac	agc	cgt	cac	gga	gaa	cac	aat	cac	gag	aag	1104
Glu	His	Lys	Lys	Phe	Asp	Ser	Arg	His	Gly	Glu	His	Asn	His	Glu	Lys	
		355				360						365				
aag	cac	ttc	gga	ggg	cgt	ttc	cac	tct	gaa	gaa	gag	cga	cct	tcc	aag	1152
Lys	His	Phe	Gly	Gly	Arg	Phe	His	Ser	Glu	Glu	Glu	Arg	Pro	Ser	Lys	
		370				375					380					
tgg	tct	ctc	aat	att	ttc	aag	tct	aag	aaa	gag	gat	gag	cct	gaa	cac	1200
Trp	Ser	Leu	Asn	Ile	Phe	Lys	Ser	Lys	Lys	Glu	Asp	Glu	Pro	Glu	His	
			385		390				395					400		
cct	ccc	ccc	cct	ccg	gtc	ttt	atc	ggc	gct	ttc	tcc	acc	tct	ggc	aac	1248
Pro	Pro	Pro	Pro	Pro	Val	Phe	Ile	Gly	Ala	Phe	Ser	Thr	Ser	Gly	Asn	
			405						410					415		
att	ctt	ctc	aag	gtc	ttc	ggt	tct	ccc	aac	gtc	tct	act	gat	act	aat	1296

-continued

Ile	Leu	Leu	Lys	Val	Phe	Gly	Ser	Pro	Asn	Val	Ser	Thr	Asp	Thr	Asn	
			420					425					430			
gtc	ttc	tcc	cat	acc	ggt	gac	gtc	gac	ggt	acc	cat	gac	aag	tca	ttc	1344
Val	Phe	Ser	His	Thr	Gly	Asp	Val	Asp	Val	Thr	His	Asp	Lys	Ser	Phe	
		435					440					445				
cac	ggt	ttg	tac	gag	gtc	ggc	agc	tta	aag	ggc	acc	tat	gat	ggt	gtc	1392
His	Gly	Leu	Tyr	Glu	Val	Gly	Ser	Leu	Lys	Gly	Thr	Tyr	Asp	Val	Val	
		450				455					460					
gtg	agg	gac	ggc	aag	gtg	cat	cga	gtc	ctg	gag	gaa	tac	gtc	act	gag	1440
Val	Arg	Asp	Gly	Lys	Val	His	Arg	Val	Leu	Glu	Glu	Tyr	Val	Thr	Glu	
		465			470				475						480	
gag	gga	ggc	aag	cag	aag	ggc	ctt	gcc	ttc	ggt	ccc	aag	aac	aga	aag	1488
Glu	Gly	Gly	Lys	Gln	Lys	Gly	Leu	Ala	Phe	Val	Pro	Lys	Asn	Arg	Lys	
			485						490					495		
act	gag	ggc	tcc	cac	gag	aag	agg	cac	ttc	cgc	aat	gct	gaa	agc	gtt	1536
Thr	Glu	Gly	Ser	His	Glu	Lys	Arg	His	Phe	Arg	Asn	Ala	Glu	Ser	Val	
			500					505					510			
gat	ggc	gag	ctt	ccc	cct	ccc	cct	cct	ggt	aag	ggc	cac	ggt	cct	gat	1584
Asp	Gly	Glu	Leu	Pro	Pro	Pro	Pro	Pro	Gly	Lys	Gly	His	Gly	Pro	Asp	
		515					520					525				
ggt	ccc	gat	ggt	cct	gat	ggt	cct	gga	ggt	cct	agt	ggt	cct	gga	ggt	1632
Gly	Pro	Asp	Gly	Pro	Asp	Gly	Pro	Gly	Gly	Pro	Ser	Gly	Pro	Gly	Gly	
		530				535					540					
cct	ggt	ggt	cct	gat	ggt	cct	ggt	ggt	cct	ggt	ggt	cct	ggt	ggc	cct	1680
Pro	Gly	Gly	Pro	Asp	Gly	Pro	Gly	Gly	Pro	Gly	Gly	Pro	Gly	Gly	Pro	
		545			550				555					560		
gga	ggt	ccc	ggt	ggt	ccc	ggt	ggt	ccc	ggt	ggt	ccc	ggc	ccc	gac	cac	1728
Gly	Gly	Pro	Gly	Gly	Pro	Gly	Gly	Pro	Gly	Gly	Pro	Gly	Pro	Asp	His	
			565						570					575		
ccc	cgt	ggt	cct	cct	cct	tgg	ggt	gtc	ttc	ccc	ccc	ggt	cac	tca	gaa	1776
Pro	Arg	Gly	Pro	Pro	Pro	Trp	Val	Val	Phe	Pro	Pro	Gly	His	Ser	Glu	
			580				585						590			
gtc	ttc	gtc	cac	act	gaa	ggt	ggc	aac	gcc	aag	att	gtc	ctc	taa		1821
Val	Phe	Val	His	Thr	Glu	Val	Gly	Asn	Ala	Lys	Ile	Val	Leu			
		595				600						605				

<210> SEQ ID NO 4
 <211> LENGTH: 606
 <212> TYPE: PRT
 <213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 4

Met	Ser	Thr	Leu	Pro	Ile	Tyr	His	Pro	Val	Pro	Thr	Asp	Glu	Lys	His
1				5					10					15	
Pro	Ile	Ser	Ala	Thr	Leu	Val	Asp	Gly	Glu	Phe	Asp	Pro	Arg	Tyr	Ile
			20					25					30		
His	Pro	Ala	Ala	Ile	Gly	Ser	Gln	Tyr	Leu	Tyr	Ile	Gly	Gly	Pro	Arg
		35					40					45			
Ser	Ala	Tyr	Gln	Ala	Ala	Lys	Asp	Lys	Tyr	Ala	Gly	Leu	Ser	Lys	Val
		50				55					60				
Lys	Lys	Gly	Leu	Leu	Ala	Leu	Ala	Val	Val	Trp	Phe	Gly	Leu	Val	Val
65					70				75					80	
Gly	His	Gln	Ala	Ala	Arg	Leu	Ala	Gly	Gly	Lys	Cys	His	Gln	Asp	Ala
			85					90						95	
His	His	Ala	Pro	Ala	Glu	Phe	Gly	Val	Lys	Gln	Trp	Arg	Asp	His	Ser
			100					105					110		
Ser	His	Arg	Phe	Gly	Gly	Pro	Ile	Phe	Leu	Glu	Asp	Gly	Pro	Leu	Asp
			115				120					125			

-continued

<400> SEQUENCE: 6

```

Met Arg Phe Thr Ser Ile Ile Val Ala Ala Leu Pro Leu Val Gly Ser
1           5           10           15
Val Phe Ala Ala Pro Phe Ala Glu Lys Asp Ser Ile Ala Ser Ser Pro
          20           25           30
Asp Leu Val Lys Lys Glu Val Asn Val Leu Ser Val Val Asn Glu Val
          35           40           45
Gln Ser Arg Val Asn Ala Ala Ala Ala Met Pro Arg Gln Ser Gln Ala
          50           55           60
Asp Val Glu Ala Cys Leu Asn Thr Val Ile Asp Ala Phe Asn Trp Cys
          65           70           75           80
Gly Gly Gln Leu Gly Ile Asp Val Ser Ala Ser Ala Ser Ala Asn Ala
          85           90           95
Gly Ala Ser Ile His Tyr Leu Arg Arg Glu Ile Ile Ala Arg Asp Asp
          100          105          110
Asp Lys Glu Ala Val Ala Gln Ala Leu Ser Ser Val Val Gln Thr Val
          115          120          125
Asn Val Gly Ile Val Gln Gln Ile Pro Ser Gln Phe Ile Asn Ile Pro
          130          135          140
Gly Val Ser Asn Leu Val Asn Gln Leu Asp Ile Ala Leu Ser Leu Ile
          145          150          155          160
Leu Lys Gly Val Asp Ala Ile Leu Ala Gly Val Leu Tyr Leu Val Lys
          165          170          175
Ala Leu Leu Ile Asp Val Gly Ile Ile Leu Asp Ser Leu Leu Gly Gly
          180          185          190
Leu Leu Ser Ile Leu
          195

```

<210> SEQ ID NO 7

<211> LENGTH: 894

<212> TYPE: DNA

<213> ORGANISM: Cryptococcus neoformans

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(894)

<400> SEQUENCE: 7

```

atg tct gcc gtc gaa gca ccc tcc gcc tcg cag gcc atc tgg ccc gag      48
Met Ser Ala Val Glu Ala Pro Ser Ala Ser Gln Ala Ile Trp Pro Glu
1           5           10           15
ctc act gaa gac cac ccc ctt tcg cag ctc aac tct cgc ctc cct act      96
Leu Thr Glu Asp His Pro Leu Ser Gln Leu Asn Ser Arg Leu Pro Thr
          20           25           30
atc ctt tca gag gct ggt cac tcc caa atc tgg ggc gtt act ctt act      144
Ile Leu Ser Glu Ala Gly His Ser Gln Ile Trp Gly Val Thr Leu Thr
          35           40           45
tac tcc act ccc cca acc ttc tct agc ctt att att ctg caa aaa ttc      192
Tyr Ser Thr Pro Pro Thr Phe Ser Ser Leu Ile Ile Leu Gln Lys Phe
          50           55           60
ctt cgt tcc gtg gat aat aac gtg gat gag gct gcc acg gct cta ggc      240
Leu Arg Ser Val Asp Asn Asn Val Asp Glu Ala Ala Thr Ala Leu Gly
          65           70           75           80
aag aca ctc aag tgg cgg aag gac tgg gga ttg gac gcg cgg gcg gac      288
Lys Thr Leu Lys Trp Arg Lys Asp Trp Gly Leu Asp Ala Arg Ala Asp
          85           90           95
aaa aaa gag aag gaa aac ttt ggg ccc gat ttt gaa ggc tta gga tat      336
Lys Lys Glu Lys Glu Asn Phe Gly Pro Asp Phe Glu Gly Leu Gly Tyr

```

-continued

100				105				110								
gtg	acc	aag	atc	aag	aaa	aat	gat	ggc	gga	gat	gag	atc	gtg	act	tgg	384
Val	Thr	Lys	Ile	Lys	Lys	Asn	Asp	Gly	Gly	Asp	Glu	Ile	Val	Thr	Trp	
		115					120					125				
aac	ggt	tat	gga	gct	gtg	aag	gat	ttg	aaa	tcg	acc	ttt	ggg	gat	ctt	432
Asn	Val	Tyr	Gly	Ala	Val	Lys	Asp	Leu	Lys	Ser	Thr	Phe	Gly	Asp	Leu	
		130				135					140					
gac	cga	ttc	ctt	cga	tgg	cgt	gtc	aat	ctt	atg	gag	gag	gct	atc	gcc	480
Asp	Arg	Phe	Leu	Arg	Trp	Arg	Val	Asn	Leu	Met	Glu	Glu	Ala	Ile	Ala	
		145			150					155				160		
cat	ctt	cat	ctc	gct	acc	acc	tct	act	ccc	atc	cca	gac	ttt	aac	gcc	528
His	Leu	His	Leu	Ala	Thr	Thr	Ser	Thr	Pro	Ile	Pro	Asp	Phe	Asn	Ala	
			165					170						175		
ggt	att	gat	ccc	cat	cgc	atg	gca	caa	gtc	cat	cta	tat	gaa	ggt	gtc	576
Gly	Ile	Asp	Pro	His	Arg	Met	Ala	Gln	Val	His	Leu	Tyr	Glu	Gly	Val	
		180					185					190				
tca	ttc	ctt	cgc	atg	gat	cct	cat	gtg	aaa	gct	gcc	tcc	aag	gca	acc	624
Ser	Phe	Leu	Arg	Met	Asp	Pro	His	Val	Lys	Ala	Ala	Ser	Lys	Ala	Thr	
		195				200						205				
att	gag	ctt	atg	gcg	gcc	aac	tat	ccc	gaa	ctt	ctt	tct	cgc	aaa	ttc	672
Ile	Glu	Leu	Met	Ala	Ala	Asn	Tyr	Pro	Glu	Leu	Leu	Ser	Arg	Lys	Phe	
		210				215					220					
ttt	gtg	ggc	gtg	cct	ttg	ata	atg	agc	tgg	atg	ttt	cag	gcc	gtg	cga	720
Phe	Val	Gly	Val	Pro	Leu	Ile	Met	Ser	Trp	Met	Phe	Gln	Ala	Val	Arg	
		225			230				235					240		
atg	ttc	ggt	tcc	gct	gag	act	gcc	aag	aag	ttt	gtg	gtc	att	agc	tac	768
Met	Phe	Val	Ser	Ala	Glu	Thr	Ala	Lys	Lys	Phe	Val	Val	Ile	Ser	Tyr	
			245					250					255			
aag	gag	aat	ctg	gcg	aat	gag	ctg	gga	gaa	ctt	gaa	ggt	gtg	ccc	aag	816
Lys	Glu	Asn	Leu	Ala	Asn	Glu	Leu	Gly	Glu	Leu	Glu	Gly	Val	Pro	Lys	
			260			265						270				
gag	tat	ggt	gga	aag	ggt	ctc	agt	ttg	ggc	gaa	ctt	cag	aac	cag	ctg	864
Glu	Tyr	Gly	Gly	Lys	Gly	Leu	Ser	Leu	Gly	Glu	Leu	Gln	Asn	Gln	Leu	
		275				280						285				
cga	ggg	gag	gac	gcg	gtg	act	tct	tcg	taa							894
Arg	Gly	Glu	Asp	Ala	Val	Thr	Ser	Ser								
		290				295										
<210> SEQ ID NO 8																
<211> LENGTH: 297																
<212> TYPE: PRT																
<213> ORGANISM: Cryptococcus neoformans																
<400> SEQUENCE: 8																
Met	Ser	Ala	Val	Glu	Ala	Pro	Ser	Ala	Ser	Gln	Ala	Ile	Trp	Pro	Glu	
1			5					10						15		
Leu	Thr	Glu	Asp	His	Pro	Leu	Ser	Gln	Leu	Asn	Ser	Arg	Leu	Pro	Thr	
		20					25						30			
Ile	Leu	Ser	Glu	Ala	Gly	His	Ser	Gln	Ile	Trp	Gly	Val	Thr	Leu	Thr	
		35				40						45				
Tyr	Ser	Thr	Pro	Pro	Thr	Phe	Ser	Ser	Leu	Ile	Ile	Leu	Gln	Lys	Phe	
		50				55					60					
Leu	Arg	Ser	Val	Asp	Asn	Val	Asp	Glu	Ala	Ala	Thr	Ala	Leu	Gly		
65					70				75					80		
Lys	Thr	Leu	Lys	Trp	Arg	Lys	Asp	Trp	Gly	Leu	Asp	Ala	Arg	Ala	Asp	
			85					90						95		
Lys	Lys	Glu	Lys	Glu	Asn	Phe	Gly	Pro	Asp	Phe	Glu	Gly	Leu	Gly	Tyr	
			100					105						110		

-continued

Val Thr Lys Ile Lys Lys Asn Asp Gly Gly Asp Glu Ile Val Thr Trp
 115 120 125

Asn Val Tyr Gly Ala Val Lys Asp Leu Lys Ser Thr Phe Gly Asp Leu
 130 135 140

Asp Arg Phe Leu Arg Trp Arg Val Asn Leu Met Glu Glu Ala Ile Ala
 145 150 155 160

His Leu His Leu Ala Thr Thr Ser Thr Pro Ile Pro Asp Phe Asn Ala
 165 170 175

Gly Ile Asp Pro His Arg Met Ala Gln Val His Leu Tyr Glu Gly Val
 180 185 190

Ser Phe Leu Arg Met Asp Pro His Val Lys Ala Ala Ser Lys Ala Thr
 195 200 205

Ile Glu Leu Met Ala Ala Asn Tyr Pro Glu Leu Leu Ser Arg Lys Phe
 210 215 220

Phe Val Gly Val Pro Leu Ile Met Ser Trp Met Phe Gln Ala Val Arg
 225 230 235 240

Met Phe Val Ser Ala Glu Thr Ala Lys Lys Phe Val Val Ile Ser Tyr
 245 250 255

Lys Glu Asn Leu Ala Asn Glu Leu Gly Glu Leu Glu Gly Val Pro Lys
 260 265 270

Glu Tyr Gly Gly Lys Gly Leu Ser Leu Gly Glu Leu Gln Asn Gln Leu
 275 280 285

Arg Gly Glu Asp Ala Val Thr Ser Ser
 290 295

<210> SEQ ID NO 9
 <211> LENGTH: 2094
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(2094)

<400> SEQUENCE: 9

atg tca gag cta ttc aag gac atc cca gag ttt gta gag acc gac atc	48
Met Ser Glu Leu Phe Lys Asp Ile Pro Glu Phe Val Glu Thr Asp Ile	
1 5 10 15	
gga gag agc ctt gca gcc aga acg gaa acc ctt ggc tcc ttc aga gaa	96
Gly Glu Ser Leu Ala Ala Arg Thr Glu Thr Leu Gly Ser Phe Arg Glu	
20 25 30	
cta ggc cct cca gac ctc tgc cat gtt atg aaa gtt tat ggg aaa ccg	144
Leu Gly Pro Pro Asp Leu Cys His Val Met Lys Val Tyr Gly Lys Pro	
35 40 45	
ccg act caa cga gag atc ggg tcc tat cac tac tgc tct gga ata gag	192
Pro Thr Gln Arg Glu Ile Gly Ser Tyr His Tyr Cys Ser Gly Ile Glu	
50 55 60	
gct tcg tcc tct gcg tca ctc gct gcc tat ctc aac tct ttg cag ttt	240
Ala Ser Ser Ser Ala Ser Leu Ala Ala Tyr Leu Asn Ser Leu Gln Phe	
65 70 75 80	
tca gtg gaa gat tcg tct gca tgg ttt ggc aag ggg tcg gca tgg aaa	288
Ser Val Glu Asp Ser Ser Ala Trp Phe Gly Lys Gly Ser Ala Trp Lys	
85 90 95	
gtt cga agc ggg acg tat tgc tgc ttc aat gcc ttt tca cgg gta gat	336
Val Arg Ser Gly Thr Tyr Cys Cys Phe Asn Ala Phe Ser Arg Val Asp	
100 105 110	
atg cgg gtg gaa gcc aat att ccc gcc ggt gtc gac gct ttt gtg gtt	384
Met Arg Val Glu Ala Asn Ile Pro Gly Gly Val Asp Ala Phe Val Val	
115 120 125	

-continued

gat ctt cac ggt caa aga cac cct gcg acc ccc gag ctc tgg caa gag	432
Asp Leu His Gly Gln Arg His Pro Ala Thr Pro Glu Leu Trp Gln Glu	
130 135 140	
acg tac ctg tct gcg atc ctg cgt gct att aga tat gcg gac gat gcc	480
Thr Tyr Leu Ser Ala Ile Leu Arg Ala Ile Arg Tyr Ala Asp Asp Ala	
145 150 155 160	
tcc tat agg ttg gca ggg tat aga aag ctg gat ccg atc aca acg cca	528
Ser Tyr Arg Leu Ala Gly Tyr Arg Lys Leu Asp Pro Ile Thr Thr Pro	
165 170 175	
gaa gca gag gaa aga ttc ctc aaa gcc gcc gaa gcg ctg ttc ttc aag	576
Glu Ala Glu Glu Arg Phe Leu Lys Ala Ala Glu Ala Leu Phe Phe Lys	
180 185 190	
ggc tgg cag ctt ggc tca gat ccc gaa ata cag gtc gcc aca gtt gtc	624
Gly Trp Gln Leu Gly Ser Asp Pro Glu Ile Gln Val Ala Thr Val Val	
195 200 205	
acc aac cac ctg acc tct gcc att ctt aaa tac ttt tcc gac tct ttc	672
Thr Asn His Leu Thr Ser Ala Ile Leu Lys Tyr Phe Ser Asp Ser Phe	
210 215 220	
aga ctt cat cga gcc gcc aac ctt ttc gaa agg atg atg gac aag gag	720
Arg Leu His Arg Ala Ala Asn Leu Phe Glu Arg Met Met Asp Lys Glu	
225 230 235 240	
cca gag gta gcc gct cta gtg gcg aag agt tac atc gcc atg aac gag	768
Pro Glu Val Ala Ala Leu Val Ala Lys Ser Tyr Ile Gly Met Asn Glu	
245 250 255	
gag atc aaa gct gtc aag atc atg aac gct gcc ctt gcc gcc aat cct	816
Glu Ile Lys Ala Val Lys Ile Met Asn Ala Ala Leu Ala Ala Asn Pro	
260 265 270	
caa tcc tat ccc atc ctt cat gcc caa gtc gat ttc ctc ctt tcc aag	864
Gln Ser Tyr Pro Ile Leu His Ala Gln Val Asp Phe Leu Leu Ser Lys	
275 280 285	
cac aaa tac gaa tgg gcc cag caa gtc gcc cag cag gcg gtc aat tct	912
His Lys Tyr Glu Trp Ala Gln Gln Val Ala Gln Gln Ala Val Asn Ser	
290 295 300	
gca ccc agc gag ttc acg act tgg gcc aaa ctc acg gag acg tac atc	960
Ala Pro Ser Glu Phe Thr Thr Trp Ala Lys Leu Thr Thr Glu Thr Tyr Ile	
305 310 315 320	
gag ttg ggg caa ctc gac cag gct ttg ttg aca ctc aac tca tgt cca	1008
Glu Leu Gly Gln Leu Asp Gln Ala Leu Leu Thr Leu Asn Ser Cys Pro	
325 330 335	
atg ttt act tat aac gaa aga gat ctc cat cgg atg cct acc cct gca	1056
Met Phe Thr Tyr Asn Glu Arg Asp Leu His Arg Met Pro Thr Pro Ala	
340 345 350	
aag tcc aat atg cca gtc aag aag ttt atc gca gac tcc aat ttg gtg	1104
Lys Ser Asn Met Pro Val Lys Lys Phe Ile Ala Asp Ser Asn Leu Val	
355 360 365	
gat gaa gat tgg tca cga gag aac gag gcc gat atc gct ctc ctc cgt	1152
Asp Glu Asp Ser Ser Arg Glu Asn Glu Ala Asp Ile Ala Leu Leu Arg	
370 375 380	
ctc ccc gct ccc aac ctc cgc ggc aca ttc gcc aaa gcg tac tcc ctc	1200
Leu Pro Ala Pro Asn Leu Arg Gly Thr Phe Ala Lys Ala Tyr Ser Leu	
385 390 395 400	
ctc act ctc ctt gtc tct aag att ggt tgg gat gag ctt ctc aaa att	1248
Leu Thr Leu Leu Val Ser Lys Ile Gly Trp Asp Glu Leu Leu Lys Ile	
405 410 415	
aga tcc tcc gtc ttc gtc atg gaa gag gaa tat cgg ctg cat aaa acg	1296
Arg Ser Ser Val Phe Val Met Glu Glu Tyr Arg Leu His Lys Thr	
420 425 430	
aac gtt tct gtt gat atg aat ggc gaa gcg ggt gac ggc gcg tcc att	1344
Asn Val Ser Val Asp Met Asn Gly Glu Ala Gly Asp Gly Ala Ser Ile	
435 440 445	

-continued

gcg ggc ttg aag agg acc tcg tcc gaa gag gtc aac act ccc agc gat 1392
Ala Gly Leu Lys Arg Thr Ser Ser Glu Glu Val Asn Thr Pro Ser Asp
450 455 460

ata cct acc atc agg ata tca agc gag tcg atg cgc act cct aat acg 1440
Ile Pro Thr Ile Arg Ile Ser Ser Glu Ser Met Arg Thr Pro Asn Thr
465 470 475 480

gct cca gga cca ggg ttc agc gaa aag gca agt act cac aag ccc gct 1488
Ala Pro Gly Pro Gly Phe Ser Glu Lys Ala Ser Thr His Lys Pro Ala
485 490 495

ctg gag aag ccc gag aca gca caa gcg aat gaa gat ccc aat tcg cct 1536
Leu Glu Lys Pro Glu Thr Ala Gln Ala Asn Glu Asp Pro Asn Ser Pro
500 505 510

ttg ggg atg aag agt gaa ggg gaa cag ccg gtt tcg gcg ttt tct cat 1584
Leu Gly Met Lys Ser Glu Gly Glu Gln Pro Val Ser Ala Phe Ser His
515 520 525

aag cga tta tgt gag aga tgg tta gat aac ctc ttt tta gtt ctg tat 1632
Lys Arg Leu Cys Glu Arg Trp Leu Asp Asn Leu Phe Leu Val Leu Tyr
530 535 540

gaa gac ttg aga gtc tac acc att tgg aga gca gag ata tct cat ttc 1680
Glu Asp Leu Arg Val Tyr Thr Ile Trp Arg Ala Glu Ile Ser His Phe
545 550 555 560

aaa acc cag cac atg tca tac cga aag act ggt acc gag tgg gag atc 1728
Lys Thr Gln His Met Ser Tyr Arg Lys Thr Gly Thr Glu Trp Glu Ile
565 570 575

ctt ggt gaa ctt gcc aca cgt ttg cat cac aaa gaa gaa gcc aag gac 1776
Leu Gly Glu Leu Ala Thr Arg Leu His His Lys Glu Glu Ala Lys Asp
580 585 590

gcg tac caa cgc tgt ctc gac tcc aaa ttc agc gca aaa gca ctt atg 1824
Ala Tyr Gln Arg Cys Leu Asp Ser Lys Phe Ser Ala Lys Ala Leu Met
595 600 605

aag ctt ctt gaa acg tat gcg aat gag ggc gat ctt caa aag acc ttg 1872
Lys Leu Leu Glu Thr Tyr Ala Asn Glu Gly Asp Leu Gln Lys Thr Leu
610 615 620

acg gcg gct gtg agg ctg aca acc tat cac cat cga tgg tat atg gac 1920
Thr Ala Ala Val Arg Leu Thr Thr Tyr His His Arg Trp Tyr Met Asp
625 630 635 640

gcg tca tac ccg tcc atg gtc gcg cat tat ttg tac aag gtc gga ctc 1968
Ala Ser Tyr Pro Ser Met Val Ala His Tyr Leu Tyr Lys Val Gly Leu
645 650 655

ata cat gga cat gcc aaa tta caa tac aca atg ctc agt atg aac ctg 2016
Ile His Gly His Ala Lys Leu Gln Tyr Thr Met Leu Ser Met Asn Leu
660 665 670

ccg gtc ggg atc ttt gaa ata atg caa ggc tat atg aaa tac ggg gcg 2064
Pro Val Gly Ile Phe Glu Ile Met Gln Gly Tyr Met Lys Tyr Gly Ala
675 680 685

acg ttc aac gtc gaa ggt tca gaa ttc tag 2094
Thr Phe Asn Val Glu Gly Ser Glu Phe
690 695

<210> SEQ ID NO 10

<211> LENGTH: 697

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 10

Met Ser Glu Leu Phe Lys Asp Ile Pro Glu Phe Val Glu Thr Asp Ile
1 5 10 15

Gly Glu Ser Leu Ala Ala Arg Thr Glu Thr Leu Gly Ser Phe Arg Glu
20 25 30

-continued

450		455		460												
Ile	Pro	Thr	Ile	Arg	Ile	Ser	Ser	Glu	Ser	Met	Arg	Thr	Pro	Asn	Thr	
465					470					475					480	
Ala	Pro	Gly	Pro	Gly	Phe	Ser	Glu	Lys	Ala	Ser	Thr	His	Lys	Pro	Ala	
				485					490					495		
Leu	Glu	Lys	Pro	Glu	Thr	Ala	Gln	Ala	Asn	Glu	Asp	Pro	Asn	Ser	Pro	
			500						505					510		
Leu	Gly	Met	Lys	Ser	Glu	Gly	Glu	Gln	Pro	Val	Ser	Ala	Phe	Ser	His	
		515					520					525				
Lys	Arg	Leu	Cys	Glu	Arg	Trp	Leu	Asp	Asn	Leu	Phe	Leu	Val	Leu	Tyr	
		530				535					540					
Glu	Asp	Leu	Arg	Val	Tyr	Thr	Ile	Trp	Arg	Ala	Glu	Ile	Ser	His	Phe	
545					550					555					560	
Lys	Thr	Gln	His	Met	Ser	Tyr	Arg	Lys	Thr	Gly	Thr	Glu	Trp	Glu	Ile	
				565					570					575		
Leu	Gly	Glu	Leu	Ala	Thr	Arg	Leu	His	His	Lys	Glu	Glu	Ala	Lys	Asp	
			580					585						590		
Ala	Tyr	Gln	Arg	Cys	Leu	Asp	Ser	Lys	Phe	Ser	Ala	Lys	Ala	Leu	Met	
			595				600						605			
Lys	Leu	Leu	Glu	Thr	Tyr	Ala	Asn	Glu	Gly	Asp	Leu	Gln	Lys	Thr	Leu	
	610					615						620				
Thr	Ala	Ala	Val	Arg	Leu	Thr	Thr	Tyr	His	His	Arg	Trp	Tyr	Met	Asp	
625					630					635					640	
Ala	Ser	Tyr	Pro	Ser	Met	Val	Ala	His	Tyr	Leu	Tyr	Lys	Val	Gly	Leu	
				645					650					655		
Ile	His	Gly	His	Ala	Lys	Leu	Gln	Tyr	Thr	Met	Leu	Ser	Met	Asn	Leu	
			660					665						670		
Pro	Val	Gly	Ile	Phe	Glu	Ile	Met	Gln	Gly	Tyr	Met	Lys	Tyr	Gly	Ala	
		675					680						685			
Thr	Phe	Asn	Val	Glu	Gly	Ser	Glu	Phe								
	690					695										
<210> SEQ ID NO 11																
<211> LENGTH: 1662																
<212> TYPE: DNA																
<213> ORGANISM: Cryptococcus neoformans																
<220> FEATURE:																
<221> NAME/KEY: CDS																
<222> LOCATION: (1)..(1662)																
<400> SEQUENCE: 11																
atg	tcg	tta	gcg	gac	gcc	ctt	ctg	gca	gac	ctt	gat	ggt	ctc	tcg	gat	48
Met	Ser	Leu	Ala	Asp	Ala	Leu	Leu	Ala	Asp	Leu	Asp	Gly	Leu	Ser	Asp	
1			5						10					15		
gac	gaa	gct	cga	tct	cct	tct	cct	ggc	ccc	gag	gcc	tcc	tcc	tcg	tca	96
Asp	Glu	Ala	Arg	Ser	Pro	Ser	Pro	Gly	Pro	Glu	Ala	Ser	Ser	Ser	Ser	
			20					25						30		
atg	ccg	cct	cct	ggt	ttg	ccc	aac	aaa	gga	aaa	cgt	ccc	gcc	agc	gct	144
Met	Pro	Pro	Pro	Gly	Leu	Pro	Asn	Lys	Gly	Lys	Arg	Pro	Ala	Ser	Ala	
			35				40						45			
atg	gaa	gtc	gat	gat	ggc	gaa	gga	ggt	gcg	aat	gaa	gat	gag	gga	gac	192
Met	Glu	Val	Asp	Asp	Gly	Glu	Gly	Gly	Ala	Asn	Glu	Asp	Glu	Gly	Asp	
			50			55						60				
gat	atg	aag	ctg	gaa	gac	ggg	acg	agt	gct	gtg	gga	ttt	gta	cct	gaa	240
Asp	Met	Lys	Leu	Glu	Asp	Gly	Thr	Ser	Ala	Val	Gly	Phe	Val	Pro	Glu	
			65			70				75				80		
gga	ggt	gta	agg	cct	gca	gat	gag	ctg	gac	aag	gag	gaa	gtg	gaa	aaa	288

-continued

Gly	Gly	Val	Arg	Pro	Ala	Asp	Glu	Leu	Asp	Lys	Glu	Glu	Val	Glu	Lys	
				85					90					95		
acc	gat	atg	aag	ggg	gtc	gag	gat	gtg	aag	aaa	gta	gcc	agg	ttg	gca	336
Thr	Asp	Met	Lys	Gly	Val	Glu	Asp	Val	Lys	Lys	Val	Ala	Arg	Leu	Ala	
			100					105					110			
gga	agc	cag	aag	ctt	cga	gat	ggt	ctg	gca	gat	atc	ata	aaa	tac	acc	384
Gly	Ser	Gln	Lys	Leu	Arg	Asp	Val	Leu	Ala	Asp	Ile	Ile	Lys	Tyr	Thr	
			115					120					125			
gag	tct	ccc	acc	gat	atg	tct	tcg	tct	gcc	ggg	ccc	ctc	gag	gag	aat	432
Glu	Ser	Pro	Thr	Asp	Met	Ser	Ser	Ser	Ala	Gly	Pro	Leu	Glu	Glu	Asn	
						135					140					
cca	gag	tac	cat	ctt	ggt	gtc	act	gcg	aac	aac	atg	tcc	gtc	gag	ggt	480
Pro	Glu	Tyr	His	Leu	Val	Val	Thr	Ala	Asn	Asn	Met	Ser	Val	Glu	Val	
145						150				155					160	
gac	aac	gag	att	ctc	atc	gtg	cac	aaa	ttc	att	cgt	gac	cac	tat	gct	528
Asp	Asn	Glu	Ile	Leu	Ile	Val	His	Lys	Phe	Ile	Arg	Asp	His	Tyr	Ala	
				165					170					175		
cct	cga	ttt	ccg	gaa	ctc	gaa	cag	ctc	att	gcc	gaa	cct	tgg	aca	tac	576
Pro	Arg	Phe	Pro	Glu	Leu	Glu	Gln	Ile	Ala	Glu	Pro	Trp	Thr	Tyr		
			180					185					190			
att	gcc	gcc	ggt	aat	gcc	atc	ggg	cag	tct	gaa	gat	cta	acg	aag	gtc	624
Ile	Ala	Ala	Val	Asn	Ala	Ile	Gly	Gln	Ser	Glu	Asp	Leu	Thr	Lys	Val	
			195				200					205				
aca	ttc	ccc	aac	acc	ctc	cct	gcg	gct	act	gta	ctc	tct	atc	act	ctt	672
Thr	Phe	Pro	Asn	Thr	Leu	Pro	Ala	Ala	Thr	Val	Leu	Ser	Ile	Thr	Leu	
						215					220					
act	gct	acg	act	tcc	cgt	ggg	ccg	ccg	ctc	acg	cct	gca	gag	tgg	gaa	720
Thr	Ala	Thr	Thr	Ser	Arg	Gly	Arg	Pro	Leu	Thr	Pro	Ala	Glu	Trp	Glu	
225					230					235					240	
aca	att	cag	cgc	gcc	atc	gct	gtc	gcc	caa	aat	ctc	cgt	tcg	gcg	cga	768
Thr	Ile	Gln	Arg	Ala	Ile	Ala	Val	Ala	Gln	Asn	Leu	Arg	Ser	Ala	Arg	
				245					250					255		
gaa	caa	att	ttt	tcc	tac	gtc	gag	tcc	cgt	atg	gct	gct	gta	gca	cct	816
Glu	Gln	Ile	Phe	Ser	Tyr	Val	Glu	Ser	Arg	Met	Ala	Ala	Val	Ala	Pro	
			260					265					270			
aat	ttg	tct	gct	att	gtg	ggc	acc	ggg	atc	gct	gcc	aaa	tta	ctt	ggg	864
Asn	Leu	Ser	Ala	Ile	Val	Gly	Thr	Gly	Ile	Ala	Ala	Lys	Leu	Leu	Gly	
			275					280				285				
tta	gca	ggg	ggg	ctc	cat	gcg	ttt	agt	cga	cag	ccg	agt	tgt	aat	gtg	912
Leu	Ala	Gly	Gly	Leu	His	Ala	Phe	Ser	Arg	Gln	Pro	Ser	Cys	Asn	Val	
						295					300					
atg	ctt	ttt	ggc	gcg	atg	aag	aag	act	ttg	gcc	acc	tct	cat	ctt	tct	960
Met	Leu	Phe	Gly	Ala	Met	Lys	Lys	Thr	Leu	Ala	Thr	Ser	His	Leu	Ser	
305					310					315					320	
gct	gcc	tct	cag	caa	cga	cat	acc	ggc	ttt	atc	ttc	caa	agc	tct	ata	1008
Ala	Ala	Ser	Gln	Gln	Arg	His	Thr	Gly	Phe	Ile	Phe	Gln	Ser	Ser	Ile	
				325						330				335		
gta	cag	agt	gcc	cag	cct	gaa	gat	cga	aga	aga	gct	cag	cga	gcg	gtg	1056
Val	Gln	Ser	Ala	Gln	Pro	Glu	Asp	Arg	Arg	Arg	Ala	Gln	Arg	Ala	Val	
				340				345					350			
tct	gcc	aag	tgt	gct	ctt	gcg	gcc	agg	atc	gat	gca	gga	aag	ggg	tct	1104
Ser	Ala	Lys	Cys	Ala	Leu	Ala	Ala	Arg	Ile	Asp	Ala	Gly	Lys	Gly	Ser	
			355					360					365			
agg	gac	gga	tct	tat	gga	aga	aag	tgt	ttg	gcg	gat	ttg	caa	aag	agg	1152
Arg	Asp	Gly	Ser	Tyr	Gly	Arg	Lys	Cys	Leu	Ala	Asp	Leu	Gln	Lys	Arg	
						375					380					
att	gaa	aag	atg	gcg	gaa	cct	cct	ccc	aac	aag	atg	atc	aag	gcg	ttg	1200
Ile	Glu	Lys	Met	Ala	Glu	Pro	Pro	Pro	Asn	Lys	Met	Ile	Lys	Ala	Leu	
385					390					395					400	

-continued

cct atc cct cag gag act aac agg aag aag cgt ggt ggt aag aga gct 1248
 Pro Ile Pro Gln Glu Thr Asn Arg Lys Lys Arg Gly Gly Lys Arg Ala
 405 410 415

cga aaa gcc aag gaa gcg tac gcc cag acc gaa ttg aga aag tta caa 1296
 Arg Lys Ala Lys Glu Ala Tyr Ala Gln Thr Glu Leu Arg Lys Leu Gln
 420 425 430

aac cga atg gag ttt gcc aag gcg gaa gaa gag atc ggg gtg gac gac 1344
 Asn Arg Met Glu Phe Gly Lys Ala Glu Glu Glu Ile Gly Val Asp Asp
 435 440 445

gag act gtt ggt ttg ggt atg atc ggt tcc gcc gga agg gtc cga ggc 1392
 Glu Thr Val Gly Leu Gly Met Ile Gly Ser Ala Gly Arg Val Arg Gly
 450 455 460

gag atg gca gat gcg agg agt aaa gct aaa ctt tct cga gcc aac aaa 1440
 Glu Met Ala Asp Ala Arg Ser Lys Ala Lys Leu Ser Arg Ala Asn Lys
 465 470 475 480

ctt cga act cag ctc ctt ggt cgc tca gtc aca tcc aac gac gct gcc 1488
 Leu Arg Thr Gln Leu Leu Gly Arg Ser Val Thr Ser Asn Asp Ala Ala
 485 490 495

agc ggt atg gcc acc tcc tta tca ttc acg cct gtc caa ggt ctt gaa 1536
 Ser Gly Met Ala Thr Ser Leu Ser Phe Thr Pro Val Gln Gly Leu Glu
 500 505 510

ata gtt aca ccc tcc ctc tct gca gcc cag aaa gta cag gct gcg aat 1584
 Ile Val Thr Pro Ser Leu Ser Ala Ala Gln Lys Val Gln Ala Ala Asn
 515 520 525

gac aga tgg ttc tcc ggg ggt aca ttt acg cat gta agg aag ggg gga 1632
 Asp Arg Trp Phe Ser Gly Gly Thr Phe Thr His Val Arg Lys Gly Gly
 530 535 540

agc agt att ccg gga cag gaa cag aaa tag 1662
 Ser Ser Ile Pro Gly Gln Glu Gln Lys
 545 550

<210> SEQ ID NO 12
 <211> LENGTH: 553
 <212> TYPE: PRT
 <213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 12

Met Ser Leu Ala Asp Ala Leu Leu Ala Asp Leu Asp Gly Leu Ser Asp
 1 5 10 15

Asp Glu Ala Arg Ser Pro Ser Pro Gly Pro Glu Ala Ser Ser Ser Ser
 20 25 30

Met Pro Pro Pro Gly Leu Pro Asn Lys Gly Lys Arg Pro Ala Ser Ala
 35 40 45

Met Glu Val Asp Asp Gly Glu Gly Gly Ala Asn Glu Asp Glu Gly Asp
 50 55 60

Asp Met Lys Leu Glu Asp Gly Thr Ser Ala Val Gly Phe Val Pro Glu
 65 70 75 80

Gly Gly Val Arg Pro Ala Asp Glu Leu Asp Lys Glu Glu Val Glu Lys
 85 90 95

Thr Asp Met Lys Gly Val Glu Asp Val Lys Lys Val Ala Arg Leu Ala
 100 105 110

Gly Ser Gln Lys Leu Arg Asp Val Leu Ala Asp Ile Ile Lys Tyr Thr
 115 120 125

Glu Ser Pro Thr Asp Met Ser Ser Ser Ala Gly Pro Leu Glu Glu Asn
 130 135 140

Pro Glu Tyr His Leu Val Val Thr Ala Asn Asn Met Ser Val Glu Val
 145 150 155 160

Asp Asn Glu Ile Leu Ile Val His Lys Phe Ile Arg Asp His Tyr Ala

-continued

165				170				175							
Pro	Arg	Phe	Pro	Glu	Leu	Glu	Gln	Leu	Ile	Ala	Glu	Pro	Trp	Thr	Tyr
			180					185					190		
Ile	Ala	Ala	Val	Asn	Ala	Ile	Gly	Gln	Ser	Glu	Asp	Leu	Thr	Lys	Val
		195					200					205			
Thr	Phe	Pro	Asn	Thr	Leu	Pro	Ala	Ala	Thr	Val	Leu	Ser	Ile	Thr	Leu
	210					215					220				
Thr	Ala	Thr	Thr	Ser	Arg	Gly	Arg	Pro	Leu	Thr	Pro	Ala	Glu	Trp	Glu
	225				230					235					240
Thr	Ile	Gln	Arg	Ala	Ile	Ala	Val	Ala	Gln	Asn	Leu	Arg	Ser	Ala	Arg
			245						250					255	
Glu	Gln	Ile	Phe	Ser	Tyr	Val	Glu	Ser	Arg	Met	Ala	Ala	Val	Ala	Pro
			260						265				270		
Asn	Leu	Ser	Ala	Ile	Val	Gly	Thr	Gly	Ile	Ala	Ala	Lys	Leu	Leu	Gly
		275					280						285		
Leu	Ala	Gly	Gly	Leu	His	Ala	Phe	Ser	Arg	Gln	Pro	Ser	Cys	Asn	Val
	290				295						300				
Met	Leu	Phe	Gly	Ala	Met	Lys	Lys	Thr	Leu	Ala	Thr	Ser	His	Leu	Ser
	305				310					315				320	
Ala	Ala	Ser	Gln	Gln	Arg	His	Thr	Gly	Phe	Ile	Phe	Gln	Ser	Ser	Ile
			325						330					335	
Val	Gln	Ser	Ala	Gln	Pro	Glu	Asp	Arg	Arg	Arg	Ala	Gln	Arg	Ala	Val
			340						345				350		
Ser	Ala	Lys	Cys	Ala	Leu	Ala	Ala	Arg	Ile	Asp	Ala	Gly	Lys	Gly	Ser
		355					360						365		
Arg	Asp	Gly	Ser	Tyr	Gly	Arg	Lys	Cys	Leu	Ala	Asp	Leu	Gln	Lys	Arg
	370					375					380				
Ile	Glu	Lys	Met	Ala	Glu	Pro	Pro	Pro	Asn	Lys	Met	Ile	Lys	Ala	Leu
	385				390					395					400
Pro	Ile	Pro	Gln	Glu	Thr	Asn	Arg	Lys	Lys	Arg	Gly	Gly	Lys	Arg	Ala
			405						410					415	
Arg	Lys	Ala	Lys	Glu	Ala	Tyr	Ala	Gln	Thr	Glu	Leu	Arg	Lys	Leu	Gln
		420					425						430		
Asn	Arg	Met	Glu	Phe	Gly	Lys	Ala	Glu	Glu	Glu	Ile	Gly	Val	Asp	Asp
		435				440							445		
Glu	Thr	Val	Gly	Leu	Gly	Met	Ile	Gly	Ser	Ala	Gly	Arg	Val	Arg	Gly
	450				455					460					
Glu	Met	Ala	Asp	Ala	Arg	Ser	Lys	Ala	Lys	Leu	Ser	Arg	Ala	Asn	Lys
	465				470					475				480	
Leu	Arg	Thr	Gln	Leu	Leu	Gly	Arg	Ser	Val	Thr	Ser	Asn	Asp	Ala	Ala
			485						490					495	
Ser	Gly	Met	Ala	Thr	Ser	Leu	Ser	Phe	Thr	Pro	Val	Gln	Gly	Leu	Glu
		500							505				510		
Ile	Val	Thr	Pro	Ser	Leu	Ser	Ala	Ala	Gln	Lys	Val	Gln	Ala	Ala	Asn
		515					520						525		
Asp	Arg	Trp	Phe	Ser	Gly	Gly	Thr	Phe	Thr	His	Val	Arg	Lys	Gly	Gly
	530					535					540				
Ser	Ser	Ile	Pro	Gly	Gln	Glu	Gln	Lys							
	545				550										

<210> SEQ ID NO 13

<211> LENGTH: 759

<212> TYPE: DNA

<213> ORGANISM: Cryptococcus neoformans

-continued

<220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1) .. (759)
 <400> SEQUENCE: 13

atg tca tca act gat ctc gga ggc caa gct gcc gtc atc act ggc ggt 48
 Met Ser Ser Thr Asp Leu Gly Gly Gln Ala Ala Val Ile Thr Gly Gly
 1 5 10 15

ggt aag aat ctt ggt gct ttg att gcg aag act ctc gcc aag cag gga 96
 Gly Lys Asn Leu Gly Ala Leu Ile Ala Lys Thr Leu Ala Lys Gln Gly
 20 25 30

gtc aac gtt gcg atc cat tac aac tcg gcc agt tcc aag tcc gag aca 144
 Val Asn Val Ala Ile His Tyr Asn Ser Ala Ser Ser Lys Ser Glu Thr
 35 40 45

gaa gct aca ttg aag aca ctc gga tcg tat ggg gtc aaa gcc gct gct 192
 Glu Ala Thr Leu Lys Thr Leu Gly Ser Tyr Gly Val Lys Ala Ala Ala
 50 55 60

ttc cag gcc aat ctt acc act gag gca tca gtt gag aaa ctc ttc tca 240
 Phe Gln Ala Asn Leu Thr Thr Glu Ala Ser Val Glu Lys Leu Phe Ser
 65 70 75 80

gac gca gca gct gct ctt gga gtg tcc aag ttc gat atc gcc atc aat 288
 Asp Ala Ala Ala Leu Gly Val Ser Lys Phe Asp Ile Ala Ile Asn
 85 90 95

acg gtc ggt aag gtt ctt aaa aag cct atc gtt gaa aca aca gag caa 336
 Thr Val Gly Lys Val Leu Lys Lys Pro Ile Val Glu Thr Thr Glu Gln
 100 105 110

gga ttc gac gac atg ttc cta gtc aac tca aag tgt gcc ttc ttt ttt 384
 Gly Phe Asp Asp Met Phe Leu Val Asn Ser Lys Cys Ala Phe Phe
 115 120 125

atc aag cat gcg gcc aag aat ctc aac gag ggg gcc acg att ata tca 432
 Ile Lys His Ala Ala Lys Asn Leu Asn Glu Gly Gly Thr Ile Ile Ser
 130 135 140

ctc gtg act tca ctc ctt gga gca ttt gcg cct ggt tat tca act tat 480
 Leu Val Thr Ser Leu Leu Gly Ala Phe Ala Pro Gly Tyr Ser Thr Tyr
 145 150 155 160

caa ggc agt aaa gct cct gta gag tgg ttc act aag tcg gct gcc aag 528
 Gln Gly Ser Lys Ala Pro Val Glu Trp Phe Thr Lys Ser Ala Ala Lys
 165 170 175

gag ctt cag cct aag aat att agg gtc aac tgt gtg gct ccg ggg cca 576
 Glu Leu Gln Pro Lys Asn Ile Arg Val Asn Cys Val Ala Pro Gly Pro
 180 185 190

atg gac act ccc ttc ttt tac ggg caa gag act gaa gat gcc gtt gct 624
 Met Asp Thr Pro Phe Phe Tyr Gly Gln Glu Thr Glu Asp Ala Val Ala
 195 200 205

ttc cat aaa agc cag gcg ctc aca gga cgg ctc aca gat att aaa gat 672
 Phe His Lys Ser Gln Ala Leu Thr Gly Arg Leu Thr Asp Ile Lys Asp
 210 215 220

att gca cca ttg gtg gag ttc ctt tgc aag gat aag tgg att acc gga 720
 Ile Ala Pro Leu Val Glu Phe Leu Cys Lys Asp Lys Trp Ile Thr Gly
 225 230 235 240

caa gtc atc ttc tca aat gga ggt tac acg act cgc tga 759
 Gln Val Ile Phe Ser Asn Gly Gly Tyr Thr Thr Arg
 245 250

<210> SEQ ID NO 14
 <211> LENGTH: 252
 <212> TYPE: PRT
 <213> ORGANISM: *Cryptococcus neoformans*
 <400> SEQUENCE: 14

Met Ser Ser Thr Asp Leu Gly Gly Gln Ala Ala Val Ile Thr Gly Gly

-continued

Trp	Pro	Asp	Ser	Ile	Cys	Ala	Leu	Lys	Glu	Trp	Pro	Ala	Lys	Trp	Leu	
				85					90						95	
gaa	gga	cta	gaa	agg	gaa	gct	gca	gtg	ttt	gag	atg	aaa	gct	ggg	cga	336
Glu	Gly	Leu	Glu	Arg	Glu	Ala	Ala	Val	Phe	Glu	Met	Lys	Ala	Gly	Arg	
			100					105						110		
ttg	gat	ttt	gag	ggg	gac	gag	aat	gat	gaa	gag	ggg	agg	atg	gca	aag	384
Leu	Asp	Phe	Glu	Gly	Asp	Glu	Asn	Asp	Glu	Glu	Gly	Arg	Met	Ala	Lys	
		115					120					125				
cgc	aga	aaa	agg	gat	ctg	gcg	ctg	ggg	gcg	gtg	gta	gag	tgg	gag	aac	432
Arg	Arg	Lys	Arg	Asp	Leu	Ala	Leu	Gly	Ala	Val	Val	Glu	Trp	Glu	Asn	
			130			135					140					
gat	ctc	aag	gtg	gaa	caa	cgg	gcg	acc	aac	tct	ttg	ctc	gtc	ctc	aga	480
Asp	Leu	Lys	Val	Glu	Gln	Arg	Ala	Thr	Asn	Ser	Leu	Leu	Val	Leu	Arg	
				145		150				155					160	
aac	gca	tcc	ttc	aac	gca	ccc	aac	gca	aag	atc	ctc	tca	agc	tca	agc	528
Asn	Ala	Ser	Phe	Asn	Ala	Pro	Asn	Ala	Lys	Ile	Leu	Ser	Ser	Ser	Ser	
				165					170						175	
ttc	ctc	gct	ttt	cta	gcc	gat	ttc	ttc	tct	ttg	cct	cta	ccg	ttt	ctc	576
Phe	Leu	Ala	Phe	Leu	Ala	Asp	Phe	Phe	Ser	Leu	Pro	Leu	Pro	Phe	Leu	
			180					185						190		
cag	cat	ctt	tgc	ctg	aga	acc	cca	gag	cct	ata	cat	cat	atc	ctc	atc	624
Gln	His	Leu	Cys	Leu	Arg	Thr	Pro	Glu	Pro	Ile	His	His	Ile	Leu	Ile	
			195				200						205			
att	gtc	cag	tcc	atc	ttc	ccc	cat	ttg	cgc	gtg	gac	atg	cca	ggt	atc	672
Ile	Val	Gln	Ser	Ile	Phe	Pro	His	Leu	Arg	Val	Asp	Met	Pro	Gly	Ile	
			210			215					220					
gac	cgc	atc	aag	cac	atc	ttt	ggc	gtc	gtc	ttc	cct	cag	ctt	ttt	gtt	720
Asp	Arg	Ile	Lys	His	Ile	Phe	Gly	Val	Val	Phe	Pro	Gln	Leu	Phe	Val	
				225		230				235					240	
gat	acc	cgc	gat	atc	gca	atg	atg	aac	aac	ctt	atc	cct	ctc	atg	atg	768
Asp	Thr	Arg	Asp	Ile	Ala	Met	Met	Asn	Asn	Leu	Ile	Pro	Leu	Met	Met	
				245					250					255		
atg	ggc	cag	aca	atc	ccc	aat	aac	cac	cct	cct	ccg	cct	gaa	ctc	atc	816
Met	Gly	Gln	Thr	Ile	Pro	Asn	Asn	His	Pro	Pro	Pro	Pro	Glu	Leu	Ile	
			260					265						270		
cct	cat	ctt	ctc	cag	ctt	ctc	gtt	ctc	cg	cca	gca	ggc	cca	ctt	ctc	864
Pro	His	Leu	Leu	Gln	Leu	Leu	Val	Leu	Arg	Pro	Ala	Gly	Pro	Leu	Leu	
			275				280					285				
gat	ttg	act	ctt	gac	atc	ctc	atc	tcc	ctc	tcc	aca	aat	ccc	atc	cac	912
Asp	Leu	Thr	Leu	Asp	Ile	Leu	Ile	Ser	Leu	Ser	Thr	Asn	Pro	Ile	His	
			290			295					300					
tcc	cg	gcc	ata	ctt	tct	cat	act	tct	ttc	ccg	cat	cat	ctc	aaa	tcc	960
Ser	Arg	Ala	Ile	Leu	Ser	His	Thr	Ser	Phe	Pro	His	His	Leu	Lys	Ser	
				305		310				315					320	
atc	aca	gcc	tta	ctc	gaa	cat	caa	gct	cg	ccg	gtg	gtg	aat	gcc	ctt	1008
Ile	Thr	Ala	Leu	Leu	Glu	His	Gln	Ala	Arg	Pro	Val	Val	Asn	Ala	Leu	
				325					330					335		
gac	cca	ccg	cct	tct	acg	aga	ggg	aaa	atg	gtg	cg	aac	cca	gcg	gga	1056
Asp	Pro	Pro	Pro	Ser	Thr	Arg	Gly	Lys	Met	Val	Arg	Asn	Pro	Ala	Gly	
				340				345					350			
ccg	agt	tgc	aga	gca	gag	gaa	ctt	aat	caa	agg	cg	acg	aag	gaa	cga	1104
Pro	Ser	Cys	Arg	Ala	Glu	Glu	Leu	Asn	Gln	Arg	Arg	Thr	Lys	Glu	Arg	
			355				360					365				
gag	gcc	gca	ttg	gga	cat	atg	gat	ccc	atg	gct	gga	ggt	aga	ccg	gtg	1152
Glu	Ala	Ala	Leu	Gly	His	Met	Asp	Pro	Met	Ala	Gly	Gly	Arg	Pro	Val	
			370			375					380					
tac	aat	gag	gta	ggg	gat	aag	cca	ccg	aca	ttt	agt	ccg	gcg	acg	aag	1200
Tyr	Asn	Glu	Val	Gly	Asp	Lys	Pro	Pro	Thr	Phe	Ser	Pro	Ala	Thr	Lys	
				385		390				395					400	

-continued

aag agg ctt ttc agg atg aaa gaa ccc gaa agg tct atc gag tgg atg Lys Arg Leu Phe Arg Met Lys Glu Pro Glu Arg Ser Ile Glu Trp Met 405 410 415	1248
cac cag gca ttc gtc tac tca tcg aca gcc caa gtc ctt caa gtg aca His Gln Ala Phe Val Tyr Ser Ser Thr Ala Gln Val Leu Gln Val Thr 420 425 430	1296
ttc tgg cac gcc tac cga gat ttc ttc acc aac cca gct tgc gta gaa Phe Trp His Ala Tyr Arg Asp Phe Phe Thr Asn Pro Ala Cys Val Glu 435 440 445	1344
cca atg ttg agt gca tct gat gtg atc aag aat gtc act gca gct ttc Pro Met Leu Ser Ala Ser Asp Val Ile Lys Asn Val Thr Ala Ala Phe 450 455 460	1392
cct gga gcg agc gca aaa gtt tgg acc gat gcg agt ggt gcg caa aag Pro Gly Ala Ser Ala Lys Val Trp Thr Asp Ala Ser Gly Ala Gln Lys 465 470 475 480	1440
ttt gtg att gct ggt gtc ggg ttc agg aag cga tca gat gac gat gaa Phe Val Ile Ala Gly Val Gly Phe Arg Lys Arg Ser Asp Asp Asp Glu 485 490 495	1488
agg ttt aca tgt tac tgg cat gca tgc acc caa cgg tac tca gct acc Arg Phe Thr Cys Tyr Trp His Ala Cys Thr Gln Arg Tyr Ser Ala Thr 500 505 510	1536
aac ccc gtc caa ctg ctc gaa cac att agc aac tac cat ctc caa acc Asn Pro Val Gln Leu Leu Glu His Ile Ser Asn Tyr His Leu Gln Thr 515 520 525	1584
ttt tct gca ccc caa tgc caa tgg ggc tca tgc gat cac aac ctc tgc Phe Ser Ala Pro Gln Cys Gln Trp Gly Ser Cys Asp His Asn Leu Cys 530 535 540	1632
acg tac tct cat ctc ctc acc cat atc ccc ctc ggc cag cct cca tcc Thr Tyr Ser His Leu Leu Thr His Ile Pro Leu Gly Gln Pro Pro Ser 545 550 555 560	1680
tcc atc tcc gtc cct gac gcc atc tct tgc cat atc gca gac cat agt Ser Ile Ser Val Pro Asp Ala Ile Ser Cys His Ile Ala Asp His Ser 565 570 575	1728
agc tcc gtc ttg cag gcg aag atc acc aat cgt acc gtc cct cct tta Ser Ser Val Leu Gln Arg Lys Ile Thr Asn Arg Thr Val Pro Pro Leu 580 585 590	1776
tcc agc gtt cgt cta gcc gtt cag ggg gca ttt acc cct gtc gac gct Ser Ser Val Arg Leu Ala Val Gln Gly Ala Phe Thr Pro Val Asp Ala 595 600 605	1824
cgt cga caa cct act ggc gcc gcc ctt ctc gcg gcg tta ctt atc cgt Arg Arg Gln Pro Thr Gly Ala Ala Leu Leu Ala Ala Leu Leu Ile Arg 610 615 620	1872
aac ctc gcc cgt acc ctc cgt gcc gag atc tcg ctc gcc gtg ccc gaa Asn Leu Ala Arg Thr Leu Arg Ala Glu Ile Ser Leu Ala Val Pro Glu 625 630 635 640	1920
ttg tct cat gct caa acg caa gaa acg gca gat gaa gct caa gcg aga Leu Ser His Ala Gln Thr Gln Glu Thr Ala Asp Glu Ala Gln Ala Arg 645 650 655	1968
aaa aaa cac ctt ctc gaa gag agg tat gga ttg cca atc ccg gat tcg Lys Lys His Leu Leu Glu Glu Arg Tyr Gly Leu Pro Ile Pro Asp Ser 660 665 670	2016
gtg ttg aaa gaa gaa gaa gag gag cag gcg aat gtg cag caa gcc caa Val Leu Lys Glu Glu Glu Glu Glu Gln Ala Asn Val Gln Gln Gly Gln 675 680 685	2064
gat tta gat atg agt gag gaa gag agg gag agg gcg aaa aag gcg ttt Asp Leu Asp Met Ser Glu Glu Glu Arg Glu Arg Ala Lys Lys Ala Phe 690 695 700	2112
gag aat gtg gag gag agg att atg aag gtc atg ttg gag aat gtt agt Glu Asn Val Glu Glu Arg Ile Met Lys Val Met Leu Glu Asn Val Ser 705 710 715 720	2160

-continued

ggg ata acg cag tat ctt ggt gat gcg ctt ggg ctg tag 2199
 Gly Ile Thr Gln Tyr Leu Gly Asp Ala Leu Gly Leu
 725 730

<210> SEQ ID NO 16
 <211> LENGTH: 732
 <212> TYPE: PRT
 <213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 16

Met Gln His His Pro Ala Val Ala Ala Gln Pro Gly Arg Thr Ile Ala
 1 5 10 15
 Pro Ile Pro His His Arg Pro Gln Gln Pro Arg Ile Thr Pro Tyr Thr
 20 25 30
 Pro Asn Val Arg Asp Leu Asn Pro Gly Pro Lys Asn Arg Leu Ile Leu
 35 40 45
 Ala Leu Arg Ser Asn Ile Pro Phe Glu Val Asp Trp Ala Leu Pro Gln
 50 55 60
 Leu Val Val Ala Ser Phe Asp Gln Ser Asp Gly Phe Lys Leu Glu Ala
 65 70 75 80
 Trp Pro Asp Ser Ile Cys Ala Leu Lys Glu Trp Pro Ala Lys Trp Leu
 85 90 95
 Glu Gly Leu Glu Arg Glu Ala Ala Val Phe Glu Met Lys Ala Gly Arg
 100 105 110
 Leu Asp Phe Glu Gly Asp Glu Asn Asp Glu Glu Gly Arg Met Ala Lys
 115 120 125
 Arg Arg Lys Arg Asp Leu Ala Leu Gly Ala Val Val Glu Trp Glu Asn
 130 135 140
 Asp Leu Lys Val Glu Gln Arg Ala Thr Asn Ser Leu Leu Val Leu Arg
 145 150 155 160
 Asn Ala Ser Phe Asn Ala Pro Asn Ala Lys Ile Leu Ser Ser Ser Ser
 165 170 175
 Phe Leu Ala Phe Leu Ala Asp Phe Phe Ser Leu Pro Leu Pro Phe Leu
 180 185 190
 Gln His Leu Cys Leu Arg Thr Pro Glu Pro Ile His His Ile Leu Ile
 195 200 205
 Ile Val Gln Ser Ile Phe Pro His Leu Arg Val Asp Met Pro Gly Ile
 210 215 220
 Asp Arg Ile Lys His Ile Phe Gly Val Val Phe Pro Gln Leu Phe Val
 225 230 235 240
 Asp Thr Arg Asp Ile Ala Met Met Asn Asn Leu Ile Pro Leu Met Met
 245 250 255
 Met Gly Gln Thr Ile Pro Asn Asn His Pro Pro Pro Pro Glu Leu Ile
 260 265 270
 Pro His Leu Leu Gln Leu Leu Val Leu Arg Pro Ala Gly Pro Leu Leu
 275 280 285
 Asp Leu Thr Leu Asp Ile Leu Ile Ser Leu Ser Thr Asn Pro Ile His
 290 295 300
 Ser Arg Ala Ile Leu Ser His Thr Ser Phe Pro His His Leu Lys Ser
 305 310 315 320
 Ile Thr Ala Leu Leu Glu His Gln Ala Arg Pro Val Val Asn Ala Leu
 325 330 335
 Asp Pro Pro Pro Ser Thr Arg Gly Lys Met Val Arg Asn Pro Ala Gly
 340 345 350

-continued

<222> LOCATION: (1) .. (1305)

<400> SEQUENCE: 17

atg aga ctc acg att att gcc cca gac tcg gtt cat gag cac gaa gtg	48
Met Arg Leu Thr Ile Ile Ala Pro Asp Ser Val His Glu His Glu Val	
1 5 10 15	
tcc cct tcc ttg ctc atc caa gac atc atc aac atc gtt gag gca act	96
Ser Pro Ser Leu Leu Ile Gln Asp Ile Ile Asn Ile Val Glu Ala Thr	
20 25 30	
gcc gac ctt ccc ccg gct gtt att gtt ctc aca agt gac gcc ggt aca	144
Ala Asp Leu Pro Pro Ala Val Ile Val Leu Thr Ser Asp Ala Gly Thr	
35 40 45	
cca ctc acg gac ccc aca aga act ctc gaa agc tat ggg tta aat gga	192
Pro Leu Thr Asp Pro Thr Arg Thr Leu Glu Ser Tyr Gly Leu Asn Gly	
50 55 60	
gag acc gcc acc atc ttc ctt aca cct aca gga cca ccc gtc gct tct	240
Glu Thr Ala Thr Ile Phe Leu Thr Pro Thr Gly Pro Pro Val Ala Ser	
65 70 75 80	
tcg tct tcc att cca ttc cct gat gca gat gcc gac att gaa agg atg	288
Ser Ser Ser Ile Pro Phe Pro Asp Ala Asp Ala Asp Ile Glu Arg Met	
85 90 95	
cgt tta caa gcg ctc gga aat cct tct ttg atg aat gat ttg cgt gag	336
Arg Leu Gln Ala Leu Gly Asn Pro Ser Leu Met Asn Asp Leu Arg Glu	
100 105 110	
cgt gat ccg gaa acc ttt gcc gct att caa ggg ggt act caa agc ttc	384
Arg Asp Pro Glu Thr Phe Ala Ala Ile Gln Gly Gly Thr Gln Ser Phe	
115 120 125	
aaa aaa gcc ctc caa ctg gcg caa tca aga caa aga gat gcc gaa ttc	432
Lys Lys Ala Leu Gln Leu Ala Gln Ser Arg Gln Arg Asp Ala Glu Phe	
130 135 140	
gaa aag caa cgc cag att gaa gca ctc aat gcc gac cct tat gac att	480
Glu Lys Gln Arg Gln Ile Glu Ala Leu Asn Ala Asp Pro Tyr Asp Ile	
145 150 155 160	
gaa gct cag aaa aag att gag gaa gca att cgg atg gag gcc gtt ttg	528
Glu Ala Gln Lys Lys Ile Glu Glu Ala Ile Arg Met Glu Ala Val Leu	
165 170 175	
gag aat atg cag cac gct atg gaa tat tcc cct gag tcg ttt gga aac	576
Glu Asn Met Gln His Ala Met Glu Tyr Ser Pro Glu Ser Phe Gly Asn	
180 185 190	
gtg acc atg ctg tat atc aat gtg gaa gta aat ggt cat cct gtt aag	624
Val Thr Met Leu Tyr Ile Asn Val Glu Val Asn Gly His Pro Val Lys	
195 200 205	
gca ttc gtt gat tct ggt gca caa aca acg atc att tcc cct gaa tgt	672
Ala Phe Val Asp Ser Gly Ala Gln Thr Thr Ile Ile Ser Pro Glu Cys	
210 215 220	
gcc gag caa tgt gga atc atg cgc ctg ctt gat act cgt ttc gcg ggt	720
Ala Glu Gln Cys Gly Ile Met Arg Leu Leu Asp Thr Arg Phe Ala Gly	
225 230 235 240	
atg gcc gaa gga gta gga aca gct cgt atc ctc ggt cgt atc cac tct	768
Met Ala Glu Gly Val Gly Thr Ala Arg Ile Leu Gly Arg Ile His Ser	
245 250 255	
gcc caa att aag ctc gcc tca ctc tac ctc cct tgt gca ttc tcc gtc	816
Ala Gln Ile Lys Leu Gly Ser Leu Tyr Leu Pro Cys Ala Phe Ser Val	
260 265 270	
ctc gaa gcc cgt tct gtc gac ctc tta ttt ggt ctt gac atg ctt aaa	864
Leu Glu Gly Arg Ser Val Asp Leu Leu Phe Gly Leu Asp Met Leu Lys	
275 280 285	
cgc cat caa tgc tgt atc gac ctc tcc acg aac acg ctc cgg ata aat	912
Arg His Gln Cys Cys Ile Asp Leu Ser Thr Asn Thr Leu Arg Ile Asn	
290 295 300	

-continued

```

aac act gaa gta ccc ttt ttg tcg gag cac gag ctg cct gac aag gcg      960
Asn Thr Glu Val Pro Phe Leu Ser Glu His Glu Leu Pro Asp Lys Ala
305                      310                      315                      320

aga aga cgt ggg gag gcg caa gtg gcc ggg gaa atg ggt gat gcg gca      1008
Arg Arg Arg Gly Glu Ala Gln Val Ala Gly Glu Met Gly Asp Ala Ala
                      325                      330                      335

ggg caa ggc gtg aaa gcg ggt gtg gcg agt ccg aag att ggg aag aag      1056
Gly Gln Gly Val Lys Ala Gly Val Ala Ser Pro Lys Ile Gly Lys Lys
                      340                      345                      350

acg ttt ccg gga gag ggg cat gcg ctt ggt gcg gcc agc tcg act gga      1104
Thr Phe Pro Gly Glu Gly His Ala Leu Gly Ala Gly Ser Ser Thr Gly
                      355                      360                      365

cca ggg acg gct acg ggg agt gca agt gcg aca ggt gca agg act ggg      1152
Pro Gly Thr Ala Thr Gly Ser Ala Ser Ala Thr Gly Ala Arg Thr Gly
                      370                      375                      380

ggg act gca agt gtc ccc tcg cct tca aat agg tgg aaa gag gac gat      1200
Gly Thr Ala Ser Val Pro Ser Pro Ser Asn Arg Trp Lys Glu Asp Asp
385                      390                      395                      400

att caa acg ctt gtg aac ctg ggt gcc cct cga gcg caa gct ata cag      1248
Ile Gln Thr Leu Val Asn Leu Gly Ala Pro Arg Ala Gln Ala Ile Gln
                      405                      410                      415

cta ctt gaa gcg tca ggt gga aac gtg gat gtt gct gct tct atg ctc      1296
Leu Leu Glu Ala Ser Gly Gly Asn Val Asp Val Ala Ala Ser Met Leu
                      420                      425                      430

ttt ggt tag      1305
Phe Gly

```

<210> SEQ ID NO 18

<211> LENGTH: 434

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 18

```

Met Arg Leu Thr Ile Ile Ala Pro Asp Ser Val His Glu His Glu Val
 1                      5                      10                      15

Ser Pro Ser Leu Leu Ile Gln Asp Ile Ile Asn Ile Val Glu Ala Thr
 20                      25                      30

Ala Asp Leu Pro Pro Ala Val Ile Val Leu Thr Ser Asp Ala Gly Thr
 35                      40                      45

Pro Leu Thr Asp Pro Thr Arg Thr Leu Glu Ser Tyr Gly Leu Asn Gly
 50                      55                      60

Glu Thr Ala Thr Ile Phe Leu Thr Pro Thr Gly Pro Pro Val Ala Ser
 65                      70                      75                      80

Ser Ser Ser Ile Pro Phe Pro Asp Ala Asp Ala Asp Ile Glu Arg Met
 85                      90                      95

Arg Leu Gln Ala Leu Gly Asn Pro Ser Leu Met Asn Asp Leu Arg Glu
 100                      105                      110

Arg Asp Pro Glu Thr Phe Ala Ala Ile Gln Gly Gly Thr Gln Ser Phe
 115                      120                      125

Lys Lys Ala Leu Gln Leu Ala Gln Ser Arg Gln Arg Asp Ala Glu Phe
 130                      135                      140

Glu Lys Gln Arg Gln Ile Glu Ala Leu Asn Ala Asp Pro Tyr Asp Ile
 145                      150                      155                      160

Glu Ala Gln Lys Lys Ile Glu Glu Ala Ile Arg Met Glu Ala Val Leu
 165                      170                      175

Glu Asn Met Gln His Ala Met Glu Tyr Ser Pro Glu Ser Phe Gly Asn
 180                      185                      190

```

-continued

Val Thr Met Leu Tyr Ile Asn Val Glu Val Asn Gly His Pro Val Lys
 195 200 205

Ala Phe Val Asp Ser Gly Ala Gln Thr Thr Ile Ile Ser Pro Glu Cys
 210 215 220

Ala Glu Gln Cys Gly Ile Met Arg Leu Leu Asp Thr Arg Phe Ala Gly
 225 230 235 240

Met Ala Glu Gly Val Gly Thr Ala Arg Ile Leu Gly Arg Ile His Ser
 245 250 255

Ala Gln Ile Lys Leu Gly Ser Leu Tyr Leu Pro Cys Ala Phe Ser Val
 260 265 270

Leu Glu Gly Arg Ser Val Asp Leu Leu Phe Gly Leu Asp Met Leu Lys
 275 280 285

Arg His Gln Cys Cys Ile Asp Leu Ser Thr Asn Thr Leu Arg Ile Asn
 290 295 300

Asn Thr Glu Val Pro Phe Leu Ser Glu His Glu Leu Pro Asp Lys Ala
 305 310 315 320

Arg Arg Arg Gly Glu Ala Gln Val Ala Gly Glu Met Gly Asp Ala Ala
 325 330 335

Gly Gln Gly Val Lys Ala Gly Val Ala Ser Pro Lys Ile Gly Lys Lys
 340 345 350

Thr Phe Pro Gly Glu Gly His Ala Leu Gly Ala Gly Ser Ser Thr Gly
 355 360 365

Pro Gly Thr Ala Thr Gly Ser Ala Ser Ala Thr Gly Ala Arg Thr Gly
 370 375 380

Gly Thr Ala Ser Val Pro Ser Pro Ser Asn Arg Trp Lys Glu Asp Asp
 385 390 395 400

Ile Gln Thr Leu Val Asn Leu Gly Ala Pro Arg Ala Gln Ala Ile Gln
 405 410 415

Leu Leu Glu Ala Ser Gly Gly Asn Val Asp Val Ala Ala Ser Met Leu
 420 425 430

Phe Gly

<210> SEQ ID NO 19
 <211> LENGTH: 3555
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(3555)

<400> SEQUENCE: 19

atg tct tcg cca gaa cca gag gag cct cgc aga ggt gca agg gtc agg 48
 Met Ser Ser Pro Glu Pro Glu Glu Pro Arg Arg Gly Ala Arg Val Arg
 1 5 10 15

aag cag gtt aat aag ttt gat gct agc cag cag aac ggg agg ggc aag 96
 Lys Gln Val Asn Lys Phe Asp Ala Ser Gln Gln Asn Gly Arg Gly Lys
 20 25 30

aga aag cac att gaa gac agg gag gac gac gac cag gag ggt ttg ata 144
 Arg Lys His Ile Glu Asp Arg Glu Asp Asp Asp Gln Glu Gly Leu Ile
 35 40 45

cca gac ccg gaa gac gag tct gat cac gaa cca act ccc aag aag aag 192
 Pro Asp Pro Glu Asp Glu Ser Asp His Glu Pro Thr Pro Lys Lys Lys
 50 55 60

aag ccg gcg gca cca cga aaa tct cga gct tct gcg ggt act acc aag 240
 Lys Pro Ala Ala Pro Arg Lys Ser Arg Ala Ser Ala Gly Thr Thr Lys
 65 70 75 80

-continued

aag gac gga cca aag aca aaa aca aag cct gca gct gaa ggc gtg agc Lys Asp Gly Pro Lys Thr Lys Thr Lys Pro Ala Ala Glu Gly Val Ser 85 90 95	288
gaa atc gta gaa aag act gat tcg cct tta ttt aat gct ctc cag caa Glu Ile Val Glu Lys Thr Asp Ser Pro Leu Phe Asn Ala Leu Gln Gln 100 105 110	336
ccc gat atc gcc ctt caa cct ctg att gat gag tgg atc gag acc tac Pro Asp Ile Ala Leu Gln Pro Leu Ile Asp Glu Trp Ile Glu Thr Tyr 115 120 125	384
caa caa gcc gct ggt gat gaa ata tca gag cag aaa tcc att cac gaa Gln Gln Ala Ala Gly Asp Glu Ile Ser Glu Gln Lys Ser Ile His Glu 130 135 140	432
ctg gtt gtc ttc ttc att cga tgt tgc ggt atg act acc gag atc gag Leu Val Val Phe Phe Ile Arg Cys Cys Gly Met Thr Thr Glu Ile Glu 145 150 155 160	480
caa gct gaa gca acg gat gac gat ggt atc ccc gat gtc atc gag cga Gln Ala Glu Ala Thr Asp Asp Asp Gly Ile Pro Asp Val Ile Glu Arg 165 170 175	528
gtg cag gat gaa agc gtt cgc gta gcg ttg gcg act tat ccc tta att Val Gln Asp Glu Ser Val Arg Val Ala Leu Ala Thr Tyr Pro Leu Ile 180 185 190	576
tcc aaa gca aag aat ttt aag ccc ttc aag tcc aat ttg aac gag ttc Ser Lys Ala Lys Asn Phe Lys Pro Phe Lys Ser Asn Leu Asn Glu Phe 195 200 205	624
att tca cac ttt att tca tcg ctc gct ctc aca cct atc ctc ttt cac Ile Ser His Phe Ile Ser Ser Leu Ala Leu Thr Pro Ile Leu Phe His 210 215 220	672
act gcc gac aat act cct cac tca tct ctg ctc atc cca ctt ctc ctc Thr Ala Asp Asn Thr Pro His Ser Ser Leu Leu Ile Pro Leu Leu Leu 225 230 235 240	720
aac tgg ctg atg tgt atg tca tca tca act ctt cga ccc atc cgt cat Asn Trp Leu Met Cys Met Ser Ser Ser Thr Leu Arg Pro Ile Arg His 245 250 255	768
acc tca aca tac gtg acg ctc agg atg aac tcg gct ttg tgt gac gtt Thr Ser Thr Tyr Val Thr Leu Arg Met Asn Ser Ala Leu Cys Asp Val 260 265 270	816
gct gcg gat gtg agc aaa gac ctg agc gtt aag caa agg cag cga gat Ala Ala Asp Val Ser Lys Asp Leu Ser Val Lys Gln Arg Gln Arg Asp 275 280 285	864
gca gaa gtc aga aaa gct gga gct aca aat gca gcg cag aag aga gtg Ala Glu Val Arg Lys Ala Gly Ala Thr Asn Ala Ala Gln Lys Arg Val 290 295 300	912
aag gct gcc gag gac agg gtc aag gaa gtg caa gaa aga aag caa act Lys Ala Ala Glu Asp Arg Val Lys Glu Val Gln Glu Arg Lys Gln Thr 305 310 315 320	960
tta gaa gag ttg atg cag gag atc ttt gat gtg atg ttc gtc cac cga Leu Glu Glu Leu Met Gln Glu Ile Phe Asp Val Met Phe Val His Arg 325 330 335	1008
gtt cgc gat gcc gat ccc aac att cga acc gat tgt ctg cgt gaa tta Val Arg Asp Ala Asp Pro Asn Ile Arg Thr Asp Cys Leu Arg Glu Leu 340 345 350	1056
ggt ctg tgg gcc aaa aaa cac cca gag tac tac gtt tcg act tct tat Gly Leu Trp Ala Lys Lys His Pro Glu Tyr Tyr Val Ser Thr Ser Tyr 355 360 365	1104
ctc tcc tac ttc acc cgt ggc tgt aac gat acc cac gct cat gcc cga Leu Ser Tyr Phe Thr Arg Gly Cys Asn Asp Thr His Ala His Ala Arg 370 375 380	1152
ctt gag act gtc aag gct ctt gcc aac ctc tac atc cga gaa acc ttt Leu Glu Thr Val Lys Ala Leu Ala Asn Leu Tyr Ile Arg Glu Thr Phe 385 390 395 400	1200

-continued

atc agt aac gct cga acc ttg acg atg cgt tta gcg cct agg gtg att Ile Ser Asn Ala Arg Thr Leu Thr Met Arg Leu Ala Pro Arg Val Ile 405 410 415	1248
gag atg gcc acc agg gat gtg gat ttg aat gtg agg gta gtg gct ttg Glu Met Ala Thr Arg Asp Val Asp Leu Asn Val Arg Val Val Ala Leu 420 425 430	1296
cag gtg att aca ctt ata gac aag acg ggt att ctg caa gac gag gag Gln Val Ile Thr Leu Ile Asp Lys Thr Gly Ile Leu Gln Asp Glu Glu 435 440 445	1344
gac gag gaa aga gat aag gtg gcg aag ctt gtt ttc gac cag gag cct Asp Glu Glu Arg Asp Lys Val Ala Lys Leu Val Phe Asp Gln Glu Pro 450 455 460	1392
cga att cga aaa gct gca ggg gcg ttc atc ctt ggt ttg tgg gaa gag Arg Ile Arg Lys Ala Ala Gly Ala Phe Ile Leu Gly Leu Trp Glu Glu 465 470 475 480	1440
agg aaa gaa ggc ctc aaa gca gtc tgg tcg ggt ctg aga gcg aac aaa Arg Lys Glu Gly Leu Lys Ala Val Trp Ser Gly Leu Arg Ala Asn Lys 485 490 495	1488
aag aag cgt gca gca aac atc acc gaa gac gaa atg tcc aac tac ctc Lys Lys Arg Ala Ala Asn Ile Thr Glu Asp Glu Met Ser Asn Tyr Leu 500 505 510	1536
aac tgg aaa tcc ctc gct gca gtt ctc ctc tac acc tct aaa tcc ctg Asn Trp Lys Ser Leu Ala Ala Val Leu Leu Tyr Thr Ser Lys Ser Leu 515 520 525	1584
gac gac gac cct tct gga caa ccc tct gcc ctc aaa cca agc cta ctc Asp Asp Asp Pro Ser Gly Gln Pro Ser Ala Leu Lys Pro Ser Leu Leu 530 535 540	1632
att ccg tct tta ccc aat aca cag atg aca agg gcg act gct gcc gtc Ile Pro Ser Leu Pro Asn Thr Gln Met Thr Arg Ala Thr Ala Ala Val 545 550 555 560	1680
gag tct atc ggt gct gag cat gag ctg tgg aaa gac tgg gag agc ttg Glu Ser Ile Gly Ala Glu His Glu Leu Trp Lys Asp Trp Glu Ser Leu 565 570 575	1728
gtg gac tat ctt ttg gtg gat cac tcg act aac gaa gaa gat atg tgg Val Asp Tyr Leu Leu Val Asp His Ser Thr Asn Glu Glu Asp Met Trp 580 585 590	1776
ctg ctc cgt gaa gat gag gaa act ttc atg ttg cag gtg ctt ttg gct Leu Leu Arg Glu Asp Glu Glu Thr Phe Met Leu Gln Val Leu Leu Ala 595 600 605	1824
tgt att aag cgg gaa gaa aat gaa gag gat gag ccg gat agg acc aaa Cys Ile Lys Arg Glu Glu Asn Glu Glu Asp Glu Pro Asp Arg Thr Lys 610 615 620	1872
acg ttg ata aag gtt ttg cct cgg tta ttt gcc aag cat cag gct gat Thr Leu Ile Lys Val Leu Pro Arg Leu Phe Ala Lys His Gln Ala Asp 625 630 635 640	1920
gtt ggt cga atg act ggg att tta tct gtt ccc gga cac atg aag ctc Val Gly Arg Met Thr Gly Ile Leu Ser Val Pro Gly His Met Lys Leu 645 650 655	1968
agt ctc tat ctc gac atg cgc atg tcc tct gcc tac gag tcc ctc tgg Ser Leu Tyr Leu Asp Met Arg Met Ser Ser Ala Tyr Glu Ser Leu Trp 660 665 670	2016
gat gac atc agc aaa cag ttc cta aaa tac act tcc cct acc atc ctc Asp Asp Ile Ser Lys Gln Phe Leu Lys Tyr Thr Ser Pro Thr Ile Leu 675 680 685	2064
aca gca tcc att tct gcg atc agc cat ctc gtc ggc aac tcg tcc ctt Thr Ala Ser Ile Ser Ala Ile Ser His Leu Val Gly Asn Ser Ser Leu 690 695 700	2112
tca tcc atc aat gaa acc aag ctt tct gag ctg cac gag tct ctc ttc Ser Ser Ile Asn Glu Thr Lys Leu Ser Glu Leu His Glu Ser Leu Phe 705 710 715	2160

-continued

705	710	715	720	
gct tct cta aga gat gcg att ggc tct gaa gat gtt gcg ctt gtc act Ala Ser Leu Arg Asp Ala Ile Gly Ser Glu Asp Val Ala Leu Val Thr 725 730 735				2208
ttg gag gac gag cag atc agc cag ctg gaa gca atc atg ctg agg ata Leu Glu Asp Glu Gln Ile Ser Gln Leu Glu Ala Ile Met Leu Arg Ile 740 745 750				2256
acg tta ctg cag aga agt atg gat ttg gta gat gtc atg gag gat gag Thr Leu Leu Gln Arg Ser Met Asp Leu Val Asp Val Met Glu Asp Glu 755 760 765				2304
gaa ggg cag cag agt agc ggc tgg gac att atc tgt gcg ttt gct gat Glu Gly Gln Gln Ser Ser Gly Trp Asp Ile Ile Cys Ala Phe Ala Asp 770 775 780				2352
agg ggc aaa ttg ggg tac aag gag gaa gct act atg gta gac tat gct Arg Gly Lys Leu Gly Tyr Lys Glu Glu Ala Thr Met Val Asp Tyr Ala 785 790 795 800				2400
gtt caa atc atc ttc ctc cac atc act tgg ctc ttc aag cgg ttc acc Val Gln Ile Ile Phe Leu His Ile Thr Trp Leu Phe Lys Arg Phe Thr 805 810 815				2448
aag gaa gat gcg caa gat gcc acc aag att gat ctc ctt tcc acc cga Lys Glu Asp Ala Gln Asp Ala Thr Lys Ile Asp Leu Leu Ser Thr Arg 820 825 830				2496
cgc gat acc gcc ctt cag aca ttt aac cag ctt ttc ctc gga gaa acg Arg Asp Thr Ala Leu Gln Thr Phe Asn Gln Leu Phe Leu Gly Glu Thr 835 840 845				2544
acc aat acc gcc agt gct gta cga cgt caa gcc ttc atc tct ttc atc Thr Asn Thr Ala Ser Ala Val Arg Arg Gln Ala Phe Ile Ser Phe Ile 850 855 860				2592
aat acg tac gta ttg ttc gcc aaa cgt gca gag ggt agg gga gga gct Asn Thr Tyr Val Leu Phe Ala Lys Arg Ala Glu Gly Arg Gly Gly Ala 865 870 875 880				2640
cca gcg agc gac gtt tgt tct gtg acg atg ccg gaa gaa gta cag cat Pro Ala Ser Asp Val Cys Ser Val Thr Met Pro Glu Glu Val Gln His 885 890 895				2688
aga ctg gga ggg gcg ttc caa gcg gtg att gag agg tat gct tcc gtc Arg Leu Gly Gly Ala Phe Gln Ala Val Ile Glu Arg Tyr Ala Ser Val 900 905 910				2736
gtg gag act aga tca gca gga cgg gaa gag agt cag cag ccc ccc gaa Val Glu Thr Arg Ser Ala Gly Arg Glu Glu Ser Gln Gln Pro Pro Glu 915 920 925				2784
ctc act cct gat gag atg cac gag gat ttc cag ttt ttc caa ctc gtt Leu Thr Pro Asp Glu Met His Glu Asp Phe Gln Phe Phe Gln Leu Val 930 935 940				2832
tcc gtt ttt gtc ggt gcc atc cga tgt ggt gtc ctc gag gtt gaa cat Ser Val Phe Val Gly Ala Ile Arg Cys Gly Val Leu Glu Val Glu His 945 950 955 960				2880
gcc aag gaa cct ctt gcc cat tac agt cgt ttt ggt cca acg tac gat Ala Lys Glu Pro Leu Ala His Tyr Ser Arg Phe Gly Pro Thr Tyr Asp 965 970 975				2928
gcg atc gtc aag aag ctc gtt gat gta ctt cga gat gag ggt atc tac Ala Ile Val Lys Lys Leu Val Asp Val Leu Arg Asp Glu Gly Ile Tyr 980 985 990				2976
aat agg gag gca gat gcg gtg cag cat gtt gcg gga agc gcc ttg cag Asn Arg Glu Ala Asp Ala Val Gln His Val Ala Gly Ser Ala Leu Gln 995 1000 1005				3024
caa tcg ttc aac atc ttc ctc gac tct gag gaa gac gaa cca act Gln Ser Phe Asn Ile Phe Leu Asp Ser Glu Glu Asp Glu Pro Thr 1010 1015 1020				3069
gct cct ctg gcc ctt gcc cgt gtt att gca act gcg ttc gtc atc				3114

-continued

145	150	155	160
Gln Ala Glu Ala Thr Asp Asp Asp Gly Ile Pro Asp Val Ile Glu Arg	165	170	175
Val Gln Asp Glu Ser Val Arg Val Ala Leu Ala Thr Tyr Pro Leu Ile	180	185	190
Ser Lys Ala Lys Asn Phe Lys Pro Phe Lys Ser Asn Leu Asn Glu Phe	195	200	205
Ile Ser His Phe Ile Ser Ser Leu Ala Leu Thr Pro Ile Leu Phe His	210	215	220
Thr Ala Asp Asn Thr Pro His Ser Ser Leu Leu Ile Pro Leu Leu Leu	225	230	235
Asn Trp Leu Met Cys Met Ser Ser Ser Thr Leu Arg Pro Ile Arg His	245	250	255
Thr Ser Thr Tyr Val Thr Leu Arg Met Asn Ser Ala Leu Cys Asp Val	260	265	270
Ala Ala Asp Val Ser Lys Asp Leu Ser Val Lys Gln Arg Gln Arg Asp	275	280	285
Ala Glu Val Arg Lys Ala Gly Ala Thr Asn Ala Ala Gln Lys Arg Val	290	295	300
Lys Ala Ala Glu Asp Arg Val Lys Glu Val Gln Glu Arg Lys Gln Thr	305	310	315
Leu Glu Glu Leu Met Gln Glu Ile Phe Asp Val Met Phe Val His Arg	325	330	335
Val Arg Asp Ala Asp Pro Asn Ile Arg Thr Asp Cys Leu Arg Glu Leu	340	345	350
Gly Leu Trp Ala Lys Lys His Pro Glu Tyr Tyr Val Ser Thr Ser Tyr	355	360	365
Leu Ser Tyr Phe Thr Arg Gly Cys Asn Asp Thr His Ala His Ala Arg	370	375	380
Leu Glu Thr Val Lys Ala Leu Ala Asn Leu Tyr Ile Arg Glu Thr Phe	385	390	395
Ile Ser Asn Ala Arg Thr Leu Thr Met Arg Leu Ala Pro Arg Val Ile	405	410	415
Glu Met Ala Thr Arg Asp Val Asp Leu Asn Val Arg Val Val Ala Leu	420	425	430
Gln Val Ile Thr Leu Ile Asp Lys Thr Gly Ile Leu Gln Asp Glu Glu	435	440	445
Asp Glu Glu Arg Asp Lys Val Ala Lys Leu Val Phe Asp Gln Glu Pro	450	455	460
Arg Ile Arg Lys Ala Ala Gly Ala Phe Ile Leu Gly Leu Trp Glu Glu	465	470	475
Arg Lys Glu Gly Leu Lys Ala Val Trp Ser Gly Leu Arg Ala Asn Lys	485	490	495
Lys Lys Arg Ala Ala Asn Ile Thr Glu Asp Glu Met Ser Asn Tyr Leu	500	505	510
Asn Trp Lys Ser Leu Ala Ala Val Leu Leu Tyr Thr Ser Lys Ser Leu	515	520	525
Asp Asp Asp Pro Ser Gly Gln Pro Ser Ala Leu Lys Pro Ser Leu Leu	530	535	540
Ile Pro Ser Leu Pro Asn Thr Gln Met Thr Arg Ala Thr Ala Ala Val	545	550	555
Glu Ser Ile Gly Ala Glu His Glu Leu Trp Lys Asp Trp Glu Ser Leu	565	570	575

-continued

```

Asn Arg Glu Ala Asp Ala Val Gln His Val Ala Gly Ser Ala Leu Gln
 995                               1000                               1005

Gln Ser Phe Asn Ile Phe Leu Asp Ser Glu Glu Asp Glu Pro Thr
1010                               1015                               1020

Ala Pro Leu Ala Leu Ala Arg Val Ile Ala Thr Ala Phe Val Ile
1025                               1030                               1035

His Gly Ser Gln Phe Ala Ile Leu Arg Gln Leu His Pro Ser Asp
1040                               1045                               1050

Val Cys Asp Phe His Leu Glu Ala Leu Asp Phe Val Ser Leu Lys
1055                               1060                               1065

Val Ser Thr Ile Val Lys Gln Glu Gly Asn Ala Arg Asn Lys Glu
1070                               1075                               1080

Gln Lys Ser Arg Leu Thr Arg Lys Lys Trp Ala Val Leu Thr Phe
1085                               1090                               1095

Phe Lys Val Leu Val Pro Leu Leu Ala Pro Val Thr Gly Arg Asp
1100                               1105                               1110

Ala Leu Lys Ile Lys Ala His Leu Glu Asp Val Ile Asp Ser Ser
1115                               1120                               1125

Gly Val Gln Leu Thr Thr Asn Lys Gly Trp Asp Gly Tyr Arg Ala
1130                               1135                               1140

Tyr Glu Lys Arg Leu Val Gly Ile Ala Ser Lys Asp Pro Asn Val
1145                               1150                               1155

Lys Met Met Ala Ser Lys Lys Val Val Glu Arg Glu Asp Thr Glu
1160                               1165                               1170

Gln Gly Asp Glu Asp Asn Val Phe Ala Arg Gln
1175                               1180
    
```

```

<210> SEQ ID NO 21
<211> LENGTH: 897
<212> TYPE: DNA
<213> ORGANISM: Cryptococcus neoformans
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(897)
    
```

<400> SEQUENCE: 21

```

atg aag tac tct gct acc gca gtc gcc gtt atg ggt gcc ctc gcc att      48
Met Lys Tyr Ser Ala Thr Ala Val Ala Val Met Gly Ala Leu Ala Ile
1                               5                               10                               15

caa gcc acc cca atc aag aga gat gct tac acc cca acc gac att gat      96
Gln Ala Thr Pro Ile Lys Arg Asp Ala Tyr Thr Pro Thr Asp Ile Asp
                               20                               25                               30

atc cta cag tat gcg ttg act ctc gag cac ctg gag aac aac ttc tac     144
Ile Leu Gln Tyr Ala Leu Thr Leu Glu His Leu Glu Asn Asn Phe Tyr
                               35                               40                               45

tcc tgc gcc ctc aac aac atg gac gct caa gcg ttc gcc gat gcc gga     192
Ser Cys Ala Leu Asn Asn Met Asp Ala Gln Ala Phe Ala Asp Ala Gly
50                               55                               60

ttc cca gcc tgg gta cgg aac agg ttt gag cag att gcc gct cac gag     240
Phe Pro Ala Trp Val Arg Asn Arg Phe Glu Gln Ile Ala Ala His Glu
65                               70                               75                               80

gcc tcc cac gtc gcc gtt ctc tcc gat gcc ctc ggc gct gac gcc acc     288
Ala Ser His Val Ala Val Leu Ser Asp Ala Leu Gly Ala Asp Ala Thr
                               85                               90                               95

aag cca tgc gag tac tcc ttc cca tac acc gac gcc aaa tcg ttc acc     336
Lys Pro Cys Glu Tyr Ser Phe Pro Tyr Thr Asp Ala Lys Ser Phe Thr
                               100                              105                              110

gct ctc gct cag gtc att gag aat gtt ggt gtt tct gct tac ctc ggt     384
    
```

-continued

Ala	Leu	Ala	Gln	Val	Ile	Glu	Asn	Val	Gly	Val	Ser	Ala	Tyr	Leu	Gly		
		115					120					125					
gcc	gcc	ggt	ttc	atc	atg	gac	aag	acc	tac	ttg	acc	ggt	gct	ggt	tcc	432	
Ala	Ala	Gly	Phe	Ile	Met	Asp	Lys	Thr	Tyr	Leu	Thr	Val	Ala	Gly	Ser		
	130				135					140							
att	ctc	acc	acc	gag	gcc	cgc	cac	cag	gcc	tgg	atc	gct	tcc	gcc	ggt	480	
Ile	Leu	Thr	Thr	Glu	Ala	Arg	His	Gln	Ala	Trp	Ile	Ala	Ser	Ala	Val		
	145			150					155					160			
aac	aag	cag	aac	cca	tgg	tcc	ggc	cca	tac	gac	act	cct	ctc	ggt	ctc	528	
Asn	Lys	Gln	Asn	Pro	Trp	Ser	Gly	Pro	Tyr	Asp	Thr	Pro	Leu	Gly	Leu		
			165					170						175			
tcc	gat	gtc	tac	tcc	att	gcc	gct	gcc	ttc	atc	acc	agc	tgt	cca	tcc	576	
Ser	Asp	Val	Tyr	Ser	Ile	Ala	Ala	Phe	Ile	Thr	Ser	Cys	Pro	Ser			
		180					185					190					
tcc	aac	cca	act	ctc	cca	gtc	aag	gca	ttc	cca	gct	ctc	act	ctc	tct	624	
Ser	Asn	Pro	Thr	Leu	Pro	Val	Lys	Ala	Phe	Pro	Ala	Leu	Thr	Leu	Ser		
		195				200						205					
tgc	gac	tcc	gcc	ggt	tcg	act	gcc	acc	ctc	aac	tat	acc	ggc	gct	gat	672	
Cys	Asp	Ser	Ala	Gly	Ser	Thr	Ala	Thr	Leu	Asn	Tyr	Thr	Gly	Ala	Asp		
	210				215						220						
tca	tcc	gac	acc	ctt	att	ctc	tac	tct	ggc	ctc	acg	acc	ctc	gct	ctc	720	
Ser	Ser	Asp	Thr	Leu	Ile	Leu	Tyr	Ser	Gly	Leu	Thr	Thr	Leu	Ala	Leu		
	225			230					235					240			
ccc	atc	acc	gac	atg	atg	gtc	acc	atc	cca	tcc	tct	ctt	cag	ggc	att	768	
Pro	Ile	Thr	Asp	Met	Met	Val	Thr	Ile	Pro	Ser	Ser	Leu	Gln	Gly	Ile		
			245						250					255			
gct	tac	gca	gtc	gtg	tct	tca	acg	tct	aac	acc	acc	atg	ggt	gac	gac	816	
Ala	Tyr	Ala	Val	Val	Ser	Ser	Thr	Ser	Asn	Thr	Thr	Met	Val	Asp	Asp		
		260					265					270					
tct	aac	acc	att	gcc	ggc	cca	gcc	atc	att	gac	ctt	cct	ttc	gct	tct	864	
Ser	Asn	Thr	Ile	Ala	Gly	Pro	Ala	Ile	Ile	Asp	Leu	Pro	Phe	Ala	Ser		
	275					280						285					
tcc	gcc	agc	aac	ccc	aac	ttc	act	ggt	atg	taa						897	
Ser	Ala	Ser	Asn	Pro	Asn	Phe	Thr	Gly	Met								
	290				295												

<210> SEQ ID NO 22
 <211> LENGTH: 298
 <212> TYPE: PRT
 <213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 22

Met	Lys	Tyr	Ser	Ala	Thr	Ala	Val	Ala	Val	Met	Gly	Ala	Leu	Ala	Ile		
1			5						10					15			
Gln	Ala	Thr	Pro	Ile	Lys	Arg	Asp	Ala	Tyr	Thr	Pro	Thr	Asp	Ile	Asp		
	20						25						30				
Ile	Leu	Gln	Tyr	Ala	Leu	Thr	Leu	Glu	His	Leu	Glu	Asn	Asn	Phe	Tyr		
	35					40						45					
Ser	Cys	Ala	Leu	Asn	Asn	Met	Asp	Ala	Gln	Ala	Phe	Ala	Asp	Ala	Gly		
	50				55						60						
Phe	Pro	Ala	Trp	Val	Arg	Asn	Arg	Phe	Glu	Gln	Ile	Ala	Ala	His	Glu		
	65			70					75					80			
Ala	Ser	His	Val	Ala	Val	Leu	Ser	Asp	Ala	Leu	Gly	Ala	Asp	Ala	Thr		
		85						90					95				
Lys	Pro	Cys	Glu	Tyr	Ser	Phe	Pro	Tyr	Thr	Asp	Ala	Lys	Ser	Phe	Thr		
		100						105					110				
Ala	Leu	Ala	Gln	Val	Ile	Glu	Asn	Val	Gly	Val	Ser	Ala	Tyr	Leu	Gly		
		115					120						125				

-continued

Ala Ala Gly Phe Ile Met Asp Lys Thr Tyr Leu Thr Val Ala Gly Ser
 130 135 140

Ile Leu Thr Thr Glu Ala Arg His Gln Ala Trp Ile Ala Ser Ala Val
 145 150 155 160

Asn Lys Gln Asn Pro Trp Ser Gly Pro Tyr Asp Thr Pro Leu Gly Leu
 165 170 175

Ser Asp Val Tyr Ser Ile Ala Ala Ala Phe Ile Thr Ser Cys Pro Ser
 180 185 190

Ser Asn Pro Thr Leu Pro Val Lys Ala Phe Pro Ala Leu Thr Leu Ser
 195 200 205

Cys Asp Ser Ala Gly Ser Thr Ala Thr Leu Asn Tyr Thr Gly Ala Asp
 210 215 220

Ser Ser Asp Thr Leu Ile Leu Tyr Ser Gly Leu Thr Thr Leu Ala Leu
 225 230 235 240

Pro Ile Thr Asp Met Met Val Thr Ile Pro Ser Ser Leu Gln Gly Ile
 245 250 255

Ala Tyr Ala Val Val Ser Ser Thr Ser Asn Thr Thr Met Val Asp Asp
 260 265 270

Ser Asn Thr Ile Ala Gly Pro Ala Ile Ile Asp Leu Pro Phe Ala Ser
 275 280 285

Ser Ala Ser Asn Pro Asn Phe Thr Gly Met
 290 295

<210> SEQ ID NO 23
 <211> LENGTH: 534
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(534)

<400> SEQUENCE: 23

atg tct cta act agt gtc act cgc gtc gta tcc aaa tcc atc ctc ggc 48
 Met Ser Leu Thr Ser Val Thr Arg Val Lys Ser Ile Leu Gly
 1 5 10 15

gct tcc ttt act agc aca act cgc agg ctt acc act acc gtt ccc aga 96
 Ala Ser Phe Thr Ser Thr Thr Arg Arg Leu Thr Thr Thr Val Pro Arg
 20 25 30

ttt ggt aga atg cct cct cct gct cac aag atg gcc cac ttc ccg agg 144
 Phe Gly Arg Met Pro Pro Pro Ala His Lys Met Ala His Phe Pro Arg
 35 40 45

atc aca tcc tct ctt ccc tca gaa cac tct gag ttt aga aca gtg atg 192
 Ile Thr Ser Ser Leu Pro Ser Glu His Ser Glu Phe Arg Thr Val Met
 50 55 60

tgg acg ggc gag agc agt caa ctt gtc ctc atg act atc cct gtc gga 240
 Trp Thr Gly Glu Ser Ser Gln Leu Val Leu Met Thr Ile Pro Val Gly
 65 70 75 80

gga gaa ata ggg gaa gaa att cac cat gtt gac caa cac ttg gtt ttc 288
 Gly Glu Ile Gly Glu Glu Ile His His Val Asp Gln His Leu Val Phe
 85 90 95

acc tct ggt act gcc aag gcc att gtt gga gga gaa gaa aaa gag atc 336
 Thr Ser Gly Thr Ala Lys Ala Ile Val Gly Gly Glu Glu Lys Glu Ile
 100 105 110

aag gct gga gat ctt gtc atc gtt cct cag ggt acc aag cat aac ttc 384
 Lys Ala Gly Asp Leu Val Ile Val Pro Gln Gly Thr Lys His Asn Phe
 115 120 125

gtc aat acg ggc cct acc cct ctt tgc ctt ttt act gta tat gct ccg 432
 Val Asn Thr Gly Pro Thr Pro Leu Cys Leu Phe Thr Val Tyr Ala Pro
 130 135 140

-continued

gcc gag cat gcc gag aca aca gtc aac aaa acg aag gag gaa ggg gat 480
 Ala Glu His Ala Glu Thr Thr Val Asn Lys Thr Lys Glu Glu Gly Asp
 145 150 155 160

aaa ttg gaa gac gag ggc aag gat gag cct cca aag tgg gca gtt agg 528
 Lys Leu Glu Asp Glu Gly Lys Asp Glu Pro Pro Lys Trp Ala Val Arg
 165 170 175

aag tag 534
 Lys

<210> SEQ ID NO 24

<211> LENGTH: 177

<212> TYPE: PRT

<213> ORGANISM: *Cryptococcus neoformans*

<400> SEQUENCE: 24

Met Ser Leu Thr Ser Val Thr Arg Val Val Ser Lys Ser Ile Leu Gly
 1 5 10 15

Ala Ser Phe Thr Ser Thr Thr Arg Arg Leu Thr Thr Thr Val Pro Arg
 20 25 30

Phe Gly Arg Met Pro Pro Pro Ala His Lys Met Ala His Phe Pro Arg
 35 40 45

Ile Thr Ser Ser Leu Pro Ser Glu His Ser Glu Phe Arg Thr Val Met
 50 55 60

Trp Thr Gly Glu Ser Ser Gln Leu Val Leu Met Thr Ile Pro Val Gly
 65 70 75 80

Gly Glu Ile Gly Glu Glu Ile His His Val Asp Gln His Leu Val Phe
 85 90 95

Thr Ser Gly Thr Ala Lys Ala Ile Val Gly Gly Glu Glu Lys Glu Ile
 100 105 110

Lys Ala Gly Asp Leu Val Ile Val Pro Gln Gly Thr Lys His Asn Phe
 115 120 125

Val Asn Thr Gly Pro Thr Pro Leu Cys Leu Phe Thr Val Tyr Ala Pro
 130 135 140

Ala Glu His Ala Glu Thr Thr Val Asn Lys Thr Lys Glu Glu Gly Asp
 145 150 155 160

Lys Leu Glu Asp Glu Gly Lys Asp Glu Pro Pro Lys Trp Ala Val Arg
 165 170 175

Lys

<210> SEQ ID NO 25

<211> LENGTH: 1074

<212> TYPE: DNA

<213> ORGANISM: *Cryptococcus neoformans*

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(1074)

<400> SEQUENCE: 25

atg cca act gta ctc ctc aca ggt atc acg gga ttt ctg tct gcg cac 48
 Met Pro Thr Val Leu Leu Thr Gly Ile Thr Gly Phe Leu Ser Ala His
 1 5 10 15

gtc gcc cat acc ttc ctg aag cat gac tgg ata gtg cac ggc aca ctt 96
 Val Ala His Thr Phe Leu Lys His Asp Trp Ile Val His Gly Thr Leu
 20 25 30

egg tcc agc tcg aag gta gcg tta atc gaa gtt att cct gaa tac tct 144
 Arg Ser Ser Ser Lys Val Ala Leu Ile Glu Val Ile Pro Glu Tyr Ser
 35 40 45

cct tat att tog tca ggc aaa cta aaa ctc ttc gtt gtc gga cct ctt 192

-continued

<210> SEQ ID NO 26
 <211> LENGTH: 357
 <212> TYPE: PRT
 <213> ORGANISM: *Cryptococcus neoformans*
 <400> SEQUENCE: 26

Met Pro Thr Val Leu Leu Thr Gly Ile Thr Gly Phe Leu Ser Ala His
 1 5 10 15
 Val Ala His Thr Phe Leu Lys His Asp Trp Ile Val His Gly Thr Leu
 20 25 30
 Arg Ser Ser Ser Lys Val Ala Leu Ile Glu Val Ile Pro Glu Tyr Ser
 35 40 45
 Pro Tyr Ile Ser Ser Gly Lys Leu Lys Leu Phe Val Val Gly Pro Leu
 50 55 60
 Glu Asn Ala Asp Tyr Thr Glu Ala Met Lys Gly Val Asp Ala Val Val
 65 70 75 80
 His Thr Ala Ser Pro Val Glu Phe Gly Gly Asp Asn Phe Arg Glu Ser
 85 90 95
 His Leu Lys Pro Ala Leu Glu Gly Thr Arg Gly Val Leu Arg Ala Val
 100 105 110
 Ala Lys Glu Lys Asn Val Lys Ser Val Val Tyr Thr Ser Thr Phe Gly
 115 120 125
 Ala Val Gly Asp His Arg Tyr His Pro Thr Glu Ile Lys Gly Lys Val
 130 135 140
 Ile Thr Glu Asp Asn Trp Asn Pro Tyr Thr Leu Glu Glu Leu Asp Lys
 145 150 155 160
 Met Val Glu Ser Gly Glu Ser Gly Asn Pro Thr Phe Pro Pro Gly Tyr
 165 170 175
 Leu Phe Tyr Lys Gly Ala Lys Lys Tyr Ala Glu Leu Ala Ala Trp Glu
 180 185 190
 Cys Gln Lys Glu Ala Arg Glu Gln Gly Ala Glu Trp Ser Leu Ala Thr
 195 200 205
 Met Asn Cys Val Met Ile Trp Gly Pro Pro Ile Gln Pro Leu Thr Ser
 210 215 220
 Leu Ser His Gly Gly Met Ser Thr Glu Phe Leu Trp Met Leu Ala Gly
 225 230 235 240
 Gly Lys Asp Ala His Ile Met Asp Ser Leu Tyr Pro Tyr Tyr Val Asp
 245 250 255
 Val Arg Asp Ala Ala Glu Ala His Tyr Gln Ala Thr Val Arg Arg Ala
 260 265 270
 Gln Gly Arg Phe Ile Ile Ser Ala Gly Pro Tyr Asp Phe Gln Glu Phe
 275 280 285
 Ala Asp Met Leu Arg Glu Leu Tyr Pro Glu Gln Lys Glu Arg Phe Ala
 290 295 300
 Leu Gly Ala Pro Gly Lys Tyr Met Tyr Arg Asp Pro Gly Val Tyr Val
 305 310 315 320
 Leu Thr Asn Glu Lys Ser Gln Arg Glu Leu Gly Ile Thr Tyr Arg Pro
 325 330 335
 Lys Gln Glu Thr Leu Lys Asp Ala Phe Asp Arg Phe Phe Ala Leu Glu
 340 345 350
 Lys Gln Gly Leu Lys
 355

<210> SEQ ID NO 27

-continued

```

<211> LENGTH: 2781
<212> TYPE: DNA
<213> ORGANISM: Cryptococcus neoformans
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(2781)

<400> SEQUENCE: 27
atg ttt agg aag aga att ctt tat ctt tct tct ttt tca atc cct ttg      48
Met Phe Arg Lys Arg Ile Leu Tyr Leu Ser Ser Phe Ser Ile Pro Leu
1          5          10          15

tac aca gtc cca gcc cac agt tat tcc tgt act ttt cag acc aac cag      96
Tyr Thr Val Pro Ala His Ser Tyr Ser Cys Thr Phe Gln Thr Asn Gln
          20          25          30

cgc cct tct act ctc ctc aaa cgc gta cat tcg ctc gct atg tcc ttc      144
Arg Pro Ser Thr Leu Leu Lys Arg Val His Ser Leu Ala Met Ser Phe
          35          40          45

ccg cca gtg cag ccc gcc gac aat ggc atg gcg gtc gtt gct ccc aat      192
Pro Pro Val Gln Pro Ala Asp Asn Gly Met Ala Val Val Ala Pro Asn
          50          55          60

ctc gag tct aac cct acc act gtt gcg tcc cac gcc cca caa att gcc      240
Leu Glu Ser Asn Pro Thr Thr Val Ala Ser His Ala Pro Gln Ile Ala
65          70          75          80

gtc aag gat gaa aat gat agt atg agc gag gat gag cag cct ttg gcg      288
Val Lys Asp Glu Asn Asp Ser Met Ser Glu Asp Glu Gln Pro Leu Ala
          85          90          95

aaa agc aaa gcg aat gga gcg agg aag aga gtc gaa aac agc agt gac      336
Lys Ser Lys Ala Asn Gly Ala Arg Lys Arg Val Glu Asn Ser Ser Asp
          100          105          110

gag gaa gag aaa cct ctc agc aaa aag ccc aga gcc aat ggt gtc aac      384
Glu Glu Lys Lys Pro Leu Ser Lys Lys Pro Arg Ala Asn Gly Val Asn
          115          120          125

aag aaa agg gtc gtc gcc agc agt gat gaa gaa agc gat gtt tca cct      432
Lys Lys Arg Val Val Ala Ser Ser Asp Glu Glu Ser Asp Val Ser Pro
          130          135          140

cct gct aag agg cct gtt tcc aag caa tcc aaa cct gcc acc ccc gat      480
Pro Ala Lys Arg Pro Val Ser Lys Gln Ser Lys Pro Ala Thr Pro Asp
          145          150          155

tct gaa tct gat gac gat caa cct ctc gcc aag aag gct aac gga ctg      528
Ser Glu Ser Asp Asp Asp Gln Pro Leu Ala Lys Lys Ala Asn Gly Leu
          165          170          175

gcc gca tcc aaa cgt cag gct aaa aaa gcg gag gaa tta tca gaa gaa      576
Ala Ala Ser Lys Arg Gln Ala Lys Lys Ala Glu Glu Leu Ser Glu Glu
          180          185          190

agc tcg gag gaa gaa aag cct ctt gcg aag gtt gcc aag agg gta tca      624
Ser Ser Glu Glu Glu Lys Pro Leu Ala Lys Val Ala Lys Arg Val Ser
          195          200          205

gca aag aag atg aag agc gag act gag gac tct gag gaa gac cgg cct      672
Ala Lys Lys Met Lys Ser Glu Thr Glu Asp Ser Glu Glu Asp Arg Pro
          210          215          220

ctt gca aag aag aag gct cct gtt aag cgt gct cca gca aag aaa tcg      720
Leu Ala Lys Lys Lys Ala Pro Val Lys Arg Ala Pro Ala Lys Lys Ser
          225          230          235          240

gcg aag aag gaa cct agt gag agt gaa gag gat gag aag cct tta gcg      768
Ala Lys Lys Glu Pro Ser Glu Ser Glu Glu Asp Glu Lys Pro Leu Ala
          245          250          255

aag aac gct aga ggg aag gcc aag gcg gcg acg gtg aag gaa gag aaa      816
Lys Asn Ala Arg Gly Lys Ala Lys Ala Ala Thr Val Lys Glu Glu Lys
          260          265          270

ggg aag aag aca aag aag gag aaa gaa gag gaa gaa gag gag gaa agg      864
Gly Lys Lys Thr Lys Lys Glu Lys Glu Glu Glu Glu Glu Glu Glu Arg

```

-continued

275			280			285										
tac	aag	tgg	tgg	gaa	cag	gat	gct	ttg	ggg	gat	ggg	tca	tcc	aag	tgg	912
Tyr	Lys	Trp	Trp	Glu	Gln	Asp	Ala	Leu	Gly	Asp	Gly	Ser	Ser	Lys	Trp	
	290					295					300					
acg	gtc	ctt	gag	cac	aac	gct	ggt	ctc	ttc	cct	cct	cct	tat	ggt	cct	960
Thr	Val	Leu	Glu	His	Asn	Ala	Val	Leu	Phe	Pro	Pro	Pro	Tyr	Val	Pro	
	305				310					315					320	
tta	ccc	aag	aac	gtg	aaa	atg	aag	tac	gat	ggc	gtc	tca	ctt	acc	ctc	1008
Leu	Pro	Lys	Asn	Val	Lys	Met	Lys	Tyr	Asp	Gly	Val	Ser	Leu	Thr	Leu	
				325					330					335		
cct	ccc	gag	tct	gaa	gaa	gtc	gcc	ggg	ttc	ttc	ggg	gcc	ctc	ctt	gaa	1056
Pro	Pro	Glu	Ser	Glu	Glu	Val	Ala	Gly	Phe	Phe	Gly	Ala	Leu	Leu	Glu	
				340				345						350		
acc	gac	tat	gct	caa	gat	gcc	aaa	ttc	cgt	gaa	aac	ttt	ttc	cga	gac	1104
Thr	Asp	Tyr	Ala	Gln	Asp	Ala	Lys	Phe	Arg	Glu	Asn	Phe	Phe	Arg	Asp	
		355				360								365		
ttt	aag	gct	atc	gtc	gaa	aaa	tat	cca	ccc	aag	gag	gac	gtc	aag	ggt	1152
Phe	Lys	Ala	Ile	Val	Glu	Lys	Tyr	Pro	Pro	Lys	Glu	Asp	Val	Lys	Val	
	370					375					380					
aag	aag	ttg	gaa	aag	tgc	gat	ttt	aga	ccg	atg	ttt	gag	tac	ttt	gaa	1200
Lys	Lys	Leu	Glu	Lys	Cys	Asp	Phe	Arg	Pro	Met	Phe	Glu	Tyr	Phe	Glu	
	385				390				395						400	
aag	gag	aag	gag	aag	aag	aag	gcg	ttg	act	aag	gaa	gag	aaa	aag	gcg	1248
Lys	Glu	Lys	Glu	Lys	Lys	Lys	Ala	Leu	Thr	Lys	Glu	Glu	Lys	Lys	Ala	
				405				410						415		
att	aaa	gcg	gag	aag	gac	aag	ctt	gaa	gca	ccg	tat	ctc	tat	gcg	aat	1296
Ile	Lys	Ala	Glu	Lys	Asp	Lys	Leu	Glu	Ala	Pro	Tyr	Leu	Tyr	Ala	Asn	
			420					425						430		
ggt	gat	gga	agg	aag	gaa	aag	gtc	ggc	aac	ttc	cgt	gca	gaa	cct	cct	1344
Val	Asp	Gly	Arg	Lys	Glu	Lys	Val	Gly	Asn	Phe	Arg	Ala	Glu	Pro	Pro	
		435					440							445		
gga	ttg	ttc	aag	ggg	cgt	ggg	gaa	cat	ccc	aag	aag	ggg	act	gtc	aag	1392
Gly	Leu	Phe	Lys	Gly	Arg	Gly	Glu	His	Pro	Lys	Lys	Gly	Thr	Val	Lys	
	450					455						460				
aac	cgt	ctc	cga	cct	gaa	gat	atc	att	atc	aac	att	ggc	aaa	gaa	gct	1440
Asn	Arg	Leu	Arg	Pro	Glu	Asp	Ile	Ile	Ile	Asn	Ile	Gly	Lys	Glu	Ala	
	465				470					475					480	
cct	atc	cct	gtg	ccc	aac	att	ccc	ggg	cag	tgg	aag	ggg	atc	cag	cat	1488
Pro	Ile	Pro	Val	Pro	Asn	Ile	Pro	Gly	Gln	Trp	Lys	Gly	Ile	Gln	His	
				485					490					495		
gat	aac	aca	gtg	act	tgg	ctc	gct	cat	tgg	aag	gag	aat	gtc	aac	ggg	1536
Asp	Asn	Thr	Val	Thr	Trp	Leu	Ala	His	Trp	Lys	Glu	Asn	Val	Asn	Gly	
			500					505						510		
aac	gcc	aaa	tac	gtc	ttc	ttg	agc	gct	ggg	agt	gcg	tgg	aaa	ggg	caa	1584
Asn	Ala	Lys	Tyr	Val	Phe	Leu	Ser	Ala	Gly	Ser	Ala	Trp	Lys	Gly	Gln	
		515						520						525		
agt	gat	cgt	gcc	aag	ttt	gaa	aag	gcc	cgt	gag	ctt	atc	aaa	cat	gtc	1632
Ser	Asp	Arg	Ala	Lys	Phe	Glu	Lys	Ala	Arg	Glu	Leu	Ile	Lys	His	Val	
		530				535								540		
gac	aaa	att	cga	aaa	gac	tac	act	gcc	gac	ctc	aaa	tcc	aaa	gtc	atg	1680
Asp	Lys	Ile	Arg	Lys	Asp	Tyr	Thr	Ala	Asp	Leu	Lys	Ser	Lys	Val	Met	
		545				550				555					560	
gct	gac	cga	caa	cgt	gcc	acc	gcc	ctg	tac	ttt	atc	gat	cgt	ctg	gct	1728
Ala	Asp	Arg	Gln	Arg	Ala	Thr	Ala	Leu	Tyr	Phe	Ile	Asp	Arg	Leu	Ala	
				565					570					575		
ctg	cga	gcg	ggg	aat	gaa	aag	ggg	gaa	gat	gaa	gcg	gat	act	gtc	ggc	1776
Leu	Arg	Ala	Gly	Asn	Glu	Lys	Gly	Glu	Asp	Glu	Ala	Asp	Thr	Val	Gly	
			580					585						590		
tgt	tgt	tct	ctg	cga	tac	gaa	cac	gtg	acg	ctc	tct	cca	ccg	aat	act	1824

-continued

Cys	Cys	Ser	Leu	Arg	Tyr	Glu	His	Val	Thr	Leu	Ser	Pro	Pro	Asn	Thr	
		595					600					605				
atc	atc	ttt	gat	ttc	ctc	ggg	aag	gac	tcg	atg	agg	ttc	cat	cag	gaa	1872
Ile	Ile	Phe	Asp	Phe	Leu	Gly	Lys	Asp	Ser	Met	Arg	Phe	His	Gln	Glu	
610						615					620					
gtc	gag	gtc	gat	ccg	caa	gtg	ttc	aag	aac	ata	aaa	ctg	ttt	aag	gct	1920
Val	Glu	Val	Asp	Pro	Gln	Val	Phe	Lys	Asn	Ile	Lys	Leu	Phe	Lys	Ala	
625					630					635					640	
gat	ccg	aag	aag	aag	ggg	gac	gat	atc	ttt	gac	cga	ctg	acc	acc	act	1968
Asp	Pro	Lys	Lys	Lys	Gly	Asp	Asp	Ile	Phe	Asp	Arg	Leu	Thr	Thr	Thr	
				645					650					655		
ctt	ctt	aac	aag	cac	ctc	aac	agc	atg	atg	cct	ggg	ctt	acc	gcc	aag	2016
Leu	Leu	Asn	Lys	His	Leu	Asn	Ser	Met	Met	Pro	Gly	Leu	Thr	Ala	Lys	
				660					665					670		
gtt	ttc	cgt	acc	tac	aac	gcc	tca	tgg	act	ttc	caa	gaa	caa	ctc	aaa	2064
Val	Phe	Arg	Thr	Tyr	Asn	Ala	Ser	Trp	Thr	Phe	Gln	Glu	Gln	Leu	Lys	
		675				680								685		
aac	aca	cct	aag	aac	gga	act	gta	gcc	gag	aag	att	gcg	gcg	tac	aac	2112
Asn	Thr	Pro	Lys	Asn	Gly	Thr	Val	Ala	Glu	Lys	Ile	Ala	Ala	Tyr	Asn	
		690				695					700					
act	gcc	aat	agg	gat	ggt	gcc	atc	ttg	tgt	aat	cac	caa	aag	agt	gtc	2160
Thr	Ala	Asn	Arg	Asp	Val	Ala	Ile	Leu	Cys	Asn	His	Gln	Lys	Ser	Val	
705					710					715					720	
agc	aag	ggg	ttt	gag	ggc	agt	ttt	gcc	aaa	gcc	gag	gat	aag	att	cgt	2208
Ser	Lys	Gly	Phe	Glu	Gly	Ser	Phe	Ala	Lys	Ala	Glu	Asp	Lys	Ile	Arg	
				725					730					735		
gcc	ctc	aag	tat	cag	cgt	ctc	aag	ctt	cgt	ctc	caa	ctt	ttt	tct	ctt	2256
Ala	Leu	Lys	Tyr	Gln	Arg	Leu	Lys	Leu	Arg	Leu	Gln	Leu	Phe	Ser	Leu	
			740					745						750		
aac	ccc	aag	att	aag	aag	aag	cat	ccc	gag	ctt	gcg	gag	gat	gag	tct	2304
Asn	Pro	Lys	Ile	Lys	Lys	Lys	His	Pro	Glu	Leu	Ala	Glu	Asp	Glu	Ser	
		755					760							765		
gat	gtg	gat	gac	gaa	ttt	atg	gag	cgc	cac	gaa	gcc	gaa	tta	ctc	gaa	2352
Asp	Val	Asp	Asp	Glu	Phe	Met	Glu	Arg	His	Glu	Ala	Glu	Leu	Leu	Glu	
						775						780				
aaa	gct	ttg	gag	aac	gca	aag	aag	aaa	tgg	gat	acg	gat	aat	gtc	aag	2400
Lys	Ala	Leu	Glu	Asn	Ala	Lys	Lys	Lys	Trp	Asp	Thr	Asp	Asn	Val	Lys	
785					790					795					800	
ctt	gaa	ggg	gat	ggg	aag	aaa	aag	aag	acg	aag	gga	gag	ttg	gat	gag	2448
Leu	Glu	Gly	Asp	Gly	Lys	Lys	Lys	Lys	Thr	Lys	Gly	Glu	Leu	Asp	Glu	
				805						810				815		
agg	ttg	agt	gag	atc	aag	gca	gag	ttt	aag	gag	ttg	aag	aag	gag	agg	2496
Arg	Leu	Ser	Glu	Ile	Lys	Ala	Glu	Phe	Lys	Glu	Leu	Lys	Lys	Glu	Arg	
				820					825					830		
aag	gct	aaa	aag	att	gat	gcc	aag	aga	gga	gcc	acg	gag	gag	aaa	ctt	2544
Lys	Ala	Lys	Lys	Ile	Asp	Ala	Lys	Arg	Gly	Ala	Thr	Glu	Glu	Lys	Leu	
				835				840						845		
ctt	gct	cag	gtc	gcc	agg	atc	gac	gaa	cgt	atc	gct	acc	gcc	aaa	gtc	2592
Leu	Ala	Gln	Val	Ala	Arg	Ile	Asp	Glu	Arg	Ile	Ala	Thr	Ala	Lys	Val	
				850			855							860		
cag	ctt	caa	gat	cga	gac	aag	ctc	aag	gat	ggt	gct	ttg	ggc	aca	tcc	2640
Gln	Leu	Gln	Asp	Arg	Asp	Lys	Leu	Lys	Asp	Val	Ala	Leu	Gly	Thr	Ser	
865					870					875					880	
aag	att	aac	tat	atc	gat	cca	aga	cta	act	gtc	gcg	tgg	gcg	aag	aag	2688
Lys	Ile	Asn	Tyr	Ile	Asp	Pro	Arg	Leu	Thr	Val	Ala	Trp	Ala	Lys	Lys	
				885					890					895		
ttt	gat	ggt	cct	ctc	gaa	aaa	ctg	ttc	tcc	aaa	acc	ctg	cga	gaa	aag	2736
Phe	Asp	Val	Pro	Leu	Glu	Lys	Leu	Phe	Ser	Lys	Thr	Leu	Arg	Glu	Lys	
				900					905					910		

-continued

```

ttc cct tgg gct gag gcg gag gct gga ccg gac tgg gtt ttc tag      2781
Phe Pro Trp Ala Glu Ala Glu Ala Gly Pro Asp Trp Val Phe
      915                920                925

```

```

<210> SEQ ID NO 28
<211> LENGTH: 926
<212> TYPE: PRT
<213> ORGANISM: Cryptococcus neoformans

```

```

<400> SEQUENCE: 28

```

```

Met Phe Arg Lys Arg Ile Leu Tyr Leu Ser Ser Phe Ser Ile Pro Leu
 1      5      10      15
Tyr Thr Val Pro Ala His Ser Tyr Ser Cys Thr Phe Gln Thr Asn Gln
 20      25      30
Arg Pro Ser Thr Leu Leu Lys Arg Val His Ser Leu Ala Met Ser Phe
 35      40      45
Pro Pro Val Gln Pro Ala Asp Asn Gly Met Ala Val Val Ala Pro Asn
 50      55      60
Leu Glu Ser Asn Pro Thr Thr Val Ala Ser His Ala Pro Gln Ile Ala
 65      70      75      80
Val Lys Asp Glu Asn Asp Ser Met Ser Glu Asp Glu Gln Pro Leu Ala
 85      90      95
Lys Ser Lys Ala Asn Gly Ala Arg Lys Arg Val Glu Asn Ser Ser Asp
 100     105     110
Glu Glu Glu Lys Pro Leu Ser Lys Lys Pro Arg Ala Asn Gly Val Asn
 115     120     125
Lys Lys Arg Val Val Ala Ser Ser Asp Glu Glu Ser Asp Val Ser Pro
 130     135     140
Pro Ala Lys Arg Pro Val Ser Lys Gln Ser Lys Pro Ala Thr Pro Asp
 145     150     155     160
Ser Glu Ser Asp Asp Asp Gln Pro Leu Ala Lys Lys Ala Asn Gly Leu
 165     170     175
Ala Ala Ser Lys Arg Gln Ala Lys Lys Ala Glu Glu Leu Ser Glu Glu
 180     185     190
Ser Ser Glu Glu Glu Lys Pro Leu Ala Lys Val Ala Lys Arg Val Ser
 195     200     205
Ala Lys Lys Met Lys Ser Glu Thr Glu Asp Ser Glu Glu Asp Arg Pro
 210     215     220
Leu Ala Lys Lys Lys Ala Pro Val Lys Arg Ala Pro Ala Lys Lys Ser
 225     230     235     240
Ala Lys Lys Glu Pro Ser Glu Ser Glu Glu Asp Glu Lys Pro Leu Ala
 245     250     255
Lys Asn Ala Arg Gly Lys Ala Lys Ala Ala Thr Val Lys Glu Glu Lys
 260     265     270
Gly Lys Lys Thr Lys Lys Glu Lys Glu Glu Glu Glu Glu Glu Arg
 275     280     285
Tyr Lys Trp Trp Glu Gln Asp Ala Leu Gly Asp Gly Ser Ser Lys Trp
 290     295     300
Thr Val Leu Glu His Asn Ala Val Leu Phe Pro Pro Pro Tyr Val Pro
 305     310     315     320
Leu Pro Lys Asn Val Lys Met Lys Tyr Asp Gly Val Ser Leu Thr Leu
 325     330     335
Pro Pro Glu Ser Glu Glu Val Ala Gly Phe Phe Gly Ala Leu Leu Glu
 340     345     350
Thr Asp Tyr Ala Gln Asp Ala Lys Phe Arg Glu Asn Phe Phe Arg Asp

```

-continued

355					360					365					
Phe	Lys	Ala	Ile	Val	Glu	Lys	Tyr	Pro	Pro	Lys	Glu	Asp	Val	Lys	Val
370						375					380				
Lys	Lys	Leu	Glu	Lys	Cys	Asp	Phe	Arg	Pro	Met	Phe	Glu	Tyr	Phe	Glu
385					390					395					400
Lys	Glu	Lys	Glu	Lys	Lys	Lys	Ala	Leu	Thr	Lys	Glu	Glu	Lys	Lys	Ala
				405					410					415	
Ile	Lys	Ala	Glu	Lys	Asp	Lys	Leu	Glu	Ala	Pro	Tyr	Leu	Tyr	Ala	Asn
			420					425						430	
Val	Asp	Gly	Arg	Lys	Glu	Lys	Val	Gly	Asn	Phe	Arg	Ala	Glu	Pro	Pro
		435					440					445			
Gly	Leu	Phe	Lys	Gly	Arg	Gly	Glu	His	Pro	Lys	Lys	Gly	Thr	Val	Lys
450						455						460			
Asn	Arg	Leu	Arg	Pro	Glu	Asp	Ile	Ile	Ile	Asn	Ile	Gly	Lys	Glu	Ala
465					470					475					480
Pro	Ile	Pro	Val	Pro	Asn	Ile	Pro	Gly	Gln	Trp	Lys	Gly	Ile	Gln	His
			485						490					495	
Asp	Asn	Thr	Val	Thr	Trp	Leu	Ala	His	Trp	Lys	Glu	Asn	Val	Asn	Gly
			500					505						510	
Asn	Ala	Lys	Tyr	Val	Phe	Leu	Ser	Ala	Gly	Ser	Ala	Trp	Lys	Gly	Gln
		515					520					525			
Ser	Asp	Arg	Ala	Lys	Phe	Glu	Lys	Ala	Arg	Glu	Leu	Ile	Lys	His	Val
		530				535					540				
Asp	Lys	Ile	Arg	Lys	Asp	Tyr	Thr	Ala	Asp	Leu	Lys	Ser	Lys	Val	Met
545					550					555					560
Ala	Asp	Arg	Gln	Arg	Ala	Thr	Ala	Leu	Tyr	Phe	Ile	Asp	Arg	Leu	Ala
			565					570						575	
Leu	Arg	Ala	Gly	Asn	Glu	Lys	Gly	Glu	Asp	Glu	Ala	Asp	Thr	Val	Gly
			580					585					590		
Cys	Cys	Ser	Leu	Arg	Tyr	Glu	His	Val	Thr	Leu	Ser	Pro	Pro	Asn	Thr
		595					600					605			
Ile	Ile	Phe	Asp	Phe	Leu	Gly	Lys	Asp	Ser	Met	Arg	Phe	His	Gln	Glu
610						615					620				
Val	Glu	Val	Asp	Pro	Gln	Val	Phe	Lys	Asn	Ile	Lys	Leu	Phe	Lys	Ala
625					630					635					640
Asp	Pro	Lys	Lys	Lys	Gly	Asp	Asp	Ile	Phe	Asp	Arg	Leu	Thr	Thr	Thr
			645					650						655	
Leu	Leu	Asn	Lys	His	Leu	Asn	Ser	Met	Met	Pro	Gly	Leu	Thr	Ala	Lys
		660						665						670	
Val	Phe	Arg	Thr	Tyr	Asn	Ala	Ser	Trp	Thr	Phe	Gln	Glu	Gln	Leu	Lys
		675					680					685			
Asn	Thr	Pro	Lys	Asn	Gly	Thr	Val	Ala	Glu	Lys	Ile	Ala	Ala	Tyr	Asn
690						695					700				
Thr	Ala	Asn	Arg	Asp	Val	Ala	Ile	Leu	Cys	Asn	His	Gln	Lys	Ser	Val
705					710					715					720
Ser	Lys	Gly	Phe	Glu	Gly	Ser	Phe	Ala	Lys	Ala	Glu	Asp	Lys	Ile	Arg
			725						730					735	
Ala	Leu	Lys	Tyr	Gln	Arg	Leu	Lys	Leu	Arg	Leu	Gln	Leu	Phe	Ser	Leu
			740					745					750		
Asn	Pro	Lys	Ile	Lys	Lys	Lys	His	Pro	Glu	Leu	Ala	Glu	Asp	Glu	Ser
		755					760						765		
Asp	Val	Asp	Asp	Glu	Phe	Met	Glu	Arg	His	Glu	Ala	Glu	Leu	Leu	Glu
770						775							780		

-continued

Lys Ala Leu Glu Asn Ala Lys Lys Lys Trp Asp Thr Asp Asn Val Lys
 785 790 795 800
 Leu Glu Gly Asp Gly Lys Lys Lys Lys Thr Lys Gly Glu Leu Asp Glu
 805 810 815
 Arg Leu Ser Glu Ile Lys Ala Glu Phe Lys Glu Leu Lys Lys Glu Arg
 820 825 830
 Lys Ala Lys Lys Ile Asp Ala Lys Arg Gly Ala Thr Glu Glu Lys Leu
 835 840 845
 Leu Ala Gln Val Ala Arg Ile Asp Glu Arg Ile Ala Thr Ala Lys Val
 850 855 860
 Gln Leu Gln Asp Arg Asp Lys Leu Lys Asp Val Ala Leu Gly Thr Ser
 865 870 875 880
 Lys Ile Asn Tyr Ile Asp Pro Arg Leu Thr Val Ala Trp Ala Lys Lys
 885 890 895
 Phe Asp Val Pro Leu Glu Lys Leu Phe Ser Lys Thr Leu Arg Glu Lys
 900 905 910
 Phe Pro Trp Ala Glu Ala Glu Ala Gly Pro Asp Trp Val Phe
 915 920 925

<210> SEQ ID NO 29
 <211> LENGTH: 1125
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1125)

<400> SEQUENCE: 29

atg gcc cac cac cac ttc gta ggc ata aac ccg gca ggc ctc tcc ttc	48
Met Ala His His His Phe Val Gly Ile Asn Pro Ala Gly Leu Ser Phe	
1 5 10 15	
tcc cat ccc acc ccg cca gca gac cac ccc gcg ccc ccc tcc tcg ggc	96
Ser His Pro Thr Pro Pro Ala Asp His Pro Ala Pro Pro Ser Ser Gly	
20 25 30	
agc atc cac acc cca gca aac ttc gcc agc att caa gaa ccc atc aca	144
Ser Ile His Thr Pro Ala Asn Phe Ala Ser Ile Gln Glu Pro Ile Thr	
35 40 45	
gac cca tcc gct gtc gcc gcc cgc cga cgc ggt cgt cct tcc aca agg	192
Asp Pro Ser Ala Val Ala Ala Arg Arg Arg Gly Arg Pro Ser Thr Arg	
50 55 60	
ggc gaa gct ggc gtc act ccg ccc cca gag atc gga tgg tgg gag gac	240
Gly Glu Ala Gly Val Thr Pro Pro Pro Glu Ile Gly Trp Trp Glu Asp	
65 70 75 80	
cgt gcg ccc agc tgg cac aag gat gcc atg cag gcc ggc aag tct tct	288
Arg Ala Pro Ser Trp His Lys Asp Ala Met Gln Gly Gly Lys Ser Ser	
85 90 95	
atg gag ctc ctg atg gaa tgg tca gag gag atg aag aat caa ggc cac	336
Met Glu Leu Leu Met Glu Trp Ser Glu Glu Met Lys Asn Gln Gly His	
100 105 110	
tac tac tgg atg ggc gtc agg gat gcc gcc aat ctg cat caa ggt gct	384
Tyr Tyr Trp Met Gly Val Arg Asp Gly Gly Asn Leu His Gln Gly Ala	
115 120 125	
tcg cgt ttt agg gac tac tta tat gcc cag cat ggt cct att agg cgg	432
Ser Arg Phe Arg Asp Tyr Leu Tyr Ala Gln His Gly Pro Ile Arg Arg	
130 135 140	
tca agt aag gct atc aga aat aaa gtg gag aat att aag caa aag ttc	480
Ser Ser Lys Ala Ile Arg Asn Lys Val Glu Asn Ile Lys Gln Lys Phe	
145 150 155 160	

-continued

```

ttt gaa gcc cag gaa tgg ctc aag gat ccc aat ggg gac cat acc acc 528
Phe Glu Ala Gln Glu Trp Leu Lys Asp Pro Asn Gly Asp His Thr Thr
      165                      170                      175

atg acc att ccg gac gtc gaa aaa aaa ctc aac aag atc tgt cgc aac 576
Met Thr Ile Pro Asp Val Glu Lys Lys Leu Asn Lys Ile Cys Arg Asn
      180                      185                      190

tac cgc ttc tgg gaa acc atc ttc gta gag ctt cct cca gtt gac cac 624
Tyr Arg Phe Trp Glu Thr Ile Phe Val Glu Leu Pro Pro Val Asp His
      195                      200                      205

gaa gct ggc cag aat gcc gaa ggg tct tca tcc aac cag act ctt cag 672
Glu Ala Gly Gln Asn Ala Glu Gly Ser Ser Ser Asn Gln Thr Leu Gln
      210                      215                      220

tct gct tct caa act gcc gtt cga cag ggt aat ggg ccc ctc atc cgc 720
Ser Ala Ser Gln Thr Ala Val Arg Gln Gly Asn Gly Pro Leu Ile Arg
      225                      230                      235                      240

ggt att cct gtt ccg gaa atg gga cag gca gcg gcc gat gat gcg cag 768
Gly Ile Pro Val Pro Glu Met Gly Gln Ala Ala Ala Asp Asp Ala Gln
      245                      250                      255

cga aat gtc cgc cga cgc ctt aat gat ggc agc tct gcc act att cct 816
Arg Asn Val Arg Arg Arg Leu Asn Asp Gly Ser Ser Ala Thr Ile Pro
      260                      265                      270

tcc gac tca tct ttg gtt ggt cgc gtg ctc cct gct agc tac ctc gaa 864
Ser Asp Ser Ser Leu Val Gly Arg Val Leu Pro Ala Ser Tyr Leu Glu
      275                      280                      285

cgc acc cgt gaa gaa cgc gat cgc gaa aag cat gaa tta gcg aaa aag 912
Arg Thr Arg Glu Glu Arg Asp Arg Glu Lys His Glu Leu Ala Lys Lys
      290                      295                      300

cag caa gcc ctc aac agg gaa caa tat gaa ctc gag cag aag aaa gat 960
Gln Gln Ala Leu Asn Arg Glu Gln Tyr Glu Leu Glu Gln Lys Lys Asp
      305                      310                      315                      320

gag aga gat cag aag aga ttt gag tgg gag cag act aag cat ctg gtg 1008
Glu Arg Asp Gln Lys Arg Phe Glu Trp Glu Gln Thr Lys His Leu Val
      325                      330                      335

gag acg gct tta aaa atc cga gaa ttg gat atc att ccg ttg gaa gcg 1056
Glu Thr Ala Leu Lys Ile Arg Glu Leu Asp Ile Ile Pro Leu Glu Ala
      340                      345                      350

gcg atg atc aaa gct aga gct ctt tat ggc cag gcg cga gag gaa gat 1104
Ala Met Ile Lys Ala Arg Ala Leu Tyr Gly Gln Ala Arg Glu Glu Asp
      355                      360                      365

caa gct gaa gct act ctt taa 1125
Gln Ala Glu Ala Thr Leu
      370

```

```

<210> SEQ ID NO 30
<211> LENGTH: 374
<212> TYPE: PRT
<213> ORGANISM: Cryptococcus neoformans

```

<400> SEQUENCE: 30

```

Met Ala His His His Phe Val Gly Ile Asn Pro Ala Gly Leu Ser Phe
1                      5                      10                      15

Ser His Pro Thr Pro Pro Ala Asp His Pro Ala Pro Pro Ser Ser Gly
20                      25                      30

Ser Ile His Thr Pro Ala Asn Phe Ala Ser Ile Gln Glu Pro Ile Thr
35                      40                      45

Asp Pro Ser Ala Val Ala Ala Arg Arg Arg Gly Arg Pro Ser Thr Arg
50                      55                      60

Gly Glu Ala Gly Val Thr Pro Pro Pro Glu Ile Gly Trp Trp Glu Asp
65                      70                      75                      80

```


-continued

Arg Ala Pro Ser Trp His Lys Asp Ala Met Gln Gly Gly Lys Ser Ser
 85 90 95

Met Glu Leu Leu Met Glu Trp Ser Glu Glu Met Lys Asn Gln Gly His
 100 105 110

Tyr Tyr Trp Met Gly Val Arg Asp Gly Gly Asn Leu His Gln Gly Ala
 115 120 125

Ser Arg Phe Arg Asp Tyr Leu Tyr Ala Gln His Gly Pro Ile Arg Arg
 130 135 140

Ser Ser Lys Ala Ile Arg Asn Lys Val Glu Asn Ile Lys Gln Lys Phe
 145 150 155 160

Phe Glu Ala Gln Glu Trp Leu Lys Asp Pro Asn Gly Asp His Thr Thr
 165 170 175

Met Thr Ile Pro Asp Val Glu Lys Lys Leu Asn Lys Ile Cys Arg Asn
 180 185 190

Tyr Arg Phe Trp Glu Thr Ile Phe Val Glu Leu Pro Pro Val Asp His
 195 200 205

Glu Ala Gly Gln Asn Ala Glu Gly Ser Ser Ser Asn Gln Thr Leu Gln
 210 215 220

Ser Ala Ser Gln Thr Ala Val Arg Gln Gly Asn Gly Pro Leu Ile Arg
 225 230 235 240

Gly Ile Pro Val Pro Glu Met Gly Gln Ala Ala Ala Asp Asp Ala Gln
 245 250 255

Arg Asn Val Arg Arg Arg Leu Asn Asp Gly Ser Ser Ala Thr Ile Pro
 260 265 270

Ser Asp Ser Ser Leu Val Gly Arg Val Leu Pro Ala Ser Tyr Leu Glu
 275 280 285

Arg Thr Arg Glu Glu Arg Asp Arg Glu Lys His Glu Leu Ala Lys Lys
 290 295 300

Gln Gln Ala Leu Asn Arg Glu Gln Tyr Glu Leu Glu Gln Lys Lys Asp
 305 310 315 320

Glu Arg Asp Gln Lys Arg Phe Glu Trp Glu Gln Thr Lys His Leu Val
 325 330 335

Glu Thr Ala Leu Lys Ile Arg Glu Leu Asp Ile Ile Pro Leu Glu Ala
 340 345 350

Ala Met Ile Lys Ala Arg Ala Leu Tyr Gly Gln Ala Arg Glu Glu Asp
 355 360 365

Gln Ala Glu Ala Thr Leu
 370

<210> SEQ ID NO 31
 <211> LENGTH: 1251
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1251)

<400> SEQUENCE: 31

atg gac gcc acc act ctt aca ggg cac gtc aag gag ctc aat gct gca	48
Met Asp Ala Thr Thr Leu Thr Gly His Val Lys Glu Leu Asn Ala Ala	
1 5 10 15	
aac caa gcg gga aaa tca gat gaa gtt atc tct ctg ctc aag aaa ctt	96
Asn Gln Ala Gly Lys Ser Asp Glu Val Ile Ser Leu Leu Lys Lys Leu	
20 25 30	
cag gct gag gtt gtt cct aca gaa gat ctc ctt cga tca tcg aaa gct	144
Gln Ala Glu Val Val Pro Thr Glu Asp Leu Leu Arg Ser Ser Lys Ala	
35 40 45	

-continued

ggt gtc gca gtc ggc aag ctt cgt acc cac gcc aca cca tca gtc tca Gly Val Ala Val Gly Lys Leu Arg Thr His Ala Thr Pro Ser Val Ser 50 55 60	192
agt ctt gcc aag gag ata gtt aag aag tgg aga gat gcg gtc gag gag Ser Leu Ala Lys Glu Ile Val Lys Lys Trp Arg Asp Ala Val Glu Glu 65 70 75 80	240
aca aag aag aag aga aaa aga gca gaa ggt gat gaa gga aaa gat gta Thr Lys Lys Lys Arg Lys Arg Ala Glu Gly Asp Glu Gly Lys Asp Val 85 90 95	288
aag aag gag aag gag gaa ggg aac ggg aaa cga gtc aag gcg gaa acg Lys Lys Glu Lys Glu Glu Gly Asn Gly Lys Arg Val Lys Ala Glu Thr 100 105 110	336
ggg tca tta gcg gcg aca cca tca gct agc aca ccc gcc tcg gcc tct Gly Ser Leu Ala Ala Thr Pro Ser Ala Ser Thr Pro Ala Ser Ala Ser 115 120 125	384
aca ccc gat gtc aaa gcg acc tcc cct cct gtc cgt caa cct ctt tca Thr Pro Asp Val Lys Ala Thr Ser Pro Pro Val Arg Gln Pro Leu Ser 130 135 140	432
acc att gac tca tca cgc act acg cct cga acc gcc aaa agc gat gga Thr Ile Asp Ser Ser Arg Thr Thr Pro Arg Thr Ala Lys Ser Asp Gly 145 150 155 160	480
gtg gcc gac agc ctg aga gct gat tcg agc gaa gga ggc agt gta gat Val Ala Asp Ser Leu Arg Ala Asp Ser Ser Glu Gly Gly Ser Val Asp 165 170 175	528
agc gtg agg gac aag tgt gtg atc atg att tat gac gca ttg gcg ttg Ser Val Arg Asp Lys Cys Val Ile Met Ile Tyr Asp Ala Leu Ala Leu 180 185 190	576
gat agc acg gct gaa ata aag att ttg aaa gag cgc gcc att gga att Asp Ser Thr Ala Glu Ile Lys Ile Leu Lys Glu Arg Ala Ile Gly Ile 195 200 205	624
gag cgc gca gcg aat aaa gct atg aac ttc tca aca gga aac gat tat Glu Arg Ala Ala Asn Lys Ala Met Asn Phe Ser Thr Gly Asn Asp Tyr 210 215 220	672
cgc gct aaa atg aga tca cta ttc ctc aac ttg aaa gac aag ggt aat Arg Ala Lys Met Arg Ser Leu Phe Leu Asn Leu Lys Asp Lys Gly Asn 225 230 235 240	720
ccc gct ttg aga aac gag att gtc ttg ggc tac gtc agc acc gaa aaa Pro Ala Leu Arg Asn Glu Ile Val Leu Gly Tyr Val Ser Thr Glu Lys 245 250 255	768
gtc gct agc atg tcc aaa gat gaa atg gcc tct gaa agc gtt cga atg Val Ala Ser Met Ser Lys Asp Glu Met Ala Ser Glu Ser Val Arg Met 260 265 270	816
cta aag gag aag att gcg agt gac aac ttg ttc aag gcc aag gct gtc Leu Lys Glu Lys Ile Ala Ser Asp Asn Leu Phe Lys Ala Lys Ala Val 275 280 285	864
gga gtc acc caa gct gag aca gac gcg ttc aag tgc gga cgg tgt cac Gly Val Thr Gln Ala Glu Thr Asp Ala Phe Lys Cys Gly Arg Cys His 290 295 300	912
cag agg aaa tgt act tat tac cag atg cag aca aga agc gcg gat gaa Gln Arg Lys Cys Thr Tyr Tyr Gln Met Gln Thr Arg Ser Ala Asp Glu 305 310 315 320	960
cct atg act act ttt gtt acg tat gtg tct gac ctg act cca aaa gaa Pro Met Thr Thr Phe Val Thr Tyr Val Ser Asp Leu Thr Pro Lys Glu 325 330 335	1008
tca ttg ctg act acg tgt acg act tgc tct ttt tat tca gat gta cta Ser Leu Leu Thr Thr Cys Ser Thr Thr Cys Ser Phe Tyr Ser Asp Val Leu 340 345 350	1056
att gta aca aca ggt gga aat tca gct agt ttc gga ttt tgc ctc tgg Ile Val Thr Thr Gly Gly Asn Ser Ala Ser Phe Gly Phe Cys Leu Trp	1104

-continued

355	360	365	
gga gca ttg tat ctt tcg ggt ttt ttg tca cgt cgt cta tgc agc cag			1152
Gly Ala Leu Tyr Leu Ser Gly Phe Leu Ser Arg Arg Leu Cys Ser Gln			
370	375	380	
tat att tac gag gcg tat cgt tgt gat ttg cgt gtc aat gtc aca aag			1200
Tyr Ile Tyr Glu Ala Tyr Arg Cys Asp Leu Arg Val Asn Val Thr Lys			
385	390	395	400
cca tta agt gcc gta aat atg cct ttt tgc agt gtt ctg aaa ttc aaa			1248
Pro Leu Ser Ala Val Asn Met Pro Phe Cys Ser Val Leu Lys Phe Lys			
405	410	415	
tga			1251
<210> SEQ ID NO 32			
<211> LENGTH: 416			
<212> TYPE: PRT			
<213> ORGANISM: Cryptococcus neoformans			
<400> SEQUENCE: 32			
Met Asp Ala Thr Thr Leu Thr Gly His Val Lys Glu Leu Asn Ala Ala			
1	5	10	15
Asn Gln Ala Gly Lys Ser Asp Glu Val Ile Ser Leu Leu Lys Lys Leu			
20	25	30	
Gln Ala Glu Val Val Pro Thr Glu Asp Leu Leu Arg Ser Ser Lys Ala			
35	40	45	
Gly Val Ala Val Gly Lys Leu Arg Thr His Ala Thr Pro Ser Val Ser			
50	55	60	
Ser Leu Ala Lys Glu Ile Val Lys Lys Trp Arg Asp Ala Val Glu Glu			
65	70	75	80
Thr Lys Lys Lys Arg Lys Arg Ala Glu Gly Asp Glu Gly Lys Asp Val			
85	90	95	
Lys Lys Glu Lys Glu Glu Gly Asn Gly Lys Arg Val Lys Ala Glu Thr			
100	105	110	
Gly Ser Leu Ala Ala Thr Pro Ser Ala Ser Thr Pro Ala Ser Ala Ser			
115	120	125	
Thr Pro Asp Val Lys Ala Thr Ser Pro Pro Val Arg Gln Pro Leu Ser			
130	135	140	
Thr Ile Asp Ser Ser Arg Thr Thr Pro Arg Thr Ala Lys Ser Asp Gly			
145	150	155	160
Val Ala Asp Ser Leu Arg Ala Asp Ser Ser Glu Gly Gly Ser Val Asp			
165	170	175	
Ser Val Arg Asp Lys Cys Val Ile Met Ile Tyr Asp Ala Leu Ala Leu			
180	185	190	
Asp Ser Thr Ala Glu Ile Lys Ile Leu Lys Glu Arg Ala Ile Gly Ile			
195	200	205	
Glu Arg Ala Ala Asn Lys Ala Met Asn Phe Ser Thr Gly Asn Asp Tyr			
210	215	220	
Arg Ala Lys Met Arg Ser Leu Phe Leu Asn Leu Lys Asp Lys Gly Asn			
225	230	235	240
Pro Ala Leu Arg Asn Glu Ile Val Leu Gly Tyr Val Ser Thr Glu Lys			
245	250	255	
Val Ala Ser Met Ser Lys Asp Glu Met Ala Ser Glu Ser Val Arg Met			
260	265	270	
Leu Lys Glu Lys Ile Ala Ser Asp Asn Leu Phe Lys Ala Lys Ala Val			
275	280	285	
Gly Val Thr Gln Ala Glu Thr Asp Ala Phe Lys Cys Gly Arg Cys His			

-continued

290			295			300										
Gln	Arg	Lys	Cys	Thr	Tyr	Tyr	Gln	Met	Gln	Thr	Arg	Ser	Ala	Asp	Glu	
305					310					315					320	
Pro	Met	Thr	Thr	Phe	Val	Thr	Tyr	Val	Ser	Asp	Leu	Thr	Pro	Lys	Glu	
			325						330					335		
Ser	Leu	Leu	Thr	Thr	Cys	Thr	Thr	Cys	Ser	Phe	Tyr	Ser	Asp	Val	Leu	
			340					345					350			
Ile	Val	Thr	Thr	Gly	Gly	Asn	Ser	Ala	Ser	Phe	Gly	Phe	Cys	Leu	Trp	
		355						360					365			
Gly	Ala	Leu	Tyr	Leu	Ser	Gly	Phe	Leu	Ser	Arg	Arg	Leu	Cys	Ser	Gln	
		370						375								
Tyr	Ile	Tyr	Glu	Ala	Tyr	Arg	Cys	Asp	Leu	Arg	Val	Asn	Val	Thr	Lys	
385					390						395				400	
Pro	Leu	Ser	Ala	Val	Asn	Met	Pro	Phe	Cys	Ser	Val	Leu	Lys	Phe	Lys	
				405						410				415		
<210> SEQ ID NO 33 <211> LENGTH: 657 <212> TYPE: DNA <213> ORGANISM: Cryptococcus neoformans <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1) .. (657)																
<400> SEQUENCE: 33																
atg	gat	tac	caa	aat	cga	gca	ggt	gca	aac	aag	ggt	agt	ggt	ggt	gtc	48
Met	Asp	Tyr	Gln	Asn	Arg	Ala	Gly	Ala	Asn	Lys	Gly	Ser	Gly	Gly	Val	
1			5					10						15		
gct	ggt	gca	tcc	gag	aca	gca	gtg	gac	agg	aga	gaa	cgt	ctt	cga	aaa	96
Ala	Gly	Ala	Ser	Glu	Thr	Ala	Val	Asp	Arg	Arg	Glu	Arg	Leu	Arg	Lys	
			20					25						30		
ctt	gct	ttg	gag	act	att	gac	ttg	gcc	aaa	gat	ccc	tat	atc	ctt	agg	144
Leu	Ala	Leu	Glu	Thr	Ile	Asp	Leu	Ala	Lys	Asp	Pro	Tyr	Ile	Leu	Arg	
			35					40						45		
acc	cat	ctc	ggt	aca	tta	gaa	tgc	cgt	ctt	tgt	ctc	act	ctt	cac	gtc	192
Thr	His	Leu	Gly	Thr	Leu	Glu	Cys	Arg	Leu	Cys	Leu	Thr	Leu	His	Val	
			50					55						60		
aac	gag	ggt	tct	tac	ctt	gcc	cac	act	caa	gga	aag	aaa	cat	caa	aca	240
Asn	Glu	Gly	Ser	Tyr	Leu	Ala	His	Thr	Gln	Gly	Lys	Lys	His	Gln	Thr	
65					70						75			80		
aac	ctt	gct	agg	cgt	gca	gcc	aag	gac	aac	aag	gat	cag	aca	tta	atg	288
Asn	Leu	Ala	Arg	Arg	Ala	Ala	Lys	Asp	Asn	Lys	Asp	Gln	Thr	Leu	Met	
			85					90						95		
atc	caa	gct	ccc	aca	gcc	gcg	caa	caa	gtg	aag	aag	aaa	gtg	ttt	gtt	336
Ile	Gln	Ala	Pro	Thr	Ala	Ala	Gln	Gln	Val	Lys	Lys	Lys	Val	Phe	Val	
			100					105						110		
aag	att	gga	aga	cct	gga	tac	aaa	atc	atc	aaa	att	cga	gag	cct	gtc	384
Lys	Ile	Gly	Arg	Pro	Gly	Tyr	Lys	Ile	Ile	Lys	Ile	Arg	Glu	Pro	Val	
			115					120						125		
agt	caa	agg	atg	ggt	tta	tta	ttc	act	gtg	tct	tta	cct	gag	ata	aaa	432
Ser	Gln	Arg	Met	Gly	Leu	Leu	Phe	Thr	Val	Ser	Leu	Pro	Glu	Ile	Lys	
			130					135						140		
gcg	gga	gag	agg	cca	aga	agg	agg	ttc	atg	tct	gct	ttt	gaa	caa	cgg	480
Ala	Gly	Glu	Arg	Pro	Arg	Arg	Arg	Phe	Met	Ser	Ala	Phe	Glu	Gln	Arg	
145					150						155			160		
cga	gag	att	ccc	aat	aaa	gct	ttc	cag	tac	tta	gtt	ttg	gca	gcc	gag	528
Arg	Glu	Ile	Pro	Asn	Lys	Ala	Phe	Gln	Tyr	Leu	Val	Leu	Ala	Ala	Glu	
			165					170						175		
cca	tac	gag	acc	ata	gca	ttt	gcc	atc	ccc	tca	aaa	gag	atg	gtt	gac	576

-continued

```

tta aga cac tac atc acg caa ttc ctt aac tct gca cca aaa aaa caa 144
Leu Arg His Tyr Ile Thr Gln Phe Leu Asn Ser Ala Pro Lys Lys Gln
      35                40                45

aca gca gct gcc gtt cgc gaa caa cgc gca ctt ggt cgc tca gct ctg 192
Thr Ala Ala Ala Val Arg Glu Gln Arg Ala Leu Gly Arg Ser Ala Leu
      50                55                60

ctt cgg gca act gcg act ctg tcc ccc ctt ccg cct gcc tct tac aag 240
Leu Arg Ala Thr Ala Thr Leu Ser Pro Leu Pro Pro Ala Ser Tyr Lys
      65                70                75                80

gct ctc tcg gga tcc ctt gct gct tca ctt tct act ggt gag tat atc 288
Ala Leu Ser Gly Ser Leu Ala Ala Ser Leu Ser Thr Gly Glu Tyr Ile
      85                90                95

aag ccc gcc cca gag tca aag ggg gat gct tct ccc gcc aat cct ctc 336
Lys Pro Ala Pro Glu Ser Lys Gly Asp Ala Ser Pro Ala Asn Pro Leu
      100               105               110

gaa ggt gct ggg atg gaa aat gcg atg gac ggt atg aaa aag cag gcc 384
Glu Gly Ala Gly Met Glu Asn Ala Met Asp Gly Met Lys Lys Gln Ala
      115               120               125

gta atg atg gta ccc aac atg gtt atc atg cag tat atc aac gtc ttt 432
Val Met Met Val Pro Asn Met Val Ile Met Gln Tyr Ile Asn Val Phe
      130               135               140

ttt tcc gga ttt atc ctt atg cgt ctg cca ttt cct tta acc gca ggc 480
Phe Ser Gly Phe Ile Leu Met Arg Leu Pro Phe Pro Leu Thr Ala Gly
      145               150               155               160

ttt aag tcg ttg ctg tca agg gat att ccc atg gct gat ctc gat gtg 528
Phe Lys Ser Leu Leu Ser Arg Asp Ile Pro Met Ala Asp Leu Asp Val
      165               170               175

cga tgg gtt tcc gct ttg tcc tgg tat ttt ctc aac ttg ttt ggc ttg 576
Arg Trp Val Ser Ala Leu Ser Trp Tyr Phe Leu Asn Leu Phe Gly Leu
      180               185               190

aac ggt gtt ttc aaa cta att ctt gga gct gag aat gct gct gta gac 624
Asn Gly Val Phe Lys Leu Ile Leu Gly Ala Glu Asn Ala Ala Val Asp
      195               200               205

agc cgt gac ctc acc tcg ctg tct gca ctt tct ggg gca gga ggc cct 672
Ser Arg Asp Leu Thr Ser Leu Ser Ala Leu Ser Gly Ala Gly Gly Pro
      210               215               220

atg ccc gcc ccc gcc ggt cca cca gac atg gtc aag ctt ttc aag gcc 720
Met Pro Gly Pro Gly Gly Pro Pro Asp Met Val Lys Leu Phe Lys Ala
      225               230               235               240

gag gtt gag aac ttg gca ttg gca gaa agt tca tac aag tgg gtc ggc 768
Glu Val Glu Asn Leu Ala Leu Ala Glu Ser Ser Tyr Lys Trp Val Gly
      245               250               255

gac gga gta gaa gat aga gtt ttg aga gct tgg ggc aaa gtt taa 813
Asp Gly Val Glu Asp Arg Val Leu Arg Ala Trp Gly Lys Val
      260               265               270

```

<210> SEQ ID NO 36

<211> LENGTH: 270

<212> TYPE: PRT

<213> ORGANISM: *Cryptococcus neoformans*

<400> SEQUENCE: 36

```

Met Thr Val Lys Ala Glu Gln Asp Leu Tyr Leu Asp Pro Ser Ile Arg
1      5      10      15

```

```

Asp Trp Val Leu Ile Pro Ile Thr Leu Ile Met Leu Leu Val Gly Val
20     25     30

```

```

Leu Arg His Tyr Ile Thr Gln Phe Leu Asn Ser Ala Pro Lys Lys Gln
35     40     45

```

```

Thr Ala Ala Ala Val Arg Glu Gln Arg Ala Leu Gly Arg Ser Ala Leu

```

-continued

50				55				60								
Leu	Arg	Ala	Thr	Ala	Thr	Leu	Ser	Pro	Leu	Pro	Pro	Ala	Ser	Tyr	Lys	
65					70					75					80	
Ala	Leu	Ser	Gly	Ser	Leu	Ala	Ala	Ser	Leu	Ser	Thr	Gly	Glu	Tyr	Ile	
				85					90					95		
Lys	Pro	Ala	Pro	Glu	Ser	Lys	Gly	Asp	Ala	Ser	Pro	Ala	Asn	Pro	Leu	
			100					105					110			
Glu	Gly	Ala	Gly	Met	Glu	Asn	Ala	Met	Asp	Gly	Met	Lys	Lys	Gln	Ala	
		115					120					125				
Val	Met	Met	Val	Pro	Asn	Met	Val	Ile	Met	Gln	Tyr	Ile	Asn	Val	Phe	
			130			135					140					
Phe	Ser	Gly	Phe	Ile	Leu	Met	Arg	Leu	Pro	Phe	Pro	Leu	Thr	Ala	Gly	
145					150					155					160	
Phe	Lys	Ser	Leu	Leu	Ser	Arg	Asp	Ile	Pro	Met	Ala	Asp	Leu	Asp	Val	
			165						170					175		
Arg	Trp	Val	Ser	Ala	Leu	Ser	Trp	Tyr	Phe	Leu	Asn	Leu	Phe	Gly	Leu	
		180							185				190			
Asn	Gly	Val	Phe	Lys	Leu	Ile	Leu	Gly	Ala	Glu	Asn	Ala	Ala	Val	Asp	
		195					200					205				
Ser	Arg	Asp	Leu	Thr	Ser	Leu	Ser	Ala	Leu	Ser	Gly	Ala	Gly	Gly	Pro	
		210				215					220					
Met	Pro	Gly	Pro	Gly	Gly	Pro	Pro	Asp	Met	Val	Lys	Leu	Phe	Lys	Ala	
225					230					235					240	
Glu	Val	Glu	Asn	Leu	Ala	Leu	Ala	Glu	Ser	Ser	Tyr	Lys	Trp	Val	Gly	
			245						250					255		
Asp	Gly	Val	Glu	Asp	Arg	Val	Leu	Arg	Ala	Trp	Gly	Lys	Val			
		260					265					270				
<210> SEQ ID NO 37																
<211> LENGTH: 1365																
<212> TYPE: DNA																
<213> ORGANISM: Cryptococcus neoformans																
<220> FEATURE:																
<221> NAME/KEY: CDS																
<222> LOCATION: (1)..(1365)																
<400> SEQUENCE: 37																
atg	acc	gcg	gtg	aac	agc	aac	cag	ggc	acc	ggc	aaa	ctg	agc	ggc	cgc	48
Met	Thr	Ala	Val	Asn	Ser	Asn	Gln	Gly	Thr	Gly	Lys	Leu	Ser	Gly	Arg	
1			5				10				15					
gtg	ggc	att	gtg	ggc	acc	ggc	cat	cgc	gcg	cgc	ctg	tat	acc	acc	gcg	96
Val	Gly	Ile	Val	Gly	Thr	Gly	His	Arg	Ala	Arg	Leu	Tyr	Thr	Thr	Ala	
			20				25				30					
gtg	gcg	agc	cgc	gcg	aac	acc	agc	ctg	gtg	gcg	ctg	tgc	gat	acc	aac	144
Val	Ala	Ser	Arg	Ala	Asn	Thr	Ser	Leu	Val	Ala	Leu	Cys	Asp	Thr	Asn	
		35				40					45					
gat	gcg	cgc	atg	gat	tgg	cat	aac	aaa	atg	ctg	cgc	gaa	gcg	ggc	cgc	192
Asp	Ala	Arg	Met	Asp	Trp	His	Asn	Lys	Met	Leu	Arg	Glu	Ala	Gly	Arg	
		50			55					60						
ccg	gaa	gcg	aaa	aaa	tat	gcg	gcg	gaa	gat	ttt	cgc	aaa	atg	ctg	gaa	240
Pro	Glu	Ala	Lys	Lys	Tyr	Ala	Ala	Glu	Asp	Phe	Arg	Lys	Met	Leu	Glu	
65			70				75							80		
cag	gaa	aaa	ctg	gat	gtg	ctg	gtg	acc	acc	att	gat	tat	acc	cat		288
Gln	Glu	Lys	Leu	Asp	Val	Leu	Val	Val	Thr	Ile	Asp	Tyr	Thr	His		
			85				90						95			
gat	atg	tat	att	att	ccg	gcg	ctg	aaa	gcg	ggc	att	aaa	gtg	ctg	agc	336
Asp	Met	Tyr	Ile	Ile	Pro	Ala	Leu	Lys	Ala	Gly	Ile	Lys	Val	Leu	Ser	
			100				105							110		

-continued

gaa aaa ccg atg acc acc aac gtg gat aaa tgc aaa gcg att ctg aac Glu Lys Pro Met Thr Thr Asn Val Asp Lys Cys Lys Ala Ile Leu Asn 115 120 125	384
gcg gtg aac gaa agc aaa ggc agc ctg acc gtg ctg ttt aac tat cgc Ala Val Asn Glu Ser Lys Gly Ser Leu Thr Val Leu Phe Asn Tyr Arg 130 135 140	432
tat aac ccg att cat tgg aaa gtg gcg gaa gtg att gcg aaa ggc gaa Tyr Asn Pro Ile His Trp Lys Val Ala Glu Val Ile Ala Lys Gly Glu 145 150 155 160	480
att ggc gaa gtg aaa agc gtg cat ttt gaa tgg ctg ctg gat acc gtg Ile Gly Glu Val Lys Ser Val His Phe Glu Trp Leu Leu Asp Thr Val 165 170 175	528
cat ggc gcg gat tat ttt cgc gcg tgg cat cgc tat aaa gat cgc agc His Gly Ala Asp Tyr Phe Arg Arg Trp His Arg Tyr Lys Asp Arg Ser 180 185 190	576
ggc ggc ctg atg att cat aaa agc agc cat cat ttt gat ctg gtg aac Gly Gly Leu Met Ile His Lys Ser Ser His His Phe Asp Leu Val Asn 195 200 205	624
ttt tgg att cag agc gtg ccg cag agc gtg ttt ggc atg ggc agc ctg Phe Trp Ile Gln Ser Val Pro Gln Ser Val Phe Gly Met Gly Ser Leu 210 215 220	672
gcg ttt tat ggc aaa gaa aac ggc aaa aaa agc ggc tgg ggc aaa aac Ala Phe Tyr Gly Lys Glu Asn Gly Lys Lys Ser Gly Trp Gly Lys Asn 225 230 235 240	720
tat gaa cgc gcg cgc gat gcg aaa gaa gcg gaa aac gat ccg ttt gcg Tyr Glu Arg Ala Arg Asp Ala Lys Glu Ala Glu Asn Asp Pro Phe Ala 245 250 255	768
att cat ctg ggc gat gaa gaa ggc ctg aaa ggc ctg tat ttt gat gcg Ile His Leu Gly Asp Glu Glu Gly Leu Lys Gly Leu Tyr Phe Asp Ala 260 265 270	816
gaa cat att gat ggc tat cat cgc gat atg aac gtg ttt gcg gat gat Glu His Ile Asp Gly Tyr His Arg Asp Met Asn Val Phe Ala Asp Asp 275 280 285	864
att acc att gaa gat gat atg agc gtg ctg gtg cat tat gaa agc ggc Ile Thr Ile Glu Asp Asp Met Ser Val Leu Val His Tyr Glu Ser Gly 290 295 300	912
gtg aac atg acc tat cat ctg acc gcg tat agc ccg tgg gaa ggc tat Val Asn Met Thr Tyr His Leu Thr Ala Tyr Ser Pro Trp Glu Gly Tyr 305 310 315 320	960
cgc gtg atg ttt aac ggc acc cat ggc cgc ctg gaa ctg gaa gtg gtg Arg Val Met Phe Asn Gly Thr His Gly Arg Leu Glu Leu Glu Val Val 325 330 335	1008
gaa aac gcg ttt cgc ctg ccg att ccg aaa ggc agc aac aac gcg agc Glu Asn Ala Phe Arg Leu Pro Ile Pro Lys Gly Ser Asn Asn Ala Ser 340 345 350	1056
gaa cat gtg cat ggc gat agc gcg ctg ccg aac gaa ggc cat agc aaa Glu His Val His Gly Asp Ser Ala Leu Pro Asn Glu Gly His Ser Lys 355 360 365	1104
att acc ctg cat aaa ctg tgg cag cag ccg gtg aac gtg ccg tat cag Ile Thr Leu His Lys Leu Trp Gln Gln Pro Val Asn Val Pro Tyr Gln 370 375 380	1152
gaa gcg aaa ggc ggc cat ggc ggc ggc gat gaa gcg atg ctg gat gaa Glu Ala Lys Gly Gly His Gly Gly Gly Asp Glu Ala Met Leu Asp Glu 385 390 395 400	1200
att ttt ggc ccg aaa gaa ggc gaa gaa gaa cgc aaa tgc ccg gtg aac Ile Phe Gly Pro Lys Glu Gly Glu Glu Glu Arg Lys Cys Pro Val Asn 405 410 415	1248
ggc ctg agc gcg gat cag aaa gat ggc gcg ctg gcg atg gcg gtg ggc Gly Leu Ser Ala Asp Gln Lys Asp Gly Ala Leu Ala Met Ala Val Gly	1296

-continued

420	425	430	
ctg gcg gcg aac gaa agc ttt aaa aac ggc aaa cag gtg ttt att aaa			1344
Leu Ala Ala Asn Glu Ser Phe Lys Asn Gly Lys Gln Val Phe Ile Lys			
435	440	445	
gaa ctg ctg ggc ggc acc ctg			1365
Glu Leu Leu Gly Gly Thr Leu			
450	455		
<210> SEQ ID NO 38			
<211> LENGTH: 455			
<212> TYPE: PRT			
<213> ORGANISM: Cryptococcus neoformans			
<400> SEQUENCE: 38			
Met Thr Ala Val Asn Ser Asn Gln Gly Thr Gly Lys Leu Ser Gly Arg			
1	5	10	15
Val Gly Ile Val Gly Thr Gly His Arg Ala Arg Leu Tyr Thr Thr Ala			
	20	25	30
Val Ala Ser Arg Ala Asn Thr Ser Leu Val Ala Leu Cys Asp Thr Asn			
	35	40	45
Asp Ala Arg Met Asp Trp His Asn Lys Met Leu Arg Glu Ala Gly Arg			
	50	55	60
Pro Glu Ala Lys Lys Tyr Ala Ala Glu Asp Phe Arg Lys Met Leu Glu			
65	70	75	80
Gln Glu Lys Leu Asp Val Leu Val Val Thr Thr Ile Asp Tyr Thr His			
	85	90	95
Asp Met Tyr Ile Ile Pro Ala Leu Lys Ala Gly Ile Lys Val Leu Ser			
	100	105	110
Glu Lys Pro Met Thr Thr Asn Val Asp Lys Cys Lys Ala Ile Leu Asn			
	115	120	125
Ala Val Asn Glu Ser Lys Gly Ser Leu Thr Val Leu Phe Asn Tyr Arg			
	130	135	140
Tyr Asn Pro Ile His Trp Lys Val Ala Glu Val Ile Ala Lys Gly Glu			
145	150	155	160
Ile Gly Glu Val Lys Ser Val His Phe Glu Trp Leu Leu Asp Thr Val			
	165	170	175
His Gly Ala Asp Tyr Phe Arg Arg Trp His Arg Tyr Lys Asp Arg Ser			
	180	185	190
Gly Gly Leu Met Ile His Lys Ser Ser His His Phe Asp Leu Val Asn			
	195	200	205
Phe Trp Ile Gln Ser Val Pro Gln Ser Val Phe Gly Met Gly Ser Leu			
	210	215	220
Ala Phe Tyr Gly Lys Glu Asn Gly Lys Lys Ser Gly Trp Gly Lys Asn			
225	230	235	240
Tyr Glu Arg Ala Arg Asp Ala Lys Glu Ala Glu Asn Asp Pro Phe Ala			
	245	250	255
Ile His Leu Gly Asp Glu Glu Gly Leu Lys Gly Leu Tyr Phe Asp Ala			
	260	265	270
Glu His Ile Asp Gly Tyr His Arg Asp Met Asn Val Phe Ala Asp Asp			
	275	280	285
Ile Thr Ile Glu Asp Asp Met Ser Val Leu Val His Tyr Glu Ser Gly			
	290	295	300
Val Asn Met Thr Tyr His Leu Thr Ala Tyr Ser Pro Trp Glu Gly Tyr			
305	310	315	320
Arg Val Met Phe Asn Gly Thr His Gly Arg Leu Glu Leu Glu Val Val			

-continued

325					330					335						
Glu	Asn	Ala	Phe	Arg	Leu	Pro	Ile	Pro	Lys	Gly	Ser	Asn	Asn	Ala	Ser	
			340						345					350		
Glu	His	Val	His	Gly	Asp	Ser	Ala	Leu	Pro	Asn	Glu	Gly	His	Ser	Lys	
		355					360					365				
Ile	Thr	Leu	His	Lys	Leu	Trp	Gln	Gln	Pro	Val	Asn	Val	Pro	Tyr	Gln	
	370					375					380					
Glu	Ala	Lys	Gly	Gly	His	Gly	Gly	Gly	Asp	Glu	Ala	Met	Leu	Asp	Glu	
385					390					395					400	
Ile	Phe	Gly	Pro	Lys	Glu	Gly	Glu	Glu	Glu	Arg	Lys	Cys	Pro	Val	Asn	
				405					410					415		
Gly	Leu	Ser	Ala	Asp	Gln	Lys	Asp	Gly	Ala	Leu	Ala	Met	Ala	Val	Gly	
			420					425					430			
Leu	Ala	Ala	Asn	Glu	Ser	Phe	Lys	Asn	Gly	Lys	Gln	Val	Phe	Ile	Lys	
		435					440						445			
Glu	Leu	Leu	Gly	Gly	Thr	Leu										
450						455										
<210> SEQ ID NO 39																
<211> LENGTH: 1338																
<212> TYPE: DNA																
<213> ORGANISM: Cryptococcus neoformans																
<220> FEATURE:																
<221> NAME/KEY: CDS																
<222> LOCATION: (1)..(1338)																
<400> SEQUENCE: 39																
atg	agc	gcg	att	cgc	gcg	ctg	aac	atg	cgc	aaa	acc	gcg	agc	gcg	ctg	48
Met	Ser	Ala	Ile	Arg	Ala	Leu	Asn	Met	Arg	Lys	Thr	Ala	Ser	Ala	Leu	
1				5					10					15		
aaa	gcg	ccg	gtg	gcg	ttt	aaa	cgc	acc	ctg	gcg	acc	ccg	gtg	aac	agc	96
Lys	Ala	Pro	Val	Ala	Phe	Lys	Arg	Thr	Leu	Ala	Thr	Pro	Val	Asn	Ser	
			20					25					30			
ctg	tat	acc	agc	gtg	ctg	ccg	gcg	aaa	att	ccg	gcg	gcg	ctg	cat	ctg	144
Leu	Tyr	Thr	Ser	Val	Leu	Pro	Ala	Lys	Ile	Pro	Ala	Ala	Leu	His	Leu	
			35				40					45				
aaa	agc	ggc	cag	agc	tat	ttt	ggc	agc	agc	ttt	ggc	agc	gaa	aac	agc	192
Lys	Ser	Gly	Gln	Ser	Tyr	Phe	Gly	Ser	Ser	Phe	Gly	Ser	Glu	Asn	Ser	
	50					55					60					
aaa	ttt	ggc	gaa	acc	gtg	ttt	agc	acc	agc	att	acc	agc	tat	acc	gat	240
Lys	Phe	Gly	Glu	Thr	Val	Phe	Ser	Thr	Ser	Ile	Thr	Ser	Tyr	Thr	Asp	
65					70					75					80	
agc	atg	acc	gat	ccg	agc	tat	ctg	ggc	cag	att	ctg	gtg	ttt	acc	agc	288
Ser	Met	Thr	Asp	Pro	Ser	Tyr	Leu	Gly	Gln	Ile	Leu	Val	Phe	Thr	Ser	
			85					90						95		
ccg	atg	att	ggc	aac	tat	ggc	gtg	ccg	agc	aac	acc	agc	agc	cag	ttt	336
Pro	Met	Ile	Gly	Asn	Tyr	Gly	Val	Pro	Ser	Asn	Thr	Ser	Ser	Gln	Phe	
			100					105					110			
ccg	ggc	att	ccg	ttt	ctg	gaa	agc	gaa	aaa	att	cag	tgc	acc	ggc	gtg	384
Pro	Gly	Ile	Pro	Phe	Leu	Glu	Ser	Glu	Lys	Ile	Gln	Cys	Thr	Gly	Val	
			115				120					125				
gtg	gtg	agc	gat	gtg	gcg	ctg	aaa	tat	agc	cat	tat	cag	gcg	gtg	gaa	432
Val	Val	Ser	Asp	Val	Ala	Leu	Lys	Tyr	Ser	His	Tyr	Gln	Ala	Val	Glu	
			130				135				140					
agc	ctg	cat	gaa	tgg	tgc	aaa	cgc	tat	gat	gtg	ccg	ggc	att	acc	ggc	480
Ser	Leu	His	Glu	Trp	Cys	Lys	Arg	Tyr	Asp	Val	Pro	Gly	Ile	Thr	Gly	
145					150					155					160	
gtg	gat	acc	cgc	gcg	att	acc	agc	ctg	ctg	cgc	gat	cag	ggc	acc	acc	528
Val	Asp	Thr	Arg	Ala	Ile	Thr	Ser	Leu	Leu	Arg	Asp	Gln	Gly	Thr	Thr	

-continued

165	170	175	
ctg ggc cgc ctg gcg gtg ggc gat gaa gcg ggc aaa ccg gcg ccg cag Leu Gly Arg Leu Ala Val Gly Asp Glu Ala Gly Lys Pro Ala Pro Gln 180 185 190			576
gaa gcg gaa tat tgg gat ccg agc aaa gaa aac ctg gtg gcg cag gcg Glu Ala Glu Tyr Trp Asp Pro Ser Lys Glu Asn Leu Val Ala Gln Ala 195 200 205			624
agc acc aaa aaa gcg tat gtg ctg aac gaa aaa ggc agc ggc ccg cgc Ser Thr Lys Lys Ala Tyr Val Leu Asn Glu Lys Gly Ser Gly Pro Arg 210 215 220			672
att gcg gtg ctg gat ttt ggc acc aaa gcg aac att ctg cgc agc ctg Ile Ala Val Leu Asp Phe Gly Thr Lys Ala Asn Ile Leu Arg Ser Leu 225 230 235			720
att cgc cgc gat gcg gtg gtg acc gtg ctg ccg tgg gat ttt gat ttt Ile Arg Arg Asp Ala Val Val Thr Val Leu Pro Trp Asp Phe Asp Phe 245 250 255			768
aac acc gtg cgc gat cag ttt gat ggc ctg ttt ctg agc aac ggc ccg Asn Thr Val Arg Asp Gln Phe Asp Gly Leu Phe Leu Ser Asn Gly Pro 260 265 270			816
ggc gat ccg aaa atg att atg gat agc gcg atg cgc gtg cgc cag acc Gly Asp Pro Lys Met Ile Met Asp Ser Ala Met Arg Val Arg Gln Thr 275 280 285			864
att aac gaa tgg aac aaa ccg att ttt ggc att tgc atg ggc cat cag Ile Asn Glu Trp Asn Lys Pro Ile Phe Gly Ile Cys Met Gly His Gln 290 295 300			912
gtg ctg ggc ctg gcg gcg ggc ctg gaa gcg tat cgc atg acc ttt ggc Val Leu Gly Leu Ala Ala Gly Leu Glu Ala Tyr Arg Met Thr Phe Gly 305 310 315 320			960
aac cgc ggc cat aac cag ccg gtg ctg gcg ctg gcg agc agc ggc agc Asn Arg Gly His Asn Gln Pro Val Leu Ala Leu Ala Ser Ser Gly Ser 325 330 335			1008
att aaa gcg ggc cgc gtg tat gtg acc agc cag aac cat cag tat gcg Ile Lys Ala Gly Arg Val Tyr Val Thr Ser Gln Asn His Gln Tyr Ala 340 345 350			1056
ctg cgc ctg acc gaa gat ttt ccg gaa ggc tgg gcg ccg ttt ttt att Leu Arg Leu Thr Glu Asp Phe Pro Glu Gly Trp Ala Pro Phe Phe Ile 355 360 365			1104
aac tgc aac gat agc agc gtg gaa ggc att att agc acc ccg gaa agc Asn Cys Asn Asp Ser Ser Val Glu Gly Ile Ile Ser Thr Pro Glu Ser 370 375 380			1152
ggc aaa cgc att tgg ggc gtg cag ttt cat ccg gaa agc gcg ggc ggc Gly Lys Arg Ile Trp Gly Val Gln Phe His Pro Glu Ser Ala Gly Gly 385 390 395 400			1200
ccg ctg gat acc att gaa atg ttt acc gat ttt gtg aac gaa tgc gat Pro Leu Asp Thr Ile Glu Met Phe Thr Asp Phe Val Asn Glu Cys Asp 405 410 415			1248
gtg agc cgc aaa ggc ttt agc ggc agc gcg atg att gcg aac gaa gtg Val Ser Arg Lys Gly Phe Ser Gly Ser Ala Met Ile Ala Asn Glu Val 420 425 430			1296
aaa gtg gat ggc cat gcg gcg aaa gcg gcg agc gtg agc gcg Lys Val Asp Gly His Ala Ala Lys Ala Ala Ser Val Ser Ala 435 440 445			1338

<210> SEQ ID NO 40

<211> LENGTH: 446

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 40

Met Ser Ala Ile Arg Ala Leu Asn Met Arg Lys Thr Ala Ser Ala Leu

-continued

1	5	10	15
Lys Ala Pro Val Ala Phe Lys Arg Thr Leu Ala Thr Pro Val Asn Ser	20	25	30
Leu Tyr Thr Ser Val Leu Pro Ala Lys Ile Pro Ala Ala Leu His Leu	35	40	45
Lys Ser Gly Gln Ser Tyr Phe Gly Ser Ser Phe Gly Ser Glu Asn Ser	50	55	60
Lys Phe Gly Glu Thr Val Phe Ser Thr Ser Ile Thr Ser Tyr Thr Asp	65	70	75
Ser Met Thr Asp Pro Ser Tyr Leu Gly Gln Ile Leu Val Phe Thr Ser	85	90	95
Pro Met Ile Gly Asn Tyr Gly Val Pro Ser Asn Thr Ser Ser Gln Phe	100	105	110
Pro Gly Ile Pro Phe Leu Glu Ser Glu Lys Ile Gln Cys Thr Gly Val	115	120	125
Val Val Ser Asp Val Ala Leu Lys Tyr Ser His Tyr Gln Ala Val Glu	130	135	140
Ser Leu His Glu Trp Cys Lys Arg Tyr Asp Val Pro Gly Ile Thr Gly	145	150	155
Val Asp Thr Arg Ala Ile Thr Ser Leu Leu Arg Asp Gln Gly Thr Thr	165	170	175
Leu Gly Arg Leu Ala Val Gly Asp Glu Ala Gly Lys Pro Ala Pro Gln	180	185	190
Glu Ala Glu Tyr Trp Asp Pro Ser Lys Glu Asn Leu Val Ala Gln Ala	195	200	205
Ser Thr Lys Lys Ala Tyr Val Leu Asn Glu Lys Gly Ser Gly Pro Arg	210	215	220
Ile Ala Val Leu Asp Phe Gly Thr Lys Ala Asn Ile Leu Arg Ser Leu	225	230	235
Ile Arg Arg Asp Ala Val Val Thr Val Leu Pro Trp Asp Phe Asp Phe	245	250	255
Asn Thr Val Arg Asp Gln Phe Asp Gly Leu Phe Leu Ser Asn Gly Pro	260	265	270
Gly Asp Pro Lys Met Ile Met Asp Ser Ala Met Arg Val Arg Gln Thr	275	280	285
Ile Asn Glu Trp Asn Lys Pro Ile Phe Gly Ile Cys Met Gly His Gln	290	295	300
Val Leu Gly Leu Ala Ala Gly Leu Glu Ala Tyr Arg Met Thr Phe Gly	305	310	315
Asn Arg Gly His Asn Gln Pro Val Leu Ala Leu Ala Ser Ser Gly Ser	325	330	335
Ile Lys Ala Gly Arg Val Tyr Val Thr Ser Gln Asn His Gln Tyr Ala	340	345	350
Leu Arg Leu Thr Glu Asp Phe Pro Glu Gly Trp Ala Pro Phe Phe Ile	355	360	365
Asn Cys Asn Asp Ser Ser Val Glu Gly Ile Ile Ser Thr Pro Glu Ser	370	375	380
Gly Lys Arg Ile Trp Gly Val Gln Phe His Pro Glu Ser Ala Gly Gly	385	390	395
Pro Leu Asp Thr Ile Glu Met Phe Thr Asp Phe Val Asn Glu Cys Asp	405	410	415
Val Ser Arg Lys Gly Phe Ser Gly Ser Ala Met Ile Ala Asn Glu Val	420	425	430

-continued

Lys Val Asp Gly His Ala Ala Lys Ala Ala Ser Val Ser Ala
 435 440 445

<210> SEQ ID NO 41
 <211> LENGTH: 843
 <212> TYPE: DNA
 <213> ORGANISM: *Cryptococcus neoformans*
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1) .. (843)

<400> SEQUENCE: 41

atg agc gtg ccg agc ctg aaa agc gcg ctg aaa aaa ccg acc aaa agc 48
 Met Ser Val Pro Ser Leu Lys Ser Ala Leu Lys Lys Pro Thr Lys Ser
 1 5 10 15

ttt gat acc ccg ccg gcg ggc ccg agc aaa ctg agc gtg gcg gcg gcg 96
 Phe Asp Thr Pro Pro Ala Gly Pro Ser Lys Leu Ser Val Ala Ala Ala
 20 25 30

gtg ccg gaa aaa agc aaa gcg aaa gcg aaa cag agc gtg agc att gcg 144
 Val Pro Glu Lys Ser Lys Ala Lys Ala Lys Gln Ser Val Ser Ile Ala
 35 40 45

gaa aaa ccg cag cgc ctg cgc ggc ccg gat ctg gaa agc gaa agc gaa 192
 Glu Lys Pro Gln Arg Leu Arg Gly Pro Asp Leu Glu Ser Glu Ser Glu
 50 55 60

ggc aac gcg agc ggc ttt gaa gat gaa agc gcg agc gaa gtg gaa gtg 240
 Gly Asn Ala Ser Gly Phe Glu Asp Glu Ser Ala Ser Glu Val Glu Val
 65 70 75 80

gat gaa gat gaa gaa atg aac acc gat gaa gaa att gaa aaa gcg aaa 288
 Asp Glu Asp Glu Glu Met Asn Thr Asp Glu Glu Ile Glu Lys Ala Lys
 85 90 95

gaa ggc aaa ccg aaa aaa agc acc aaa cgc aaa aaa gcg ccg acc acc 336
 Glu Gly Lys Pro Lys Lys Ser Thr Lys Arg Lys Lys Ala Pro Thr Thr
 100 105 110

gcg gcg gat ttt ggc gcg acc ctg acc agc ctg ctg gcg gat ccg ctg 384
 Ala Ala Asp Phe Gly Ala Thr Leu Thr Ser Leu Leu Ala Asp Pro Leu
 115 120 125

acc aaa agc aac aaa aaa gcg aaa acc gcg gat agc acc aaa aaa gcg 432
 Thr Lys Ser Asn Lys Lys Ala Lys Thr Ala Asp Ser Thr Lys Lys Ala
 130 135 140

gcg gcg gcg ccg att ctg gcg ctg agc gcg cat aaa ctg ccg acc aaa 480
 Ala Ala Ala Pro Ile Leu Ala Leu Ser Ala His Lys Leu Pro Thr Lys
 145 150 155 160

gcg agc gtg agc ctg gaa gcg aaa gcg aaa cgc cag ctg aaa gcg gaa 528
 Ala Ser Val Ser Leu Glu Ala Lys Ala Lys Arg Gln Leu Lys Ala Glu
 165 170 175

aaa gaa gaa aaa gaa gat cgc gcg cgc gtg cag aac gtg ctg gaa ggc 576
 Lys Glu Glu Lys Glu Asp Arg Ala Arg Val Gln Asn Val Leu Glu Gly
 180 185 190

tgg agc ggc gat ggc gtg gtg ggc ggc cag gaa ttt gaa cgc aac ctg 624
 Trp Ser Gly Asp Gly Val Val Gly Gly Gln Glu Phe Glu Arg Asn Leu
 195 200 205

cgc aaa acc gcg cag aaa ggc gtg gtg aaa ctg ttt aac gcg att ctg 672
 Arg Lys Thr Ala Gln Lys Gly Val Val Lys Leu Phe Asn Ala Ile Leu
 210 215 220

gtg gcg agc aaa aac gcg gaa gcg gcg cag acc acc ctg agc gaa aaa 720
 Val Ala Ser Lys Asn Ala Glu Ala Ala Gln Thr Thr Leu Ser Glu Lys
 225 230 235 240

gcg cgc ctg aaa ccg gaa gcg gcg aaa aaa aaa gaa aaa gat aac att 768
 Ala Arg Leu Lys Pro Glu Ala Ala Lys Lys Lys Glu Lys Asp Asn Ile
 245 250 255

-continued

```

ctg ggc cgc ggc ggc aaa gaa gat gtg ctg acc aaa gaa agc ttt ctg      816
Leu Gly Arg Gly Gly Lys Glu Asp Val Leu Thr Lys Glu Ser Phe Leu
                260                    265                270

```

```

gaa atg gtg cgc aaa ggc agc agc aaa      843
Glu Met Val Arg Lys Gly Ser Ser Lys
                275                    280

```

```

<210> SEQ ID NO 42
<211> LENGTH: 281
<212> TYPE: PRT
<213> ORGANISM: Cryptococcus neoformans

```

```

<400> SEQUENCE: 42

```

```

Met Ser Val Pro Ser Leu Lys Ser Ala Leu Lys Lys Pro Thr Lys Ser
 1                    5                    10                15

```

```

Phe Asp Thr Pro Pro Ala Gly Pro Ser Lys Leu Ser Val Ala Ala Ala
 20                    25                    30

```

```

Val Pro Glu Lys Ser Lys Ala Lys Ala Lys Gln Ser Val Ser Ile Ala
 35                    40                    45

```

```

Glu Lys Pro Gln Arg Leu Arg Gly Pro Asp Leu Glu Ser Glu Ser Glu
 50                    55                    60

```

```

Gly Asn Ala Ser Gly Phe Glu Asp Glu Ser Ala Ser Glu Val Glu Val
 65                    70                    75                80

```

```

Asp Glu Asp Glu Glu Met Asn Thr Asp Glu Glu Ile Glu Lys Ala Lys
 85                    90                    95

```

```

Glu Gly Lys Pro Lys Lys Ser Thr Lys Arg Lys Lys Ala Pro Thr Thr
100                    105                110

```

```

Ala Ala Asp Phe Gly Ala Thr Leu Thr Ser Leu Leu Ala Asp Pro Leu
115                    120                125

```

```

Thr Lys Ser Asn Lys Lys Ala Lys Thr Ala Asp Ser Thr Lys Lys Ala
130                    135                140

```

```

Ala Ala Ala Pro Ile Leu Ala Leu Ser Ala His Lys Leu Pro Thr Lys
145                    150                155                160

```

```

Ala Ser Val Ser Leu Glu Ala Lys Ala Lys Arg Gln Leu Lys Ala Glu
165                    170                175

```

```

Lys Glu Glu Lys Glu Asp Arg Ala Arg Val Gln Asn Val Leu Glu Gly
180                    185                190

```

```

Trp Ser Gly Asp Gly Val Val Gly Gly Gln Glu Phe Glu Arg Asn Leu
195                    200                205

```

```

Arg Lys Thr Ala Gln Lys Gly Val Val Lys Leu Phe Asn Ala Ile Leu
210                    215                220

```

```

Val Ala Ser Lys Asn Ala Glu Ala Ala Gln Thr Thr Leu Ser Glu Lys
225                    230                235                240

```

```

Ala Arg Leu Lys Pro Glu Ala Ala Lys Lys Lys Glu Lys Asp Asn Ile
245                    250                255

```

```

Leu Gly Arg Gly Gly Lys Glu Asp Val Leu Thr Lys Glu Ser Phe Leu
260                    265                270

```

```

Glu Met Val Arg Lys Gly Ser Ser Lys
 275                    280

```

```

<210> SEQ ID NO 43
<211> LENGTH: 600
<212> TYPE: DNA
<213> ORGANISM: Cryptococcus neoformans
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(600)

```

-continued

```

<400> SEQUENCE: 43

atg acc tgc gcg ctg att ccg ctg ctg cgc aaa agc gat ctg cgc agc      48
Met Thr Cys Ala Leu Ile Pro Leu Leu Arg Lys Ser Asp Leu Arg Ser
1           5           10           15

gtg gtg att att gcg agc att gcg ggc ctg gcg aac cag cgc gcg acc      96
Val Val Ile Ile Ala Ser Ile Ala Gly Leu Ala Asn Gln Arg Ala Thr
20           25           30

ggc agc gtg agc tat ggc gtg agc aaa gcg gcg gcg att cat ctg ggc     144
Gly Ser Val Ser Tyr Gly Val Ser Lys Ala Ala Ala Ile His Leu Gly
35           40           45

aaa ctg ctg gcg ggc cgc ctg cat ccg ctg aaa att cgc gtg aac acc     192
Lys Leu Leu Ala Gly Arg Leu His Pro Leu Lys Ile Arg Val Asn Thr
50           55           60

att tgc ccg ggc att ttt ccg agc gaa atg acc ggc aaa aac gat gcg     240
Ile Cys Pro Gly Ile Phe Pro Ser Glu Met Thr Gly Lys Asn Asp Ala
65           70           75           80

ggc cag ggc ctg gaa tat gat att ggc gaa att ccg acc aaa gcg gcg     288
Gly Gln Gly Leu Glu Tyr Asp Ile Gly Glu Ile Pro Thr Lys Ala Ala
85           90           95

aaa cgc agc acc gtg ggc cgc ccg ggc ctg ccg gaa gaa att gtg ggc     336
Lys Arg Ser Thr Val Gly Arg Pro Gly Leu Pro Glu Glu Ile Val Gly
100          105          110

ccg gtg ctg ctg ctg agc agc aaa gcg ggc ggc tat ttt gat ggc gcg     384
Pro Val Leu Leu Leu Ser Ser Lys Ala Gly Gly Tyr Phe Asp Gly Ala
115          120          125

atg ctg acc gtg gat ggc ggc cgc ctg atg gtg agc ggc ccg ttt tgc     432
Met Leu Thr Val Asp Gly Gly Arg Leu Met Val Ser Gly Pro Phe Cys
130          135          140

ttt gtg ttt agc ccg agc agc ctg ccg gtg gat aac ctg cgc tgc ttt     480
Phe Val Phe Ser Pro Ser Ser Leu Pro Val Asp Asn Leu Arg Cys Phe
145          150          155          160

ctg ctg ctg acc acc gtg ggc aac cgc gtg ccg gcg ttt atg atg gtg     528
Leu Leu Leu Thr Val Gly Asn Arg Val Pro Ala Phe Met Met Val
165          170          175

agc gat tgc ctg cgc att cgc att ttt gaa ctg aac gaa cag cgc aaa     576
Ser Asp Cys Leu Arg Ile Arg Ile Phe Glu Leu Asn Glu Gln Arg Lys
180          185          190

aac gaa acc gat gtg gaa atg ggc                                     600
Asn Glu Thr Asp Val Glu Met Gly
195          200

```

<210> SEQ ID NO 44

<211> LENGTH: 200

<212> TYPE: PRT

<213> ORGANISM: *Cryptococcus neoformans*

<400> SEQUENCE: 44

```

Met Thr Cys Ala Leu Ile Pro Leu Leu Arg Lys Ser Asp Leu Arg Ser
1           5           10           15

Val Val Ile Ile Ala Ser Ile Ala Gly Leu Ala Asn Gln Arg Ala Thr
20           25           30

Gly Ser Val Ser Tyr Gly Val Ser Lys Ala Ala Ala Ile His Leu Gly
35           40           45

Lys Leu Leu Ala Gly Arg Leu His Pro Leu Lys Ile Arg Val Asn Thr
50           55           60

Ile Cys Pro Gly Ile Phe Pro Ser Glu Met Thr Gly Lys Asn Asp Ala
65           70           75           80

Gly Gln Gly Leu Glu Tyr Asp Ile Gly Glu Ile Pro Thr Lys Ala Ala
85           90           95

```

-continued

Lys Arg Ser Thr Val Gly Arg Pro Gly Leu Pro Glu Glu Ile Val Gly
 100 105 110

Pro Val Leu Leu Leu Ser Ser Lys Ala Gly Gly Tyr Phe Asp Gly Ala
 115 120 125

Met Leu Thr Val Asp Gly Gly Arg Leu Met Val Ser Gly Pro Phe Cys
 130 135 140

Phe Val Phe Ser Pro Ser Ser Leu Pro Val Asp Asn Leu Arg Cys Phe
 145 150 155 160

Leu Leu Leu Thr Thr Val Gly Asn Arg Val Pro Ala Phe Met Met Val
 165 170 175

Ser Asp Cys Leu Arg Ile Arg Ile Phe Glu Leu Asn Glu Gln Arg Lys
 180 185 190

Asn Glu Thr Asp Val Glu Met Gly
 195 200

<210> SEQ ID NO 45
 <211> LENGTH: 1440
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1440)

<400> SEQUENCE: 45

atg ctg gtg aac agc agc agc atg ctg gtg acc cgc acc cat ggc ctg	48
Met Leu Val Asn Ser Ser Ser Met Leu Val Thr Arg Thr His Gly Leu	
1 5 10 15	
atg ggc gat gaa gcg tgg aaa gaa ctg gcg aaa tat ggc ctg acc cgc	96
Met Gly Asp Glu Ala Trp Lys Glu Leu Ala Lys Tyr Gly Leu Thr Arg	
20 25 30	
tgg agc gat gat ggc gcg ttt ctg acc gtg ccg gcg cgc ggc tgc agc	144
Trp Ser Asp Asp Gly Ala Phe Leu Thr Val Pro Ala Arg Gly Cys Ser	
35 40 45	
atg tgc gaa gtg gat ccg gtg ctg tgc gaa gaa att ggc gaa gat aac	192
Met Cys Glu Val Asp Pro Val Leu Cys Glu Glu Ile Gly Glu Asp Asn	
50 55 60	
ctg aaa cgc agc ctg gcg ttt agc ggc acc aac cgc cgc ctg aaa cgc	240
Leu Lys Arg Ser Leu Ala Phe Ser Gly Thr Asn Arg Arg Leu Lys Arg	
65 70 75 80	
gtg ctg gcg aaa ctg cgc cgc ggc gaa acc att aac gtg ggc gcg att	288
Val Leu Ala Lys Leu Arg Arg Gly Glu Thr Ile Asn Val Gly Ala Ile	
85 90 95	
ggc ggc agc gtg acc aaa ggc tat ggc ctg aac cgc tat aac gaa ccg	336
Gly Gly Ser Val Thr Lys Gly Tyr Gly Leu Asn Arg Tyr Asn Glu Pro	
100 105 110	
tat tat ccg gat acc ccg acc aac ctg cat cgc att att ttt gat cat	384
Tyr Tyr Pro Asp Thr Pro Thr Asn Leu His Arg Ile Ile Phe Asp His	
115 120 125	
ctg gtg agc ctg tat ccg gcg ccg aac ggc gtg aaa acc gat gat agc	432
Leu Val Ser Leu Tyr Pro Ala Pro Asn Gly Val Lys Thr Asp Asp Ser	
130 135 140	
ggc cgc aaa gaa ggc aaa cat ggc tat att aac ggc ggc cag ggc gcg	480
Gly Arg Lys Glu Gly Lys His Gly Tyr Ile Asn Gly Gly Gln Gly Ala	
145 150 155 160	
acc ggc acc ggc tat ttt agc tat tgc tgg gaa gaa cat gtg ccg gcg	528
Thr Gly Thr Gly Tyr Phe Ser Tyr Cys Trp Glu Glu His Val Pro Ala	
165 170 175	
gat ctg gat ctg att ttt ctg gaa cag gcg att aac gat gaa ctg ctg	576
Asp Leu Asp Leu Ile Phe Leu Glu Gln Ala Ile Asn Asp Glu Leu Leu	

-continued

180	185	190	
ctg cgc aac att gat agc tat gaa ctg ctg gtg cgc agc ctg ctg gat Leu Arg Asn Ile Asp Ser Tyr Glu Leu Leu Val Arg Ser Leu Leu Asp 195 200 205			624
ctg ccg acc agc ccg gcg att gtg aac ctg cat gtg ttt gcg ctg atg Leu Pro Thr Ser Pro Ala Ile Val Asn Leu His Val Phe Ala Leu Met 210 215 220			672
ttt aac agc att acc ctg ggc ggc gat ctg cat cag agc att gcg cag Phe Asn Ser Ile Thr Leu Gly Gly Asp Leu His Gln Ser Ile Ala Gln 225 230 235 240			720
ttt tat gat ctg ccg gtg ctg agc ctg cgc aac gcg ctg ctg aac gat Phe Tyr Asp Leu Pro Val Leu Ser Leu Arg Asn Ala Leu Leu Asn Asp 245 250 255			768
atg ctg aaa aac gaa agc ctg att agc gaa tat ttt ttt gtg cat ccg Met Leu Lys Asn Glu Ser Leu Ile Ser Glu Tyr Phe Phe Val His Pro 260 265 270			816
gaa ggc gat att gat ctg cgc cat att agc cgc aaa ggc cat aac gtg Glu Gly Asp Ile Asp Leu Arg His Ile Ser Arg Lys Gly His Asn Val 275 280 285			864
atg ggc cgc att ggc gcg gcg tat atg gat agc cag att tgc gaa atg Met Gly Arg Ile Gly Ala Ala Tyr Met Asp Ser Gln Ile Cys Glu Met 290 295 300			912
gat aaa tat gaa cag ggc att ccg ggc gcg gat agc atg agc att gat Asp Lys Tyr Glu Gln Gly Ile Pro Gly Ala Asp Ser Met Ser Ile Asp 305 310 315 320			960
cag ctg tat ccg gtg gaa ccg att ccg cgc atg cag att aac atg aaa Gln Leu Tyr Pro Val Glu Pro Ile Pro Arg Met Gln Ile Asn Met Lys 325 330 335			1008
tat gat aaa gat ctg gtg ctg ccg acc att aaa ccg cag tgc ttt agc Tyr Asp Lys Asp Leu Val Leu Pro Thr Ile Lys Pro Gln Cys Phe Ser 340 345 350			1056
gcg aac agc gaa aaa cat ccg ctg gtg ccg gtg gaa aac aac ggc tgg Ala Asn Ser Glu Lys His Pro Leu Val Pro Val Glu Asn Asn Gly Trp 355 360 365			1104
cgc aaa tgg aac tgg aaa gaa aaa cat tat ctg gtg gcg gat gtg ccg Arg Lys Trp Asn Trp Lys Glu Lys His Tyr Leu Val Ala Asp Val Pro 370 375 380			1152
ggc agc cgc gtg agc ttt aaa ctg aaa acc aac atg ggc aaa att gaa Gly Ser Arg Val Ser Phe Lys Leu Lys Thr Asn Met Gly Lys Ile Glu 385 390 395 400			1200
gtg cag tat ctg cgc agc tat cag tat cat cag ggc agc gcg aaa tgc Val Gln Tyr Leu Arg Ser Tyr Gln Tyr His Gln Gly Ser Ala Lys Cys 405 410 415			1248
tgg gtg gat gaa gaa gtg gaa aaa gcg att aaa ctg gat ggc tat tgg Trp Val Asp Glu Glu Val Glu Lys Ala Ile Lys Leu Asp Gly Tyr Trp 420 425 430			1296
aaa gaa ccg tat aac att ggc cgc gcg gtg acc att cgc gaa ggc ctg Lys Glu Pro Tyr Asn Ile Gly Arg Ala Val Thr Ile Arg Glu Gly Leu 435 440 445			1344
gaa ccg ggc gaa cat acc ctg acc tgc gaa ctg ctg aaa cag acc gcg Glu Pro Gly Glu His Thr Leu Thr Cys Glu Leu Leu Lys Gln Thr Ala 450 455 460			1392
gat ccg gaa ggc ggc ctg gaa ttt cgc ctg att agc att atg agc att Asp Pro Glu Gly Gly Leu Glu Phe Arg Leu Ile Ser Ile Met Ser Ile 465 470 475 480			1440

<210> SEQ ID NO 46

<211> LENGTH: 480

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

-continued

<400> SEQUENCE: 46

Met Leu Val Asn Ser Ser Ser Met Leu Val Thr Arg Thr His Gly Leu
 1 5 10 15
 Met Gly Asp Glu Ala Trp Lys Glu Leu Ala Lys Tyr Gly Leu Thr Arg
 20 25 30
 Trp Ser Asp Asp Gly Ala Phe Leu Thr Val Pro Ala Arg Gly Cys Ser
 35 40 45
 Met Cys Glu Val Asp Pro Val Leu Cys Glu Glu Ile Gly Glu Asp Asn
 50 55 60
 Leu Lys Arg Ser Leu Ala Phe Ser Gly Thr Asn Arg Arg Leu Lys Arg
 65 70 75 80
 Val Leu Ala Lys Leu Arg Arg Gly Glu Thr Ile Asn Val Gly Ala Ile
 85 90 95
 Gly Gly Ser Val Thr Lys Gly Tyr Gly Leu Asn Arg Tyr Asn Glu Pro
 100 105 110
 Tyr Tyr Pro Asp Thr Pro Thr Asn Leu His Arg Ile Ile Phe Asp His
 115 120 125
 Leu Val Ser Leu Tyr Pro Ala Pro Asn Gly Val Lys Thr Asp Asp Ser
 130 135 140
 Gly Arg Lys Glu Gly Lys His Gly Tyr Ile Asn Gly Gly Gln Gly Ala
 145 150 155 160
 Thr Gly Thr Gly Tyr Phe Ser Tyr Cys Trp Glu Glu His Val Pro Ala
 165 170 175
 Asp Leu Asp Leu Ile Phe Leu Glu Gln Ala Ile Asn Asp Glu Leu Leu
 180 185 190
 Leu Arg Asn Ile Asp Ser Tyr Glu Leu Leu Val Arg Ser Leu Leu Asp
 195 200 205
 Leu Pro Thr Ser Pro Ala Ile Val Asn Leu His Val Phe Ala Leu Met
 210 215 220
 Phe Asn Ser Ile Thr Leu Gly Gly Asp Leu His Gln Ser Ile Ala Gln
 225 230 235 240
 Phe Tyr Asp Leu Pro Val Leu Ser Leu Arg Asn Ala Leu Leu Asn Asp
 245 250 255
 Met Leu Lys Asn Glu Ser Leu Ile Ser Glu Tyr Phe Phe Val His Pro
 260 265 270
 Glu Gly Asp Ile Asp Leu Arg His Ile Ser Arg Lys Gly His Asn Val
 275 280 285
 Met Gly Arg Ile Gly Ala Ala Tyr Met Asp Ser Gln Ile Cys Glu Met
 290 295 300
 Asp Lys Tyr Glu Gln Gly Ile Pro Gly Ala Asp Ser Met Ser Ile Asp
 305 310 315 320
 Gln Leu Tyr Pro Val Glu Pro Ile Pro Arg Met Gln Ile Asn Met Lys
 325 330 335
 Tyr Asp Lys Asp Leu Val Leu Pro Thr Ile Lys Pro Gln Cys Phe Ser
 340 345 350
 Ala Asn Ser Glu Lys His Pro Leu Val Pro Val Glu Asn Asn Gly Trp
 355 360 365
 Arg Lys Trp Asn Trp Lys Glu Lys His Tyr Leu Val Ala Asp Val Pro
 370 375 380
 Gly Ser Arg Val Ser Phe Lys Leu Lys Thr Asn Met Gly Lys Ile Glu
 385 390 395 400
 Val Gln Tyr Leu Arg Ser Tyr Gln Tyr His Gln Gly Ser Ala Lys Cys

-continued

210	215	220	
gaa ggc ttt tat gcg gat ctg gat gaa agc ggc cgc gaa gtg acc ccg Glu Gly Phe Tyr Ala Asp Leu Asp Glu Ser Gly Arg Glu Val Thr Pro 225 230 235 240			720
ccg ccg ccg gcg tat att att ccg cgc ccg ggc ccg gaa ggc cat gtg Pro Pro Pro Ala Tyr Ile Ile Pro Arg Pro Gly Pro Glu Gly His Val 245 250 255			768
gtg ctg ggc ggc gtg tat cag cgc gat aac tgg agc acc ctg ccg gat Val Leu Gly Gly Val Tyr Gln Arg Asp Asn Trp Ser Thr Leu Pro Asp 260 265 270			816
ctg aaa gaa gcg gaa cgc att ctg aaa gat tgc tat aac ctg gcg ccg Leu Lys Glu Ala Glu Arg Ile Leu Lys Asp Cys Tyr Asn Leu Ala Pro 275 280 285			864
gaa ctg gcg ggc ccg aac ggc aaa acc tgg aaa gat att gaa att att Glu Leu Ala Gly Pro Asn Gly Lys Thr Trp Lys Asp Ile Glu Ile Ile 290 295 300			912
agc cat aac gtg ggc ctg cgc ccg gcg cgc gaa ggc ggc ccg cgc ctg Ser His Asn Val Gly Leu Arg Pro Ala Arg Glu Gly Gly Pro Arg Leu 305 310 315 320			960
gaa att gaa gaa cgc gaa gtg ggc acc ggc gcg aac gaa ggc aac gcg Glu Ile Glu Glu Arg Glu Val Gly Thr Gly Ala Asn Glu Gly Asn Ala 325 330 335			1008
tat gat gtg gcg ccg atg att ggc cgc att ggc gaa cgc cgc aaa gtg Tyr Asp Val Ala Pro Met Ile Gly Arg Ile Gly Glu Arg Arg Lys Val 340 345 350			1056
gcg gtg gtg cat gcg tat ggc att ggc agc gcg ggc ttt cag gcg agc Ala Val Val His Ala Tyr Gly Ile Gly Ser Ala Gly Phe Gln Ala Ser 355 360 365			1104
ctg ggc atg gcg gaa aaa gcg agc gat ctg acc gtg aaa tat ctg agc Leu Gly Met Ala Glu Lys Ala Ser Asp Leu Thr Val Lys Tyr Leu Ser 370 375 380			1152
ggc aaa cgc agc ccg gcg cgc ctg Gly Lys Arg Ser Pro Ala Arg Leu 385 390			1176
<p><210> SEQ ID NO 48 <211> LENGTH: 392 <212> TYPE: PRT <213> ORGANISM: Cryptococcus neoformans <400> SEQUENCE: 48</p>			
Met Ser Phe Asp Ala Val Val Ile Gly Ser Gly Val Ile Gly Leu Ser 1 5 10 15			
Ile Ala Arg Glu Leu His Asn Arg Gly Leu Lys Val Ala Ile Val Ala 20 25 30			
Arg Asp Leu Ala Glu Asp Ser Ile Ser Val Gly Phe Ala Ser Pro Trp 35 40 45			
Ala Gly Cys Asn Trp Phe Ser Phe Ala Glu Gly Gly Thr Pro Ala Ala 50 55 60			
Glu Trp Asp Thr Ile Thr Phe Gly Lys Leu Ala Lys Leu Ala Lys Asp 65 70 75 80			
His Pro His Ile Cys Gln Lys Ile Pro Phe Cys Ser Val Trp Asp Leu 85 90 95			
Pro Lys Ser Asp Ala Glu Ser Glu Pro Trp Phe Lys Asp Leu Val Phe 100 105 110			
Asp Tyr Lys Asn Leu Lys Ser Thr Pro Gly Gln Pro Leu Pro Gly Gly 115 120 125			
Lys Lys Phe Gly His Ser Phe Ala Ser Tyr Val Leu His Ala Pro Asn			

-continued

130	135	140	
Tyr Ile Arg His Leu Ser Ser	Glu Thr Arg Ala Leu Gly Ile Pro Val		
145	150	155	160
His Arg Tyr Arg Leu Ser Ser	Leu Asp Glu Ala Tyr Asn Leu Ser Gly		
	165	170	175
Ile Gly Lys Val Ser Leu Val Val	Asn Ala Ser Gly Leu Gly Ala Lys		
	180	185	190
Ala Leu Ile Gly Val Glu Asp	Glu Lys Val Tyr Pro Gly Arg Gly Gln		
	195	200	205
Thr Val Leu Val Arg Ala Pro	Gly Phe Lys Ala Cys Ile Met His Thr		
	210	215	220
Glu Gly Phe Tyr Ala Asp Leu	Asp Glu Ser Gly Arg Glu Val Thr Pro		
	225	230	235
Pro Pro Pro Ala Tyr Ile Ile	Pro Arg Pro Gly Pro Glu Gly His Val		
	245	250	255
Val Leu Gly Gly Val Tyr Gln	Arg Asp Asn Trp Ser Thr Leu Pro Asp		
	260	265	270
Leu Lys Glu Ala Glu Arg Ile	Leu Lys Asp Cys Tyr Asn Leu Ala Pro		
	275	280	285
Glu Leu Ala Gly Pro Asn Gly	Lys Thr Trp Lys Asp Ile Glu Ile Ile		
	290	295	300
Ser His Asn Val Gly Leu Arg	Pro Ala Arg Glu Gly Gly Pro Arg Leu		
	305	310	315
Glu Ile Glu Glu Arg Glu Val	Gly Thr Gly Ala Asn Glu Gly Asn Ala		
	325	330	335
Tyr Asp Val Ala Pro Met Ile	Gly Arg Ile Gly Glu Arg Arg Lys Val		
	340	345	350
Ala Val Val His Ala Tyr Gly	Ile Gly Ser Ala Gly Phe Gln Ala Ser		
	355	360	365
Leu Gly Met Ala Glu Lys Ala	Ser Asp Leu Thr Val Lys Tyr Leu Ser		
	370	375	380
Gly Lys Arg Ser Pro Ala Arg	Leu		
	385	390	
<p><210> SEQ ID NO 49 <211> LENGTH: 198 <212> TYPE: DNA <213> ORGANISM: Cryptococcus neoformans <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: (1)..(198)</p>			
<p><400> SEQUENCE: 49</p>			
atg ccg ggc ttt cag gat gtg att tat aac acc ttt ttt cgc cgc aac			48
Met Pro Gly Phe Gln Asp Val Ile Tyr Asn Thr Phe Phe Arg Arg Asn			
1 5 10 15			
agc gtg ttt gtg gcg acc acc ttt att gcg gcg ttt agc ttt agc atg			96
Ser Val Phe Val Ala Thr Thr Phe Ile Ala Ala Phe Ser Phe Ser Met			
20 25 30			
ggc ttt gat ctg gcg acc acc gcg ttt tgg gat agc cat aac cgc ggc			144
Gly Phe Asp Leu Ala Thr Thr Ala Phe Trp Asp Ser His Asn Arg Gly			
35 40 45			
aaa cag tgg aaa gat att cgc cat aaa tat att gaa gcg gcg ggc gat			192
Lys Gln Trp Lys Asp Ile Arg His Lys Tyr Ile Glu Ala Ala Gly Asp			
50 55 60			
gat gaa			198
Asp Glu			

-continued

65

<210> SEQ ID NO 50
 <211> LENGTH: 66
 <212> TYPE: PRT
 <213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 50

```
Met Pro Gly Phe Gln Asp Val Ile Tyr Asn Thr Phe Phe Arg Arg Asn
1                               5 10 15
Ser Val Phe Val Ala Thr Thr Phe Ile Ala Ala Phe Ser Phe Ser Met
                20                25 30
Gly Phe Asp Leu Ala Thr Thr Ala Phe Trp Asp Ser His Asn Arg Gly
                35                40 45
Lys Gln Trp Lys Asp Ile Arg His Lys Tyr Ile Glu Ala Ala Gly Asp
                50                55 60
Asp Glu
65
```

<210> SEQ ID NO 51
 <211> LENGTH: 1368
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1368)

<400> SEQUENCE: 51

```
atg agc agc ggc aac gtg ccg aaa att gaa cgc ctg agc tgc gtg ccg      48
Met Ser Ser Gly Asn Val Pro Lys Ile Glu Arg Leu Ser Cys Val Pro
1                               5 10 15
aac gat tat ccg tgg ggc gaa gtg ggc aac gat agc ctg gcg gcg cgc      96
Asn Asp Tyr Pro Trp Gly Glu Val Gly Asn Asp Ser Leu Ala Ala Arg
                20                25 30
ctg gcg agc aaa aac ggc gcg gtg agc ttt gat ctg aaa ccg gaa cag      144
Leu Ala Ser Lys Asn Gly Ala Val Ser Phe Asp Leu Lys Pro Glu Gln
                35                40 45
gcg tat gcg gaa ctg tgg atg ggc acc cat ccg aac aac ccg gcg cat      192
Ala Tyr Ala Glu Leu Trp Met Gly Thr His Pro Asn Asn Pro Ala His
                50                55 60
ctg ttt agc agc ccg gat acc ctg ctg agc acc cat ctg aaa aaa aac      240
Leu Phe Ser Ser Pro Asp Thr Leu Leu Ser Thr His Leu Lys Lys Asn
65                70                75 80
ccg agc ctg ctg ggc gcg gcg aac cgc ttt agc ccg ccg ttt acc ggc      288
Pro Ser Leu Leu Gly Ala Ala Asn Arg Phe Ser Pro Pro Phe Thr Gly
                85                90 95
gcg aaa ggc agc ggc gcg gaa ggc cag gaa gaa ggc cat gtg ccg ttt      336
Ala Lys Gly Ser Gly Ala Glu Gly Gln Glu Glu Gly His Val Pro Phe
                100                105 110
ctg ttt aaa gtg ctg acc tgc aaa cag gcg ctg ccg ctg cag att cat      384
Leu Phe Lys Val Leu Thr Cys Lys Gln Ala Leu Pro Leu Gln Ile His
                115                120 125
ccg gat aaa gcg ctg gcg aaa aaa ctg cat gaa gaa aac ccg aaa cag      432
Pro Asp Lys Ala Leu Ala Lys Lys Leu His Glu Glu Asn Pro Lys Gln
                130                135 140
ttt ggc gat att aac cat aaa ccg gaa att gcg gtg tgc ctg agc gat      480
Phe Gly Asp Ile Asn His Lys Pro Glu Ile Ala Val Cys Leu Ser Asp
145                150                155 160
cgc ttt ctg ggc ttt gcg agc ttt cgc ccg tat gat aaa att gcg agc      528
Arg Phe Leu Gly Phe Ala Ser Phe Arg Pro Tyr Asp Lys Ile Ala Ser
                165                170 175
```

-continued

ctg ctg aaa agc gtg cag gaa att agc ctg ctg ccg agc ctg ctg cag Leu Leu Lys Ser Val Gln Glu Ile Ser Leu Leu Pro Ser Leu Leu Gln 180 185 190	576
aaa agc att aaa agc ttt att agc gcg ccg agc gcg gaa acc ctg cag Lys Ser Ile Lys Ser Phe Ile Ser Ala Pro Ser Ala Glu Thr Leu Gln 195 200 205	624
ccg acc tgg gaa ggc ttt att aaa ctg ggc gat aac gaa gaa agc gtg Pro Thr Trp Glu Gly Phe Ile Lys Leu Gly Asp Asn Glu Glu Ser Val 210 215 220	672
aaa aaa ttt agc gat cgc gtg ctg agc cag ggc ctg aaa gcg ttt gat Lys Lys Phe Ser Asp Arg Val Leu Ser Gln Gly Leu Lys Ala Phe Asp 225 230 235 240	720
agc gtg gat att gaa gat gaa gat aaa aac cgc ctg gtg cgc gcg gtg Ser Val Asp Ile Glu Asp Glu Asp Lys Asn Arg Leu Val Arg Ala Val 245 250 255	768
gaa ctg ggc aaa aaa tat aac ccg ggc gat gcg ggc ctg ttt agc agc Glu Leu Gly Lys Lys Tyr Asn Pro Gly Asp Ala Gly Leu Phe Ser Ser 260 265 270	816
ctg ctg ttt ctg aac ctg att gaa ctg aaa aaa gat cag ggc atg tat Leu Leu Phe Leu Asn Leu Ile Glu Leu Lys Lys Asp Gln Gly Met Tyr 275 280 285	864
gtg ggc gcg gat ggc ccg cat gcg tgg ctg gaa ggc gaa att gtg gaa Val Gly Ala Asp Gly Pro His Ala Trp Leu Glu Gly Glu Ile Val Glu 290 295 300	912
ctg atg gcg att agc gat aac gtg ctg aac gtg ggc ttt acc agc gat Leu Met Ala Ile Ser Asp Asn Val Leu Asn Val Gly Phe Thr Ser Asp 305 310 315 320	960
gat agc aaa gat gat ccg agc ctg gtg gcg aaa gcg gtg acc tgc acc Asp Ser Lys Asp Asp Pro Ser Leu Val Ala Lys Ala Val Thr Cys Thr 325 330 335	1008
ccg aaa gcg att aaa gat ctg ctg ctg gat gcg agc aaa tat agc aaa Pro Lys Ala Ile Lys Asp Leu Leu Leu Asp Ala Ser Lys Tyr Ser Lys 340 345 350	1056
agc cag aac ggc cgc acc acc gtg tat agc acc ccg ttt gaa gaa ttt Ser Gln Asn Gly Arg Thr Thr Val Tyr Ser Thr Pro Phe Glu Glu Phe 355 360 365	1104
agc att atg aaa att gcg ggc gat gaa att ctg agc ccg ctg gat ggc Ser Ile Met Lys Ile Ala Gly Asp Glu Ile Leu Ser Pro Leu Asp Gly 370 375 380	1152
gcg ggc gtg gcg gtg gtg ctg gaa ggc gaa tgg acc gtg gaa gat cag Ala Gly Val Ala Val Val Leu Glu Gly Glu Trp Thr Val Glu Asp Gln 385 390 395 400	1200
gaa ggc acc aaa cgc ggc ggc gaa ggc acc gat ggc gaa ggc ggc gaa Glu Gly Thr Lys Arg Gly Gly Glu Gly Thr Asp Gly Glu Gly Gly Glu 405 410 415	1248
ggc acc att tgg ttt att ggc agc gcg acc gaa acc aaa tgg acc gcg Gly Thr Ile Trp Phe Ile Gly Ser Ala Thr Glu Thr Lys Trp Thr Ala 420 425 430	1296
aaa ggc ggc aaa ggc cag att tgg att gcg ttt tat gat aaa acc gcg Lys Gly Gly Lys Gly Gln Ile Trp Ile Ala Phe Tyr Asp Lys Thr Ala 435 440 445	1344
aaa aaa gat gat gtg ggc aaa aaa Lys Lys Asp Asp Val Gly Lys Lys 450 455	1368

<210> SEQ ID NO 52

<211> LENGTH: 456

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

-continued

<400> SEQUENCE: 52

Met Ser Ser Gly Asn Val Pro Lys Ile Glu Arg Leu Ser Cys Val Pro
 1 5 10 15
 Asn Asp Tyr Pro Trp Gly Glu Val Gly Asn Asp Ser Leu Ala Ala Arg
 20 25 30
 Leu Ala Ser Lys Asn Gly Ala Val Ser Phe Asp Leu Lys Pro Glu Gln
 35 40 45
 Ala Tyr Ala Glu Leu Trp Met Gly Thr His Pro Asn Asn Pro Ala His
 50 55 60
 Leu Phe Ser Ser Pro Asp Thr Leu Leu Ser Thr His Leu Lys Lys Asn
 65 70 75 80
 Pro Ser Leu Leu Gly Ala Ala Asn Arg Phe Ser Pro Pro Phe Thr Gly
 85 90 95
 Ala Lys Gly Ser Gly Ala Glu Gly Gln Glu Glu Gly His Val Pro Phe
 100 105 110
 Leu Phe Lys Val Leu Thr Cys Lys Gln Ala Leu Pro Leu Gln Ile His
 115 120 125
 Pro Asp Lys Ala Leu Ala Lys Lys Leu His Glu Glu Asn Pro Lys Gln
 130 135 140
 Phe Gly Asp Ile Asn His Lys Pro Glu Ile Ala Val Cys Leu Ser Asp
 145 150 155 160
 Arg Phe Leu Gly Phe Ala Ser Phe Arg Pro Tyr Asp Lys Ile Ala Ser
 165 170 175
 Leu Leu Lys Ser Val Gln Glu Ile Ser Leu Leu Pro Ser Leu Leu Gln
 180 185 190
 Lys Ser Ile Lys Ser Phe Ile Ser Ala Pro Ser Ala Glu Thr Leu Gln
 195 200 205
 Pro Thr Trp Glu Gly Phe Ile Lys Leu Gly Asp Asn Glu Glu Ser Val
 210 215 220
 Lys Lys Phe Ser Asp Arg Val Leu Ser Gln Gly Leu Lys Ala Phe Asp
 225 230 235 240
 Ser Val Asp Ile Glu Asp Glu Asp Lys Asn Arg Leu Val Arg Ala Val
 245 250 255
 Glu Leu Gly Lys Lys Tyr Asn Pro Gly Asp Ala Gly Leu Phe Ser Ser
 260 265 270
 Leu Leu Phe Leu Asn Leu Ile Glu Leu Lys Lys Asp Gln Gly Met Tyr
 275 280 285
 Val Gly Ala Asp Gly Pro His Ala Trp Leu Glu Gly Glu Ile Val Glu
 290 295 300
 Leu Met Ala Ile Ser Asp Asn Val Leu Asn Val Gly Phe Thr Ser Asp
 305 310 315 320
 Asp Ser Lys Asp Asp Pro Ser Leu Val Ala Lys Ala Val Thr Cys Thr
 325 330 335
 Pro Lys Ala Ile Lys Asp Leu Leu Leu Asp Ala Ser Lys Tyr Ser Lys
 340 345 350
 Ser Gln Asn Gly Arg Thr Thr Val Tyr Ser Thr Pro Phe Glu Glu Phe
 355 360 365
 Ser Ile Met Lys Ile Ala Gly Asp Glu Ile Leu Ser Pro Leu Asp Gly
 370 375 380
 Ala Gly Val Ala Val Val Leu Glu Gly Glu Trp Thr Val Glu Asp Gln
 385 390 395 400
 Glu Gly Thr Lys Arg Gly Gly Glu Gly Thr Asp Gly Glu Gly Gly Glu
 405 410 415

-continued

Gly Thr Ile Trp Phe Ile Gly Ser Ala Thr Glu Thr Lys Trp Thr Ala
 420 425 430

Lys Gly Gly Lys Gly Gln Ile Trp Ile Ala Phe Tyr Asp Lys Thr Ala
 435 440 445

Lys Lys Asp Asp Val Gly Lys Lys
 450 455

<210> SEQ ID NO 53
 <211> LENGTH: 1962
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1962)

<400> SEQUENCE: 53

atg acc cgc gat ttt gat agc ctg ttt ttt acc ggc ccg att ttt gtg 48
 Met Thr Arg Asp Phe Asp Ser Leu Phe Phe Thr Gly Pro Ile Phe Val
 1 5 10 15

gat tat agc ttt acc gcg cgc cat ctg gaa agc ttt ctg agc agc ttt 96
 Asp Tyr Ser Phe Thr Ala Arg His Leu Glu Ser Phe Leu Ser Ser Phe
 20 25 30

ccg ccg cag gtg agc cat gcg atg agc agc gcg agc acc ccg acc gcg 144
 Pro Pro Gln Val Ser His Ala Met Ser Ser Ala Ser Thr Pro Thr Ala
 35 40 45

ccg tat ctg gaa gat ctg gtg cgc aac agc ctg gat cag acc ctg ccg 192
 Pro Tyr Leu Glu Asp Leu Val Arg Asn Ser Leu Asp Gln Thr Leu Pro
 50 55 60

tgg gtg gtg cag aaa tat ggc ggc acc agc gtg ggc aaa agc ctg gat 240
 Trp Val Val Gln Lys Tyr Gly Gly Thr Ser Val Gly Lys Ser Leu Asp
 65 70 75 80

aac att acc aaa att gtg ggc agc tat att gat aac ggc agc aaa gtg 288
 Asn Ile Thr Lys Ile Val Gly Ser Tyr Ile Asp Asn Gly Ser Lys Val
 85 90 95

gcg att gtg tgc agc gcg cgc agc acc cag acc aaa agc ctg ggc acc 336
 Ala Ile Val Cys Ser Ala Arg Ser Thr Gln Thr Lys Ser Leu Gly Thr
 100 105 110

acc aac ctg ctg ctg cag gcg agc cgc gaa gcg ctg cag ccg gcg ctg 384
 Thr Asn Leu Leu Leu Gln Ala Ser Arg Glu Ala Leu Gln Pro Ala Leu
 115 120 125

agc agc agc ggc gat ggc cgc agc ggc agc atg agc ggc acc gcg acc 432
 Ser Ser Ser Gly Asp Gly Arg Ser Gly Ser Met Ser Gly Thr Ala Thr
 130 135 140

ccg ttt tat ccg aaa cgc gtg ggc agc ggc ttt ttt ggc aaa gat cag 480
 Pro Phe Tyr Pro Lys Arg Val Gly Ser Gly Phe Phe Gly Lys Asp Gln
 145 150 155 160

agc acc agc atg gtg agc agc gtg agc agc ctg agc cag ctg gaa ccg 528
 Ser Thr Ser Met Val Ser Ser Val Ser Ser Leu Ser Gln Leu Glu Pro
 165 170 175

cag ctg ggc cgc agc ggc agc ccg agc ccg ttt cag agc agc agc agc 576
 Gln Leu Gly Arg Ser Gly Ser Pro Ser Pro Phe Gln Ser Ser Ser Ser
 180 185 190

cgc agc ccg ccg cgc agc ccg gcg acc ccg agc cag gat agc agc gtg 624
 Arg Ser Pro Pro Arg Ser Pro Ala Thr Pro Ser Gln Asp Ser Ser Val
 195 200 205

agc cag gaa ccg gcg ttt cat gcg acc gtg gat ctg att aaa aaa ggc 672
 Ser Gln Glu Pro Ala Phe His Ala Thr Val Asp Leu Ile Lys Lys Gly
 210 215 220

cat ctg gaa gcg gcg cgc gcg agc ctg aaa gaa ggc ccg ctg cgc gat 720
 His Leu Glu Ala Ala Arg Ala Ser Leu Lys Glu Gly Pro Leu Arg Asp

-continued

225	230	235	240	
gaa ctg gaa gaa gaa att gaa cgc gat tgc gaa agc ctg cgc agc ttt Glu Leu Glu Glu Glu Ile Glu Arg Asp Cys Glu Ser Leu Arg Ser Phe 245 250 255				768
ctg tat gcg gcg cag att att gat gaa att agc ccg cgc agc cag gat Leu Tyr Ala Ala Gln Ile Ile Asp Glu Ile Ser Pro Arg Ser Gln Asp 260 270				816
agc att gtg ggc acc ggc gaa cgc ctg gcg tgc aaa att gtg gcg gcg Ser Ile Val Gly Thr Gly Glu Arg Leu Ala Cys Lys Ile Val Ala Ala 275 280 285				864
gcg ctg cgc gat cgc ggc gtg gat agc gaa ctg gtg gtg ctg gat aac Ala Leu Arg Asp Arg Gly Val Asp Ser Glu Leu Val Val Leu Asp Asn 290 295 300				912
att gtg gat gcg agc atg agc gcg gcg agc gaa gcg att agc gtg gat Ile Val Asp Ala Ser Met Ser Ala Ala Ser Glu Ala Ile Ser Val Asp 305 310 315 320				960
gcg ggc gat cag ggc gtg gcg cag ctg ggc cag gaa ttt tat gat cag Ala Gly Asp Gln Gly Val Ala Gln Leu Gly Gln Glu Phe Tyr Asp Gln 325 330 335				1008
ctg agc ttt cgc ctg ggc gaa cgc ctg cgc gaa tgc ggc cag cgc gtg Leu Ser Phe Arg Leu Gly Glu Arg Leu Arg Glu Cys Gly Gln Arg Val 340 345 350				1056
ccg gtg gtg acc ggc tat ttt ggc ccg gtg ccg ggc agc ctg ctg gcg Pro Val Val Thr Gly Tyr Phe Gly Pro Val Pro Gly Ser Leu Leu Ala 355 360 365				1104
cag att ggc cgc ggc tat acc gat ctg tgc gcg gcg ctg tgc gcg gtg Gln Ile Gly Arg Gly Tyr Thr Asp Leu Cys Ala Ala Leu Cys Ala Val 370 375 380				1152
ggc ctg aaa gcg agc gaa ctg cag gtg tgg aaa gaa gtg gat ggc att Gly Leu Lys Ala Ser Glu Leu Gln Val Trp Lys Glu Val Asp Gly Ile 385 390 395 400				1200
ttt acc gcg gat ccg cgc aaa gtg ccg agc gcg cgc ctg gtg ccg att Phe Thr Ala Asp Pro Arg Lys Val Pro Ser Ala Arg Leu Val Pro Ile 405 410 415				1248
att acc ccg gat gaa gcg gcg gaa ctg acc tat tat ggc agc gaa gtg Ile Thr Pro Asp Glu Ala Ala Glu Leu Thr Tyr Tyr Gly Ser Glu Val 420 425 430				1296
att cat ccg ttt acc atg gaa cag gtg att cgc gcg cgc att ccg att Ile His Pro Phe Thr Met Glu Gln Val Ile Arg Ala Arg Ile Pro Ile 435 440 445				1344
cgc att aaa aac gtg gaa aac ccg agc ggc gcg ggc acc gtg att tat Arg Ile Lys Asn Val Glu Asn Pro Ser Gly Ala Gly Thr Val Ile Tyr 450 455 460				1392
ccg gat ctg ggc ttt ccg cgc ggc ctg gat acc gaa ccg ccg aaa gcg Pro Asp Leu Gly Phe Pro Arg Gly Leu Asp Thr Glu Pro Pro Lys Ala 465 470 475 480				1440
gaa cgc att gtg gaa ggc gtg gat gaa cgc atg ccg acc gcg gtg acc Glu Arg Ile Val Glu Gly Val Asp Glu Arg Met Pro Thr Ala Val Thr 485 490 495				1488
att aaa gat gaa att att gtg ctg aac att cat agc aac cgc aaa acc Ile Lys Asp Glu Ile Ile Val Leu Asn Ile His Ser Asn Arg Lys Thr 500 505 510				1536
ctg agc cat ggc ttt ctg gcg cgc att ttt ggc acc ctg gat cgc gcg Leu Ser His Gly Phe Leu Ala Arg Ile Phe Gly Thr Leu Asp Arg Ala 515 520 525				1584
ggc gtg gtg gtg gat ctg att agc acc agc gaa gtg cat gtg agc atg Gly Val Val Val Asp Leu Ile Ser Thr Ser Glu Val His Val Ser Met 530 535 540				1632
gcg atg cag gat ttt ctg aac cgc aaa cgc ctg gaa cgc ctg gtg aaa				1680

-continued

Ala Met Gln Asp Phe Leu Asn Arg Lys Arg Leu Glu Arg Leu Val Lys	
545	550 555 560
gat ctg gaa aaa att ggc gaa gtg acc gtg agc aaa gat atg gcg att	1728
Asp Leu Glu Lys Ile Gly Glu Val Thr Val Ser Lys Asp Met Ala Ile	
	565 570 575
ctg agc ctg gtg ggc cgc aac atg cgc aac gcg att ggc agc gcg ggc	1776
Leu Ser Leu Val Gly Arg Asn Met Arg Asn Ala Ile Gly Ser Ala Gly	
	580 585 590
ctg atg ttt gcg agc ctg gcg cgc gcg atg att aac att gaa atg att	1824
Leu Met Phe Ala Ser Leu Ala Arg Ala Met Ile Asn Ile Glu Met Ile	
	595 600 605
agc cag ggc gcg agc gaa att aac att agc tgc gtg att gaa aac aaa	1872
Ser Gln Gly Ala Ser Glu Ile Asn Ile Ser Cys Val Ile Glu Asn Lys	
	610 615 620
gat gcg att aaa gcg ctg aac gtg att cat gaa agc tgc ctg agc tat	1920
Asp Ala Ile Lys Ala Leu Asn Val Ile His Glu Ser Cys Leu Ser Tyr	
	625 630 635 640
ccg cgc agc ccg gcg acc gaa atg gcg ggc ctg cag ctg cag	1962
Pro Arg Ser Pro Ala Thr Glu Met Ala Gly Leu Gln Leu Gln	
	645 650

<210> SEQ ID NO 54

<211> LENGTH: 654

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 54

Met Thr Arg Asp Phe Asp Ser Leu Phe Phe Thr Gly Pro Ile Phe Val	
1	5 10 15
Asp Tyr Ser Phe Thr Ala Arg His Leu Glu Ser Phe Leu Ser Ser Phe	
	20 25 30
Pro Pro Gln Val Ser His Ala Met Ser Ser Ala Ser Thr Pro Thr Ala	
	35 40 45
Pro Tyr Leu Glu Asp Leu Val Arg Asn Ser Leu Asp Gln Thr Leu Pro	
	50 55 60
Trp Val Val Gln Lys Tyr Gly Gly Thr Ser Val Gly Lys Ser Leu Asp	
65	70 75 80
Asn Ile Thr Lys Ile Val Gly Ser Tyr Ile Asp Asn Gly Ser Lys Val	
	85 90 95
Ala Ile Val Cys Ser Ala Arg Ser Thr Gln Thr Lys Ser Leu Gly Thr	
	100 105 110
Thr Asn Leu Leu Leu Gln Ala Ser Arg Glu Ala Leu Gln Pro Ala Leu	
	115 120 125
Ser Ser Ser Gly Asp Gly Arg Ser Gly Ser Met Ser Gly Thr Ala Thr	
	130 135 140
Pro Phe Tyr Pro Lys Arg Val Gly Ser Gly Phe Phe Gly Lys Asp Gln	
145	150 155 160
Ser Thr Ser Met Val Ser Ser Val Ser Ser Leu Ser Gln Leu Glu Pro	
	165 170 175
Gln Leu Gly Arg Ser Gly Ser Pro Ser Pro Phe Gln Ser Ser Ser Ser	
	180 185 190
Arg Ser Pro Pro Arg Ser Pro Ala Thr Pro Ser Gln Asp Ser Ser Val	
	195 200 205
Ser Gln Glu Pro Ala Phe His Ala Thr Val Asp Leu Ile Lys Lys Gly	
	210 215 220
His Leu Glu Ala Ala Arg Ala Ser Leu Lys Glu Gly Pro Leu Arg Asp	
225	230 235 240

-continued

```

<210> SEQ ID NO 55
<211> LENGTH: 1269
<212> TYPE: DNA
<213> ORGANISM: Cryptococcus neoformans
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(1269)

<400> SEQUENCE: 55

atg ccg aaa cag tgg ccg acc att gtg aaa ctg gaa acc ttt att ccg      48
Met Pro Lys Gln Trp Pro Thr Ile Val Lys Leu Glu Thr Phe Ile Pro
1          5          10          15

agc gcg cat ggc agc ggc ggc gat tat cat cgc cag ggc ggc gat cat      96
Ser Ala His Gly Ser Gly Gly Asp Tyr His Arg Gln Gly Gly Asp His
          20          25          30

tgg att gtg cag ggc aac att agc tgc ccg atg cat aaa tat gaa gaa      144
Trp Ile Val Gln Gly Asn Ile Ser Cys Pro Met His Lys Tyr Glu Glu
          35          40          45

tat aaa gtg agc cgc acc agc tgg ggc att ggc gtg ctg ggc agc att      192
Tyr Lys Val Ser Arg Thr Ser Trp Gly Ile Gly Val Leu Gly Ser Ile
          50          55          60

ttt gtg aaa gtg cat gcg agc gat ggc acc gtg ggc tat gcg acc ggc      240
Phe Val Lys Val His Ala Ser Asp Gly Thr Val Gly Tyr Ala Thr Gly
65          70          75          80

ttt ggc ggc ccg ccg gcg tgc tgg ctg att gaa gaa cat ttt aaa cgc      288
Phe Gly Gly Pro Ala Cys Trp Leu Ile Glu Glu His Phe Lys Arg
          85          90          95

ttt att gtg ggc cag gat ccg cgc gat acc aac aaa atg tgg gat cag      336
Phe Ile Val Gly Gln Asp Pro Arg Asp Thr Asn Lys Met Trp Asp Gln
          100          105          110

atg ttt cgc gcg agc atg ttt tat ggc cgc aaa ggc ctg ccg ctg gcg      384
Met Phe Arg Ala Ser Met Phe Tyr Gly Arg Lys Gly Leu Pro Leu Ala
          115          120          125

gcg att agc gtg gtg gat ctg gcg att tgg gat ctg ctg ggc aaa att      432
Ala Ile Ser Val Val Asp Leu Ala Ile Trp Asp Leu Leu Gly Lys Ile
          130          135          140

cgc ggc gaa ccg att tat aaa atg att ggc ggc cgc acc aaa aaa gat      480
Arg Gly Glu Pro Ile Tyr Lys Met Ile Gly Gly Arg Thr Lys Lys Asp
145          150          155          160

att ccg ctg tat ctg acc ggc ccg cgc ccg gaa gtg gcg aaa aaa ctg      528
Ile Pro Leu Tyr Leu Thr Gly Pro Arg Pro Glu Val Ala Lys Lys Leu
          165          170          175

ggc ttt tgg ggc agc aaa gtg gcg ctg ccg cat ggc ccg ccg gat ggc      576
Gly Phe Trp Gly Ser Lys Val Ala Leu Pro His Gly Pro Pro Asp Gly
          180          185          190

cat gaa ggc att cgc aaa aac gtg gaa tat ctg aaa gcg tgc aaa gaa      624
His Glu Gly Ile Arg Lys Asn Val Glu Tyr Leu Lys Ala Cys Lys Glu
          195          200          205

gcg gtg ggc ccg gat tat ccg gtg cag gtg gat tgc tat atg agc ctg      672
Ala Val Gly Pro Asp Tyr Pro Val Gln Val Asp Cys Tyr Met Ser Leu
210          215          220

gat gtg ccg tat acc att gcg ctg gtg aaa gcg tgc gaa aaa gcg ggc      720
Asp Val Pro Tyr Thr Ile Ala Leu Val Lys Ala Cys Glu Lys Ala Gly
225          230          235          240

gtg gaa att aac tgg tgg gaa gaa gtg ctg cat ccg gat gat ttt gat      768
Val Glu Ile Asn Trp Trp Glu Glu Val Leu His Pro Asp Asp Phe Asp
          245          250          255

ggc cat att aaa ctg aaa gaa gcg ctg ccg tat gtg aaa ttt acc acc      816
Gly His Ile Lys Leu Lys Glu Ala Leu Pro Tyr Val Lys Phe Thr Thr
          260          265          270

```

-continued

ggc gaa cat gaa tat agc aaa tat ggc ttt cgc aaa ctg att gaa aac	864
Gly Glu His Glu Tyr Ser Lys Tyr Gly Phe Arg Lys Leu Ile Glu Asn	
275 280 285	
cgc gcg gtg gat att att cag ccg gat gtg atg tgg ctg ggc ggc ctg	912
Arg Ala Val Asp Ile Ile Gln Pro Asp Val Met Trp Leu Gly Gly Leu	
290 295 300	
acc gaa ctg att aaa gtg gcg gcg atg gcg gcg gcg tat gat att ccg	960
Thr Glu Leu Ile Lys Val Ala Ala Met Ala Ala Ala Tyr Asp Ile Pro	
305 310 315 320	
gtg gtg ccg cat ggc agc ggc ccg tat agc ttt cag gcg att atg agc	1008
Val Val Pro His Gly Ser Gly Pro Tyr Ser Phe Gln Ala Ile Met Ser	
325 330 335	
ttt ccg aac agc gat ttt tgc gaa tat att gcg aac agc ccg gat ggc	1056
Phe Pro Asn Ser Asp Phe Cys Glu Tyr Ile Ala Asn Ser Pro Asp Gly	
340 345 350	
aaa agc att gaa ccg agc ttt ggc aac ctg ttt ctg aac gaa gtg ctg	1104
Lys Ser Ile Glu Pro Ser Phe Gly Asn Leu Phe Leu Asn Glu Val Leu	
355 360 365	
ccg gcg aac ggc gcg gtg gat ctg acc gat gaa ccg ggc ttt ggc ctg	1152
Pro Arg Asn Gly Arg Val Asp Leu Thr Asp Glu Pro Gly Phe Gly Leu	
370 375 380	
gaa ctg aac ccg agc gcg gaa ctg gtg ccg tat aaa agc ttt ttt acc	1200
Glu Leu Asn Pro Ser Ala Glu Leu Val Pro Tyr Lys Ser Phe Phe Thr	
385 390 395 400	
ccg agc aaa agc ctg ggc gcg gcg ggc gaa gtg gaa gat gat ggc aaa	1248
Pro Ser Lys Ser Leu Gly Ala Ala Gly Glu Val Glu Asp Asp Gly Lys	
405 410 415	
gcg aaa gtg aac ggc aaa cat	1269
Ala Lys Val Asn Gly Lys His	
420	

<210> SEQ ID NO 56

<211> LENGTH: 423

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 56

Met Pro Lys Gln Trp Pro Thr Ile Val Lys Leu Glu Thr Phe Ile Pro	1 5 10 15
Ser Ala His Gly Ser Gly Gly Asp Tyr His Arg Gln Gly Gly Asp His	20 25 30
Trp Ile Val Gln Gly Asn Ile Ser Cys Pro Met His Lys Tyr Glu Glu	35 40 45
Tyr Lys Val Ser Arg Thr Ser Trp Gly Ile Gly Val Leu Gly Ser Ile	50 55 60
Phe Val Lys Val His Ala Ser Asp Gly Thr Val Gly Tyr Ala Thr Gly	65 70 75 80
Phe Gly Gly Pro Pro Ala Cys Trp Leu Ile Glu Glu His Phe Lys Arg	85 90 95
Phe Ile Val Gly Gln Asp Pro Arg Asp Thr Asn Lys Met Trp Asp Gln	100 105 110
Met Phe Arg Ala Ser Met Phe Tyr Gly Arg Lys Gly Leu Pro Leu Ala	115 120 125
Ala Ile Ser Val Val Asp Leu Ala Ile Trp Asp Leu Leu Gly Lys Ile	130 135 140
Arg Gly Glu Pro Ile Tyr Lys Met Ile Gly Gly Arg Thr Lys Lys Asp	145 150 155 160
Ile Pro Leu Tyr Leu Thr Gly Pro Arg Pro Glu Val Ala Lys Lys Leu	

-continued

165					170					175						
Gly	Phe	Trp	Gly	Ser	Lys	Val	Ala	Leu	Pro	His	Gly	Pro	Pro	Asp	Gly	
			180					185					190			
His	Glu	Gly	Ile	Arg	Lys	Asn	Val	Glu	Tyr	Leu	Lys	Ala	Cys	Lys	Glu	
		195					200					205				
Ala	Val	Gly	Pro	Asp	Tyr	Pro	Val	Gln	Val	Asp	Cys	Tyr	Met	Ser	Leu	
		210					215					220				
Asp	Val	Pro	Tyr	Thr	Ile	Ala	Leu	Val	Lys	Ala	Cys	Glu	Lys	Ala	Gly	
		225				230					235				240	
Val	Glu	Ile	Asn	Trp	Trp	Glu	Glu	Val	Leu	His	Pro	Asp	Asp	Phe	Asp	
			245						250					255		
Gly	His	Ile	Lys	Leu	Lys	Glu	Ala	Leu	Pro	Tyr	Val	Lys	Phe	Thr	Thr	
			260					265					270			
Gly	Glu	His	Glu	Tyr	Ser	Lys	Tyr	Gly	Phe	Arg	Lys	Leu	Ile	Glu	Asn	
		275					280					285				
Arg	Ala	Val	Asp	Ile	Ile	Gln	Pro	Asp	Val	Met	Trp	Leu	Gly	Gly	Leu	
		290				295					300					
Thr	Glu	Leu	Ile	Lys	Val	Ala	Ala	Met	Ala	Ala	Ala	Tyr	Asp	Ile	Pro	
		305				310					315				320	
Val	Val	Pro	His	Gly	Ser	Gly	Pro	Tyr	Ser	Phe	Gln	Ala	Ile	Met	Ser	
			325						330					335		
Phe	Pro	Asn	Ser	Asp	Phe	Cys	Glu	Tyr	Ile	Ala	Asn	Ser	Pro	Asp	Gly	
			340					345					350			
Lys	Ser	Ile	Glu	Pro	Ser	Phe	Gly	Asn	Leu	Phe	Leu	Asn	Glu	Val	Leu	
		355					360					365				
Pro	Arg	Asn	Gly	Arg	Val	Asp	Leu	Thr	Asp	Glu	Pro	Gly	Phe	Gly	Leu	
		370				375					380					
Glu	Leu	Asn	Pro	Ser	Ala	Glu	Leu	Val	Pro	Tyr	Lys	Ser	Phe	Phe	Thr	
		385				390					395				400	
Pro	Ser	Lys	Ser	Leu	Gly	Ala	Ala	Gly	Glu	Val	Glu	Asp	Asp	Gly	Lys	
			405					410						415		
Ala	Lys	Val	Asn	Gly	Lys	His										
			420													
<210> SEQ ID NO 57																
<211> LENGTH: 1743																
<212> TYPE: DNA																
<213> ORGANISM: Cryptococcus neoformans																
<220> FEATURE:																
<221> NAME/KEY: CDS																
<222> LOCATION: (1) .. (1743)																
<400> SEQUENCE: 57																
atg	gcg	aac	gcg	ccg	cat	ggc	ggc	gtg	ctg	aaa	gat	ctg	ctg	gtg	cgc	48
Met	Ala	Asn	Ala	Pro	His	Gly	Gly	Val	Leu	Lys	Asp	Leu	Leu	Val	Arg	
1			5					10					15			
gat	gcg	gcg	ctg	cat	gat	agc	ctg	ctg	cag	gaa	gcg	cgc	agc	ctg	aac	96
Asp	Ala	Ala	Leu	His	Asp	Ser	Leu	Leu	Gln	Glu	Ala	Arg	Ser	Leu	Asn	
			20				25					30				
gat	att	ttt	ctg	acc	gaa	cgc	cag	ctg	tgc	gat	ctg	gaa	ctg	att	ctg	144
Asp	Ile	Phe	Leu	Thr	Glu	Arg	Gln	Leu	Cys	Asp	Leu	Glu	Leu	Ile	Leu	
		35				40					45					
aac	ggc	ggc	ttt	agc	ccg	ctg	gaa	ggc	ttt	atg	aac	gaa	cgc	gat	tat	192
Asn	Gly	Gly	Phe	Ser	Pro	Leu	Glu	Gly	Phe	Met	Asn	Glu	Arg	Asp	Tyr	
		50				55					60					
acc	agc	gtg	gtg	gaa	acc	ctg	cgc	ctg	gcg	ccg	tat	aac	ggc	cag	aaa	240
Thr	Ser	Val	Val	Glu	Thr	Leu	Arg	Leu	Ala	Pro	Tyr	Asn	Gly	Gln	Lys	

-continued

65	70	75	80	
cat ggc gat gtg ttt ccg att ccg att acc ctg gat gtg agc cag gaa				288
His Gly Asp Val Phe Pro Ile Pro Ile Thr Leu Asp Val Ser Gln Glu	85	90	95	
gat att aac acc ctg ggc ctg aaa cag ggc ggc cgc gtg gcg ctg cgc				336
Asp Ile Asn Thr Leu Gly Leu Lys Gln Gly Gly Arg Val Ala Leu Arg	100	105	110	
gat ccg cgc gat gat gcg gcg ctg gcg att ctg acc gtg agc gat att				384
Asp Pro Arg Asp Asp Ala Ala Leu Ala Ile Leu Thr Val Ser Asp Ile	115	120	125	
tat cgc ccg aac aaa gcg att gaa gcg gaa aaa gtg atg ggc gcg gat				432
Tyr Arg Pro Asn Lys Ala Ile Glu Ala Glu Lys Val Met Gly Ala Asp	130	135	140	
gat att gcg cat ccg agc gtg gcg tat ctg cgc aac aac gtg aaa gaa				480
Asp Ile Ala His Pro Ser Val Ala Tyr Leu Arg Asn Asn Val Lys Glu	145	150	155	160
ttt tat gtg ggc ggc aaa gtg cag gcg att cag gcg ccg acc cat ttt				528
Phe Tyr Val Gly Gly Lys Val Gln Ala Ile Gln Ala Pro Thr His Phe	165	170	175	
gat tat gtg ccg ctg cgc ttt acc ccg gcg gaa ctg cgc gcg cat ttt				576
Asp Tyr Val Pro Leu Arg Phe Thr Pro Ala Glu Leu Arg Ala His Phe	180	185	190	
cat aaa ctg gcg tgg cgc aaa gtg gtg gcg ttt cag acc cgc aac ccg				624
His Lys Leu Ala Trp Arg Lys Val Val Ala Phe Gln Thr Arg Asn Pro	195	200	205	
atg cat cgc gcg cat cgc gaa ctg acc gtg cgc gcg gcg cgc cag cgc				672
Met His Arg Ala His Arg Glu Leu Thr Val Arg Ala Ala Arg Gln Arg	210	215	220	
cgc gcg aac gtg ctg att cat ccg gtg gtg ggc ctg acc aaa ccg ggc				720
Arg Ala Asn Val Leu Ile His Pro Val Val Gly Leu Thr Lys Pro Gly	225	230	235	240
gat gtg gat cat tat acc cgc gtg cgc gcg tat cag gcg ctg atg ccg				768
Asp Val Asp His Tyr Thr Arg Val Arg Ala Tyr Gln Ala Leu Met Pro	245	250	255	
agc tat ccg gaa ggc atg gcg cat ctg gcg ctg ctg ccg ctg gcg atg				816
Ser Tyr Pro Glu Gly Met Ala His Leu Ala Leu Leu Pro Leu Ala Met	260	265	270	
cgc atg gcg ggc ccg cgc gaa gcg gtg tgg cat gcg gtg att cgc aaa				864
Arg Met Ala Gly Pro Arg Glu Ala Val Trp His Ala Val Ile Arg Lys	275	280	285	
aac ttt ggc gcg acc cat ttt att gtg ggc cgc gat cat gcg ggc ccg				912
Asn Phe Gly Ala Thr His Phe Ile Val Gly Arg Asp His Ala Gly Pro	290	295	300	
ggc aaa aac agc cag ggc cag gat ttt tat ggc ccg tat gat gcg cag				960
Gly Lys Asn Ser Gln Gly Gln Asp Phe Tyr Gly Pro Tyr Asp Ala Gln	305	310	315	320
gaa ctg gtg acc cag ttt aaa gat gaa ctg cag att gaa atg gtg ccg				1008
Glu Leu Val Thr Gln Phe Lys Asp Glu Leu Gln Ile Glu Met Val Pro	325	330	335	
ttt cag gcg atg acc tat ctg ccg ggc agc gat gaa tat cag ccg gtg				1056
Phe Gln Ala Met Thr Tyr Leu Pro Gly Ser Asp Glu Tyr Gln Pro Val	340	345	350	
gat gaa gtg ccg aaa ggc acc ccg acc gcg gat att agc ggc acc gaa				1104
Asp Glu Val Pro Lys Gly Thr Pro Thr Ala Asp Ile Ser Gly Thr Glu	355	360	365	
ctg cgc aaa cgc ctg cgc acc ggc gcg agc att ccg gat tgg ttt agc				1152
Leu Arg Lys Arg Leu Arg Thr Gly Ala Ser Ile Pro Asp Trp Phe Ser	370	375	380	
tat acc ggc gtg gtg aaa gtg ctg cgc gaa agc tat ccg ccg cgc ccg				1200

-continued

Tyr	Thr	Gly	Val	Val	Lys	Val	Leu	Arg	Glu	Ser	Tyr	Pro	Pro	Arg	Pro	
385					390					395					400	
cag	cag	ggc	ttt	acc	att	ctg	ctg	acc	ggc	ctg	cat	aac	agc	ggc	aaa	1248
Gln	Gln	Gly	Phe	Thr	Ile	Leu	Leu	Thr	Gly	Leu	His	Asn	Ser	Gly	Lys	
			405						410					415		
gat	acc	att	gcg	cgc	gcg	ctg	cag	gtg	acc	ctg	cag	cag	cag	ggc	agc	1296
Asp	Thr	Ile	Ala	Arg	Ala	Leu	Gln	Val	Thr	Leu	Gln	Gln	Gln	Gly	Ser	
			420					425					430			
cgc	agc	gtg	agc	ctg	ctg	ctg	ggc	gaa	gaa	ctg	cgc	agc	gat	ctg	gat	1344
Arg	Ser	Val	Ser	Leu	Leu	Leu	Gly	Glu	Glu	Leu	Arg	Ser	Asp	Leu	Asp	
		435				440						445				
ccg	cag	att	ggc	cgc	gcg	att	acc	ccg	gaa	cag	aaa	cat	att	aac	ctg	1392
Pro	Gln	Ile	Gly	Arg	Ala	Ile	Thr	Pro	Glu	Gln	Lys	His	Ile	Asn	Leu	
		450				455					460					
gaa	cgc	att	ggc	ttt	gtg	gcg	ggc	gaa	ctg	acc	aaa	gcg	ggc	gcg	gcg	1440
Glu	Arg	Ile	Gly	Phe	Val	Ala	Gly	Glu	Leu	Thr	Lys	Ala	Gly	Ala	Ala	
		465			470					475				480		
gtg	att	gcg	gcg	ccg	acc	gcg	ccg	tat	gaa	cgc	agc	cgc	cag	gcg	ttt	1488
Val	Ile	Ala	Ala	Pro	Thr	Ala	Pro	Tyr	Glu	Arg	Ser	Arg	Gln	Ala	Phe	
			485						490					495		
aaa	aaa	cag	gtg	gtg	ggc	agc	ggc	ggc	aac	tat	ttt	ctg	gtg	cat		1536
Lys	Lys	Gln	Val	Val	Gly	Ser	Gly	Gly	Gly	Asn	Tyr	Phe	Leu	Val	His	
			500				505						510			
gtg	gcg	acc	ccg	ctg	gaa	tgg	tgc	gaa	aaa	gtg	gat	cgc	cgc	ggc	ctg	1584
Val	Ala	Thr	Pro	Leu	Glu	Trp	Cys	Glu	Lys	Val	Asp	Arg	Arg	Gly	Leu	
		515				520						525				
tat	aaa	gcg	gcg	cgc	gcg	ggc	gaa	att	aaa	aac	ctg	acc	ggc	gtg	gat	1632
Tyr	Lys	Ala	Ala	Arg	Ala	Gly	Glu	Ile	Lys	Asn	Leu	Thr	Gly	Val	Asp	
		530				535					540					
gat	gtg	tat	gaa	gcg	ccg	gaa	gat	gcg	gat	ctg	gtg	tgc	gat	ctg	cgc	1680
Asp	Val	Tyr	Glu	Ala	Pro	Glu	Asp	Ala	Asp	Leu	Val	Cys	Asp	Leu	Arg	
		545			550				555					560		
aac	gat	acc	gtg	ccg	gaa	att	gtg	cat	agc	att	att	atg	att	ctg	gaa	1728
Asn	Asp	Thr	Val	Pro	Glu	Ile	Val	His	Ser	Ile	Ile	Met	Ile	Leu	Glu	
			565						570					575		
agc	cag	aac	ctg	gtg												1743
Ser	Gln	Asn	Leu	Val												
			580													
<210> SEQ ID NO 58																
<211> LENGTH: 581																
<212> TYPE: PRT																
<213> ORGANISM: Cryptococcus neoformans																
<400> SEQUENCE: 58																
Met	Ala	Asn	Ala	Pro	His	Gly	Gly	Val	Leu	Lys	Asp	Leu	Leu	Val	Arg	
1				5					10					15		
Asp	Ala	Ala	Leu	His	Asp	Ser	Leu	Leu	Gln	Glu	Ala	Arg	Ser	Leu	Asn	
		20						25					30			
Asp	Ile	Phe	Leu	Thr	Glu	Arg	Gln	Leu	Cys	Asp	Leu	Glu	Leu	Ile	Leu	
		35					40					45				
Asn	Gly	Gly	Phe	Ser	Pro	Leu	Glu	Gly	Phe	Met	Asn	Glu	Arg	Asp	Tyr	
		50				55					60					
Thr	Ser	Val	Val	Glu	Thr	Leu	Arg	Leu	Ala	Pro	Tyr	Asn	Gly	Gln	Lys	
65					70					75				80		
His	Gly	Asp	Val	Phe	Pro	Ile	Pro	Ile	Thr	Leu	Asp	Val	Ser	Gln	Glu	
			85					90						95		
Asp	Ile	Asn	Thr	Leu	Gly	Leu	Lys	Gln	Gly	Gly	Arg	Val	Ala	Leu	Arg	
			100					105					110			

-continued

Asp Pro Arg Asp Asp Ala Ala Leu Ala Ile Leu Thr Val Ser Asp Ile
 115 120 125
 Tyr Arg Pro Asn Lys Ala Ile Glu Ala Glu Lys Val Met Gly Ala Asp
 130 135 140
 Asp Ile Ala His Pro Ser Val Ala Tyr Leu Arg Asn Asn Val Lys Glu
 145 150 155 160
 Phe Tyr Val Gly Gly Lys Val Gln Ala Ile Gln Ala Pro Thr His Phe
 165 170 175
 Asp Tyr Val Pro Leu Arg Phe Thr Pro Ala Glu Leu Arg Ala His Phe
 180 185 190
 His Lys Leu Ala Trp Arg Lys Val Val Ala Phe Gln Thr Arg Asn Pro
 195 200 205
 Met His Arg Ala His Arg Glu Leu Thr Val Arg Ala Ala Arg Gln Arg
 210 215 220
 Arg Ala Asn Val Leu Ile His Pro Val Val Gly Leu Thr Lys Pro Gly
 225 230 235 240
 Asp Val Asp His Tyr Thr Arg Val Arg Ala Tyr Gln Ala Leu Met Pro
 245 250 255
 Ser Tyr Pro Glu Gly Met Ala His Leu Ala Leu Leu Pro Leu Ala Met
 260 265 270
 Arg Met Ala Gly Pro Arg Glu Ala Val Trp His Ala Val Ile Arg Lys
 275 280 285
 Asn Phe Gly Ala Thr His Phe Ile Val Gly Arg Asp His Ala Gly Pro
 290 295 300
 Gly Lys Asn Ser Gln Gly Gln Asp Phe Tyr Gly Pro Tyr Asp Ala Gln
 305 310 315 320
 Glu Leu Val Thr Gln Phe Lys Asp Glu Leu Gln Ile Glu Met Val Pro
 325 330 335
 Phe Gln Ala Met Thr Tyr Leu Pro Gly Ser Asp Glu Tyr Gln Pro Val
 340 345 350
 Asp Glu Val Pro Lys Gly Thr Pro Thr Ala Asp Ile Ser Gly Thr Glu
 355 360 365
 Leu Arg Lys Arg Leu Arg Thr Gly Ala Ser Ile Pro Asp Trp Phe Ser
 370 375 380
 Tyr Thr Gly Val Val Lys Val Leu Arg Glu Ser Tyr Pro Pro Arg Pro
 385 390 395 400
 Gln Gln Gly Phe Thr Ile Leu Leu Thr Gly Leu His Asn Ser Gly Lys
 405 410 415
 Asp Thr Ile Ala Arg Ala Leu Gln Val Thr Leu Gln Gln Gln Gly Ser
 420 425 430
 Arg Ser Val Ser Leu Leu Leu Gly Glu Glu Leu Arg Ser Asp Leu Asp
 435 440 445
 Pro Gln Ile Gly Arg Ala Ile Thr Pro Glu Gln Lys His Ile Asn Leu
 450 455 460
 Glu Arg Ile Gly Phe Val Ala Gly Glu Leu Thr Lys Ala Gly Ala Ala
 465 470 475 480
 Val Ile Ala Ala Pro Thr Ala Pro Tyr Glu Arg Ser Arg Gln Ala Phe
 485 490 495
 Lys Lys Gln Val Val Gly Ser Gly Gly Asn Tyr Phe Leu Val His
 500 505 510
 Val Ala Thr Pro Leu Glu Trp Cys Glu Lys Val Asp Arg Arg Gly Leu
 515 520 525

-continued

Tyr Lys Ala Ala Arg Ala Gly Glu Ile Lys Asn Leu Thr Gly Val Asp
 530 535 540

Asp Val Tyr Glu Ala Pro Glu Asp Ala Asp Leu Val Cys Asp Leu Arg
 545 550 555 560

Asn Asp Thr Val Pro Glu Ile Val His Ser Ile Ile Met Ile Leu Glu
 565 570 575

Ser Gln Asn Leu Val
 580

<210> SEQ ID NO 59
 <211> LENGTH: 1716
 <212> TYPE: DNA
 <213> ORGANISM: *Cryptococcus neoformans*
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1) .. (1716)

<400> SEQUENCE: 59

atg cac atc gca tac att ctc ggc ctc gta ccc ctc gct ttc gcc ggt 48
 Met His Ile Ala Tyr Ile Leu Gly Leu Val Pro Leu Ala Phe Ala Gly
 1 5 10 15

gtc atc aag cac gac cct ccc aag ttc cag cct att cag tct acc agg 96
 Val Ile Lys His Asp Pro Pro Lys Phe Gln Pro Ile Gln Ser Thr Arg
 20 25 30

att gtg cgg ctg cac cca aac ggg gac aaa agc aag tgc gtt gac ctc 144
 Ile Val Arg Leu His Pro Asn Gly Asp Lys Ser Lys Cys Val Asp Leu
 35 40 45

ctg ggt aat act cgc cag gat ggt cag ccc gtg cag att tgc gac tgc 192
 Leu Gly Asn Thr Arg Gln Asp Gly Gln Pro Val Gln Ile Cys Asp Cys
 50 55 60

gac ggt acc ccg gct cag gac tgg gtc ctc aat gcc ggc cgc ggt cag 240
 Asp Gly Thr Pro Ala Gln Asp Trp Val Leu Asn Ala Gly Arg Gly Gln
 65 70 75 80

acc aag gtc cag ctc gcc ggc acc agt ttc tgt ctc gat gcc acc cac 288
 Thr Lys Val Gln Leu Ala Gly Thr Ser Phe Cys Leu Asp Ala Thr His
 85 90 95

cct tac gca gcc gac ggg acc aac atg aag atc tgg aag tgc ttg gac 336
 Pro Tyr Ala Ala Asp Gly Thr Asn Met Lys Ile Trp Lys Cys Leu Asp
 100 105 110

gtc caa cag caa gac tgg tat tgg acg agt gat aac aga atc gtt ctc 384
 Val Gln Gln Gln Asp Trp Tyr Trp Thr Ser Asp Asn Arg Ile Val Leu
 115 120 125

cgc gac cag ggc aag tgc ctc gac tgg gcc act ggg gat cgg tct gat 432
 Arg Asp Gln Gly Lys Cys Leu Asp Trp Ala Thr Gly Asp Arg Ser Asp
 130 135 140

ttc aac cag ctg cag gtc tgg cgg tgc agc acg gat aac aac aat cag 480
 Phe Asn Gln Leu Gln Val Trp Arg Cys Ser Thr Asp Asn Asn Asn Gln
 145 150 155 160

gtc tgg aca acg gga cgg gac tac ggt ggg aac cat ggg ggt gat gct 528
 Val Trp Thr Thr Gly Pro Asp Tyr Gly Gly Asn His Gly Gly Asp Ala
 165 170 175

ggt ggg aac ccc gga ggt aat caa ggc gat gat tca aga ggc aaa acc 576
 Gly Gly Asn Pro Gly Gly Asn Gln Gly Asp Asp Ser Arg Gly Lys Thr
 180 185 190

aat act ggt gga aac ccc gga ggt aat caa ggt ggt gat tca gga ggg 624
 Asn Thr Gly Gly Asn Pro Gly Gly Asn Gln Gly Gly Asp Ser Gly Gly
 195 200 205

aaa acc aat cac atc att ccc gac ccc cca ggg cca gac ccc aac agc 672
 Lys Thr Asn His Ile Ile Pro Asp Pro Pro Gly Pro Asp Pro Asn Ser
 210 215 220

-continued

gag ccc ctc aac ccc gcc ctt gaa gcc att gtt aac gtc acc gag gca Glu Pro Leu Asn Pro Ala Leu Glu Ala Ile Val Asn Val Thr Glu Ala 225 230 235 240	720
gct gga ccc tgg ccg ccc atg atc aac ttc gac ggc gat tac agc aat Ala Gly Pro Trp Pro Pro Met Ile Asn Phe Asp Gly Asp Tyr Ser Asn 245 250 255	768
gac gac gtg acc gta tcg gac caa gta ccg ttc gac tac tgt atc ggg Asp Asp Val Thr Val Ser Asp Gln Val Pro Phe Asp Tyr Cys Ile Gly 260 265 270	816
gag ggg tct ggt aac ccg acg gat gat gaa gga cag cag caa gga caa Glu Gly Ser Gly Asn Pro Thr Asp Asp Glu Gly Gln Gln Gln Gly Gln 275 280 285	864
aac ttc aca gca aat gta gct ggg ata ggg aga gac ttc tgc ctg gac Asn Phe Thr Ala Asn Val Ala Gly Ile Gly Arg Asp Phe Cys Leu Asp 290 295 300	912
aat ttt ggc aat cct gac att cgg aac acc att tct ttc gac aac aac Asn Phe Gly Asn Pro Asp Ile Arg Asn Thr Ile Ser Phe Asp Asn Asn 305 310 315 320	960
acc agc att ggg aac gga gcg gac act ggg cga gcc ctt cac aag cgg Thr Ser Ile Gly Asn Gly Ala Asp Thr Gly Arg Ala Leu His Lys Arg 325 330 335	1008
aca ttt cgg gat tca ggg gcg acg ggt acg ccc aac cgg tgg aga cga Thr Phe Ala Asp Ser Gly Ala Thr Gly Thr Pro Asn Arg Trp Arg Arg 340 345 350	1056
ggg tcg gtg att tcc att tgc gtc gag agg aac aac aat tat ctg gtt Gly Ser Val Ile Ser Ile Cys Val Glu Arg Asn Asn Asn Tyr Leu Val 355 360 365	1104
cca tat cgg tcc tcc ccc gtt ccc atc cga gca tcg gct atc gtc gca Pro Tyr Ala Ser Ser Pro Val Pro Ile Arg Ala Ser Ala Ile Val Ala 370 375 380	1152
tcc gcc atg gta cgt gca atc aac ttc tgg aac gca ggt ctg aac aag Ser Ala Met Val Arg Ala Ile Asn Phe Trp Asn Ala Gly Leu Asn Lys 385 390 395 400	1200
cga ttc gtc tcg ttc gag ttt gtg gag aac tgc aac gac gcc gtg ttc Arg Phe Val Ser Phe Glu Phe Val Glu Asn Cys Asn Asp Ala Val Phe 405 410 415	1248
cat act ctt gct gtt gac cag atc aag tct gcc aaa gag cct act gtg His Thr Leu Ala Val Asp Gln Ile Lys Ser Ala Lys Glu Pro Thr Val 420 425 430	1296
ctc cgg act gcc ccc ttc cct cct cgg ggt gaa gag ggt gct agg aac Leu Ala Thr Ala Pro Phe Pro Pro Arg Gly Glu Glu Gly Ala Arg Asn 435 440 445	1344
cgc aac atc ttc gtg tgg aat acg gct ttc gag gcc aac ttt cag aac Arg Asn Ile Phe Val Trp Asn Thr Ala Phe Glu Ala Asn Phe Gln Asn 450 455 460	1392
gtc ctt acc ttt atc atg tca cat gag ctg ggg cac act ctt ggc ctg Val Leu Thr Phe Ile Met Ser His Glu Leu Gly His Thr Leu Gly Leu 465 470 475 480	1440
gcy cat gag gac tgc aaa tcc aga gac caa cct tgc gaa gtt atc act Ala His Glu Asp Cys Lys Ser Arg Asp Gln Pro Cys Glu Val Ile Thr 485 490 495	1488
gac aag gtg gct ggg tca gtc gtg gaa agc cgt atc tcc ggc agc acc Asp Lys Val Ala Gly Ser Val Val Glu Ser Arg Ile Ser Gly Ser Thr 500 505 510	1536
aca cag ctg ttc aat ggc ccc acc ccg ctt gac ata gca ggg gcy aac Thr Gln Leu Phe Asn Gly Pro Thr Pro Leu Asp Ile Ala Gly Ala Asn 515 520 525	1584
gag tac tac tca ctt gca gcy gga ccc aac acc ccg gag aac atc gta Glu Tyr Tyr Ser Leu Ala Ala Gly Pro Asn Thr Pro Glu Asn Ile Val 530 535 540	1632

-continued

ctc tgg cct gcg acg agg ggt ccg ttt atc aac tac ccg ccg cta ccg 1680
 Leu Trp Pro Ala Thr Arg Gly Pro Phe Ile Asn Tyr Pro Pro Leu Pro
 545 550 555 560

aaa tgc aag tgg ttc ctc ggt att tgc tat tac tag 1716
 Lys Cys Lys Trp Phe Leu Gly Ile Cys Tyr Tyr
 565 570

<210> SEQ ID NO 60

<211> LENGTH: 571

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 60

Met His Ile Ala Tyr Ile Leu Gly Leu Val Pro Leu Ala Phe Ala Gly
 1 5 10 15

Val Ile Lys His Asp Pro Pro Lys Phe Gln Pro Ile Gln Ser Thr Arg
 20 25 30

Ile Val Arg Leu His Pro Asn Gly Asp Lys Ser Lys Cys Val Asp Leu
 35 40 45

Leu Gly Asn Thr Arg Gln Asp Gly Gln Pro Val Gln Ile Cys Asp Cys
 50 55 60

Asp Gly Thr Pro Ala Gln Asp Trp Val Leu Asn Ala Gly Arg Gly Gln
 65 70 75 80

Thr Lys Val Gln Leu Ala Gly Thr Ser Phe Cys Leu Asp Ala Thr His
 85 90 95

Pro Tyr Ala Ala Asp Gly Thr Asn Met Lys Ile Trp Lys Cys Leu Asp
 100 105 110

Val Gln Gln Gln Asp Trp Tyr Trp Thr Ser Asp Asn Arg Ile Val Leu
 115 120 125

Arg Asp Gln Gly Lys Cys Leu Asp Trp Ala Thr Gly Asp Arg Ser Asp
 130 135 140

Phe Asn Gln Leu Gln Val Trp Arg Cys Ser Thr Asp Asn Asn Asn Gln
 145 150 155 160

Val Trp Thr Thr Gly Pro Asp Tyr Gly Gly Asn His Gly Gly Asp Ala
 165 170 175

Gly Gly Asn Pro Gly Gly Asn Gln Gly Asp Asp Ser Arg Gly Lys Thr
 180 185 190

Asn Thr Gly Gly Asn Pro Gly Gly Asn Gln Gly Gly Asp Ser Gly Gly
 195 200 205

Lys Thr Asn His Ile Ile Pro Asp Pro Pro Gly Pro Asp Pro Asn Ser
 210 215 220

Glu Pro Leu Asn Pro Ala Leu Glu Ala Ile Val Asn Val Thr Glu Ala
 225 230 235 240

Ala Gly Pro Trp Pro Pro Met Ile Asn Phe Asp Gly Asp Tyr Ser Asn
 245 250 255

Asp Asp Val Thr Val Ser Asp Gln Val Pro Phe Asp Tyr Cys Ile Gly
 260 265 270

Glu Gly Ser Gly Asn Pro Thr Asp Asp Glu Gly Gln Gln Gln Gly Gln
 275 280 285

Asn Phe Thr Ala Asn Val Ala Gly Ile Gly Arg Asp Phe Cys Leu Asp
 290 295 300

Asn Phe Gly Asn Pro Asp Ile Arg Asn Thr Ile Ser Phe Asp Asn Asn
 305 310 315 320

Thr Ser Ile Gly Asn Gly Ala Asp Thr Gly Arg Ala Leu His Lys Arg
 325 330 335

-continued

Thr Phe Ala Asp Ser Gly Ala Thr Gly Thr Pro Asn Arg Trp Arg Arg
 340 345 350

Gly Ser Val Ile Ser Ile Cys Val Glu Arg Asn Asn Asn Tyr Leu Val
 355 360 365

Pro Tyr Ala Ser Ser Pro Val Pro Ile Arg Ala Ser Ala Ile Val Ala
 370 375 380

Ser Ala Met Val Arg Ala Ile Asn Phe Trp Asn Ala Gly Leu Asn Lys
 385 390 395 400

Arg Phe Val Ser Phe Glu Phe Val Glu Asn Cys Asn Asp Ala Val Phe
 405 410 415

His Thr Leu Ala Val Asp Gln Ile Lys Ser Ala Lys Glu Pro Thr Val
 420 425 430

Leu Ala Thr Ala Pro Phe Pro Pro Arg Gly Glu Glu Gly Ala Arg Asn
 435 440 445

Arg Asn Ile Phe Val Trp Asn Thr Ala Phe Glu Ala Asn Phe Gln Asn
 450 455 460

Val Leu Thr Phe Ile Met Ser His Glu Leu Gly His Thr Leu Gly Leu
 465 470 475 480

Ala His Glu Asp Cys Lys Ser Arg Asp Gln Pro Cys Glu Val Ile Thr
 485 490 495

Asp Lys Val Ala Gly Ser Val Val Glu Ser Arg Ile Ser Gly Ser Thr
 500 505 510

Thr Gln Leu Phe Asn Gly Pro Thr Pro Leu Asp Ile Ala Gly Ala Asn
 515 520 525

Glu Tyr Tyr Ser Leu Ala Ala Gly Pro Asn Thr Pro Glu Asn Ile Val
 530 535 540

Leu Trp Pro Ala Thr Arg Gly Pro Phe Ile Asn Tyr Pro Pro Leu Pro
 545 550 555 560

Lys Cys Lys Trp Phe Leu Gly Ile Cys Tyr Tyr
 565 570

<210> SEQ ID NO 61
 <211> LENGTH: 1500
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1) .. (1500)

<400> SEQUENCE: 61

atg ccg agc ctg acc cag acc aaa gat ctg gcg agc ctg ctg agc gat	48
Met Pro Ser Leu Thr Gln Thr Lys Asp Leu Ala Ser Leu Leu Ser Asp	
1 5 10 15	
gcg agc cat ttt aaa cag aaa ggc tat att aac ggc gaa tgg gtg agc	96
Ala Ser His Phe Lys Gln Lys Gly Tyr Ile Asn Gly Glu Trp Val Ser	
20 25 30	
gcg agc gat ggc gcg acc ttt ccg ctg tat aac ccg gcg acc ggc gcg	144
Ala Ser Asp Gly Ala Thr Phe Pro Leu Tyr Asn Pro Ala Thr Gly Ala	
35 40 45	
aaa ctg gcg gat atg ccg cat atg ccg cgc agc cag gtg gcg gaa gcg	192
Lys Leu Ala Asp Met Pro His Met Pro Arg Ser Gln Val Ala Glu Ala	
50 55 60	
att aac gcg gcg aaa gcg gcg ttt ccg gcg tgg gcg gcg ctg acc gcg	240
Ile Asn Ala Ala Lys Ala Ala Phe Pro Ala Trp Ala Ala Leu Thr Ala	
65 70 75 80	
tat cag cgc cag aac tat ctg ctg aaa ctg ttt aaa gaa atg gaa gaa	288
Tyr Gln Arg Gln Asn Tyr Leu Leu Lys Leu Phe Lys Glu Met Glu Glu	

-continued

85				90				95								
cat	agc	gaa	gat	ctg	gcg	att	att	ctg	tgc	acc	gaa	aac	ggc	aaa	ccg	336
His	Ser	Glu	Asp	Leu	Ala	Ile	Ile	Leu	Cys	Thr	Glu	Asn	Gly	Lys	Pro	
		100						105					110			
ctg	gcg	gaa	agc	cgc	gtg	gaa	att	agc	tat	ggc	gcg	agc	ttt	ctg	acc	384
Leu	Ala	Glu	Ser	Arg	Val	Glu	Ile	Ser	Tyr	Gly	Ala	Ser	Phe	Leu	Thr	
		115					120						125			
tgg	aac	gcg	gcg	gaa	gcg	ctg	cgc	acc	tat	ggc	cag	acc	att	ccg	agc	432
Trp	Asn	Ala	Ala	Glu	Ala	Leu	Arg	Thr	Tyr	Gly	Gln	Thr	Ile	Pro	Ser	
		130				135						140				
ccg	ttt	ccg	ggc	acc	cgc	aac	acc	gtg	att	aaa	cag	ccg	att	ggc	gtg	480
Pro	Phe	Pro	Gly	Thr	Arg	Asn	Thr	Val	Ile	Lys	Gln	Pro	Ile	Gly	Val	
		145			150					155					160	
tgc	ggc	ctg	att	acc	ccg	tgg	aac	ttt	ccg	aac	gcg	atg	att	acc	cgc	528
Cys	Gly	Leu	Ile	Thr	Pro	Trp	Asn	Phe	Pro	Asn	Ala	Met	Ile	Thr	Arg	
			165						170						175	
aaa	atg	gcg	ccg	gcg	ctg	gcg	gcg	ggc	tgc	acc	gtg	gtg	att	aaa	gcg	576
Lys	Met	Ala	Pro	Ala	Leu	Ala	Ala	Gly	Cys	Thr	Val	Val	Ile	Lys	Ala	
			180					185							190	
ccg	gcg	gaa	acc	ccg	ctg	agc	gcg	ctg	gcg	atg	tgc	gtg	ctg	tgc	gaa	624
Pro	Ala	Glu	Thr	Pro	Leu	Ser	Ala	Leu	Ala	Met	Cys	Val	Leu	Cys	Glu	
		195					200						205			
cgc	gtg	ggc	att	ccg	ccg	ggc	gtg	gtg	aac	gtg	gtg	acc	atg	gat	aaa	672
Arg	Val	Gly	Ile	Pro	Pro	Gly	Val	Val	Asn	Val	Val	Thr	Met	Asp	Lys	
		210				215						220				
ggc	cag	cgc	gaa	atg	gcg	gcg	ggc	ctg	gaa	ctg	tgc	gaa	aac	gtg	aaa	720
Gly	Gln	Arg	Glu	Met	Ala	Ala	Gly	Leu	Glu	Leu	Cys	Glu	Asn	Val	Lys	
				230						235					240	
gtg	agc	aaa	att	agc	ttt	acc	ggc	agc	acc	ccg	gtg	ggc	cgc	ctg	ctg	768
Val	Ser	Lys	Ile	Ser	Phe	Thr	Gly	Ser	Thr	Pro	Val	Gly	Arg	Leu	Leu	
			245						250						255	
atg	aaa	cag	agc	agc	ggc	acc	ctg	aaa	aaa	ctg	agc	ttt	gaa	ctg	ggc	816
Met	Lys	Gln	Ser	Ser	Gly	Thr	Leu	Lys	Lys	Leu	Ser	Phe	Glu	Leu	Gly	
			260					265					270			
ggc	aac	gcg	gcg	ttt	att	att	ttt	gat	gat	gcg	gat	ctg	gat	ctg	gcg	864
Gly	Asn	Ala	Ala	Phe	Ile	Ile	Phe	Asp	Asp	Ala	Asp	Leu	Asp	Leu	Ala	
		275					280						285			
gtg	aac	ggc	gtg	att	ctg	agc	aaa	ttt	cgc	gcg	gcg	ggc	cag	acc	tgc	912
Val	Asn	Gly	Val	Ile	Leu	Ser	Lys	Phe	Arg	Ala	Ala	Gly	Gln	Thr	Cys	
		290					295					300				
att	tgc	gcg	aac	cgc	att	ttt	gtg	cat	agc	aaa	att	tat	gat	gat	ttt	960
Ile	Cys	Ala	Asn	Arg	Ile	Phe	Val	His	Ser	Lys	Ile	Tyr	Asp	Asp	Phe	
		305			310					315					320	
gcg	cgc	cgc	ctg	gtg	gaa	cgc	gtg	aaa	gcg	ttt	aaa	gtg	ggc	aac	ggc	1008
Ala	Arg	Arg	Leu	Val	Glu	Arg	Val	Lys	Ala	Phe	Lys	Val	Gly	Asn	Gly	
			325							330				335		
att	gaa	gaa	ggc	gtg	acc	att	ggc	ccg	ctg	gtg	agc	cag	cgc	ggc	gtg	1056
Ile	Glu	Glu	Gly	Val	Thr	Ile	Gly	Pro	Leu	Val	Ser	Gln	Arg	Gly	Val	
			340					345					350			
gaa	aaa	gtg	gaa	cgc	cat	gtg	cag	gat	gcg	gtg	ggc	ctg	ggc	gcg	aaa	1104
Glu	Lys	Val	Glu	Arg	His	Val	Gln	Asp	Ala	Val	Gly	Leu	Gly	Ala	Lys	
			355				360						365			
gtg	ctg	gtg	ggc	ggc	aaa	cgc	att	gat	aaa	ggc	gaa	ggc	agc	tgc	ttt	1152
Val	Leu	Val	Gly	Gly	Lys	Arg	Ile	Asp	Lys	Gly	Glu	Gly	Ser	Cys	Phe	
		370				375						380				
tat	gaa	ccg	acc	gtg	ctg	gtg	gat	gtg	ccg	cgc	cag	tgc	gcg	gtg	agc	1200
Tyr	Glu	Pro	Thr	Val	Leu	Val	Asp	Val	Pro	Arg	Gln	Cys	Ala	Val	Ser	
				390						395					400	
aac	gaa	gaa	acc	ttt	ggc	ccg	ctg	gcg	ccg	ctg	ttt	aaa	ttt	gat	gat	1248

-continued

Asn	Glu	Glu	Thr	Phe	Gly	Pro	Leu	Ala	Pro	Leu	Phe	Lys	Phe	Asp	Asp	
				405					410					415		
gaa	gat	gat	gtg	gtg	gaa	cgc	gcg	aac	agc	agc	gaa	gtg	ggc	ctg	gcg	1296
Glu	Asp	Asp	Val	Val	Glu	Arg	Ala	Asn	Ser	Ser	Glu	Val	Gly	Leu	Ala	
			420					425					430			
gcg	tat	ttt	ttt	acc	aaa	gat	ctg	gcg	gcg	acc	cat	gcg	gtg	gcg	gaa	1344
Ala	Tyr	Phe	Phe	Thr	Lys	Asp	Leu	Ala	Arg	Thr	His	Arg	Val	Ala	Glu	
			435				440					445				
aaa	ctg	gaa	gtg	ggc	atg	gtg	gcg	gtg	aac	acc	ggc	gcg	att	gcg	cag	1392
Lys	Leu	Glu	Val	Gly	Met	Val	Ala	Val	Asn	Thr	Gly	Ala	Ile	Ala	Gln	
	450					455					460					
agc	tgc	gtg	ccg	ttt	ggc	ggc	gtg	aaa	cag	agc	ggc	ttt	ggc	gcg	gaa	1440
Ser	Cys	Val	Pro	Phe	Gly	Gly	Val	Lys	Gln	Ser	Gly	Phe	Gly	Arg	Glu	
465					470					475					480	
ggc	ggc	ccg	agc	ggc	att	gat	gaa	ttt	atg	gtg	gaa	aaa	ctg	att	acc	1488
Gly	Gly	Pro	Ser	Gly	Ile	Asp	Glu	Phe	Met	Val	Glu	Lys	Leu	Ile	Thr	
				485					490					495		
att	ggc	ggc	ctg													1500
Ile	Gly	Gly	Leu													
			500													

<210> SEQ ID NO 62
 <211> LENGTH: 500
 <212> TYPE: PRT
 <213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 62

Met	Pro	Ser	Leu	Thr	Gln	Thr	Lys	Asp	Leu	Ala	Ser	Leu	Leu	Ser	Asp	
1				5					10					15		
Ala	Ser	His	Phe	Lys	Gln	Lys	Gly	Tyr	Ile	Asn	Gly	Glu	Trp	Val	Ser	
			20					25					30			
Ala	Ser	Asp	Gly	Ala	Thr	Phe	Pro	Leu	Tyr	Asn	Pro	Ala	Thr	Gly	Ala	
			35				40					45				
Lys	Leu	Ala	Asp	Met	Pro	His	Met	Pro	Arg	Ser	Gln	Val	Ala	Glu	Ala	
	50					55					60					
Ile	Asn	Ala	Ala	Lys	Ala	Ala	Phe	Pro	Ala	Trp	Ala	Ala	Leu	Thr	Ala	
65				70					75					80		
Tyr	Gln	Arg	Gln	Asn	Tyr	Leu	Leu	Lys	Leu	Phe	Lys	Glu	Met	Glu	Glu	
			85					90						95		
His	Ser	Glu	Asp	Leu	Ala	Ile	Ile	Leu	Cys	Thr	Glu	Asn	Gly	Lys	Pro	
			100					105					110			
Leu	Ala	Glu	Ser	Arg	Val	Glu	Ile	Ser	Tyr	Gly	Ala	Ser	Phe	Leu	Thr	
		115				120						125				
Trp	Asn	Ala	Ala	Glu	Ala	Leu	Arg	Thr	Tyr	Gly	Gln	Thr	Ile	Pro	Ser	
	130					135					140					
Pro	Phe	Pro	Gly	Thr	Arg	Asn	Thr	Val	Ile	Lys	Gln	Pro	Ile	Gly	Val	
145					150					155					160	
Cys	Gly	Leu	Ile	Thr	Pro	Trp	Asn	Phe	Pro	Asn	Ala	Met	Ile	Thr	Arg	
				165				170						175		
Lys	Met	Ala	Pro	Ala	Leu	Ala	Ala	Gly	Cys	Thr	Val	Val	Ile	Lys	Ala	
			180					185					190			
Pro	Ala	Glu	Thr	Pro	Leu	Ser	Ala	Leu	Ala	Met	Cys	Val	Leu	Cys	Glu	
		195				200						205				
Arg	Val	Gly	Ile	Pro	Pro	Gly	Val	Val	Asn	Val	Val	Thr	Met	Asp	Lys	
		210				215						220				
Gly	Gln	Arg	Glu	Met	Ala	Ala	Gly	Leu	Glu	Leu	Cys	Glu	Asn	Val	Lys	
225					230					235					240	

-continued

Val Ser Lys Ile Ser Phe Thr Gly Ser Thr Pro Val Gly Arg Leu Leu
 245 250 255

Met Lys Gln Ser Ser Gly Thr Leu Lys Lys Leu Ser Phe Glu Leu Gly
 260 265 270

Gly Asn Ala Ala Phe Ile Ile Phe Asp Asp Ala Asp Leu Asp Leu Ala
 275 280 285

Val Asn Gly Val Ile Leu Ser Lys Phe Arg Ala Ala Gly Gln Thr Cys
 290 295 300

Ile Cys Ala Asn Arg Ile Phe Val His Ser Lys Ile Tyr Asp Asp Phe
 305 310 315 320

Ala Arg Arg Leu Val Glu Arg Val Lys Ala Phe Lys Val Gly Asn Gly
 325 330 335

Ile Glu Glu Gly Val Thr Ile Gly Pro Leu Val Ser Gln Arg Gly Val
 340 345 350

Glu Lys Val Glu Arg His Val Gln Asp Ala Val Gly Leu Gly Ala Lys
 355 360 365

Val Leu Val Gly Gly Lys Arg Ile Asp Lys Gly Glu Gly Ser Cys Phe
 370 375 380

Tyr Glu Pro Thr Val Leu Val Asp Val Pro Arg Gln Cys Ala Val Ser
 385 390 395 400

Asn Glu Glu Thr Phe Gly Pro Leu Ala Pro Leu Phe Lys Phe Asp Asp
 405 410 415

Glu Asp Asp Val Val Glu Arg Ala Asn Ser Ser Glu Val Gly Leu Ala
 420 425 430

Ala Tyr Phe Phe Thr Lys Asp Leu Ala Arg Thr His Arg Val Ala Glu
 435 440 445

Lys Leu Glu Val Gly Met Val Ala Val Asn Thr Gly Ala Ile Ala Gln
 450 455 460

Ser Cys Val Pro Phe Gly Gly Val Lys Gln Ser Gly Phe Gly Arg Glu
 465 470 475 480

Gly Gly Pro Ser Gly Ile Asp Glu Phe Met Val Glu Lys Leu Ile Thr
 485 490 495

Ile Gly Gly Leu
 500

<210> SEQ ID NO 63
 <211> LENGTH: 1200
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1200)

<400> SEQUENCE: 63

atg tgc agc agc cat gcg acc gcg gtc gaa agc gtc agc ccg gcg ccg	48
Met Cys Ser Ser His Ala Thr Ala Val Glu Ser Val Ser Pro Ala Pro	
1 5 10 15	
cgc aaa agc cag tat gaa gtc aaa tat gat ccg gat ctg gtc ctg aaa	96
Arg Lys Ser Gln Tyr Glu Val Lys Tyr Asp Pro Asp Leu Val Leu Lys	
20 25 30	
agc gcg gaa ttt aaa gaa ctg aaa cag ggc gat aaa gaa ctg gaa gat	144
Ser Ala Glu Phe Lys Glu Leu Lys Gln Gly Asp Lys Glu Leu Glu Asp	
35 40 45	
ccg aaa gcg aac ctg gcg tgc gcg tat gat gaa aaa cat aac gtc aaa	192
Pro Lys Ala Asn Leu Ala Cys Ala Tyr Asp Glu Lys His Asn Val Lys	
50 55 60	

-continued

atg att aac aaa ccg att ccg aaa gcg cgc cag gat gaa gtg gtg gtg	240
Met Ile Asn Lys Pro Ile Pro Lys Ala Arg Gln Asp Glu Val Val Val	
65 70 75 80	
cat att aaa gcg acc gcc att tgc gcc agc gat gtg cat ttt tgg aaa	288
His Ile Lys Ala Thr Gly Ile Cys Gly Ser Asp Val His Phe Trp Lys	
85 90 95	
cat gcc cag att gcc ccg acc atg att gtg acc gat acc tgc gcc gcg	336
His Gly Gln Ile Gly Pro Thr Met Ile Val Thr Asp Thr Cys Gly Ala	
100 105 110	
ggc cat gaa agc gcg gcc gaa gtg gtg gaa gtg gcc ccg gcc gtg gaa	384
Gly His Glu Ser Ala Gly Glu Val Val Glu Val Gly Pro Gly Val Glu	
115 120 125	
cag tgg aaa gtg gcc gat ccg gtg gcg att gaa tgc gcc gtg ccg tgc	432
Gln Trp Lys Val Gly Asp Arg Val Ala Ile Glu Cys Gly Val Pro Cys	
130 135 140	
ggc cag gcg agc tgc gcc ccg tgc gtg acc gcc cgc tat aac gcg tgc	480
Gly Gln Ala Ser Cys Gly Pro Cys Val Thr Gly Arg Tyr Asn Ala Cys	
145 150 155 160	
ccg cag gtg gtg ttt ttt agc acc ccg ccg tat cat gcc acc ctg acc	528
Pro Gln Val Val Phe Phe Ser Thr Pro Pro Tyr His Gly Thr Leu Thr	
165 170 175	
cgc tat cat gcg cat ccg gcg agc tgg ctg cat cgc ctg ccg gat aac	576
Arg Tyr His Ala His Pro Ala Ser Trp Leu His Arg Leu Pro Asp Asn	
180 185 190	
ctg agc tat gaa gaa gcc gcg ctg tgc gaa ccg ttt gcg gtg gcg ctg	624
Leu Ser Tyr Glu Glu Gly Ala Leu Cys Glu Pro Phe Ala Val Ala Leu	
195 200 205	
gcg gcg ctg gaa cgc gcg gcc aac cgc ctg gcc gat ccg gtg ctg att	672
Ala Ala Leu Glu Arg Ala Gly Asn Arg Leu Gly Asp Pro Val Leu Ile	
210 215 220	
tgc gcc gcg gcc ccg att gcc ctg gtg acc ctg ctg gcg agc cat gcg	720
Cys Gly Ala Gly Pro Ile Gly Leu Val Thr Leu Leu Ala Ser His Ala	
225 230 235 240	
gcg gcc tgc acc ccg att gtg att acc gat ctg cag gcg agc cgc ctg	768
Ala Gly Cys Thr Pro Ile Val Ile Thr Asp Leu Gln Ala Ser Arg Leu	
245 250 255	
gaa gtg gcg aaa aaa ctg att ccg acc gtg aaa acc gtg cag att gaa	816
Glu Val Ala Lys Lys Leu Ile Pro Thr Val Lys Thr Val Gln Ile Glu	
260 265 270	
cgc agc tgg acc agc aaa gaa acc agc gaa gcg att aaa gaa gcg gcg	864
Arg Ser Trp Thr Ser Lys Glu Thr Ser Glu Ala Ile Lys Glu Ala Ala	
275 280 285	
ggc acc gcc att cgc gtg gcg att gat gcg acc gcc ttt gaa agc agc	912
Gly Thr Gly Ile Arg Val Ala Ile Asp Ala Thr Gly Phe Glu Ser Ser	
290 295 300	
att acc gcg gcg att tat agc gtg gtg ttt gcc gcc aaa gtg ttt gtg	960
Ile Thr Ala Ala Ile Tyr Ser Val Val Phe Gly Gly Lys Val Phe Val	
305 310 315 320	
att gcc gcg gcc ccg agc gaa cag aaa tat ccg ttt gcc tat tgc agc	1008
Ile Gly Ala Gly Pro Ser Glu Gln Lys Tyr Pro Phe Gly Tyr Cys Ser	
325 330 335	
gcg aac gaa att gat ctg cag ttt cag tat cgc tat gcg cat cag tat	1056
Ala Asn Glu Ile Asp Leu Gln Phe Gln Tyr Arg Tyr Ala His Gln Tyr	
340 345 350	
ccg aaa gcg ctg cgc att gtg agc gcc gcc ctg att aac ctg aaa ccg	1104
Pro Lys Ala Leu Arg Ile Val Ser Gly Gly Leu Ile Asn Leu Lys Pro	
355 360 365	
ctg ctg acc cat acc ttt ccg ctg aac aaa gcg gtg gaa gcg ttt cat	1152
Leu Leu Thr His Thr Phe Pro Leu Asn Lys Ala Val Glu Ala Phe His	
370 375 380	

-continued

gtg gcg gcg gat ccg acc aaa ggc gcg att aaa gtg cag att att gat 1200
 Val Ala Ala Asp Pro Thr Lys Gly Ala Ile Lys Val Gln Ile Ile Asp
 385 390 395 400

<210> SEQ ID NO 64
 <211> LENGTH: 400
 <212> TYPE: PRT
 <213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 64

Met Cys Ser Ser His Ala Thr Ala Val Glu Ser Val Ser Pro Ala Pro
 1 5 10 15
 Arg Lys Ser Gln Tyr Glu Val Lys Tyr Asp Pro Asp Leu Val Leu Lys
 20 25 30
 Ser Ala Glu Phe Lys Glu Leu Lys Gln Gly Asp Lys Glu Leu Glu Asp
 35 40 45
 Pro Lys Ala Asn Leu Ala Cys Ala Tyr Asp Glu Lys His Asn Val Lys
 50 55 60
 Met Ile Asn Lys Pro Ile Pro Lys Ala Arg Gln Asp Glu Val Val Val
 65 70 75 80
 His Ile Lys Ala Thr Gly Ile Cys Gly Ser Asp Val His Phe Trp Lys
 85 90 95
 His Gly Gln Ile Gly Pro Thr Met Ile Val Thr Asp Thr Cys Gly Ala
 100 105 110
 Gly His Glu Ser Ala Gly Glu Val Val Glu Val Gly Pro Gly Val Glu
 115 120 125
 Gln Trp Lys Val Gly Asp Arg Val Ala Ile Glu Cys Gly Val Pro Cys
 130 135 140
 Gly Gln Ala Ser Cys Gly Pro Cys Val Thr Gly Arg Tyr Asn Ala Cys
 145 150 155 160
 Pro Gln Val Val Phe Phe Ser Thr Pro Pro Tyr His Gly Thr Leu Thr
 165 170 175
 Arg Tyr His Ala His Pro Ala Ser Trp Leu His Arg Leu Pro Asp Asn
 180 185 190
 Leu Ser Tyr Glu Glu Gly Ala Leu Cys Glu Pro Phe Ala Val Ala Leu
 195 200 205
 Ala Ala Leu Glu Arg Ala Gly Asn Arg Leu Gly Asp Pro Val Leu Ile
 210 215 220
 Cys Gly Ala Gly Pro Ile Gly Leu Val Thr Leu Leu Ala Ser His Ala
 225 230 235 240
 Ala Gly Cys Thr Pro Ile Val Ile Thr Asp Leu Gln Ala Ser Arg Leu
 245 250 255
 Glu Val Ala Lys Lys Leu Ile Pro Thr Val Lys Thr Val Gln Ile Glu
 260 265 270
 Arg Ser Trp Thr Ser Lys Glu Thr Ser Glu Ala Ile Lys Glu Ala Ala
 275 280 285
 Gly Thr Gly Ile Arg Val Ala Ile Asp Ala Thr Gly Phe Glu Ser Ser
 290 295 300
 Ile Thr Ala Ala Ile Tyr Ser Val Val Phe Gly Gly Lys Val Phe Val
 305 310 315 320
 Ile Gly Ala Gly Pro Ser Glu Gln Lys Tyr Pro Phe Gly Tyr Cys Ser
 325 330 335
 Ala Asn Glu Ile Asp Leu Gln Phe Gln Tyr Arg Tyr Ala His Gln Tyr
 340 345 350

-continued

Pro Lys Ala Leu Arg Ile Val Ser Gly Gly Leu Ile Asn Leu Lys Pro
 355 360 365

Leu Leu Thr His Thr Phe Pro Leu Asn Lys Ala Val Glu Ala Phe His
 370 375 380

Val Ala Ala Asp Pro Thr Lys Gly Ala Ile Lys Val Gln Ile Ile Asp
 385 390 395 400

<210> SEQ ID NO 65
 <211> LENGTH: 1689
 <212> TYPE: DNA
 <213> ORGANISM: *Cryptococcus neoformans*
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1689)

<400> SEQUENCE: 65

atg gtg tgc gtg att agc gat ccg gat tgg tgg cgc cag gcg gtg gtg 48
 Met Val Cys Val Ile Ser Asp Pro Asp Trp Trp Arg Gln Ala Val Val
 1 5 10 15

tat cag att tat ccg cgc agc ttt gcg gat gcg aac ggc gat ggc att 96
 Tyr Gln Ile Tyr Pro Arg Ser Phe Ala Asp Ala Asn Gly Asp Gly Ile
 20 25 30

ggc gat ctg aaa ggc att acc gcg cgc gtg ccg tat ctg aaa gcg ctg 144
 Gly Asp Leu Lys Gly Ile Thr Ala Arg Val Pro Tyr Leu Lys Ala Leu
 35 40 45

ggc gtg gat gcg att tgg ctg agc ccg ttt tat ccg agc gcg ctg cgc 192
 Gly Val Asp Ala Ile Trp Leu Ser Pro Phe Tyr Pro Ser Ala Leu Arg
 50 55 60

gat ggc ggc tat gat gtg gcg gat tat cgc gat gtg gat ccg aaa att 240
 Asp Gly Gly Tyr Asp Val Ala Asp Tyr Arg Asp Val Asp Pro Lys Ile
 65 70 75 80

ggc acc ctg gaa gaa ttt gat gaa atg acc gcg gcg ttt cag aaa gtg 288
 Gly Thr Leu Glu Glu Phe Asp Glu Met Thr Ala Ala Phe Gln Lys Val
 85 90 95

ggc att cgc gtg att gtg gat att gtg ccg aac cat agc agc gat gat 336
 Gly Ile Arg Val Ile Val Asp Ile Val Pro Asn His Ser Ser Asp Asp
 100 105 110

cat gaa tgg ttt cag gcg gcg ctg aaa gcg ggc aaa ggc agc ccg gaa 384
 His Glu Trp Phe Gln Ala Ala Leu Lys Ala Gly Lys Gly Ser Pro Glu
 115 120 125

cgc gaa cgc tat att ttt cgc gat ggc ctg ggc ccg aac aaa gat cag 432
 Arg Glu Arg Tyr Ile Phe Arg Asp Gly Leu Gly Pro Asn Lys Asp Gln
 130 135 140

ccg ccg acc gat tgg att tgc agc ttt ggc ggc agc gcg tgg agc ccg 480
 Pro Pro Thr Asp Trp Ile Cys Ser Phe Gly Gly Ser Ala Trp Ser Pro
 145 150 155 160

agc ggc atg aac gat ggc cag tgg tat ttt cat tgg ttt gat agc agc 528
 Ser Gly Met Asn Asp Gly Gln Trp Tyr Phe His Trp Phe Asp Ser Ser
 165 170 175

cag ccg gat tgg aac tgg gaa aac ccg gat gtg aaa gcg gat ttt ctg 576
 Gln Pro Asp Trp Asn Trp Glu Asn Pro Asp Val Lys Ala Asp Phe Leu
 180 185 190

aaa acc ctg aaa ttt tgg ggc gat cgc ggc gtg agc ggc ttt cgc att 624
 Lys Thr Leu Lys Phe Trp Gly Asp Arg Gly Val Ser Gly Phe Arg Ile
 195 200 205

gat gtg gcg cat ggc ctg gcg aaa gat atg agc gaa ccg ctg ccg aac 672
 Asp Val Ala His Gly Leu Ala Lys Asp Met Ser Glu Pro Leu Pro Asn
 210 215 220

tgg gaa cag ctg acc aaa ctg acc cat cag aaa ctg acc aac ggc aac 720
 Trp Glu Gln Leu Thr Lys Leu Thr His Gln Lys Leu Thr Asn Gly Asn
 225 230 235 240

-continued

agc gaa ctg gat cat ccg ctg ctg gat cgc aaa gaa gtg cat gat att Ser Glu Leu Asp His Pro Leu Leu Asp Arg Lys Glu Val His Asp Ile 245 250 255	768
tat cgc agc tgg cgc gaa gtg ttt aac cag ttt aac ccg ccg ctg atg Tyr Arg Ser Trp Arg Glu Val Phe Asn Gln Phe Asn Pro Pro Leu Met 260 265 270	816
gcg gtg gcg gaa gcg tgg gtg gcg ccg gat cag aaa ccg ctg tat gcg Ala Val Ala Glu Ala Trp Val Ala Pro Asp Gln Lys Pro Leu Tyr Ala 275 280 285	864
agc agc gaa ggc ctg gcc cag acc ttt agc ttt gat att ctg ctg tgc Ser Ser Glu Gly Leu Gly Gln Thr Phe Ser Phe Asp Ile Leu Leu Cys 290 295 300	912
aac ttt gat gcg gaa gaa tat cgc cag tgc att aaa agc agc ctg gcg Asn Phe Asp Ala Glu Glu Tyr Arg Gln Cys Ile Lys Ser Ser Leu Ala 305 310 315 320	960
ggc agc aaa aaa agc gat agc acc acc acc tgg gtg ctg agc aac cat Gly Ser Lys Lys Ser Asp Ser Thr Thr Thr Trp Val Leu Ser Asn His 325 330 335	1008
gat gtg atg cgc cat ccg acc cgc ttt ggc ctg ccg aac gtg ccg aac Asp Val Met Arg His Pro Thr Arg Phe Gly Leu Pro Asn Val Pro Asn 340 345 350	1056
gcg aac cat gcg atg acc acc gat acc tat aac aaa ttt ctg aaa acc Ala Asn His Ala Met Thr Thr Asp Thr Tyr Asn Lys Phe Leu Lys Thr 355 360 365	1104
aaa ctg acc gat ccg aaa gtg gat att gaa cag ggc ctg cgc cgc gcg Lys Leu Thr Asp Pro Lys Val Asp Ile Glu Gln Gly Leu Arg Arg Ala 370 375 380	1152
aaa gcg gcg acc ctg atg att ctg gcg ctg ccg ggc agc acc tat ctg Lys Ala Ala Thr Leu Met Ile Leu Ala Leu Pro Gly Ser Thr Tyr Leu 385 390 395 400	1200
tat cag ggc gaa gaa ctg gcc ctg cag gaa gtg gtg gaa att ccg gat Tyr Gln Gly Glu Glu Leu Gly Leu Gln Glu Val Val Glu Ile Pro Asp 405 410 415	1248
gaa gaa cgc cag gat ccg att ttt att cgc acc aaa ggc gaa gaa gtg Glu Glu Arg Gln Asp Pro Ile Phe Ile Arg Thr Lys Gly Glu Glu Val 420 425 430	1296
ggc cgc gat gcc tgc cgc gtg ccg att ccg tgg gtg gcg gat gaa aaa Gly Arg Asp Gly Cys Arg Val Pro Ile Pro Trp Val Ala Asp Glu Lys 435 440 445	1344
aac ttt ggc tat gcc ccg gcc aaa cgc gcg cat ctg ccg cag ccg gcg Asn Phe Gly Tyr Gly Pro Gly Lys Arg Ala His Leu Pro Gln Pro Ala 450 455 460	1392
tgg ttt aaa gat tat gcg gtg gat gtg gaa gaa aaa gat gcg aac agc Trp Phe Lys Asp Tyr Ala Val Asp Val Glu Glu Lys Asp Ala Asn Ser 465 470 475 480	1440
gtg ctg agc ctg tat cgc cgc gcg ctg gcc ctg cgc aaa ggc ctg cag Val Leu Ser Leu Tyr Arg Arg Ala Leu Gly Leu Arg Lys Gly Leu Gln 485 490 495	1488
agc gcg gaa gaa ctg gaa tgg gtg gaa aac ccg aac aaa gaa gtg ctg Ser Ala Glu Glu Leu Glu Trp Val Glu Asn Pro Asn Lys Glu Val Leu 500 505 510	1536
cat ttt cgc cgc ccg gcc gcc tgg gaa gtg gtg gtg aac att gcc aaa His Phe Arg Arg Pro Gly Gly Trp Glu Val Val Val Asn Ile Gly Lys 515 520 525	1584
gat agc gtg gat ctg ccg aaa gcc agc gtg ctg att agc agc agc aac Asp Ser Val Asp Leu Pro Lys Gly Ser Val Leu Ile Ser Ser Ser Asn 530 535 540	1632
aac gcg ctg aaa gcc gcc agc att ccg gcc gaa acc acc gtg tgg ctg Asn Ala Leu Lys Gly Gly Ser Ile Pro Gly Glu Thr Thr Val Trp Leu	1680

-continued

Ala Asn His Ala Met Thr Thr Asp Thr Tyr Asn Lys Phe Leu Lys Thr
 355 360 365

Lys Leu Thr Asp Pro Lys Val Asp Ile Glu Gln Gly Leu Arg Arg Ala
 370 375 380

Lys Ala Ala Thr Leu Met Ile Leu Ala Leu Pro Gly Ser Thr Tyr Leu
 385 390 395 400

Tyr Gln Gly Glu Glu Leu Gly Leu Gln Glu Val Val Glu Ile Pro Asp
 405 410 415

Glu Glu Arg Gln Asp Pro Ile Phe Ile Arg Thr Lys Gly Glu Glu Val
 420 425 430

Gly Arg Asp Gly Cys Arg Val Pro Ile Pro Trp Val Ala Asp Glu Lys
 435 440 445

Asn Phe Gly Tyr Gly Pro Gly Lys Arg Ala His Leu Pro Gln Pro Ala
 450 455 460

Trp Phe Lys Asp Tyr Ala Val Asp Val Glu Glu Lys Asp Ala Asn Ser
 465 470 475 480

Val Leu Ser Leu Tyr Arg Arg Ala Leu Gly Leu Arg Lys Gly Leu Gln
 485 490 495

Ser Ala Glu Glu Leu Glu Trp Val Glu Asn Pro Asn Lys Glu Val Leu
 500 505 510

His Phe Arg Arg Pro Gly Gly Trp Glu Val Val Val Asn Ile Gly Lys
 515 520 525

Asp Ser Val Asp Leu Pro Lys Gly Ser Val Leu Ile Ser Ser Ser Asn
 530 535 540

Asn Ala Leu Lys Gly Gly Ser Ile Pro Gly Glu Thr Thr Val Trp Leu
 545 550 555 560

Lys Ser Ala

<210> SEQ ID NO 67
 <211> LENGTH: 729
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(729)

<400> SEQUENCE: 67

atg ccg agc gtg gtg ttt gat gtg gtg ggc acc tgc ttt agc tat gat	48
Met Pro Ser Val Val Phe Asp Val Val Gly Thr Cys Phe Ser Tyr Asp	
1 5 10 15	
aac ggc gcg gaa gcg ctg cag gcg cgc ctg ggc ccg aaa ctg gcg aaa	96
Asn Gly Ala Glu Ala Leu Gln Ala Arg Leu Gly Pro Lys Leu Ala Lys	
20 25 30	
tat ggc att ccg agc aaa ctg ctg ttt tat agc tgg gtg tgc agc acc	144
Tyr Gly Ile Pro Ser Lys Leu Leu Phe Tyr Ser Trp Val Cys Ser Thr	
35 40 45	
gaa cgc gat tat agc tat ctg agc cag att aaa cag tat aaa gcg ttt	192
Glu Arg Asp Tyr Ser Tyr Leu Ser Gln Ile Lys Gln Tyr Lys Ala Phe	
50 55 60	
ttt gcg att ctg agc aac acc ctg acc cgc gtg ctg ttt cag gcg ggc	240
Phe Ala Ile Leu Ser Asn Thr Leu Thr Arg Val Leu Phe Gln Ala Gly	
65 70 75 80	
gtg ccg gtg gaa gcg ctg gat gat ttt ttt acc gcg gat gat gtg gat	288
Val Pro Val Glu Ala Leu Asp Asp Phe Phe Thr Ala Asp Asp Val Asp	
85 90 95	
tat att atg aac gaa tat aaa aaa ctg aaa gcg cgc ccg ggc ctg gcg	336
Tyr Ile Met Asn Glu Tyr Lys Lys Leu Lys Ala Arg Pro Gly Leu Ala	
100 105 110	

-continued

```

gaa atg atg cag acc ctg cgc gat ggc ggc ttt gaa gtg tgg tgc tgc   384
Glu Met Met Gln Thr Leu Arg Asp Gly Gly Phe Glu Val Trp Cys Cys
      115                120                125

agc gat gcg aac gtg gat cgc gtg aaa ggc tat ttt gat aac gcg ggc   432
Ser Asp Ala Asn Val Asp Arg Val Lys Gly Tyr Phe Asp Asn Ala Gly
      130                135                140

gtg gaa atg ccg ctg gat cat att ctg agc gcg gat atg gtg aaa gcg   480
Val Glu Met Pro Leu Asp His Ile Leu Ser Ala Asp Met Val Lys Ala
      145                150                155                160

ggc aaa ccg gaa gcg gcg gtg tat aaa ttt gcg cgc gaa aaa gcg ggc   528
Gly Lys Pro Glu Ala Ala Val Tyr Lys Phe Ala Arg Glu Lys Ala Gly
      165                170                175

agc gat cag ccg ggc gaa gtg agc gtg ttt gcg gcg agc cat gcg tgg   576
Ser Asp Gln Pro Gly Glu Val Ser Val Phe Ala Ala Ser His Ala Trp
      180                185                190

gat tgc gcg gcg gcg aaa gcg gcg ggc ttt ctg acc gcg tat acc acc   624
Asp Cys Ala Ala Ala Lys Ala Ala Gly Phe Leu Thr Ala Tyr Thr Thr
      195                200                205

acc tat gaa tat gat gaa tgc gaa gtg att ttt ggc aaa agc gat ctg   672
Thr Tyr Glu Tyr Asp Glu Cys Glu Val Ile Phe Gly Lys Ser Asp Leu
      210                215                220

gtg gcg ccg gat ctg gtg agc ctg ggc aaa ggc att gtg gaa aaa tgg   720
Val Ala Pro Asp Leu Val Ser Leu Gly Lys Gly Ile Val Glu Lys Trp
      225                230                235                240

ggc aaa aaa   729
Gly Lys Lys

```

<210> SEQ ID NO 68

<211> LENGTH: 243

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 68

```

Met Pro Ser Val Val Phe Asp Val Val Gly Thr Cys Phe Ser Tyr Asp
 1      5      10      15

Asn Gly Ala Glu Ala Leu Gln Ala Arg Leu Gly Pro Lys Leu Ala Lys
 20     25     30

Tyr Gly Ile Pro Ser Lys Leu Leu Phe Tyr Ser Trp Val Cys Ser Thr
 35     40     45

Glu Arg Asp Tyr Ser Tyr Leu Ser Gln Ile Lys Gln Tyr Lys Ala Phe
 50     55     60

Phe Ala Ile Leu Ser Asn Thr Leu Thr Arg Val Leu Phe Gln Ala Gly
 65     70     75     80

Val Pro Val Glu Ala Leu Asp Asp Phe Phe Thr Ala Asp Asp Val Asp
 85     90     95

Tyr Ile Met Asn Glu Tyr Lys Lys Leu Lys Ala Arg Pro Gly Leu Ala
100    105    110

Glu Met Met Gln Thr Leu Arg Asp Gly Gly Phe Glu Val Trp Cys Cys
115    120    125

Ser Asp Ala Asn Val Asp Arg Val Lys Gly Tyr Phe Asp Asn Ala Gly
130    135    140

Val Glu Met Pro Leu Asp His Ile Leu Ser Ala Asp Met Val Lys Ala
145    150    155    160

Gly Lys Pro Glu Ala Ala Val Tyr Lys Phe Ala Arg Glu Lys Ala Gly
165    170    175

Ser Asp Gln Pro Gly Glu Val Ser Val Phe Ala Ala Ser His Ala Trp
180    185    190

```


-continued

Asp	Cys	Ala	Ala	Ala	Lys	Ala	Ala	Gly	Phe	Leu	Thr	Ala	Tyr	Thr	Thr
	195						200					205			
Thr	Tyr	Glu	Tyr	Asp	Glu	Cys	Glu	Val	Ile	Phe	Gly	Lys	Ser	Asp	Leu
210					215						220				
Val	Ala	Pro	Asp	Leu	Val	Ser	Leu	Gly	Lys	Gly	Ile	Val	Glu	Lys	Trp
225					230					235					240
Gly	Lys	Lys													

What is claimed is:

1. A method of testing compounds for activity to inhibit germination of spores, the method comprising:
 - (a) providing bacterial, fungal, or plant spores transformed to contain and express a detectable marker, wherein the marker when expressed, is operationally linked to a spore-specific or yeast-specific protein, in a medium and under environmental conditions in which the spores will germinate, and measuring a first signal output generated by the marker prior to the spores initiating germination;
 - (b) contacting the spores of step (a) with a compound whose activity to inhibit germination of spores is to be measured;
 - (c) incubating the spores of step (b) under environmental conditions and for a time wherein spores not treated with the compound will germinate; and
 - (d) determining extent of germination of the spores by measuring a second signal output generated by the marker, wherein a difference between the first signal output and the second signal output is proportional to the extent of germination of the spores.
2. The method of claim 1, wherein the spores of step (a) are of a genus selected from the group consisting of *Histoplasma*, *Blastomyces*, *Aspergillus*, *Coccidioides*, *Sporothrix*, *Penicillium*, and *Cryptococcus*.
3. The method of claim 1, wherein the spores of step (a) are a species selected from the group consisting of *Histoplasma capsulatum*, *Blastomyces dermatitidis*, *Aspergillus fumigatus*, *Coccidioides immitis*, *Sporothrix schenckii*, *Penicillium marneffeii*, and *Cryptococcus neoformans*.
4. The method of claim 1, wherein the detectable marker, when expressed, is a fluorophore or a chemiluminescent marker.
5. A method of testing compounds for activity to inhibit germination of spores, the method comprising:
 - (a) providing bacterial, fungal, or plant spores transformed to contain and express a detectable marker, wherein the marker when expressed, is operationally linked to a gene selected from the group consisting of SEQ. ID. NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 30, 31, 33, and 35, in a medium and under environmental conditions in which the spores will germinate, and measuring a first signal output generated by the marker prior to the spores initiating germination, wherein the detectable marker, when expressed, is a fluorophore or a chemiluminescent marker;
 - (b) contacting the spores of step (a) with a compound whose activity to inhibit germination of spores is to be measured;
 - (c) incubating the spores of step (b) under environmental conditions and for a time wherein spores not treated with the compound will germinate; and
 - (d) determining extent of germination of the spores by measuring a second signal output generated by the marker, wherein a difference between the first signal
6. The method of claim 4, wherein the spores of step (a) are of a genus selected from the group consisting of *Histoplasma*, *Blastomyces*, *Aspergillus*, *Coccidioides*, *Sporothrix*, *Penicillium*, and *Cryptococcus*.
7. The method of claim 4, wherein the spores of step (a) are a species selected from the group consisting of *Histoplasma capsulatum*, *Blastomyces dermatitidis*, *Aspergillus fumigatus*, *Coccidioides immitis*, *Sporothrix schenckii*, *Penicillium marneffeii*, and *Cryptococcus neoformans*.
8. The method of claim 1, wherein the detectable marker, when expressed, is a fluorophore or a chemiluminescent marker.
9. The method of claim 1, wherein the detectable marker, when expressed, is luciferase.
10. The method of claim 1, wherein the detectable marker, when expressed, is luciferase.
11. A method of testing compounds for activity to inhibit germination of spores, the method comprising:
 - (a) providing bacterial, fungal, or plant spores transformed to contain and express a detectable marker, wherein the marker when expressed, is operationally linked to a gene encoding a spore-specific protein selected from the group consisting of XP_567740.1 (SEQ. ID. NO: 2), XP_566791.1 (SEQ. ID. NO: 4), XP_570303.1 (SEQ. ID. NO: 6), XP_571089.1 (SEQ. ID. NO: 8), XP_571997.1 (SEQ. ID. NO: 10), XP_569295.1 (SEQ. ID. NO: 12), XP_569173.1 (SEQ. ID. NO: 14), XP_569068.1 (SEQ. ID. NO: 16), XP_569336.1 (SEQ. ID. NO: 18), XP_567136.1 (SEQ. ID. NO: 20), XP_568990.1 (SEQ. ID. NO: 22), XP_570610.1 (SEQ. ID. NO: 24), XP_571921.1 (SEQ. ID. NO: 26), XP_572925.1 (SEQ. ID. NO: 28), XP_570796.1 (SEQ. ID. NO: 30), XP_571548.1 (SEQ. ID. NO: 32), XP_570447.1 (SEQ. ID. NO: 34), and XP_571343.1 (SEQ. ID. NO: 36), in a medium and under environmental conditions in which the spores will germinate, and measuring a first signal output generated by the marker prior to the spores initiating germination;
 - (b) contacting the spores of step (a) with a compound whose activity to inhibit germination of spores is to be measured;
 - (c) incubating the spores of step (b) under environmental conditions and for a time wherein spores not treated with the compound will germinate; and
 - (d) determining extent of germination of the spores by measuring a second signal output generated by the marker, wherein a difference between the first signal

213

output and the second signal output is proportional to the extent of germination of the spores.

12. A method of testing compounds for activity to inhibit germination of spores, the method comprising:

- (a) providing bacterial, fungal, or plant spores transformed to contain and express a detectable marker, wherein the marker when expressed, is operationally linked to a gene selected from the group consisting of SEQ. ID. NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 30, 31, 33, and 35, in a medium and under environmental conditions in which the spores will germinate, and measuring a first signal output generated by the marker prior to the spores initiating germination;
- (b) contacting the spores of step (a) with a compound whose activity to inhibit germination of spores is to be measured;
- (c) incubating the spores of step (b) under environmental conditions and for a time wherein spores not treated with the compound will germinate; and
- (d) determining extent of germination of the spores by measuring a second signal output generated by the marker, wherein a difference between the first signal output and the second signal output is proportional to the extent of germination of the spores.

13. The method of claim **12**, wherein the marker, when expressed, is operationally connected to a protein encoded by gene CNK01510 (SEQ. ID. NO: 1).

14. A method of testing compounds for activity to inhibit germination of spores, the method comprising:

- (a) providing bacterial, fungal, or plant spores transformed to contain and express a detectable marker, wherein the marker is operationally linked to a spore-specific or yeast-specific protein, in a medium and under environmental conditions in which the spores will germinate, and measuring a first signal output generated by the marker prior to the spores initiating germination;
- (b) contacting the spores of step (a) with a compound whose activity to inhibit germination of spores is to be measured;
- (c) incubating the spores of step (b) under environmental conditions and for a time wherein spores not treated with the compound will germinate;
- (d) determining extent of germination of the spores by measuring a second signal output generated by the marker, wherein a difference between the first signal

214

output and the second signal output is proportional to the extent of germination of the spores, and

(e) plotting area and aspect ratio of the spores and any germinated cells after the incubation of step (c).

15. A method of testing compounds for activity to inhibit germination of spores, the method comprising:

- (a) providing bacterial, fungal, or plant spores transformed to contain and express a detectable marker, wherein the marker when expressed, is operationally linked to a gene encoding a spore-specific protein selected from the group consisting of XP_567740.1 (SEQ. ID. NO: 2), XP_566791.1 (SEQ. ID. NO: 4), XP_570303.1 (SEQ. ID. NO: 6), XP_571089.1 (SEQ. ID. NO: 8), XP_571997.1 (SEQ. ID. NO: 10), XP_569295.1 (SEQ. ID. NO: 12), XP_569173.1 (SEQ. ID. NO: 14), XP_569068.1 (SEQ. ID. NO: 16), XP_569336.1 (SEQ. ID. NO: 18), XP_567136.1 (SEQ. ID. NO: 20), XP_568990.1 (SEQ. ID. NO: 22), XP_570610.1 (SEQ. ID. NO: 24), XP_571921.1 (SEQ. ID. NO: 26), XP_572925.1 (SEQ. ID. NO: 28), XP_570796.1 (SEQ. ID. NO: 30), XP_571548.1 (SEQ. ID. NO: 32), XP_570447.1 (SEQ. ID. NO: 34), and XP_571343.1 (SEQ. ID. NO: 36)), in a medium and under environmental conditions in which the spores will germinate, and measuring a first signal output generated by the marker prior to the spores initiating germination, wherein the detectable marker, when expressed, is a fluorophore or a chemiluminescent marker;
- (b) contacting the spores of step (a) with a compound whose activity to inhibit germination of spores is to be measured;
- (c) incubating the spores of step (b) under environmental conditions and for a time wherein spores not treated with the compound will germinate; and
- (d) determining extent of germination of the spores by measuring a second signal output generated by the marker, wherein a difference between the first signal output and the second signal output is proportional to the extent of germination of the spores.

16. The method of claim **5**, wherein the marker, when expressed, is operationally connected to a protein encoded by gene CNK01510 (SEQ. ID. NO: 1).

* * * * *